Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jun. 30, 2024 | Aug. 06, 2024 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Entity Registrant Name | Metropolitan Life Insurance Co | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2024 | |
Document Transition Report | false | |
Entity File Number | 000-55029 | |
Entity Incorporation, State or Country Code | NY | |
Entity Tax Identification Number | 13-5581829 | |
Entity Address, Address Line One | 200 Park Avenue, | |
Entity Address, City or Town | New York, | |
Entity Address, State or Province | NY | |
Entity Address, Postal Zip Code | 10166-0188 | |
City Area Code | 212 | |
Local Phone Number | 578-9500 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Central Index Key | 0000937834 | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 494,466,664 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2024 | |
Document Fiscal Period Focus | Q2 | |
Current Fiscal Year End Date | --12-31 |
Consolidated Balance Sheets (Un
Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Investments: | ||
Fixed maturity securities available-for-sale, at estimated fair value (net of allowance for credit loss of $77 and $132, respectively); and amortized cost: $154,560 and $152,080, respectively | $ 142,156 | $ 142,805 |
Mortgage loans (net of allowance for credit loss of $533 and $509, respectively; includes $191 and $166, respectively, relating to variable interest entities) | 60,577 | 62,584 |
Policy loans | 5,713 | 5,671 |
Real estate and real estate joint ventures (includes $1,739 and $1,427, respectively, relating to variable interest entities, $321 and $317, respectively, under the fair value option) | 9,069 | 8,690 |
Other limited partnership interests | 7,225 | 7,765 |
Short-term investments, at estimated fair value | 1,668 | 3,048 |
Other invested assets (includes $768 and $805, respectively, of leveraged and direct financing leases; $138 and $117, respectively, relating to variable interest entities) | 16,865 | 17,040 |
Total investments | 243,273 | 247,603 |
Cash and cash equivalents, principally at estimated fair value | 7,349 | 6,795 |
Accrued investment income | 1,998 | 2,026 |
Premiums, reinsurance and other receivables | 28,893 | 28,236 |
Market risk benefits, at estimated fair value | 230 | 177 |
Deferred policy acquisition costs and value of business acquired | 3,219 | 3,305 |
Current income tax recoverable | 204 | 112 |
Deferred income tax asset | 2,839 | 2,922 |
Other assets | 4,284 | 4,312 |
Separate account assets | 79,585 | 83,197 |
Total assets | 371,874 | 378,685 |
Liabilities | ||
Future policy benefits | 126,035 | 129,182 |
Policyholder account balances | 103,774 | 103,894 |
Market risk benefits, at estimated fair value | 2,391 | 2,878 |
Other policy-related balances | 8,361 | 8,289 |
Policyholder dividends payable | 229 | 233 |
Payables for collateral under securities loaned and other transactions | 11,744 | 11,790 |
Long-term debt | 1,648 | 1,887 |
Other liabilities | 24,228 | 23,719 |
Separate account liabilities | 79,585 | 83,197 |
Total liabilities | 357,995 | 365,069 |
Contingencies, Commitments and Guarantees (Note 15) | ||
Metropolitan Life Insurance Company stockholder’s equity: | ||
Common stock, par value $0.01 per share; 1,000,000,000 shares authorized; 494,466,664 shares issued and outstanding | 5 | 5 |
Additional paid-in capital | 12,475 | 12,475 |
Retained earnings | 7,315 | 7,645 |
Accumulated other comprehensive income (loss) | (6,408) | (6,872) |
Total Metropolitan Life Insurance Company stockholder’s equity | 13,387 | 13,253 |
Noncontrolling interests | 492 | 363 |
Total equity | 13,879 | 13,616 |
Total liabilities and equity | $ 371,874 | $ 378,685 |
Consolidated Balance Sheets (_2
Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Assets | ||
Amortized cost of fixed maturity securities valuation allowances | $ 77 | $ 132 |
Amortized Cost | 154,560 | 152,080 |
Mortgage loans valuation allowances | 533 | 509 |
Mortgage loans (net of allowance for credit loss of $533 and $509, respectively; includes $191 and $166, respectively, relating to variable interest entities) | 60,577 | 62,584 |
Real estate and real estate joint ventures - FVO | 9,069 | 8,690 |
Other Invested Assets - Leveraged and Direct Financing Leases | 768 | 805 |
Other invested assets - VIE | $ 16,865 | $ 17,040 |
Metropolitan Life Insurance Company stockholder’s equity: | ||
Common stock, par value | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 1,000,000,000 | 1,000,000,000 |
Common stock, shares issued | 494,466,664 | 494,466,664 |
Common stock, shares outstanding | 494,466,664 | 494,466,664 |
Residential mortgage loans — FVO | ||
Assets | ||
Real estate and real estate joint ventures - FVO | $ 321 | $ 317 |
Variable Interest Entity | ||
Assets | ||
Mortgage loans (net of allowance for credit loss of $533 and $509, respectively; includes $191 and $166, respectively, relating to variable interest entities) | 191 | 166 |
Real estate and real estate joint ventures - FVO | 1,739 | 1,427 |
Other invested assets - VIE | $ 138 | $ 117 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Revenues | ||||
Premiums | $ 7,366 | $ 5,953 | $ 13,580 | $ 11,802 |
Universal life and investment-type product policy fees | 381 | 422 | 740 | 852 |
Net investment income | 2,903 | 2,873 | 5,760 | 5,558 |
Other revenues | 447 | 419 | 902 | 834 |
Net investment gains (losses) | (106) | (659) | (242) | (761) |
Net derivative gains (losses) | 60 | (232) | 4 | (792) |
Total revenues | 11,051 | 8,776 | 20,744 | 17,493 |
Expenses | ||||
Policyholder benefits and claims | 7,525 | 6,436 | 14,215 | 12,659 |
Policyholder liability remeasurement (gains) losses | 3 | 17 | 16 | (40) |
Market risk benefit remeasurement (gains) losses | (130) | (670) | (716) | (426) |
Interest credited to policyholder account balances | 957 | 893 | 1,880 | 1,724 |
Policyholder dividends | 112 | 116 | 227 | 239 |
Other expenses | 1,405 | 1,396 | 2,794 | 2,944 |
Total expenses | 9,872 | 8,188 | 18,416 | 17,100 |
Income (loss) before provision for income tax | 1,179 | 588 | 2,328 | 393 |
Provision for income tax expense (benefit) | 228 | 78 | 442 | (26) |
Net income (loss) | 951 | 510 | 1,886 | 419 |
Less: Net income (loss) attributable to noncontrolling interests | 0 | 43 | (3) | 41 |
Net income (loss) attributable to Metropolitan Life Insurance Company | 951 | 467 | 1,889 | 378 |
Comprehensive income (loss) | 1,271 | (81) | 2,350 | 1,317 |
Less: Comprehensive income (loss) attributable to noncontrolling interests, net of income tax | 0 | 43 | (3) | 42 |
Comprehensive income (loss) attributable to Metropolitan Life Insurance Company | $ 1,271 | $ (124) | $ 2,353 | $ 1,275 |
Consolidated Statements of Equi
Consolidated Statements of Equity (Unaudited) - USD ($) $ in Millions | Total | Cumulative Effect, Period of Adoption, Adjustment | Common Stock | Additional Paid-in Capital | Retained Earnings | Retained Earnings Cumulative Effect, Period of Adoption, Adjustment | Accumulated Other Comprehensive Income (Loss) | Total Metropolitan Life Insurance Company Stockholder’s Equity | Total Metropolitan Life Insurance Company Stockholder’s Equity Cumulative Effect, Period of Adoption, Adjustment | Noncontrolling Interests |
Beginning Balance at Dec. 31, 2022 | $ 13,395 | $ 5 | $ 12,476 | $ 9,022 | $ (8,320) | $ 13,183 | $ 212 | |||
Dividends to MetLife, Inc. | (618) | (618) | (618) | |||||||
Change in equity of noncontrolling interests | 1 | 0 | 1 | |||||||
Net income (loss) | (91) | (89) | (89) | (2) | ||||||
Other comprehensive income (loss), net of income tax | 1,489 | 1,488 | 1,488 | 1 | ||||||
Ending Balance at Mar. 31, 2023 | 14,176 | 5 | 12,476 | 8,315 | (6,832) | 13,964 | 212 | |||
Beginning Balance at Dec. 31, 2022 | 13,395 | 5 | 12,476 | 9,022 | (8,320) | 13,183 | 212 | |||
Net income (loss) | 419 | |||||||||
Ending Balance at Jun. 30, 2023 | 13,599 | 5 | 12,475 | 8,374 | (7,423) | 13,431 | 168 | |||
Beginning Balance at Mar. 31, 2023 | 14,176 | 5 | 12,476 | 8,315 | (6,832) | 13,964 | 212 | |||
Returns of capital | (1) | (1) | (1) | |||||||
Dividends to MetLife, Inc. | (408) | (408) | (408) | |||||||
Change in equity of noncontrolling interests | (87) | 0 | (87) | |||||||
Net income (loss) | 510 | 467 | 467 | 43 | ||||||
Other comprehensive income (loss), net of income tax | (591) | (591) | (591) | |||||||
Ending Balance at Jun. 30, 2023 | 13,599 | 5 | 12,475 | 8,374 | (7,423) | 13,431 | 168 | |||
Beginning Balance at Dec. 31, 2023 | 13,616 | $ (219) | 5 | 12,475 | 7,645 | $ (219) | (6,872) | 13,253 | $ (219) | 363 |
Dividends to MetLife, Inc. | (1,200) | (1,200) | (1,200) | |||||||
Change in equity of noncontrolling interests | 17 | 0 | 17 | |||||||
Net income (loss) | 935 | 938 | 938 | (3) | ||||||
Other comprehensive income (loss), net of income tax | 144 | 144 | 144 | |||||||
Ending Balance at Mar. 31, 2024 | 13,293 | 5 | 12,475 | 7,164 | (6,728) | 12,916 | 377 | |||
Beginning Balance at Dec. 31, 2023 | 13,616 | $ (219) | 5 | 12,475 | 7,645 | $ (219) | (6,872) | 13,253 | $ (219) | 363 |
Net income (loss) | 1,886 | |||||||||
Ending Balance at Jun. 30, 2024 | 13,879 | 5 | 12,475 | 7,315 | (6,408) | 13,387 | 492 | |||
Beginning Balance at Mar. 31, 2024 | 13,293 | 5 | 12,475 | 7,164 | (6,728) | 12,916 | 377 | |||
Dividends to MetLife, Inc. | (800) | (800) | (800) | |||||||
Change in equity of noncontrolling interests | 115 | 0 | 115 | |||||||
Net income (loss) | 951 | 951 | 951 | |||||||
Other comprehensive income (loss), net of income tax | 320 | 320 | 320 | |||||||
Ending Balance at Jun. 30, 2024 | $ 13,879 | $ 5 | $ 12,475 | $ 7,315 | $ (6,408) | $ 13,387 | $ 492 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Statement of Cash Flows [Abstract] | ||
Net cash provided by (used in) operating activities | $ 2,388 | $ 2,088 |
Cash flows from investing activities | ||
Sales, maturities and repayments of fixed maturity securities available-for-sale | 14,256 | 16,676 |
Sales, maturities and repayments of equity securities | 193 | 52 |
Sales, maturities and repayments of mortgage loans | 3,497 | 2,903 |
Sales, maturities and repayments of real estate and real estate joint ventures | 214 | 25 |
Sales, maturities and repayments of other limited partnership interests | 349 | 304 |
Sales, maturities and repayments of short-term investments | 3,424 | 3,018 |
Purchases of fixed maturity securities available-for-sale | (15,274) | (17,635) |
Purchases of equity securities | (177) | (11) |
Purchases of mortgage loans | (2,041) | (4,212) |
Purchases of real estate and real estate joint ventures | (424) | (379) |
Purchases of other limited partnership interests | (220) | (397) |
Purchases of short-term investments | (2,101) | (3,743) |
Cash received in connection with freestanding derivatives | 431 | 381 |
Cash paid in connection with freestanding derivatives | (860) | (1,334) |
Receipts on loans to affiliates | 0 | 100 |
Net change in policy loans | (42) | 37 |
Net change in other invested assets | 85 | (307) |
Other, net | 20 | 20 |
Net cash provided by (used in) investing activities | 1,330 | (4,502) |
Cash flows from financing activities | ||
Policyholder account balances - deposits | 36,757 | 39,547 |
Policyholder account balances - withdrawals | (37,694) | (40,094) |
Net change in payables for collateral under securities loaned and other transactions | (46) | (1,476) |
Long-term debt issued | 0 | 210 |
Long-term debt repaid | (150) | 0 |
Derivatives with certain financing elements and other derivative-related transactions, net | (77) | (50) |
Dividends paid to MetLife, Inc. | (2,000) | (1,026) |
Other, net | 48 | 5 |
Net cash provided by (used in) financing activities | (3,162) | (2,884) |
Effect of change in foreign currency exchange rates on cash and cash equivalents balances | (2) | (1) |
Change in cash and cash equivalents | 554 | (5,299) |
Cash and cash equivalents, beginning of period | 6,795 | 9,405 |
Cash and cash equivalents, end of period | 7,349 | 4,106 |
Supplemental disclosures of cash flow information | ||
Net cash paid for Interest | 66 | 62 |
Net cash paid (received) for Income tax | 372 | 216 |
Non-cash transactions: | ||
Fixed maturity securities available-for-sale received from an affiliate | 0 | 502 |
Fixed maturity securities available-for-sale received in connection with pension risk transfer transactions | 876 | 0 |
Real estate and real estate joint ventures acquired in satisfaction of debt | 290 | 8 |
Other invested assets received in connection with the sale of other limited partnership interests | 297 | 0 |
Policyholder account balances received in connection with affiliated reinsurance transactions | $ 0 | $ 502 |
Business, Basis of Presentation
Business, Basis of Presentation and Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2024 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Business, Basis of Presentation and Summary of Significant Accounting Policies | 1. Business, Basis of Presentation and Summary of Significant Accounting Policies Business Metropolitan Life Insurance Company and its subsidiaries (collectively, “MLIC” or the “Company”) is a provider of insurance, annuities, employee benefits and asset management and is organized into three segments: Group Benefits, Retirement and Income Solutions (“RIS”), and MetLife Holdings. Metropolitan Life Insurance Company is a wholly-owned subsidiary of MetLife, Inc. (MetLife, Inc., together with its subsidiaries and affiliates, “MetLife”). Basis of Presentation The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the interim condensed consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company’s business and operations. Actual results could differ from these estimates. The accompanying interim condensed consolidated financial statements are unaudited and reflect all adjustments (including normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in conformity with GAAP. Interim results are not necessarily indicative of full year performance. The December 31, 2023 consolidated balance sheet data was derived from audited consolidated financial statements included in Metropolitan Life Insurance Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”), which include all disclosures required by GAAP. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company included in the 2023 Annual Report. Consolidation The accompanying interim condensed consolidated financial statements include the accounts of Metropolitan Life Insurance Company and its subsidiaries, as well as partnerships and joint ventures in which the Company has a controlling financial interest, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany accounts and transactions have been eliminated. The Company uses the equity method of accounting, unless the fair value option (“FVO”) is applied, for real estate joint ventures and other limited partnership interests (“investee”) when it has more than a minor ownership interest or more than a minor influence over the investee’s operations. The Company generally recognizes its share of the investee’s earnings in net investment income on a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period. Since the Company is a member of a controlled group of affiliated companies, its results may not be indicative of those of a stand-alone entity. Recent Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (each, an “ASU”) to the FASB Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. The following tables provide a description of ASUs recently issued by the FASB and the impact of their adoption on the Company’s consolidated financial statements. Adopted Accounting Pronouncements The table below describes the impacts of ASUs adopted by the Company. Standard Description Effective Date and Impact on Financial Statements ASU 2023-02, Investments—Equity Method and Joint Ventures (Topic 323): Accounting for Investments in Tax Credit Structures Using the Proportional Amortization Method The amendments in this update permit reporting entities to elect to account for their tax equity investments, regardless of the tax credit program from which the income tax credits are received, using the proportional amortization method if certain conditions are met. In addition, disclosures describing the nature of the investments and related income tax credits and benefits will be required. January 1, 2024. The Company adopted this update, applying a modified retrospective basis. The Company has elected to use the proportional amortization method to account for its tax equity investments that meet the required criteria. The adoption of this update resulted in a decrease to retained earnings of $219 million, net of income tax, primarily related to the Company’s tax equity investments reported within other invested assets, as of January 1, 2024. Future Adoption of Accounting Pronouncements ASUs not listed below were assessed and either determined to be not applicable or are not expected to have a material impact on the Company’s consolidated financial statements or disclosures. ASUs issued but not yet adopted as of June 30, 2024 that are currently being assessed and may or may not have a material impact on the Company’s consolidated financial statements or disclosures are summarized in the table below. Standard Description Effective Date and Impact on Financial Statements ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures Among other things, the amendments in this update require that public business entities, on an annual basis: (i) disclose specific categories in the rate reconciliation; and (ii) provide additional information for reconciling items that meet a quantitative threshold. In addition, the amendments in this update require that all entities disclose on an annual basis the following information about income taxes paid: (i) the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes; and (ii) the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than five percent of total income taxes paid (net of refunds received). Effective for annual periods beginning January 1, 2025, to be applied prospectively with an option for retrospective application (with early adoption permitted). The Company is evaluating the impact of the guidance on its consolidated financial statements. ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures The amendments in this update are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The key amendments include: (i) disclosures on significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss on an annual and interim basis; (ii) disclosures on an amount for other segment items by reportable segment and a description of its composition on an annual and interim basis. The other segment items category is the difference between segment revenue less the significant expenses disclosed and each reported measure of segment profit or loss; (iii) providing all annual disclosures on a reportable segment’s profit or loss and assets currently required by FASB ASC Topic 280, Segment Reporting in interim periods; and (iv) specifying the title and position of the CODM. Effective for annual periods beginning January 1, 2024 and interim periods beginning January 1, 2025, to be applied on a retrospective basis unless it is impracticable (with early adoption permitted). The Company is evaluating the impact of the guidance on its consolidated financial statements. |
Segment Information
Segment Information | 6 Months Ended |
Jun. 30, 2024 | |
Segment Reporting [Abstract] | |
Segment Information | 2. Segment Information In the fourth quarter of 2023, MLIC reorganized from two segments into the following three segments to reflect changes in management’s responsibilities: Group Benefits, RIS and MetLife Holdings. The Group Benefits and RIS businesses were previously reported as the U.S. segment. These changes were applied retrospectively and did not have an impact on prior period total consolidated net income (loss) or adjusted earnings. In addition, the Company continues to report certain of its results of operations in Corporate & Other. Group Benefits The Group Benefits segment, based in the U.S., offers a broad range of products to corporations and their respective employees, other institutions and their respective members, as well as individuals. These products include term, variable and universal life insurance, dental, group and individual disability and accident & health insurance. RIS The RIS segment, based in the U.S., offers a broad range of life and annuity-based insurance and investment products to corporations and their respective employees, other institutions and their respective members, as well as individuals. These products include stable value and pension risk transfer products, institutional income annuities, structured settlements, benefit funding solutions and capital markets investment products. MetLife Holdings The MetLife Holdings segment consists of operations relating to products and businesses that the Company no longer actively markets in the U.S. These include variable, universal, term and whole life insurance, variable, fixed and index-linked annuities and long-term care insurance. Corporate & Other Corporate & Other contains various start-up, developing and run-off businesses, including the Company’s ancillary non-U.S. operations. Also included in Corporate & Other are: the excess capital, as well as certain charges and activities, not allocated to the segments (including enterprise-wide strategic initiatives), interest expense related to the majority of the Company’s outstanding debt, expenses associated with certain legal proceedings and income tax audit issues, and the elimination of intersegment amounts (which generally relate to intersegment loans bearing interest rates commensurate with related borrowings). Financial Measures and Segment Accounting Policies Adjusted earnings is used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings is also the Company’s GAAP measure of segment performance and is reported below. Adjusted earnings should not be viewed as a substitute for net income (loss). The Company believes the presentation of adjusted earnings, as the Company measures it for management purposes, enhances the understanding of its performance by highlighting the results of operations and the underlying profitability drivers of the business. Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. These financial measures focus on the Company’s primary businesses principally by excluding the impact of (i) market volatility which could distort trends, (ii) asymmetrical and non-economic accounting, and (iii) revenues and costs related to divested businesses, non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP. Market volatility can have a significant impact on the Company’s financial results. Adjusted earnings excludes net investment gains (losses), net derivative gains (losses), market risk benefits (“MRBs”) remeasurement gains (losses) and goodwill impairments. Further, policyholder benefits and claims exclude (i) changes in the discount rate on certain annuitization guarantees accounted for as additional liabilities, and (ii) market value adjustments. Asymmetrical and non-economic accounting adjustments are made to the line items indicated in calculating adjusted earnings: • Net investment income includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment. • Other revenues include settlements of foreign currency earnings hedges and exclude asymmetrical accounting associated with in-force reinsurance. • Policyholder benefits and claims excludes (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits (“FPBs”), (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments, (iii) asymmetrical accounting associated with in-force reinsurance, and (iv) non-economic losses incurred at contract inception for certain single premium annuity business. These losses are amortized into adjusted earnings within policyholder benefits and claims over the estimated lives of the contracts . • Interest credited to policyholder account balances (“PABs”) excludes amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments and asymmetrical accounting associated with in-force reinsurance. Divested businesses are those that have been or will be sold or exited by MLIC but do not meet the discontinued operations criteria under GAAP. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MLIC that do not meet the criteria to be included in results of discontinued operations under GAAP. Other adjustments are made to the line items indicated in calculating adjusted earnings: • Net investment income and interest credited to PABs excludes certain amounts related to contractholder-directed equity securities . • Other revenues include fee revenue on synthetic guaranteed interest contracts (“GICs”) accounted for as freestanding derivatives . • Other revenues exclude and other expenses include fees received in connection with services provided under transition service agreements . • Other expenses exclude (i) implementation of new insurance regulatory requirements and other costs, and (ii) acquisition, integration and other related costs. Other expenses include (i) deductions for net income attributable to noncontrolling interests, and (ii) benefits accrued on synthetic GICs accounted for as freestanding derivatives. Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance . The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from the Company’s effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms. Set forth in the tables below is certain financial information with respect to the Company’s segments, as well as Corporate & Other, for the three months and six months ended June 30, 2024 and 2023. The segment accounting policies are the same as those used to prepare the Company’s interim condensed consolidated financial statements, except for adjusted earnings adjustments as defined above. In addition, segment accounting policies include the method of capital allocation described below. Economic capital is an internally developed risk capital model, the purpose of which is to measure the risk in the business and to provide a basis upon which capital is deployed. The economic capital model accounts for the unique and specific nature of the risks inherent in MetLife’s and the Company’s businesses. MetLife’s economic capital model, coupled with considerations of local capital requirements, aligns segment allocated equity with emerging standards and consistent risk principles. The model applies statistics-based risk evaluation principles to the material risks to which the Company is exposed. These consistent risk principles include calibrating required economic capital shock factors to a specific confidence level and time horizon while applying an industry standard method for the inclusion of diversification benefits among risk types. MetLife’s management is responsible for the ongoing production and enhancement of the economic capital model and reviews its approach periodically to ensure that it remains consistent with emerging industry practice standards. Segment net investment income is credited or charged based on the level of allocated equity; however, changes in allocated equity do not impact the Company’s consolidated net investment income, net income (loss) or adjusted earnings. Net investment income is based upon the actual results of each segment’s specifically identifiable investment portfolios adjusted for allocated equity. Other costs are allocated to each of the segments based upon: (i) a review of the nature of such costs; (ii) time studies analyzing the amount of employee compensation costs incurred by each segment; and (iii) cost estimates included in the Company’s product pricing. Three Months Ended June 30, 2024 Group Benefits RIS MetLife Corporate Total Adjustments Total (In millions) Revenues Premiums $ 5,337 $ 1,455 $ 572 $ 2 $ 7,366 $ — $ 7,366 Universal life and investment-type product policy fees 229 59 88 5 381 — 381 Net investment income 303 1,679 921 116 3,019 (116) 2,903 Other revenues 189 70 37 123 419 28 447 Net investment gains (losses) — — — — — (106) (106) Net derivative gains (losses) — — — — — 60 60 Total revenues 6,058 3,263 1,618 246 11,185 (134) 11,051 Expenses Policyholder benefits and claims and policyholder dividends 4,488 2,099 1,064 1 7,652 (15) 7,637 Policyholder liability remeasurement (gains) losses 1 (14) 16 — 3 — 3 MRB remeasurement (gains) losses — — — — — (130) (130) Interest credited to PABs 48 708 99 84 939 18 957 Capitalization of deferred policy acquisition costs (“DAC”) (3) (25) 1 — (27) — (27) Amortization of DAC and value of business acquired (“VOBA”) 7 9 49 3 68 — 68 Interest expense on debt 1 3 3 23 30 — 30 Other expenses 885 100 193 155 1,333 1 1,334 Total expenses 5,427 2,880 1,425 266 9,998 (126) 9,872 Provision for income tax expense (benefit) 131 80 38 (21) 228 — 228 Adjusted earnings $ 500 $ 303 $ 155 $ 1 959 Adjustments to: Total revenues (134) Total expenses 126 Provision for income tax (expense) benefit — Net income (loss) $ 951 $ 951 Three Months Ended June 30, 2023 Group Benefits RIS MetLife Corporate & Other Total Adjustments Total Consolidated (In millions) Revenues Premiums $ 5,189 $ 179 $ 585 $ — $ 5,953 $ — $ 5,953 Universal life and investment-type product policy fees 223 60 138 1 422 — 422 Net investment income 320 1,660 1,044 46 3,070 (197) 2,873 Other revenues 181 69 50 122 422 (3) 419 Net investment gains (losses) — — — — — (659) (659) Net derivative gains (losses) — — — — — (232) (232) Total revenues 5,913 1,968 1,817 169 9,867 (1,091) 8,776 Expenses Policyholder benefits and claims and policyholder dividends 4,588 837 1,123 1 6,549 3 6,552 Policyholder liability remeasurement (gains) losses 3 (8) 22 — 17 — 17 MRB remeasurement (gains) losses — — — — — (670) (670) Interest credited to PABs 48 609 156 81 894 (1) 893 Capitalization of DAC (5) (5) 1 (3) (12) — (12) Amortization of DAC and VOBA 7 7 56 4 74 — 74 Interest expense on debt 1 3 3 27 34 — 34 Other expenses 837 83 187 247 1,354 (54) 1,300 Total expenses 5,479 1,526 1,548 357 8,910 (722) 8,188 Provision for income tax expense (benefit) 92 92 53 (80) 157 (79) 78 Adjusted earnings $ 342 $ 350 $ 216 $ (108) 800 Adjustments to: Total revenues (1,091) Total expenses 722 Provision for income tax (expense) benefit 79 Net income (loss) $ 510 $ 510 Six Months Ended June 30, 2024 Group Benefits RIS MetLife Corporate & Other Total Adjustments Total Consolidated (In millions) Revenues Premiums $ 10,804 $ 1,631 $ 1,144 $ 1 $ 13,580 $ — $ 13,580 Universal life and investment-type product policy fees 451 124 158 7 740 — 740 Net investment income 608 3,355 1,831 206 6,000 (240) 5,760 Other revenues 378 132 87 245 842 60 902 Net investment gains (losses) — — — — — (242) (242) Net derivative gains (losses) — — — — — 4 4 Total revenues 12,241 5,242 3,220 459 21,162 (418) 20,744 Expenses Policyholder benefits and claims and policyholder dividends 9,433 2,926 2,110 1 14,470 (28) 14,442 Policyholder liability remeasurement (gains) losses (2) (22) 40 — 16 — 16 MRB remeasurement (gains) losses — — — — — (716) (716) Interest credited to PABs 96 1,384 193 167 1,840 40 1,880 Capitalization of DAC (7) (46) 1 — (52) — (52) Amortization of DAC and VOBA 13 17 99 9 138 — 138 Interest expense on debt 1 7 7 47 62 — 62 Other expenses 1,757 202 393 290 2,642 4 2,646 Total expenses 11,291 4,468 2,843 514 19,116 (700) 18,416 Provision for income tax expense (benefit) 200 162 74 (55) 381 61 442 Adjusted earnings $ 750 $ 612 $ 303 $ — 1,665 Adjustments to: Total revenues (418) Total expenses 700 Provision for income tax (expense) benefit (61) Net income (loss) $ 1,886 $ 1,886 Six Months Ended June 30, 2023 Group Benefits RIS MetLife Corporate & Other Total Adjustments Total Consolidated (In millions) Revenues Premiums $ 10,405 $ 233 $ 1,163 $ 1 $ 11,802 $ — $ 11,802 Universal life and investment-type product policy fees 441 127 283 1 852 — 852 Net investment income 623 3,211 2,033 89 5,956 (398) 5,558 Other revenues 360 132 106 244 842 (8) 834 Net investment gains (losses) — — — — — (761) (761) Net derivative gains (losses) — — — — — (792) (792) Total revenues 11,829 3,703 3,585 335 19,452 (1,959) 17,493 Expenses Policyholder benefits and claims and policyholder dividends 9,282 1,370 2,239 1 12,892 6 12,898 Policyholder liability remeasurement (gains) losses (1) (76) 37 — (40) — (40) MRB remeasurement (gains) losses — — — — — (426) (426) Interest credited to PABs 94 1,172 311 147 1,724 — 1,724 Capitalization of DAC (11) (24) 1 (55) (89) — (89) Amortization of DAC and VOBA 13 15 115 8 151 — 151 Interest expense on debt 1 6 6 51 64 — 64 Other expenses 1,646 380 393 448 2,867 (49) 2,818 Total expenses 11,024 2,843 3,102 600 17,569 (469) 17,100 Provision for income tax expense (benefit) 170 179 94 (155) 288 (314) (26) Adjusted earnings $ 635 $ 681 $ 389 $ (110) 1,595 Adjustments to: Total revenues (1,959) Total expenses 469 Provision for income tax (expense) benefit 314 Net income (loss) $ 419 $ 419 The following table presents total assets with respect to the Company’s segments, as well as Corporate & Other, at: June 30, 2024 December 31, 2023 (In millions) Group Benefits $ 33,669 $ 34,185 RIS 177,906 180,625 MetLife Holdings 129,230 133,219 Corporate & Other 31,069 30,656 Total $ 371,874 $ 378,685 |
Future Policy Benefits
Future Policy Benefits | 6 Months Ended |
Jun. 30, 2024 | |
Insurance [Abstract] | |
Liability for Future Policy Benefits and Unpaid Claims Disclosure | 3. Future Policy Benefits The Company establishes liabilities for amounts payable under insurance policies. These liabilities are comprised of traditional and limited-payment contracts and associated deferred profit liability (“DPL”), additional insurance liabilities, participating life and short-duration contracts. The Company’s FPBs on the interim condensed consolidated balance sheets was as follows at: June 30, 2024 December 31, 2023 (In millions) Traditional and Limited-Payment Contracts: RIS - Annuities $ 46,998 $ 48,695 MetLife Holdings - Long-term care 14,455 15,240 Deferred Profit Liabilities: RIS - Annuities 3,005 3,000 Additional Insurance Liabilities: MetLife Holdings - Universal and variable universal life 1,913 1,841 MetLife Holdings - Participating life 43,039 43,586 Other long-duration (1) 6,278 6,605 Short-duration and other 10,347 10,215 Total $ 126,035 $ 129,182 __________________ Rollforwards - Traditional and Limited-Payment Contracts The following information about the direct and assumed liability for FPBs includes disaggregated rollforwards of expected future net premiums and expected future benefits. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. The adjusted balance in each disaggregated rollforward reflects the remeasurement (gains) losses. All amounts presented in the rollforwards and accompanying financial information do not include a reduction for amounts ceded to reinsurers, except with respect to ending net liability for FPB balances where applicable. RIS - Annuities The RIS segment’s annuity products include pension risk transfers, certain structured settlements and certain institutional income annuities, which are mainly single premium spread-based products. Information regarding these products was as follows: Six Months 2024 2023 (Dollars in millions) Present Value of Expected Net Premiums Balance, beginning of period, at current discount rate at balance sheet date $ — $ — Balance, beginning of period, at original discount rate $ — $ — Effect of actual variances from expected experience (1) (2) 2 Adjusted balance (2) 2 Issuances 1,575 183 Net premiums collected (1,573) (185) Ending balance at original discount rate — — Balance, end of period, at current discount rate at balance sheet date $ — $ — Present Value of Expected FPBs Balance, beginning of period, at current discount rate at balance sheet date $ 48,886 $ 48,190 Balance, beginning of period, at original discount rate $ 47,991 $ 49,194 Effect of actual variances from expected experience (1) (55) (299) Adjusted balance 47,936 48,895 Issuances 1,572 183 Interest accrual 1,197 1,196 Benefit payments (2,224) (2,386) Ending balance at original discount rate 48,481 47,888 Effect of changes in discount rate assumptions (1,146) (385) Balance, end of period, at current discount rate at balance sheet date 47,335 47,503 Cumulative amount of fair value hedging adjustments (337) (204) Net liability for FPBs $ 46,998 $ 47,299 Undiscounted - Expected future benefit payments $ 90,171 $ 93,997 Discounted - Expected future benefit payments (at current discount rate at balance sheet date) $ 47,335 $ 47,503 Weighted-average duration of the liability 9 years 9 years Weighted-average interest accretion (original locked-in) rate 5.1 % 5.1 % Weighted-average current discount rate at balance sheet date 5.6 % 5.4 % __________________ (1) For the six months ended June 30, 2024, the net effect of actual variances from expected experience was partially offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $30 million. For the six months ended June 30, 2023, the net effect of actual variances from expected experience was largely offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $225 million. Excluding the corresponding impact in DPL, for the six months ended June 30, 2023, the net effect of actual variances from expected experience was primarily driven by favorable mortality and the amendment of an affiliated reinsurance treaty. MetLife Holdings - Long-term Care The MetLife Holdings segment’s long-term care products offer protection against potentially high costs of long-term health care services. Information regarding these products was as follows: Six Months 2024 2023 (Dollars in millions) Present Value of Expected Net Premiums Balance, beginning of period, at current discount rate at balance sheet date $ 5,687 $ 5,775 Balance, beginning of period, at original discount rate $ 5,566 $ 5,807 Effect of actual variances from expected experience 13 83 Adjusted balance 5,579 5,890 Interest accrual 141 149 Net premiums collected (286) (293) Ending balance at original discount rate 5,434 5,746 Effect of changes in discount rate assumptions (80) 3 Balance, end of period, at current discount rate at balance sheet date $ 5,354 $ 5,749 Present Value of Expected FPBs Balance, beginning of period, at current discount rate at balance sheet date $ 20,927 $ 19,619 Balance, beginning of period, at original discount rate $ 20,494 $ 20,165 Effect of actual variances from expected experience 31 99 Adjusted balance 20,525 20,264 Interest accrual 540 534 Benefit payments (421) (382) Ending balance at original discount rate 20,644 20,416 Effect of changes in discount rate assumptions (835) (169) Balance, end of period, at current discount rate at balance sheet date 19,809 20,247 Net liability for FPBs $ 14,455 $ 14,498 Undiscounted: Expected future gross premiums $ 10,280 $ 10,893 Expected future benefit payments $ 44,653 $ 45,653 Discounted (at current discount rate at balance sheet date): Expected future gross premiums $ 6,715 $ 7,089 Expected future benefit payments $ 19,809 $ 20,247 Weighted-average duration of the liability 14 years 15 years Weighted-average interest accretion (original locked-in) rate 5.4 % 5.4 % Weighted-average current discount rate at balance sheet date 5.8 % 5.5 % Rollforward - Additional Insurance Liabilities The Company establishes additional insurance liabilities for annuitization, death or other insurance benefits for universal life and variable universal life contract features where the Company guarantees to the contractholder either a secondary guarantee or a guaranteed paid-up benefit. The policy can remain in force, even if the base policy account value is zero, as long as contractual secondary guarantee requirements have been met. The following information about the direct liability for additional insurance liabilities includes a disaggregated rollforward. The products grouped within the rollforward were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. The adjusted balance in the disaggregated rollforward reflects the remeasurement (gains) losses. All amounts presented in the rollforward and accompanying financial information do not include a reduction for amounts ceded to reinsurers. MetLife Holdings The MetLife Holdings segment’s universal life and variable universal life products offer a contract feature where the Company guarantees to the contractholder a secondary guarantee or a guaranteed paid-up benefit. Information regarding these additional insurance liabilities was as follows: Six Months 2024 2023 Universal and Variable Universal Life (Dollars in millions) Balance, beginning of period $ 1,841 $ 1,642 Less: Accumulated other comprehensive income (loss) (“AOCI”) adjustment (14) (63) Balance, beginning of period, before AOCI adjustment 1,855 1,705 Effect of actual variances from expected experience 18 6 Adjusted balance 1,873 1,711 Assessments accrual 44 47 Interest accrual 48 44 Excess benefits paid (36) (41) Balance, end of period, before AOCI adjustment 1,929 1,761 Add: AOCI adjustment (16) 2 Balance, end of period 1,913 1,763 Less: Reinsurance recoverables 1,913 649 Balance, end of period, net of reinsurance $ — $ 1,114 Weighted-average duration of the liability 16 years 17 years Weighted-average interest accretion rate 5.2 % 5.2 % The Company’s gross premiums or assessments and interest expense recognized in the interim condensed consolidated statements of operations and comprehensive income (loss) for long-duration contracts, excluding MetLife Holdings’ participating life contracts, were as follows: Six Months 2024 2023 Gross Premiums or Assessments (1) Interest Expense (2) Gross Premiums or Assessments (1) Interest Expense (2) (In millions) Traditional and Limited-Payment Contracts: RIS - Annuities $ 1,613 $ 1,197 $ 168 $ 1,196 MetLife Holdings - Long-term care 362 399 366 385 Deferred Profit Liabilities: RIS - Annuities N/A 74 N/A 70 Additional Insurance Liabilities: MetLife Holdings - Universal and variable universal life 198 48 236 44 Other long-duration 374 153 400 152 Total $ 2,547 $ 1,871 $ 1,170 $ 1,847 __________________ (1) Gross premiums are related to traditional and limited-payment contracts and are included in premiums. Assessments are related to additional insurance liabilities and are included in universal life and investment-type product policy fees and net investment income. (2) Interest expense is included in policyholder benefits and claims. Liabilities for Unpaid Claims and Claim Expenses Rollforward of Claims and Claim Adjustment Expenses Information regarding the liabilities for unpaid claims and claim adjustment expenses was as follows: Six Months 2024 2023 (In millions) Balance, beginning of period $ 11,609 $ 11,300 Less: Reinsurance recoverables 1,740 1,633 Net balance, beginning of period 9,869 9,667 Incurred related to: Current period 10,373 10,270 Prior periods (1) (240) (32) Total incurred 10,133 10,238 Paid related to: Current period (6,108) (5,919) Prior periods (4,073) (4,020) Total paid (10,181) (9,939) Net balance, end of period 9,821 9,966 Add: Reinsurance recoverables 1,998 1,794 Balance, end of period (included in FPBs and other policy-related balances) $ 11,819 $ 11,760 __________________ (1) For the six months ended June 30, 2024 and 2023, incurred claims and claim adjustment expenses associated with prior periods decreased due to favorable claims experience in the respective current period. |
Policyholder Account Balances
Policyholder Account Balances | 6 Months Ended |
Jun. 30, 2024 | |
Insurance [Abstract] | |
Policyholder Account Balances | 4. Policyholder Account Balances The Company establishes liabilities for PABs, which are generally equal to the account value, and which includes accrued interest credited, but excludes the impact of any applicable charge that may be incurred upon surrender. The Company’s PABs on the interim condensed consolidated balance sheets were as follows at: June 30, 2024 December 31, 2023 (In millions) Group Benefits - Group life $ 7,487 $ 7,605 RIS: Capital markets investment products and stable value GICs 59,253 58,554 Annuities and risk solutions 10,991 10,650 MetLife Holdings - Annuities 10,118 10,888 Other 15,925 16,197 Total $ 103,774 $ 103,894 Rollforwards The following information about the direct and assumed liability for PABs includes year-to-date disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. Policy charges presented in each disaggregated rollforward reflect a premium and/or assessment based on the account balance. Group Benefits Group Life The Group Benefits segment’s group life PABs predominantly consist of retained asset accounts, universal life products, and the fixed account of variable life insurance products. Information regarding this liability was as follows: Six Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 7,605 $ 7,954 Deposits 1,799 1,644 Policy charges (327) (318) Surrenders and withdrawals (1,676) (1,573) Benefit payments (6) (6) Net transfers from (to) separate accounts (3) 1 Interest credited 95 93 Balance, end of period $ 7,487 $ 7,795 Weighted-average annual crediting rate 2.6 % 2.4 % At period end: Cash surrender value $ 7,427 $ 7,732 Net amount at risk, excluding offsets from reinsurance: In the event of death $ 264,497 $ 251,590 The Group Benefits segment’s group life product account values by range of guaranteed minimum crediting rates (“GMCR”) and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or greater than 0.50% but less than 1.50% Equal to or greater than 1.50% above GMCR Total (In millions) June 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ 819 $ 4,574 $ 5,393 Equal to or greater than 2% but less than 4% 1,217 9 59 1 1,286 Equal to or greater than 4% 697 — 39 34 770 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 38 Total $ 1,914 $ 9 $ 917 $ 4,609 $ 7,487 June 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 910 $ 4,615 $ 5,525 Equal to or greater than 2% but less than 4% 1,252 10 63 2 1,327 Equal to or greater than 4% 746 1 43 34 824 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 119 Total $ 1,998 $ 11 $ 1,016 $ 4,651 $ 7,795 RIS Capital Markets Investment Products and Stable Value GICs The RIS segment’s capital markets investment products and stable value GICs in PABs are investment-type products, mainly funding agreements. Information regarding this liability was as follows: Six Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 58,554 $ 58,508 Deposits 33,817 34,800 Surrenders and withdrawals (33,744) (36,458) Interest credited 1,066 890 Effect of foreign currency translation and other, net (440) 750 Balance, end of period $ 59,253 $ 58,490 Weighted-average annual crediting rate 3.7 % 3.1 % Cash surrender value at period end $ 1,445 $ 1,776 The RIS segment’s capital markets investment products and stable value GICs account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or greater than 0.50% but less than 1.50% Equal to or greater than 1.50% above GMCR Total (In millions) June 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ — $ 2,647 $ 2,647 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 56,606 Total $ — $ — $ — $ 2,647 $ 59,253 June 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 1 $ 2,595 $ 2,596 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 55,894 Total $ — $ — $ 1 $ 2,595 $ 58,490 Annuities and Risk Solutions The RIS segment’s annuity and risk solutions PABs include certain structured settlements and institutional income annuities, and benefit funding solutions that include postretirement benefits and company-, bank- or trust-owned life insurance used to finance nonqualified benefit programs for executives. Information regarding this liability was as follows: Six Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 10,650 $ 10,244 Deposits 657 348 Policy charges (57) (87) Surrenders and withdrawals (186) (88) Benefit payments (287) (271) Net transfers from (to) separate accounts 20 54 Interest credited 225 213 Other (31) (9) Balance, end of period $ 10,991 $ 10,404 Weighted-average annual crediting rate 4.2 % 4.2 % At period end: Cash surrender value $ 6,952 $ 6,672 Net amount at risk, excluding offsets from ceded reinsurance: In the event of death $ 35,769 $ 36,065 The RIS segment’s annuity and risk solutions account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or greater than 0.50% but less than 1.50% Equal to or greater than 1.50% above GMCR Total (In millions) June 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ 19 $ 1,748 $ 1,767 Equal to or greater than 2% but less than 4% 201 35 11 421 668 Equal to or greater than 4% 3,509 — 268 5 3,782 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 4,774 Total $ 3,710 $ 35 $ 298 $ 2,174 $ 10,991 June 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 53 $ 1,406 $ 1,459 Equal to or greater than 2% but less than 4% 227 35 44 448 754 Equal to or greater than 4% 3,673 117 14 6 3,810 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 4,381 Total $ 3,900 $ 152 $ 111 $ 1,860 $ 10,404 MetLife Holdings Annuities The MetLife Holdings segment’s annuity PABs primarily include fixed deferred annuities, the fixed account portion of variable annuities, certain income annuities, and embedded derivatives related to equity-indexed annuities. Information regarding this liability was as follows: Six Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 10,888 $ 12,598 Deposits 81 129 Policy charges (6) (6) Surrenders and withdrawals (870) (1,004) Benefit payments (206) (218) Net transfers from (to) separate accounts 58 47 Interest credited 166 182 Other 7 13 Balance, end of period $ 10,118 $ 11,741 Weighted-average annual crediting rate 3.2 % 3.0 % At period end: Cash surrender value $ 9,458 $ 10,964 Net amount at risk, excluding offsets from ceded reinsurance (1): In the event of death $ 2,541 $ 3,246 At annuitization or exercise of other living benefits $ 665 $ 770 __________________ (1) Includes amounts for certain variable annuities recorded as PABs with the related guarantees recorded as MRBs which are disclosed in “MetLife Holdings – Annuities” in Note 5. The MetLife Holdings segment’s annuity account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or greater than 0.50% but less than 1.50% Equal to or greater than 1.50% above GMCR Total (In millions) June 30, 2024 Equal to or greater than 0% but less than 2% $ 4 $ 195 $ 446 $ 38 $ 683 Equal to or greater than 2% but less than 4% 1,048 6,754 467 198 8,467 Equal to or greater than 4% 409 145 19 — 573 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 395 Total $ 1,461 $ 7,094 $ 932 $ 236 $ 10,118 June 30, 2023 Equal to or greater than 0% but less than 2% $ 444 $ 158 $ 219 $ 25 $ 846 Equal to or greater than 2% but less than 4% 3,914 5,441 390 72 9,817 Equal to or greater than 4% 609 3 14 — 626 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 452 Total $ 4,967 $ 5,602 $ 623 $ 97 $ 11,741 5. Market Risk Benefits The Company establishes liabilities for variable annuity contract features which include a minimum benefit guarantee that provides to the contractholder a minimum return based on their initial deposit less withdrawals. In some cases, the benefit base may be increased by additional deposits, bonus amounts, accruals or optional market value resets. The Company’s MRB assets and MRB liabilities on the interim condensed consolidated balance sheets were as follows at: June 30, 2024 December 31, 2023 Asset Liability Net Asset Liability Net (In millions) MetLife Holdings - Annuities $ 211 $ 2,366 $ 2,155 $ 156 $ 2,858 $ 2,702 Other 19 25 6 21 20 (1) Total $ 230 $ 2,391 $ 2,161 $ 177 $ 2,878 $ 2,701 Rollforwards The following information about the direct liability for MRBs includes a disaggregated rollforward. The products grouped within this rollforward were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. MetLife Holdings - Annuities The MetLife Holdings segment’s variable annuity products offer contract features where the Company guarantees to the contractholder a minimum benefit, which includes guaranteed minimum death benefits (“GMDBs”) and living benefit guarantees. The GMDB contract features include return of premium, which provides a return of the purchase payment upon death, annual step-up and roll-up and step-up combinations. The living benefit guarantees contract features primarily include guaranteed minimum income benefits (“GMIBs”), which provide a minimum accumulation of purchase payments that can be annuitized to receive a monthly income stream, and guaranteed minimum withdrawal benefits (“GMWBs”), which provide a series of withdrawals, provided that withdrawals in a contract year do not exceed a contractual limit. Information regarding MetLife Holdings annuity products was as follows: Six Months 2024 2023 (In millions) Balance, beginning of period $ 2,702 $ 3,071 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk $ 2,741 $ 3,164 Attributed fees collected 151 160 Benefit payments (44) (21) Effect of changes in interest rates (544) (15) Effect of changes in capital markets (286) (504) Effect of changes in equity index volatility 24 (98) Actual policyholder behavior different from expected behavior 109 44 Effect of foreign currency translation and other, net (1) 30 174 Effect of changes in risk margin (57) (35) Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk 2,124 2,869 Cumulative effect of changes in the instrument-specific credit risk 31 (109) Balance, end of period $ 2,155 $ 2,760 At period end: Net amount at risk, excluding offsets from hedging (2): In the event of death $ 2,541 $ 3,246 At annuitization or exercise of other living benefits $ 665 $ 770 Weighted-average attained age of contractholders: In the event of death 71 years 70 years At annuitization or exercise of other living benefits 71 years 70 years __________________ (1) Included is the covariance impact from aggregating the market observable inputs, mostly driven by interest rate and capital market volatility. (2) Includes amounts for certain variable annuity guarantees recorded as MRBs on contracts also recorded as PABs which are disclosed in “MetLife Holdings – Annuities” in Note 4. Significant Methodologies and Assumptions The Company issues GMDBs, GMWBs, guaranteed minimum accumulation benefits (“GMABs”) and GMIBs that typically meet the definition of MRBs, which are measured in aggregate, as one compound MRB, at estimated fair value separately from the variable annuity contract, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in other comprehensive income (loss) (“OCI”). The Company calculates the fair value of these MRBs, which is estimated as the present value of projected future benefits minus the present value of projected attributed fees, using actuarial and capital market assumptions including expectations concerning policyholder behavior. The calculation is based on in-force business, projecting future cash flows from the MRB over multiple risk neutral stochastic scenarios using observable risk-free rates. Capital market assumptions, such as risk-free rates and implied volatilities, are based on market prices for publicly traded instruments to the extent that prices for such instruments are observable. Implied volatilities beyond the observable period are extrapolated based on observable implied volatilities and historical volatilities. Actuarial assumptions, including mortality, lapse, withdrawal and utilization, are unobservable and are reviewed at least annually based on actuarial studies of historical experience. See Note 11 for additional information on significant unobservable inputs. The valuation of these MRBs includes a nonperformance risk adjustment and adjustments for a risk margin related to non-capital market inputs. The nonperformance adjustment is determined by taking into consideration publicly available information relating to spreads in the secondary market for MetLife, Inc.’s debt, including related credit default swaps. These observable spreads are then adjusted, as necessary, to reflect the priority of these liabilities and the claims paying ability of the issuing insurance subsidiaries as compared to MetLife, Inc. Risk margins are established to capture the non-capital market risks of the instrument which represent the additional compensation a market participant would require to assume the risks related to the uncertainties of such actuarial assumptions at annuitization, premium persistency, partial withdrawal and surrenders. The establishment of risk margins requires the use of significant management judgment, including assumptions of the amount and cost of capital needed to cover the guarantees. These guarantees may be more costly than expected in volatile or declining equity markets. Market conditions, including changes in interest rates, equity indices, market volatility and foreign currency exchange rates; and variations in actuarial assumptions regarding policyholder behavior, mortality and risk margins related to non-capital market inputs, impact the estimated fair value of the guarantees and affect net income, and changes in nonperformance risk of the Company affect OCI. Other In addition to the disaggregated MRB product rollforward above, the Company offers other products with guaranteed minimum benefit features. These MRBs are measured at estimated fair value, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in OCI. See Note 11 for additional information on significant unobservable inputs used in the fair value measurement of MRBs. Information regarding these product liabilities was as follows: Six Months 2024 2023 (In millions) Balance, beginning of period $ (1) $ 25 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk $ 2 $ 34 Attributed fees collected 1 1 Effect of changes in interest rates (6) 2 Actual policyholder behavior different from expected behavior — (26) Effect of foreign currency translation and other, net 12 15 Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk 9 26 Cumulative effect of changes in the instrument-specific credit risk (3) (7) Balance, end of period $ 6 $ 19 |
Market Risk Benefits
Market Risk Benefits | 6 Months Ended |
Jun. 30, 2024 | |
Insurance [Abstract] | |
Market Risk Benefits | 4. Policyholder Account Balances The Company establishes liabilities for PABs, which are generally equal to the account value, and which includes accrued interest credited, but excludes the impact of any applicable charge that may be incurred upon surrender. The Company’s PABs on the interim condensed consolidated balance sheets were as follows at: June 30, 2024 December 31, 2023 (In millions) Group Benefits - Group life $ 7,487 $ 7,605 RIS: Capital markets investment products and stable value GICs 59,253 58,554 Annuities and risk solutions 10,991 10,650 MetLife Holdings - Annuities 10,118 10,888 Other 15,925 16,197 Total $ 103,774 $ 103,894 Rollforwards The following information about the direct and assumed liability for PABs includes year-to-date disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. Policy charges presented in each disaggregated rollforward reflect a premium and/or assessment based on the account balance. Group Benefits Group Life The Group Benefits segment’s group life PABs predominantly consist of retained asset accounts, universal life products, and the fixed account of variable life insurance products. Information regarding this liability was as follows: Six Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 7,605 $ 7,954 Deposits 1,799 1,644 Policy charges (327) (318) Surrenders and withdrawals (1,676) (1,573) Benefit payments (6) (6) Net transfers from (to) separate accounts (3) 1 Interest credited 95 93 Balance, end of period $ 7,487 $ 7,795 Weighted-average annual crediting rate 2.6 % 2.4 % At period end: Cash surrender value $ 7,427 $ 7,732 Net amount at risk, excluding offsets from reinsurance: In the event of death $ 264,497 $ 251,590 The Group Benefits segment’s group life product account values by range of guaranteed minimum crediting rates (“GMCR”) and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or greater than 0.50% but less than 1.50% Equal to or greater than 1.50% above GMCR Total (In millions) June 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ 819 $ 4,574 $ 5,393 Equal to or greater than 2% but less than 4% 1,217 9 59 1 1,286 Equal to or greater than 4% 697 — 39 34 770 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 38 Total $ 1,914 $ 9 $ 917 $ 4,609 $ 7,487 June 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 910 $ 4,615 $ 5,525 Equal to or greater than 2% but less than 4% 1,252 10 63 2 1,327 Equal to or greater than 4% 746 1 43 34 824 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 119 Total $ 1,998 $ 11 $ 1,016 $ 4,651 $ 7,795 RIS Capital Markets Investment Products and Stable Value GICs The RIS segment’s capital markets investment products and stable value GICs in PABs are investment-type products, mainly funding agreements. Information regarding this liability was as follows: Six Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 58,554 $ 58,508 Deposits 33,817 34,800 Surrenders and withdrawals (33,744) (36,458) Interest credited 1,066 890 Effect of foreign currency translation and other, net (440) 750 Balance, end of period $ 59,253 $ 58,490 Weighted-average annual crediting rate 3.7 % 3.1 % Cash surrender value at period end $ 1,445 $ 1,776 The RIS segment’s capital markets investment products and stable value GICs account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or greater than 0.50% but less than 1.50% Equal to or greater than 1.50% above GMCR Total (In millions) June 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ — $ 2,647 $ 2,647 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 56,606 Total $ — $ — $ — $ 2,647 $ 59,253 June 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 1 $ 2,595 $ 2,596 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 55,894 Total $ — $ — $ 1 $ 2,595 $ 58,490 Annuities and Risk Solutions The RIS segment’s annuity and risk solutions PABs include certain structured settlements and institutional income annuities, and benefit funding solutions that include postretirement benefits and company-, bank- or trust-owned life insurance used to finance nonqualified benefit programs for executives. Information regarding this liability was as follows: Six Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 10,650 $ 10,244 Deposits 657 348 Policy charges (57) (87) Surrenders and withdrawals (186) (88) Benefit payments (287) (271) Net transfers from (to) separate accounts 20 54 Interest credited 225 213 Other (31) (9) Balance, end of period $ 10,991 $ 10,404 Weighted-average annual crediting rate 4.2 % 4.2 % At period end: Cash surrender value $ 6,952 $ 6,672 Net amount at risk, excluding offsets from ceded reinsurance: In the event of death $ 35,769 $ 36,065 The RIS segment’s annuity and risk solutions account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or greater than 0.50% but less than 1.50% Equal to or greater than 1.50% above GMCR Total (In millions) June 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ 19 $ 1,748 $ 1,767 Equal to or greater than 2% but less than 4% 201 35 11 421 668 Equal to or greater than 4% 3,509 — 268 5 3,782 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 4,774 Total $ 3,710 $ 35 $ 298 $ 2,174 $ 10,991 June 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 53 $ 1,406 $ 1,459 Equal to or greater than 2% but less than 4% 227 35 44 448 754 Equal to or greater than 4% 3,673 117 14 6 3,810 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 4,381 Total $ 3,900 $ 152 $ 111 $ 1,860 $ 10,404 MetLife Holdings Annuities The MetLife Holdings segment’s annuity PABs primarily include fixed deferred annuities, the fixed account portion of variable annuities, certain income annuities, and embedded derivatives related to equity-indexed annuities. Information regarding this liability was as follows: Six Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 10,888 $ 12,598 Deposits 81 129 Policy charges (6) (6) Surrenders and withdrawals (870) (1,004) Benefit payments (206) (218) Net transfers from (to) separate accounts 58 47 Interest credited 166 182 Other 7 13 Balance, end of period $ 10,118 $ 11,741 Weighted-average annual crediting rate 3.2 % 3.0 % At period end: Cash surrender value $ 9,458 $ 10,964 Net amount at risk, excluding offsets from ceded reinsurance (1): In the event of death $ 2,541 $ 3,246 At annuitization or exercise of other living benefits $ 665 $ 770 __________________ (1) Includes amounts for certain variable annuities recorded as PABs with the related guarantees recorded as MRBs which are disclosed in “MetLife Holdings – Annuities” in Note 5. The MetLife Holdings segment’s annuity account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or greater than 0.50% but less than 1.50% Equal to or greater than 1.50% above GMCR Total (In millions) June 30, 2024 Equal to or greater than 0% but less than 2% $ 4 $ 195 $ 446 $ 38 $ 683 Equal to or greater than 2% but less than 4% 1,048 6,754 467 198 8,467 Equal to or greater than 4% 409 145 19 — 573 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 395 Total $ 1,461 $ 7,094 $ 932 $ 236 $ 10,118 June 30, 2023 Equal to or greater than 0% but less than 2% $ 444 $ 158 $ 219 $ 25 $ 846 Equal to or greater than 2% but less than 4% 3,914 5,441 390 72 9,817 Equal to or greater than 4% 609 3 14 — 626 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 452 Total $ 4,967 $ 5,602 $ 623 $ 97 $ 11,741 5. Market Risk Benefits The Company establishes liabilities for variable annuity contract features which include a minimum benefit guarantee that provides to the contractholder a minimum return based on their initial deposit less withdrawals. In some cases, the benefit base may be increased by additional deposits, bonus amounts, accruals or optional market value resets. The Company’s MRB assets and MRB liabilities on the interim condensed consolidated balance sheets were as follows at: June 30, 2024 December 31, 2023 Asset Liability Net Asset Liability Net (In millions) MetLife Holdings - Annuities $ 211 $ 2,366 $ 2,155 $ 156 $ 2,858 $ 2,702 Other 19 25 6 21 20 (1) Total $ 230 $ 2,391 $ 2,161 $ 177 $ 2,878 $ 2,701 Rollforwards The following information about the direct liability for MRBs includes a disaggregated rollforward. The products grouped within this rollforward were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. MetLife Holdings - Annuities The MetLife Holdings segment’s variable annuity products offer contract features where the Company guarantees to the contractholder a minimum benefit, which includes guaranteed minimum death benefits (“GMDBs”) and living benefit guarantees. The GMDB contract features include return of premium, which provides a return of the purchase payment upon death, annual step-up and roll-up and step-up combinations. The living benefit guarantees contract features primarily include guaranteed minimum income benefits (“GMIBs”), which provide a minimum accumulation of purchase payments that can be annuitized to receive a monthly income stream, and guaranteed minimum withdrawal benefits (“GMWBs”), which provide a series of withdrawals, provided that withdrawals in a contract year do not exceed a contractual limit. Information regarding MetLife Holdings annuity products was as follows: Six Months 2024 2023 (In millions) Balance, beginning of period $ 2,702 $ 3,071 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk $ 2,741 $ 3,164 Attributed fees collected 151 160 Benefit payments (44) (21) Effect of changes in interest rates (544) (15) Effect of changes in capital markets (286) (504) Effect of changes in equity index volatility 24 (98) Actual policyholder behavior different from expected behavior 109 44 Effect of foreign currency translation and other, net (1) 30 174 Effect of changes in risk margin (57) (35) Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk 2,124 2,869 Cumulative effect of changes in the instrument-specific credit risk 31 (109) Balance, end of period $ 2,155 $ 2,760 At period end: Net amount at risk, excluding offsets from hedging (2): In the event of death $ 2,541 $ 3,246 At annuitization or exercise of other living benefits $ 665 $ 770 Weighted-average attained age of contractholders: In the event of death 71 years 70 years At annuitization or exercise of other living benefits 71 years 70 years __________________ (1) Included is the covariance impact from aggregating the market observable inputs, mostly driven by interest rate and capital market volatility. (2) Includes amounts for certain variable annuity guarantees recorded as MRBs on contracts also recorded as PABs which are disclosed in “MetLife Holdings – Annuities” in Note 4. Significant Methodologies and Assumptions The Company issues GMDBs, GMWBs, guaranteed minimum accumulation benefits (“GMABs”) and GMIBs that typically meet the definition of MRBs, which are measured in aggregate, as one compound MRB, at estimated fair value separately from the variable annuity contract, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in other comprehensive income (loss) (“OCI”). The Company calculates the fair value of these MRBs, which is estimated as the present value of projected future benefits minus the present value of projected attributed fees, using actuarial and capital market assumptions including expectations concerning policyholder behavior. The calculation is based on in-force business, projecting future cash flows from the MRB over multiple risk neutral stochastic scenarios using observable risk-free rates. Capital market assumptions, such as risk-free rates and implied volatilities, are based on market prices for publicly traded instruments to the extent that prices for such instruments are observable. Implied volatilities beyond the observable period are extrapolated based on observable implied volatilities and historical volatilities. Actuarial assumptions, including mortality, lapse, withdrawal and utilization, are unobservable and are reviewed at least annually based on actuarial studies of historical experience. See Note 11 for additional information on significant unobservable inputs. The valuation of these MRBs includes a nonperformance risk adjustment and adjustments for a risk margin related to non-capital market inputs. The nonperformance adjustment is determined by taking into consideration publicly available information relating to spreads in the secondary market for MetLife, Inc.’s debt, including related credit default swaps. These observable spreads are then adjusted, as necessary, to reflect the priority of these liabilities and the claims paying ability of the issuing insurance subsidiaries as compared to MetLife, Inc. Risk margins are established to capture the non-capital market risks of the instrument which represent the additional compensation a market participant would require to assume the risks related to the uncertainties of such actuarial assumptions at annuitization, premium persistency, partial withdrawal and surrenders. The establishment of risk margins requires the use of significant management judgment, including assumptions of the amount and cost of capital needed to cover the guarantees. These guarantees may be more costly than expected in volatile or declining equity markets. Market conditions, including changes in interest rates, equity indices, market volatility and foreign currency exchange rates; and variations in actuarial assumptions regarding policyholder behavior, mortality and risk margins related to non-capital market inputs, impact the estimated fair value of the guarantees and affect net income, and changes in nonperformance risk of the Company affect OCI. Other In addition to the disaggregated MRB product rollforward above, the Company offers other products with guaranteed minimum benefit features. These MRBs are measured at estimated fair value, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in OCI. See Note 11 for additional information on significant unobservable inputs used in the fair value measurement of MRBs. Information regarding these product liabilities was as follows: Six Months 2024 2023 (In millions) Balance, beginning of period $ (1) $ 25 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk $ 2 $ 34 Attributed fees collected 1 1 Effect of changes in interest rates (6) 2 Actual policyholder behavior different from expected behavior — (26) Effect of foreign currency translation and other, net 12 15 Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk 9 26 Cumulative effect of changes in the instrument-specific credit risk (3) (7) Balance, end of period $ 6 $ 19 |
Separate Account
Separate Account | 6 Months Ended |
Jun. 30, 2024 | |
Separate Accounts Disclosure [Abstract] | |
Separate Account | 6. Separate Accounts Separate account assets consist of investment accounts established and maintained by the Company. The investment objectives of these assets are directed by the contractholder. An equivalent amount is reported as separate account liabilities. These accounts are reported separately from the general account assets and liabilities. Separate Account Liabilities The Company’s separate account liabilities on the interim condensed consolidated balance sheets were as follows at: June 30, 2024 December 31, 2023 (In millions) RIS: Stable Value and Risk Solutions $ 32,256 $ 35,562 Annuities 11,246 11,659 MetLife Holdings - Annuities 28,780 29,162 Other 7,303 6,814 Total $ 79,585 $ 83,197 Rollforwards The following information about the separate account liabilities includes disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. The separate account liabilities are primarily comprised of the following: RIS stable value and risk solutions contracts, RIS annuities participating and non-participating group contracts, and MetLife Holdings variable annuities. The balances of and changes in separate account liabilities were as follows: RIS RIS MetLife Holdings (In millions) Six Months Ended June 30, 2024 Balance, beginning of period $ 35,562 $ 11,659 $ 29,162 Premiums and deposits 541 25 123 Policy charges (108) (10) (296) Surrenders and withdrawals (2,919) (401) (1,851) Benefit payments (49) — (259) Investment performance 490 (95) 1,964 Net transfers from (to) general account (20) — (58) Other (1) (1,241) 68 (5) Balance, end of period $ 32,256 $ 11,246 $ 28,780 Six Months Ended June 30, 2023 Balance, beginning of period $ 43,249 $ 11,694 $ 28,443 Premiums and deposits 1,069 120 139 Policy charges (121) (11) (305) Surrenders and withdrawals (7,532) (360) (1,359) Benefit payments (44) — (242) Investment performance 1,145 448 2,924 Net transfers from (to) general account (57) 3 (47) Other (667) (102) — Balance, end of period $ 37,042 $ 11,792 $ 29,553 Cash surrender value at June 30, 2024 (2) $ 28,766 N/A $ 28,643 Cash surrender value at June 30, 2023 (2) $ 32,886 N/A $ 29,471 __________________ (1) Other for RIS stable value and risk solutions primarily includes changes related to unsettled trades of mortgage-backed securities. (2) Cash surrender value represents the amount of the contractholders’ account balances distributable at the balance sheet date less policy loans and certain surrender charges. Separate Account Assets The Company’s aggregate fair value of assets, by major investment asset category, supporting separate account liabilities was as follows at: June 30, 2024 Group Benefits RIS MetLife Holdings Total (In millions) Fixed maturity securities: Bonds: Foreign government $ — $ 530 $ — $ 530 U.S. government and agency — 9,237 — 9,237 Public utilities — 1,065 — 1,065 Municipals — 275 — 275 Corporate bonds: Materials — 125 — 125 Communications — 750 — 750 Consumer — 1,742 — 1,742 Energy — 828 — 828 Financial — 2,465 — 2,465 Industrial and other — 698 — 698 Technology — 468 — 468 Foreign — 1,915 — 1,915 Total corporate bonds — 8,991 — 8,991 Total bonds — 20,098 — 20,098 Mortgage-backed securities — 9,211 — 9,211 Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”) — 2,097 — 2,097 Redeemable preferred stock — 9 — 9 Total fixed maturity securities — 31,415 — 31,415 Equity securities: Common stock: Industrial, miscellaneous and all other — 2,308 — 2,308 Banks, trust and insurance companies — 690 — 690 Public utilities — 62 — 62 Non-redeemable preferred stock — — — — Mutual funds 1,270 3,796 34,718 39,784 Total equity securities 1,270 6,856 34,718 42,844 Other invested assets — 1,351 — 1,351 Total investments 1,270 39,622 34,718 75,610 Other assets — 3,975 — 3,975 Total $ 1,270 $ 43,597 $ 34,718 $ 79,585 December 31, 2023 Group Benefits RIS MetLife Holdings Total (In millions) Fixed maturity securities: Bonds: Foreign government $ — $ 509 $ — $ 509 U.S. government and agency — 9,603 — 9,603 Public utilities — 1,066 — 1,066 Municipals — 346 — 346 Corporate bonds: Materials — 143 — 143 Communications — 883 — 883 Consumer — 1,843 — 1,843 Energy — 906 — 906 Financial — 2,670 — 2,670 Industrial and other — 757 — 757 Technology — 541 — 541 Foreign — 1,889 — 1,889 Total corporate bonds — 9,632 — 9,632 Total bonds — 21,156 — 21,156 Mortgage-backed securities — 9,515 — 9,515 ABS & CLO — 2,341 — 2,341 Redeemable preferred stock — 9 — 9 Total fixed maturity securities — 33,021 — 33,021 Equity securities: Common stock: Industrial, miscellaneous and all other — 2,338 — 2,338 Banks, trust and insurance companies — 716 — 716 Public utilities — 65 — 65 Non-redeemable preferred stock — — — — Mutual funds 1,159 3,672 34,728 39,559 Total equity securities 1,159 6,791 34,728 42,678 Other invested assets — 1,425 — 1,425 Total investments 1,159 41,237 34,728 77,124 Other assets — 6,073 — 6,073 Total $ 1,159 $ 47,310 $ 34,728 $ 83,197 |
Deferred Policy Acquisition Cos
Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue | 6 Months Ended |
Jun. 30, 2024 | |
Deferred Policy Acquisition Costs and Present Value of Future Insurance Profits, Net [Abstract] | |
Intangible Assets and Liabilities and Unearned Revenue, excluding Goodwill [Text Block] | 7. Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue DAC and VOBA Information regarding total DAC and VOBA by segment, as well as Corporate & Other, was as follows at: Group Benefits RIS MetLife Holdings (1) Corporate & Other Total (In millions) DAC: Balance at January 1, 2024 $ 255 $ 155 $ 2,723 $ 158 $ 3,291 Capitalizations 7 46 (1) — 52 Amortization (13) (16) (99) (9) (137) Balance at June 30, 2024 $ 249 $ 185 $ 2,623 $ 149 $ 3,206 Balance at January 1, 2023 $ 264 $ 137 $ 3,220 $ 120 $ 3,741 Capitalizations 11 24 (1) 55 89 Amortization (13) (14) (115) (8) (150) Balance at June 30, 2023 $ 262 $ 147 $ 3,104 $ 167 $ 3,680 Total DAC and VOBA: Balance at June 30, 2024 $ 3,219 Balance at June 30, 2023 $ 3,695 Balance at December 31, 2023 $ 3,305 __________________ (1) Includes DAC balances primarily related to whole life, variable annuities, disability income, term life, long-term care and universal life products. Unearned Revenue Information regarding the Company’s unearned revenue primarily related to universal life and variable universal life products by segment included in other policy-related balances was as follows: Six Months RIS MetLife Holdings Total (In millions) Balance, beginning of period $ 16 $ 5 $ 21 Deferrals 1 — 1 Amortization (2) — (2) Balance, end of period $ 15 $ 5 $ 20 Six Months RIS MetLife Holdings Total (In millions) Balance, beginning of period $ 18 $ 227 $ 245 Deferrals 1 20 21 Amortization (2) (9) (11) Balance, end of period $ 17 $ 238 $ 255 |
Closed Block
Closed Block | 6 Months Ended |
Jun. 30, 2024 | |
Closed Block Disclosure [Abstract] | |
Closed Block | 8. Closed Block On April 7, 2000 (the “Demutualization Date”), Metropolitan Life Insurance Company converted from a mutual life insurance company to a stock life insurance company and became a wholly-owned subsidiary of MetLife, Inc. The conversion was pursuant to an order by the New York Superintendent of Insurance approving Metropolitan Life Insurance Company’s plan of reorganization, as amended (the “Plan of Reorganization”). On the Demutualization Date, Metropolitan Life Insurance Company established a closed block for the benefit of holders of certain individual life insurance policies of Metropolitan Life Insurance Company. See Note 9 to the Notes to the Consolidated Financial Statements included in the 2023 Annual Report for further information on the closed block. Experience within the closed block, in particular mortality and investment yields, as well as realized and unrealized gains and losses, directly impact the policyholder dividend obligation. Amortization of the closed block DAC, which resides outside of the closed block, is based upon policy count within the closed block. Closed block assets, liabilities, revenues and expenses are combined on a line-by-line basis with the assets, liabilities, revenues and expenses outside the closed block based on the nature of the particular item. Information regarding the liabilities and assets designated to the closed block was as follows at: June 30, 2024 December 31, 2023 (In millions) Closed Block Liabilities FPBs $ 35,492 $ 36,142 Other policy-related balances 283 319 Policyholder dividends payable 172 174 Policyholder dividend obligation — — Current income tax payable 4 — Other liabilities 797 668 Total closed block liabilities 36,748 37,303 Assets Designated to the Closed Block Investments: Fixed maturity securities available-for-sale (“AFS”), at estimated fair value 19,247 19,939 Mortgage loans 5,938 6,151 Policy loans 3,876 3,960 Real estate and real estate joint ventures (“REJV”) 688 668 Other invested assets 498 506 Total investments 30,247 31,224 Cash and cash equivalents 759 717 Accrued investment income 374 383 Premiums, reinsurance and other receivables 67 54 Current income tax recoverable — 3 Deferred income tax asset 397 312 Total assets designated to the closed block 31,844 32,693 Excess of closed block liabilities over assets designated to the closed block 4,904 4,610 AOCI: Unrealized investment gains (losses), net of income tax (1,204) (820) Unrealized gains (losses) on derivatives, net of income tax 164 130 Total amounts included in AOCI (1,040) (690) Maximum future earnings to be recognized from closed block assets and liabilities $ 3,864 $ 3,920 Information regarding the closed block revenues and expenses was as follows: Three Months Six Months 2024 2023 2024 2023 (In millions) Revenues Premiums $ 216 $ 226 $ 434 $ 461 Net investment income 342 341 685 679 Net investment gains (losses) (13) 5 (20) 9 Net derivative gains (losses) 2 5 7 3 Total revenues 547 577 1,106 1,152 Expenses Policyholder benefits and claims 415 445 819 858 Policyholder dividends 86 89 176 186 Other expenses 20 22 40 44 Total expenses 521 556 1,035 1,088 Revenues, net of expenses before provision for income tax expense (benefit) 26 21 71 64 Provision for income tax expense (benefit) 5 4 15 13 Revenues, net of expenses and provision for income tax expense (benefit) $ 21 $ 17 $ 56 $ 51 Metropolitan Life Insurance Company charges the closed block with federal income taxes, state and local premium taxes and other state or local taxes, as well as investment management expenses relating to the closed block as provided in the Plan of Reorganization. Metropolitan Life Insurance Company also charges the closed block for expenses of maintaining the policies included in the closed block. |
Investments
Investments | 6 Months Ended |
Jun. 30, 2024 | |
Investments, Debt and Equity Securities [Abstract] | |
Investments | 9. Investments Fixed Maturity Securities AFS Fixed Maturity Securities AFS by Sector The following table presents fixed maturity securities AFS by sector. U.S. corporate and foreign corporate sectors include redeemable preferred stock. Residential mortgage-backed securities (“RMBS”) includes agency, prime, prime investor, non-qualified residential mortgage, alternative, reperforming and sub-prime mortgage-backed securities. ABS & CLO includes securities collateralized by consumer loans, corporate loans and broadly syndicated bank loans. Municipals includes taxable and tax-exempt revenue bonds and, to a much lesser extent, general obligations of states, municipalities and political subdivisions. Commercial mortgage-backed securities (“CMBS”) primarily includes securities collateralized by multiple commercial mortgage loans. RMBS, ABS & CLO and CMBS are, collectively, “Structured Products.” June 30, 2024 December 31, 2023 Amortized Gross Unrealized Estimated Amortized Gross Unrealized Estimated Sector Allowance for Credit Loss (“ACL”) Gains Losses ACL Gains Losses (In millions) U.S. corporate $ 52,045 $ (27) $ 684 $ 3,855 $ 48,847 $ 52,479 $ (62) $ 1,126 $ 3,050 $ 50,493 Foreign corporate 27,381 (2) 334 3,284 24,429 27,520 (2) 536 2,839 25,215 U.S. government and agency 25,542 — 97 3,100 22,539 23,100 — 243 2,283 21,060 RMBS 22,572 (1) 183 2,190 20,564 20,700 (1) 228 1,979 18,948 ABS & CLO 12,188 (7) 47 318 11,910 12,049 (6) 30 432 11,641 Municipals 5,837 — 148 508 5,477 6,429 — 318 428 6,319 CMBS 5,828 (7) 26 433 5,414 6,387 (11) 28 570 5,834 Foreign government 3,167 (33) 109 267 2,976 3,416 (50) 156 227 3,295 Total fixed maturity securities AFS $ 154,560 $ (77) $ 1,628 $ 13,955 $ 142,156 $ 152,080 $ (132) $ 2,665 $ 11,808 $ 142,805 Maturities of Fixed Maturity Securities AFS The amortized cost, net of ACL, and estimated fair value of fixed maturity securities AFS, by contractual maturity date, were as follows at June 30, 2024: Due in One Due After Due After Due After Structured Total Fixed (In millions) Amortized cost, net of ACL $ 5,015 $ 24,950 $ 27,900 $ 56,045 $ 40,573 $ 154,483 Estimated fair value $ 4,907 $ 24,189 $ 26,450 $ 48,722 $ 37,888 $ 142,156 Actual maturities may differ from contractual maturities due to the exercise of call or prepayment options. Fixed maturity securities AFS not due at a single maturity date have been presented in the year of final contractual maturity. Structured Products are shown separately, as they are not due at a single maturity. Continuous Gross Unrealized Losses for Fixed Maturity Securities AFS by Sector The following table presents the estimated fair value and gross unrealized losses of fixed maturity securities AFS in an unrealized loss position without an ACL by sector and aggregated by length of time that the securities have been in a continuous unrealized loss position. June 30, 2024 December 31, 2023 Less than 12 Months Equal to or Greater Less than 12 Months Equal to or Greater Sector & Credit Quality Estimated Gross Estimated Gross Estimated Gross Estimated Gross (Dollars in millions) U.S. corporate $ 5,310 $ 136 $ 25,251 $ 3,701 $ 3,537 $ 95 $ 25,752 $ 2,924 Foreign corporate 2,376 84 15,847 3,200 714 64 16,982 2,775 U.S. government and agency 6,186 121 11,194 2,979 4,322 228 9,980 2,055 RMBS 2,615 43 12,667 2,147 1,470 37 12,813 1,941 ABS & CLO 751 3 4,928 314 937 20 8,250 410 Municipals 412 9 2,199 499 262 10 2,102 418 CMBS 702 6 3,475 426 587 23 4,096 542 Foreign government 385 7 1,455 251 431 12 1,452 212 Total fixed maturity securities AFS $ 18,737 $ 409 $ 77,016 $ 13,517 $ 12,260 $ 489 $ 81,427 $ 11,277 Investment grade $ 17,504 $ 364 $ 73,674 $ 13,098 $ 11,499 $ 453 $ 77,325 $ 10,849 Below investment grade 1,233 45 3,342 419 761 36 4,102 428 Total fixed maturity securities AFS $ 18,737 $ 409 $ 77,016 $ 13,517 $ 12,260 $ 489 $ 81,427 $ 11,277 Total number of securities in an unrealized loss position 2,588 8,129 1,679 8,441 Evaluation of Fixed Maturity Securities AFS for Credit Loss Evaluation and Measurement Methodologies See Note 10 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report for a description of the Company’s Evaluation and Measurement Methodologies of Fixed Maturity Securities AFS for Credit Loss. Evaluation of Fixed Maturity Securities AFS in an Unrealized Loss Position Gross unrealized losses on securities without an ACL increased $2.2 billion for the six months ended June 30, 2024 to $13.9 billion primarily due to an increase in interest rates and the impact of weakening foreign currencies on certain non-functional currency denominated fixed maturity securities. As shown in the table above, most of the gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater at June 30, 2024, relate to investment grade securities. These unrealized losses are principally due to widening credit spreads since purchase and, with respect to fixed-rate securities, rising interest rates since purchase. As of June 30, 2024, $419 million of gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater on below investment grade securities were concentrated in the consumer, transportation and communications sectors within corporate securities and in foreign government securities. These unrealized losses are the result of significantly wider credit spreads resulting from higher risk premiums since purchase, largely due to economic and market uncertainty and, with respect to fixed-rate securities, rising interest rates since purchase. At June 30, 2024, the Company did not intend to sell its securities in an unrealized loss position without an ACL, and it was not more likely than not that the Company would be required to sell these securities before the anticipated recovery of the remaining amortized cost. Therefore, the Company concluded that these securities had not incurred a credit loss and should not have an ACL at June 30, 2024. Future provisions for credit loss will depend primarily on economic fundamentals, issuer performance (including changes in the present value of future cash flows expected to be collected), changes in credit ratings and collateral valuation. Rollforward of ACL for Fixed Maturity Securities AFS By Sector The rollforward of ACL for fixed maturity securities AFS by sector is as follows: U.S. Foreign Corporate Foreign RMBS ABS & CLO CMBS Total Three Months Ended June 30, 2024 (In millions) Balance, at beginning of period $ 10 $ 2 $ 35 $ 1 $ 7 $ 11 $ 66 ACL not previously recorded 14 — — — — — 14 Changes for securities with previously recorded ACL 6 — — — — — 6 Securities sold or exchanged (3) — (2) — — (4) (9) Balance, at end of period $ 27 $ 2 $ 33 $ 1 $ 7 $ 7 $ 77 Three Months Ended June 30, 2023 Balance, at beginning of period $ 57 $ 3 $ 68 $ — $ — $ 7 $ 135 ACL not previously recorded — — — — — — — Changes for securities with previously recorded ACL 6 (1) 2 — — — 7 Securities sold or exchanged — — — — — — — Balance, at end of period $ 63 $ 2 $ 70 $ — $ — $ 7 $ 142 U.S. Foreign Foreign RMBS ABS & CLO CMBS Total (In millions) Six Months Ended June 30, 2024 Balance, at beginning of period $ 62 $ 2 $ 50 $ 1 $ 6 $ 11 $ 132 ACL not previously recorded 14 — — — — — 14 Changes for securities with previously recorded ACL 6 — (2) — 1 — 5 Securities sold or exchanged (55) — (15) — — (4) (74) Balance, at end of period $ 27 $ 2 $ 33 $ 1 $ 7 $ 7 $ 77 Six Months Ended June 30, 2023 Balance, at beginning of period $ 28 $ 3 $ 68 $ — $ — $ 15 $ 114 ACL not previously recorded 31 — — — — — 31 Changes for securities with previously recorded ACL 6 (1) 2 — — 2 9 Securities sold or exchanged (2) — — — — (10) (12) Balance, at end of period $ 63 $ 2 $ 70 $ — $ — $ 7 $ 142 Mortgage Loans Mortgage Loans by Portfolio Segment Mortgage loans are summarized as follows at: June 30, 2024 December 31, 2023 Portfolio Segment Carrying % of Carrying % of (Dollars in millions) Commercial $ 35,433 58.5 % $ 37,129 59.3 % Agricultural 15,588 25.7 15,831 25.3 Residential 10,089 16.7 10,133 16.2 Total amortized cost 61,110 100.9 63,093 100.8 ACL (533) (0.9) (509) (0.8) Total mortgage loans $ 60,577 100.0 % $ 62,584 100.0 % The amount of net (discounts) premiums and deferred (fees) expenses, included within total amortized cost, primarily attributable to residential mortgage loans was ($749) million and ($720) million at June 30, 2024 and December 31, 2023, respectively. The accrued interest income excluded from total amortized cost for commercial, agricultural and residential mortgage loans at June 30, 2024 was $189 million, $158 million and $79 million, respectively. The accrued interest income excluded from total amortized cost for commercial, agricultural and residential mortgage loans at December 31, 2023 was $196 million, $166 million and $79 million, respectively. Purchases of mortgage loans from unaffiliated parties, consisting primarily of residential mortgage loans, were $198 million and $453 million for the three months and six months ended June 30, 2024, respectively, and $100 million and $857 million for the three months and six months ended June 30, 2023, respectively. See “— Related Party Investment Transactions” for information regarding transfers of mortgage loans to and from affiliates. For both the three months and six months ended June 30, 2024, the Company contributed commercial mortgage loans with an amortized cost of $181 million to REJVs which subsequently completed foreclosure on those mortgage loans. See “— Real Estate and REJV” for the carrying value of wholly-owned real estate acquired through foreclosure. Rollforward of ACL for Mortgage Loans by Portfolio Segment The rollforward of ACL for mortgage loans, by portfolio segment, is as follows: Six Months Ended June 30, 2024 2023 Commercial Agricultural Residential Total Commercial Agricultural Residential Total (In millions) Balance, beginning of period $ 210 $ 152 $ 147 $ 509 $ 174 $ 105 $ 169 $ 448 Provision (release) 74 6 (37) 43 37 48 5 90 Charge-offs, net of recoveries (12) (7) — (19) — (13) — (13) Balance, end of period $ 272 $ 151 $ 110 $ 533 $ 211 $ 140 $ 174 $ 525 ACL Methodology The Company records an allowance for expected lifetime credit loss in earnings within net investment gains (losses) in an amount that represents the portion of the amortized cost basis of mortgage loans that the Company does not expect to collect, resulting in mortgage loans being presented at the net amount expected to be collected. In determining the Company’s ACL, management applies significant judgment to estimate expected lifetime credit loss, including: (i) pooling mortgage loans that share similar risk characteristics, (ii) considering expected lifetime credit loss over the contractual term of its mortgage loans adjusted for expected prepayments and any extensions, and (iii) considering past events and current and forecasted economic conditions. Each of the Company’s commercial, agricultural and residential mortgage loan portfolio segments are evaluated separately. The ACL is calculated for each mortgage loan portfolio segment based on inputs unique to each loan portfolio segment. On a quarterly basis, mortgage loans within a portfolio segment that share similar risk characteristics, such as internal risk ratings or consumer credit scores, are pooled for calculation of ACL. On an ongoing basis, mortgage loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), such as collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is reasonably possible or probable), are evaluated individually for credit loss. The ACL for loans evaluated individually are established using the same methodologies for all three portfolio segments. For example, the ACL for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost when foreclosure is probable. Accordingly, the change in the estimated fair value of collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the ACL which is recorded on a quarterly basis as a charge or credit to earnings in net investment gains (losses). Commercial and Agricultural Mortgage Loan Portfolio Segments Within each loan portfolio segment, commercial and agricultural loans are pooled by internal risk rating. Estimated lifetime loss rates, which vary by internal risk rating, are applied to the amortized cost of each loan, excluding accrued investment income, on a quarterly basis to develop the ACL. Internal risk ratings are based on an assessment of the loan’s credit quality, which can change over time. The estimated lifetime loss rates are based on several loan portfolio segment-specific factors, including (i) the Company’s experience with defaults and loss severity, (ii) expected default and loss severity over the forecast period, (iii) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, (iv) loan specific characteristics including loan-to-value (“LTV”) ratios, and (v) internal risk ratings. These evaluations are revised as conditions change and new information becomes available. The Company uses its several decades of historical default and loss severity experience which capture multiple economic cycles. The Company uses a forecast of economic assumptions for a two-year period for most of its commercial and agricultural mortgage loans, while a one-year period is used for loans originated in certain markets. After the applicable forecast period, the Company reverts to its historical loss experience using a straight-line basis over two years. For evaluations of commercial mortgage loans, in addition to historical experience, management considers factors that include the impact of a rapid change to the economy, which may not be reflected in the loan portfolio, recent loss and recovery trend experience as compared to historical loss and recovery experience, and loan specific characteristics including debt service coverage ratios (“DSCR”). In estimating expected lifetime credit loss over the term of its commercial mortgage loans, the Company adjusts for expected prepayment and extension experience during the forecast period using historical prepayment and extension experience considering the expected position in the economic cycle and the loan profile (i.e., floating rate, shorter-term fixed rate and longer-term fixed rate) and after the forecast period using long-term historical prepayment experience. For evaluations of agricultural mortgage loans, in addition to historical experience, management considers factors that include increased stress in certain sectors, which may be evidenced by higher delinquency rates, or a change in the number of higher risk loans. In estimating expected lifetime credit loss over the term of its agricultural mortgage loans, the Company’s experience is much less sensitive to the position in the economic cycle and by loan profile; accordingly, historical prepayment experience is used, while extension terms are not prevalent with the Company’s agricultural mortgage loans. Commercial mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, an analysis of the property financial statements and rent roll, lease rollover analysis, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios, DSCR and tenant creditworthiness. The monitoring process focuses on higher risk loans, which include those that are classified as restructured, delinquent or in foreclosure, as well as loans with higher LTV ratios and lower DSCR. Agricultural mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios and borrower creditworthiness, as well as reviews on a geographic and property-type basis. The monitoring process for agricultural mortgage loans also focuses on higher risk loans. For commercial mortgage loans, the primary credit quality indicator is the DSCR, which compares a property’s net operating income to amounts needed to service the principal and interest due under the loan. Generally, the lower the DSCR, the higher the risk of experiencing a credit loss. The Company also reviews the LTV ratio of its commercial mortgage loan portfolio. LTV ratios compare the unpaid principal balance of the loan to the estimated fair value of the underlying collateral. Generally, the higher the LTV ratio, the higher the risk of experiencing a credit loss. The DSCR and the values utilized in calculating the ratio are updated routinely. In addition, the LTV ratio is routinely updated for all but the lowest risk loans as part of the Company’s ongoing review of its commercial mortgage loan portfolio. For agricultural mortgage loans, the Company’s primary credit quality indicator is the LTV ratio. The values utilized in calculating this ratio are developed in connection with the ongoing review of the agricultural mortgage loan portfolio and are routinely updated. After commercial and agricultural mortgage loans are approved, the Company makes commitments to lend and, typically, borrowers draw down on some or all of the commitments. The timing of mortgage loan funding is based on the commitment expiration dates. A liability for credit loss for unfunded commercial and agricultural mortgage loan commitments that is not unconditionally cancellable is recognized in earnings and is reported within net investment gains (losses). The liability is based on estimated lifetime loss rates as described above and the amount of the outstanding commitments, which for lines of credit, considers estimated utilization rates. When the commitment is funded or expires, the liability is adjusted accordingly. Residential Mortgage Loan Portfolio Segment The Company’s residential mortgage loan portfolio is comprised primarily of purchased closed end, amortizing residential mortgage loans, including both performing loans purchased within 12 months of origination and reperforming loans purchased after they have been performing for at least 12 months post-modification. Residential mortgage loans are pooled by loan type (i.e., new origination and reperforming) and pooled by similar risk profiles (including consumer credit score and LTV ratios). Estimated lifetime loss rates, which vary by loan type and risk profile, are applied to the amortized cost of each loan excluding accrued investment income on a quarterly basis to develop the ACL. The estimated lifetime loss rates are based on several factors, including (i) industry historical experience and expected results over the forecast period for defaults, (ii) loss severity, (iii) prepayment rates, (iv) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, and (v) loan pool specific characteristics including consumer credit scores, LTV ratios, payment history and home prices. These evaluations are revised as conditions change and new information becomes available. The Company uses industry historical experience which captures multiple economic cycles as the Company has purchased most of its residential mortgage loans in the last five years. The Company uses a forecast of economic assumptions for a two-year period for most of its residential mortgage loans. After the applicable forecast period, the Company reverts to industry historical loss experience using a straight-line basis over one year. For residential mortgage loans, the Company’s primary credit quality indicator is whether the loan is performing or nonperforming. The Company generally defines nonperforming residential mortgage loans as those that are 60 or more days past due and/or in nonaccrual status which is assessed monthly. Generally, nonperforming residential mortgage loans have a higher risk of experiencing a credit loss. Modifications to Borrowers Experiencing Financial Difficulty The Company may modify mortgage loans to borrowers. Each mortgage loan modification is evaluated to determine whether the borrower was experiencing financial difficulties. Disclosed below are those modifications, in materially impacted mortgage segments, where the borrower was determined to be experiencing financial difficulties and the mortgage loans were modified by any of the following means: principal forgiveness, interest rate reduction, other-than-insignificant payment delay or term extension. The amount, timing and extent of modifications granted and subsequent performance are considered in determining any ACL recorded. These mortgage loan modifications are summarized as follows: Three Months Ended June 30, 2024 2023 Maturity Extension Weighted Average Life Increase Maturity Extension Weighted Average Life Increase Amortized Cost Affected Loans (in Years) % of Book Value Amortized Cost Affected Loans (in Years) % of Book Value (Dollars in millions) Commercial $ 137 Less than one year < 1% $ 149 One year < 1% Six Months Ended June 30, 2024 2023 Maturity Extension Weighted Average Life Increase Maturity Extension Weighted Average Life Increase Amortized Cost Affected Loans (in Years) % of Book Value Amortized Cost Affected Loans (in Years) % of Book Value (Dollars in millions) Commercial $ 167 Less than one year <1% $ 180 Less than one year < 1% During the three months ended June 30, 2024, commercial mortgage loans with an amortized cost of $171 million which were extended over the past 12 months became foreclosed. During the six months ended June 30, 2024, commercial mortgage loans with an amortized cost of $171 million which were extended over the past 12 months became delinquent and foreclosed. For both the three months and six months ended June 30, 2023, all commercial mortgage loans which were modified to borrowers experiencing financial difficulties were current. Credit Quality of Mortgage Loans by Portfolio Segment The amortized cost of commercial mortgage loans by credit quality indicator and vintage year was as follows at June 30, 2024: Credit Quality Indicator 2024 2023 2022 2021 2020 Prior Revolving Total % of (Dollars in millions) LTV ratios: Less than 65% $ 839 $ 1,603 $ 1,035 $ 1,682 $ 867 $ 9,166 $ 2,251 $ 17,443 49.2 % 65% to 75% 32 226 3,013 1,388 841 3,802 — 9,302 26.3 76% to 80% — — 314 192 74 1,705 — 2,285 6.4 Greater than 80% 1 42 598 746 568 4,448 — 6,403 18.1 Total $ 872 $ 1,871 $ 4,960 $ 4,008 $ 2,350 $ 19,121 $ 2,251 $ 35,433 100.0 % DSCR: > 1.20x $ 837 $ 1,397 $ 4,284 $ 3,708 $ 2,092 $ 15,920 $ 2,251 $ 30,489 86.0 % 1.00x - 1.20x 5 385 528 300 119 1,816 — 3,153 8.9 <1.00x 30 89 148 — 139 1,385 — 1,791 5.1 Total $ 872 $ 1,871 $ 4,960 $ 4,008 $ 2,350 $ 19,121 $ 2,251 $ 35,433 100.0 % The amortized cost of agricultural mortgage loans by credit quality indicator and vintage year was as follows at June 30, 2024: Credit Quality Indicator 2024 2023 2022 2021 2020 Prior Revolving Total % of (Dollars in millions) LTV ratios: Less than 65% $ 257 $ 770 $ 1,981 $ 1,465 $ 1,885 $ 6,703 $ 1,326 $ 14,387 92.3 % 65% to 75% 5 47 73 193 126 494 125 1,063 6.8 76% to 80% — — — — — — — — — Greater than 80% — — — 14 29 77 18 138 0.9 Total $ 262 $ 817 $ 2,054 $ 1,672 $ 2,040 $ 7,274 $ 1,469 $ 15,588 100.0 % The amortized cost of residential mortgage loans by credit quality indicator and vintage year was as follows at June 30, 2024: Credit Quality Indicator 2024 2023 2022 2021 2020 Prior Revolving Total % of (Dollars in millions) Performance indicators: Performing $ 87 $ 331 $ 1,833 $ 948 $ 147 $ 6,424 $ — $ 9,770 96.8 % Nonperforming (1) — 7 53 16 6 237 — 319 3.2 Total $ 87 $ 338 $ 1,886 $ 964 $ 153 $ 6,661 $ — $ 10,089 100.0 % __________________ (1) Includes residential mortgage loans in process of foreclosure of $125 million and $134 million at June 30, 2024 and December 31, 2023, respectively. Past Due and Nonaccrual Mortgage Loans The Company has a high quality, well performing mortgage loan portfolio, with 99% of all mortgage loans classified as performing at both June 30, 2024 and December 31, 2023. The Company defines delinquency consistent with industry practice, when mortgage loans are past due more than two or more months, as applicable, by portfolio segment. The past due and nonaccrual mortgage loans at amortized cost, prior to ACL, by portfolio segment, were as follows: Past Due Past Due Nonaccrual Portfolio Segment June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 (In millions) Commercial $ 271 $ 19 $ — $ — $ 381 $ 303 Agricultural 188 40 15 — 182 206 Residential 319 343 — — 319 343 Total $ 778 $ 402 $ 15 $ — $ 882 $ 852 Real Estate and REJV The Company’s real estate investment portfolio is diversified by property type, geography and income stream, including income from operating leases, operating income and equity in earnings from equity method REJV. Real estate investments, by income type, as well as income earned, were as follows at and for the periods indicated: June 30, 2024 December 31, 2023 Three Months Six Months 2024 2023 2024 2023 Income Type Carrying Value Income (In millions) Wholly-owned real estate: Leased real estate $ 1,656 $ 1,594 $ 38 $ 41 $ 76 $ 83 Other real estate 518 506 77 83 120 129 REJV 6,895 6,590 (57) (7) (107) (43) Total real estate and REJV $ 9,069 $ 8,690 $ 58 $ 117 $ 89 $ 169 The carrying value of wholly-owned real estate acquired through foreclosure was $263 million and $190 million at June 30, 2024 and December 31, 2023, respectively. Depreciation expense on real estate investments was $23 million and $44 million for the three months and six months ended June 30, 2024, respectively, and $22 million and $42 million for the three months and six months ended June 30, 2023, respectively. Real estate investments net of accumulated depreciation were $683 million and $638 million at June 30, 2024 and December 31, 2023, respectively. Leased Real Estate Investments - Operating Leases The Company, as lessor, leases investment real estate, principally commercial real estate for office, apartment and retail use, through a variety of operating lease arrangements, which typically include tenant reimbursement for property operating costs and options to renew or extend the lease. In some circumstances, leases may include an option for the lessee to purchase the property. In addition, certain leases of retail space may stipulate that a portion of the income earned is contingent upon the level of the tenants’ revenues. The Company has elected a practical expedient of not separating non-lease components related to reimbursement of property operating costs from associated lease components. These property operating costs have the same timing and pattern of transfer as the related lease component, because they are incurred over the same period of time as the operating lease. Therefore, the combined component is accounted for as a single operating lease. Risk is managed through lessee credit analysis, property type diversification and geographic diversification. See Note 10 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report for a summary of leased real estate investments and income earned, by property type. Other Invested Assets Tax Equity Investments The Company invests in certain tax equity investments, including low income housing tax credit partnerships and renewable energy partnerships. The carrying value of tax equity investments, reported in other invested assets on the interim condensed consolidated balance sheet, was $787 million and $1.0 billion at June 30, 2024 and December 31, 2023, respectively. Beginning January 1, 2024, tax equity investments that meet certain criteria are accounted for using the proportional amortization method, where the initial cost of the investment is amortized in proportion to the tax credits received and recognized as a component of income tax expense (benefit) in the interim condensed consolidated statements of operations. Investments which do not meet the qualification criteria for the proportional amortization method are accounted for using the equity method of accounting. For the three months and six months ended June 30, 2024, income tax credits and other income tax benefits of $38 million and $75 million, respectively, and amortized expense of $34 million and $67 million , respectively, were recognized net as a component of income tax expense in the Company’s interim condensed consolidated statement of operations. FVO Securities and Equity Securities The following table presents FVO securities and equity securities by asset type. FVO securities include fixed maturity and equity securities to support asset and liability management strategies for certain insurance products and investments in certain separate accounts. June 30, 2024 December 31, 2023 Cost Net Unrealized Gains (Losses) (1) Estimated Fair Value Cost Net Unrealized Gains (Losses) (1) Estimated Fair Value Asset Type (In millions) FVO securities $ 315 $ 493 $ 808 $ 379 $ 367 $ 746 Equity securities Common stock (2) $ 119 $ 49 $ 168 $ 118 $ 45 $ 163 Non-redeemable preferred stock 173 15 188 177 7 184 Total equity securities $ 292 $ 64 $ 356 $ 295 $ 52 $ 347 __________________ (1) Represents cumulative changes in estimated fair value, recognized in earnings, and not in OCI. (2) Includes common stock and certain mutual funds. Cash Equivalents Cash equivalents, which includes securities and other investments with an original or remaining maturity of three months or less at the time of purchase, was $4.5 billion and $3.5 billion, principally at estimated fair value, at June 30, 2024 and December 31, 2023, respectively. Concentrations of Credit Risk There were no investments in any counterparty that were greater than 10% of the Company’s equity, other than the U.S. government and its agencies, at both June 30, 2024 and December 31, 2023. Securities Lending Transactions and Repurchase Agreements Securities, Collateral and Reinvestment Portfolio A summary of these transactions and agreements accounted for as secured borrowings were as follows: June 30, 2024 December 31, 2023 Securities (1) Securities (1) Agreement Type Estimated Fair Value Cash Collateral Received from Counterparties (2) Reinvestment Portfolio at Estimated Estimated Fair Value Cash Collateral Received from Counterparties (2) Reinvestment Portfolio at Estimated (In millions) Securities lending $ 5,761 $ 5,964 $ 5,837 $ 5,528 $ 5,684 $ 5,565 Repurchase agreements $ 2,984 $ 2,975 $ 2,912 $ 3,029 $ 2,975 $ 2,913 __________________ (1) These securities were included within fixed maturity securities AFS, short-term investments and cash equivalents at both June 30, 2024 and December 31, 2023. (2) The liability for cash collateral is included within payables for collateral under securities loaned and other transactions. Contractual Maturities Contractual maturities of these transactions and agreements accounted for as secured borrowings were as follows: June 30, 2024 December 31, 2023 Remaining Maturities Remaining Maturities Security Type Open (1) 1 Month Over 1 Over 6 Total Open (1) 1 Month Over 1 Over 6 Months to 1 Year Total (In millions) Cash collateral liability by security type: Securities lending: U.S. government and agency $ 1,238 $ 2,676 $ 2,050 $ — $ 5,964 $ 943 $ 2,523 $ 2,218 $ — $ 5,684 Repurchase agreements: U.S. government and agency $ — $ 2,975 $ — $ — $ 2,975 $ — $ 2,975 $ — $ — $ 2,975 __________________ (1) The related security could be returned to the Company on the next business day, which would require the Company to immediately return the cash collateral. If the Company is required to return significant amounts of cash collateral on short notice and is forced to sell investments to meet the return obligation, it may have difficulty selling such collateral that is invested in a timely manner, be forced to sell investments in a volatile or illiquid market for less than what otherwise would have been realized under normal market conditions, or both . The securities lending and repurchase agreement reinvestment portfolios consist principally of high quality, liquid, publicly traded fixed maturity securities AFS, short-term investments, cash equivalents or cash. If the securities in the reinvestment portfolio become less liquid, liquidity resources within the general account are available to meet any potential |
Derivatives
Derivatives | 6 Months Ended |
Jun. 30, 2024 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivatives | 10. Derivatives Accounting for Derivatives See Note 1 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report for a description of the Company’s accounting policies for derivatives and Note 11 for information about the fair value hierarchy for derivatives. Derivative Strategies Types of Derivative Instruments and Derivative Strategies The Company is exposed to various risks relating to its ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. The Company uses a variety of strategies to manage these risks, including the use of derivatives. Commonly used derivative instruments include, but are not limited to: • Interest rate derivatives: swaps, total return swaps, caps, floors, futures, swaptions, forwards and synthetic GICs; • Foreign currency exchange rate derivatives: swaps and forwards; • Credit derivatives: purchased or written single name or index credit default swaps, and forwards; and • Equity derivatives: index options, variance swaps, exchange-traded futures and total return swaps. For detailed information on these contracts and the related strategies, see Note 11 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report. Primary Risks Managed by Derivatives The following table presents the primary underlying risk exposure, gross notional amount, and estimated fair value of the Company’s derivatives, excluding embedded derivatives, held at: June 30, 2024 December 31, 2023 Primary Underlying Risk Exposure Gross Notional Amount Estimated Fair Value Gross Estimated Fair Value Assets Liabilities Assets Liabilities (In millions) Derivatives Designated as Hedging Instruments: Fair value hedges: Interest rate swaps Interest rate $ 4,870 $ 1,094 $ 610 $ 4,443 $ 1,257 $ 508 Foreign currency swaps Foreign currency exchange rate 1,317 37 13 1,459 55 1 Subtotal 6,187 1,131 623 5,902 1,312 509 Cash flow hedges: Interest rate swaps Interest rate 3,788 — 323 3,789 1 246 Interest rate forwards Interest rate 369 — 81 970 — 175 Foreign currency swaps Foreign currency exchange rate 31,966 2,181 851 30,342 1,977 846 Subtotal 36,123 2,181 1,255 35,101 1,978 1,267 Total qualifying hedges 42,310 3,312 1,878 41,003 3,290 1,776 Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate swaps Interest rate 15,482 1,428 731 15,516 1,476 638 Interest rate floors Interest rate 8,078 29 — 13,921 39 — Interest rate caps Interest rate 24,970 236 — 28,890 355 — Interest rate futures Interest rate 70 — — 25 — — Interest rate options Interest rate 37,416 216 66 39,226 361 27 Synthetic GICs Interest rate 5,966 — — 6,145 — — Foreign currency swaps Foreign currency exchange rate 4,259 454 9 4,304 446 24 Foreign currency forwards Foreign currency exchange rate 1,097 8 4 1,176 8 10 Credit default swaps — purchased Credit 749 6 3 809 3 7 Credit default swaps — written Credit 11,522 197 5 10,007 186 4 Equity futures Equity market 647 3 1 941 3 — Equity index options Equity market 13,203 222 189 17,703 339 193 Equity total return swaps Equity market 2,020 1 100 1,912 — 218 Total non-designated or nonqualifying derivatives 125,479 2,800 1,108 140,575 3,216 1,121 Total $ 167,789 $ 6,112 $ 2,986 $ 181,578 $ 6,506 $ 2,897 Based on gross notional amounts, a substantial portion of the Company’s derivatives was not designated or did not qualify as part of a hedging relationship at both June 30, 2024 and December 31, 2023. The Company’s use of derivatives includes (i) derivatives that serve as macro hedges of the Company’s exposure to various risks and that generally do not qualify for hedge accounting due to the criteria required under the portfolio hedging rules, (ii) derivatives that economically hedge insurance liabilities that contain mortality or morbidity risk and that generally do not qualify for hedge accounting because the lack of these risks in the derivatives cannot support an expectation of a highly effective hedging relationship, (iii) derivatives that economically hedge MRBs that do not qualify for hedge accounting because the changes in estimated fair value of the MRBs are already recorded in net income, and (iv) written credit default swaps and interest rate swaps that are used to synthetically create investments and that do not qualify for hedge accounting because they do not involve a hedging relationship. For these nonqualified derivatives, changes in market factors can lead to the recognition of fair value changes on the statement of operations without an offsetting gain or loss recognized in earnings for the item being hedged. The Effects of Derivatives on the Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) The following table presents the interim condensed consolidated financial statement location and amount of gain (loss) recognized on fair value, cash flow, nonqualifying hedging relationships and embedded derivatives: Three Months Ended June 30, 2024 Net Net Net Policyholder Interest Credited to PABs OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ — $ — N/A $ (41) $ (14) N/A Hedged items — — N/A 34 12 N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) (2) — N/A — (7) N/A Hedged items 2 — N/A — 7 N/A Subtotal — — N/A (7) (2) N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A $ (71) Amount of gains (losses) reclassified from AOCI into income 6 — — — — (6) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A 206 Amount of gains (losses) reclassified from AOCI into income 1 95 — — — (96) Foreign currency transaction gains (losses) on hedged items — (99) — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A — Amount of gains (losses) reclassified from AOCI into income — 1 — — — (1) Subtotal 7 (3) — — — 32 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — N/A (79) N/A N/A N/A Foreign currency exchange rate derivatives (1) — N/A 7 N/A N/A N/A Credit derivatives — purchased (1) — N/A 5 N/A N/A N/A Credit derivatives — written (1) — N/A (14) N/A N/A N/A Equity derivatives (1) (11) N/A (86) N/A N/A N/A Foreign currency transaction gains (losses) on hedged items — N/A (15) N/A N/A N/A Subtotal (11) N/A (182) N/A N/A N/A Earned income on derivatives 53 — 118 (2) (43) — Synthetic GICs N/A N/A 3 N/A N/A N/A Embedded derivatives N/A N/A 121 N/A N/A N/A Total $ 49 $ (3) $ 60 $ (9) $ (45) $ 32 Three Months Ended June 30, 2023 Net Investment Income Net Investment Gains (Losses) Net Derivative Gains (Losses) Policyholder Benefits and Claims Interest Credited to PABs OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ — $ — N/A $ (135) $ (32) N/A Hedged items (1) — N/A 121 31 N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) (6) — N/A — 13 N/A Hedged items 5 — N/A — (11) N/A Subtotal (2) — N/A (14) 1 N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A $ (156) Amount of gains (losses) reclassified from AOCI into income 13 55 — — — (68) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A 56 Amount of gains (losses) reclassified from AOCI into income 1 310 — — — (311) Foreign currency transaction gains (losses) on hedged items — (293) — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A (1) Amount of gains (losses) reclassified from AOCI into income — — — — — — Subtotal 14 72 — — — (480) Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — N/A (336) N/A N/A N/A Foreign currency exchange rate derivatives (1) — N/A (44) N/A N/A N/A Credit derivatives — purchased (1) — N/A (8) N/A N/A N/A Credit derivatives — written (1) — N/A 60 N/A N/A N/A Equity derivatives (1) (36) N/A (348) N/A N/A N/A Foreign currency transaction gains (losses) on hedged items — N/A 39 N/A N/A N/A Subtotal (36) N/A (637) N/A N/A N/A Earned income on derivatives 39 — 189 3 (34) — Synthetic GICs N/A N/A 4 N/A N/A N/A Embedded derivatives N/A N/A 212 N/A N/A N/A Total $ 15 $ 72 $ (232) $ (11) $ (33) $ (480) Six Months Ended June 30, 2024 Net Net Net Policyholder Interest Credited to PABs OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ — $ — N/A $ (150) $ (53) N/A Hedged items — — N/A 137 50 N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) 2 — N/A — (31) N/A Hedged items — — N/A — 35 N/A Subtotal 2 — N/A (13) 1 N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A $ (215) Amount of gains (losses) reclassified from AOCI into income 14 2 — — — (16) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A 207 Amount of gains (losses) reclassified from AOCI into income 2 (175) — — — 173 Foreign currency transaction gains (losses) on hedged items — 164 — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A — Amount of gains (losses) reclassified from AOCI into income — 1 — — — (1) Subtotal 16 (8) — — — 148 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — N/A (278) N/A N/A N/A Foreign currency exchange rate derivatives (1) — N/A 81 N/A N/A N/A Credit derivatives — purchased (1) — N/A 5 N/A N/A N/A Credit derivatives — written (1) — N/A 9 N/A N/A N/A Equity derivatives (1) (36) N/A (367) N/A N/A N/A Foreign currency transaction gains (losses) on hedged items — N/A (51) N/A N/A N/A Subtotal (36) N/A (601) N/A N/A N/A Earned income on derivatives 83 — 245 (6) (91) — Synthetic GICs N/A N/A 5 N/A N/A N/A Embedded derivatives N/A N/A 355 N/A N/A N/A Total $ 65 $ (8) $ 4 $ (19) $ (90) $ 148 Six Months Ended June 30, 2023 Net Investment Income Net Investment Gains (Losses) Net Derivative Gains (Losses) Policyholder Benefits and Claims Interest Credited to PABs OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ (1) $ — N/A $ (9) $ — N/A Hedged items — — N/A (5) (1) N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) (22) — N/A — 13 N/A Hedged items 21 — N/A — (11) N/A Subtotal (2) — N/A (14) 1 N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A $ 44 Amount of gains (losses) reclassified from AOCI into income 27 57 — — — (84) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A 15 Amount of gains (losses) reclassified from AOCI into income 2 439 — — — (441) Foreign currency transaction gains (losses) on hedged items — (417) — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A (1) Amount of gains (losses) reclassified from AOCI into income — — — — — — Subtotal 29 79 — — — (467) Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — N/A (397) N/A N/A N/A Foreign currency exchange rate derivatives (1) — N/A (139) N/A N/A N/A Credit derivatives — purchased (1) — N/A (17) N/A N/A N/A Credit derivatives — written (1) — N/A 66 N/A N/A N/A Equity derivatives (1) (42) N/A (751) N/A N/A N/A Foreign currency transaction gains (losses) on hedged items — N/A 71 N/A N/A N/A Subtotal (42) N/A (1,167) N/A N/A N/A Earned income on derivatives 82 — 434 8 (67) — Synthetic GICs N/A N/A 9 N/A N/A N/A Embedded derivatives N/A N/A (68) N/A N/A N/A Total $ 67 $ 79 $ (792) $ (6) $ (66) $ (467) __________________ (1) Excludes earned income on derivatives. Fair Value Hedges The Company designates and accounts for the following as fair value hedges when they have met the requirements of fair value hedging: (i) interest rate swaps to convert fixed rate assets and liabilities to floating rate assets and liabilities, and (ii) foreign currency swaps to hedge the foreign currency fair value exposure of foreign currency denominated assets and liabilities. The following table presents the balance sheet classification, carrying amount and cumulative fair value hedging adjustments for items designated and qualifying as hedged items in fair value hedges: Balance Sheet Line Item Carrying Amount of the Cumulative Amount June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 (In millions) Fixed maturity securities AFS $ 118 $ 120 $ 1 $ 1 Mortgage loans $ 208 $ 345 $ (5) $ (10) FPBs $ (2,661) $ (2,863) $ 337 $ 191 PABs $ (2,198) $ (1,844) $ 141 $ 2 __________________ (1) Includes ($101) million and ($113) million of hedging adjustments on discontinued hedging relationships at June 30, 2024 and December 31, 2023, respectively. All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness. Cash Flow Hedges The Company designates and accounts for the following as cash flow hedges when they have met the requirements of cash flow hedging: (i) interest rate swaps to convert floating rate assets and liabilities to fixed rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency cash flow exposure of foreign currency denominated assets and liabilities, (iii) interest rate forwards and credit forwards to lock in the price to be paid for forward purchases of investments, and (iv) interest rate swaps and interest rate forwards to hedge the forecasted purchases of fixed-rate investments. In certain instances, the Company discontinued cash flow hedge accounting because the forecasted transactions were no longer probable of occurring. Because certain of the forecasted transactions also were not probable of occurring within two months of the anticipated date, the Company reclassified amounts from AOCI into income. These amounts were $2 million for both the three months and six months ended June 30, 2024, and $19 million and $20 million for the three months and six months ended June 30, 2023, respectively. At both June 30, 2024 and December 31, 2023, the maximum length of time over which the Company was hedging its exposure to variability in future cash flows for forecasted transactions did not exceed five years. At June 30, 2024 and December 31, 2023, the balance in AOCI associated with cash flow hedges was $1.0 billion and $894 million, respectively. All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness. At June 30, 2024, the Company expected to reclassify $289 million of deferred net gains (losses) on derivatives in AOCI to earnings within the next 12 months. Credit Derivatives In connection with synthetically created credit investment transactions, the Company writes credit default swaps for which it receives a premium to insure credit risk. Such credit derivatives are included within the effects of derivatives on the interim condensed consolidated statements of operations and comprehensive income (loss) table. If a credit event occurs, as defined by the contract, the contract may be cash settled or it may be settled gross by the Company paying the counterparty the specified swap notional amount in exchange for the delivery of par quantities of the referenced credit obligation. The Company can terminate these contracts at any time through cash settlement with the counterparty at an amount equal to the then current estimated fair value of the credit default swaps. The following table presents the estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps at: June 30, 2024 December 31, 2023 Rating Agency Designation of Referenced Estimated Maximum Weighted Estimated Maximum Weighted (Dollars in millions) Aaa/Aa/A Single name credit default swaps (3) $ — $ — — $ — $ 10 0.5 Credit default swaps referencing indices 82 4,125 2.6 80 3,831 2.7 Subtotal 82 4,125 2.6 80 3,841 2.7 Baa Single name credit default swaps (3) 1 55 1.8 1 55 2.3 Credit default swaps referencing indices 105 7,213 4.4 102 5,982 5.6 Subtotal 106 7,268 4.4 103 6,037 5.5 Ba Credit default swaps referencing indices 2 25 2.5 2 25 3.0 Subtotal 2 25 2.5 2 25 3.0 B Credit default swaps referencing indices 5 74 4.5 1 74 5.0 Subtotal 5 74 4.5 1 74 5.0 Caa Credit default swaps referencing indices (3) 30 2.0 (4) 30 2.5 Subtotal (3) 30 2.0 (4) 30 2.5 Total $ 192 $ 11,522 3.7 $ 182 $ 10,007 4.4 __________________ (1) The rating agency designations are based on availability and the midpoint of the applicable ratings among Moody’s Investors Service (“Moody’s”), S&P Global Ratings (“S&P”) and Fitch Ratings. If no rating is available from a rating agency, then an internally developed rating is used. (2) The weighted average years to maturity of the credit default swaps is calculated based on weighted average gross notional amounts. (3) Single name credit default swaps may be referenced to the credit of corporations, foreign governments, or municipals. Credit Risk on Freestanding Derivatives The Company may be exposed to credit-related losses in the event of nonperformance by its counterparties to derivatives. Generally, the current credit exposure of the Company’s derivatives is limited to the net positive estimated fair value of derivatives at the reporting date after taking into consideration the existence of master netting or similar agreements and any collateral received pursuant to such agreements. The Company manages its credit risk related to derivatives by entering into transactions with creditworthy counterparties in jurisdictions in which it understands that close-out netting should be enforceable and establishing and monitoring exposure limits. The Company’s bilateral contracts between two counterparties (“OTC-bilateral”) derivative transactions are governed by International Swaps and Derivatives Association, Inc. (“ISDA”) Master Agreements which provide for legally enforceable set-off and close-out netting of exposures to specific counterparties in the event of early termination of a transaction, which includes, but is not limited to, events of default and bankruptcy. In the event of an early termination, close-out netting permits the Company (subject to financial regulations such as the Orderly Liquidation Authority under Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act) to set off receivables from the counterparty against payables to the same counterparty arising out of all included transactions and to apply collateral to the obligations without application of the automatic stay, upon the counterparty’s bankruptcy. All of the Company’s ISDA Master Agreements also include Credit Support Annex provisions which require both the pledging and accepting of collateral in connection with its OTC-bilateral derivatives as required by applicable law. Additionally, the Company is required to pledge initial margin for certain new OTC-bilateral derivative transactions to third party custodians. The Company’s over-the-counter cleared (“OTC-cleared”) derivatives are effected through central clearing counterparties and its exchange-traded derivatives are effected through regulated exchanges. Such positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by brokers and central clearinghouses to such derivatives. See Note 11 for a description of the impact of credit risk on the valuation of derivatives. The estimated fair values of the Company’s net derivative assets and net derivative liabilities after the application of master netting agreements and collateral were as follows at: June 30, 2024 December 31, 2023 Derivatives Subject to a Master Netting Arrangement or a Similar Arrangement Assets Liabilities Assets Liabilities (In millions) Gross estimated fair value of derivatives: OTC-bilateral (1) $ 6,083 $ 3,013 $ 6,534 $ 2,892 OTC-cleared (1) 143 41 112 13 Exchange-traded 3 1 3 — Total gross estimated fair value of derivatives presented on the interim condensed consolidated balance sheets (1) 6,229 3,055 6,649 2,905 Gross amounts not offset on the interim condensed consolidated balance sheets: Gross estimated fair value of derivatives: (2) OTC-bilateral (2,411) (2,411) (2,350) (2,350) OTC-cleared (12) (12) (4) (4) Exchange-traded (1) (1) — — Cash collateral: (3), (4) OTC-bilateral (2,645) — (2,872) — OTC-cleared (113) — (105) (1) Securities collateral: (5) OTC-bilateral (1,021) (602) (1,283) (542) OTC-cleared — (29) — (8) Exchange-traded — — — — Net amount after application of master netting agreements and collateral $ 26 $ — $ 35 $ — __________________ (1) At June 30, 2024 and December 31, 2023, derivative assets included income (expense) accruals reported in accrued investment income or in other liabilities of $117 million and $143 million, respectively, and derivative liabilities included (income) expense accruals reported in accrued investment income or in other liabilities of $69 million and $8 million, respectively. (2) Estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals. (3) Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives, where the central clearinghouse treats variation margin as collateral, is included in cash and cash equivalents, short-term investments or in fixed maturity securities AFS, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet. (4) The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange- traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after app lication of netting agreements. At June 30, 2024 and December 31, 2023, the Company received excess cash collateral of $48 million and $154 million, respectively, and provided excess cash collateral of $4 million for both periods, which are not included in the table above due to the foregoing limitation. (5) Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at June 30, 2024, none of the collateral had been sold or re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities AFS on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At June 30, 2024 and December 31, 2023, the Company received excess securities collateral with an estimated fair value of $455 million and $286 million, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At June 30, 2024 and December 31, 2023, the Company provided excess securities collateral with an estimated fair value of $905 million and $1.1 billion, respectively, for its OTC-bilateral derivatives, $416 million and $495 million, respectively, for its OTC-cleared derivatives, and $31 million and $56 million, respectively, for its exchange-traded derivatives, which are not included in the table above due to th e foregoing limitation. The Company’s collateral arrangements for its OTC-bilateral derivatives generally require the counterparty in a net liability position, after considering the effect of netting agreements, to pledge collateral when the collateral amount owed by that counterparty reaches a minimum transfer amount. All of the Company’s netting agreements for derivatives contain provisions that require both Metropolitan Life Insurance Company and the counterparty to maintain a specific investment grade financial strength or credit rating from each of Moody’s and S&P. If a party’s financial strength or credit rating were to fall below that specific investment grade financial strength or credit rating, that party would be in violation of these provisions, and the other party to the derivatives could terminate the transactions and demand immediate settlement payment based on such party’s reasonable valuation of the derivatives. The following table presents the estimated fair value of the Company’s OTC-bilateral derivatives that were in a net liability position after considering the effect of netting agreements, together with the estimated fair value and balance sheet location of the collateral pledged. June 30, 2024 December 31, 2023 Derivatives Strength-Contingent Derivatives Total Derivatives Strength-Contingent Derivatives Total (In millions) Estimated fair value of derivatives in a net liability position (1) $ 595 $ 7 $ 602 $ 542 $ — $ 542 Estimated fair value of collateral provided: Fixed maturity securities AFS $ 916 $ 8 $ 924 $ 896 $ — $ 896 __________________ (1) After taking into consideration the existence of netting agreements. Embedded Derivatives The Company issues certain products or purchases certain investments that contain embedded derivatives that are required to be separated from their host contracts and accounted for as freestanding derivatives. The following table presents the estimated fair value and balance sheet location of the Company’s embedded derivatives that have been separated from their host contracts at: Balance Sheet Location June 30, 2024 December 31, 2023 (In millions) Embedded derivatives within asset host contracts: Assumed on affiliated reinsurance Other invested assets $ 148 $ 41 Funds withheld on affiliated reinsurance Other invested assets (22) (26) Total $ 126 $ 15 Embedded derivatives within liability host contracts: Assumed on affiliated reinsurance Other liabilities $ — $ 104 Funds withheld on affiliated reinsurance Other liabilities (447) (304) Fixed annuities with equity indexed returns PABs 168 163 Total $ (279) $ (37) |
Fair Value
Fair Value | 6 Months Ended |
Jun. 30, 2024 | |
Fair Value Disclosures [Abstract] | |
Fair Value | 11. Fair Value Considerable judgment is often required in interpreting the market data used to develop estimates of fair value, and the use of different assumptions or valuation methodologies may have a material effect on the estimated fair value amounts. Recurring Fair Value Measurements The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy, including those items for which the Company has elected the FVO, are presented below at: June 30, 2024 Fair Value Hierarchy Level 1 Level 2 Level 3 Total Estimated Fair Value (In millions) Assets Fixed maturity securities AFS: U.S. corporate $ — $ 39,926 $ 8,921 $ 48,847 Foreign corporate — 15,875 8,554 24,429 U.S. government and agency 10,834 11,705 — 22,539 RMBS — 18,818 1,746 20,564 ABS & CLO — 10,043 1,867 11,910 Municipals — 5,477 — 5,477 CMBS — 4,914 500 5,414 Foreign government — 2,965 11 2,976 Total fixed maturity securities AFS 10,834 109,723 21,599 142,156 Short-term investments 1,479 186 3 1,668 Other investments 46 91 1,434 1,571 Derivative assets: (1) Interest rate — 3,003 — 3,003 Foreign currency exchange rate — 2,680 — 2,680 Credit — 203 — 203 Equity market 3 217 6 226 Total derivative assets 3 6,103 6 6,112 Embedded derivatives within asset host contracts (4) — — 126 126 MRBs — — 230 230 Separate account assets (2) 13,630 64,986 969 79,585 Total assets (3) $ 25,992 $ 181,089 $ 24,367 $ 231,448 Liabilities Derivative liabilities: (1) Interest rate $ — $ 1,730 $ 81 $ 1,811 Foreign currency exchange rate — 877 — 877 Credit — 8 — 8 Equity market 1 289 — 290 Total derivative liabilities 1 2,904 81 2,986 Embedded derivatives within liability host contracts (4) — — (279) (279) MRBs — — 2,391 2,391 Separate account liabilities (2) — 3 — 3 Total liabilities $ 1 $ 2,907 $ 2,193 $ 5,101 December 31, 2023 Fair Value Hierarchy Level 1 Level 2 Level 3 Total Estimated Fair Value (In millions) Assets Fixed maturity securities AFS: U.S. corporate $ — $ 41,718 $ 8,775 $ 50,493 Foreign corporate — 16,875 8,340 25,215 U.S. government and agency 8,963 12,097 — 21,060 RMBS 3 17,616 1,329 18,948 ABS & CLO — 10,109 1,532 11,641 Municipals — 6,319 — 6,319 CMBS — 5,499 335 5,834 Foreign government — 3,281 14 3,295 Total fixed maturity securities AFS 8,966 113,514 20,325 142,805 Short-term investments 2,745 288 15 3,048 Other investments 76 77 1,317 1,470 Derivative assets: (1) Interest rate — 3,489 — 3,489 Foreign currency exchange rate — 2,486 — 2,486 Credit — 181 8 189 Equity market 3 332 7 342 Total derivative assets 3 6,488 15 6,506 Embedded derivatives within asset host contracts (4) — — 15 15 MRBs — — 177 177 Separate account assets (2) 13,945 68,284 968 83,197 Total assets (3) $ 25,735 $ 188,651 $ 22,832 $ 237,218 Liabilities Derivative liabilities: (1) Interest rate $ — $ 1,419 $ 175 $ 1,594 Foreign currency exchange rate — 881 — 881 Credit — 11 — 11 Equity market — 411 — 411 Total derivative liabilities — 2,722 175 2,897 Embedded derivatives within liability host contracts (4) — — (37) (37) MRBs — — 2,878 2,878 Separate account liabilities (2) 4 4 — 8 Total liabilities $ 4 $ 2,726 $ 3,016 $ 5,746 __________________ (1) Derivative assets are presented within other invested assets on the interim condensed consolidated balance sheets and derivative liabilities are presented within other liabilities on the interim condensed consolidated balance sheets. The amounts are presented gross in the tables above to reflect the presentation on the interim condensed consolidated balance sheets, but are presented net for purposes of the rollforward in the Fair Value Measurements Using Significant Unobservable Inputs (Level 3) tables. (2) Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders whose liability is reflected within separate account liabilities. Separate account liabilities are set equal to the estimated fair value of separate account assets. Separate account liabilities presented in the tables above represent derivative liabilities. (3) Total assets included in the fair value hierarchy exclude OLPI that are measured at estimated fair value using the net asset value (“NAV”) per share (or its equivalent) practical expedient. The estimated fair value of such investments was $48 million at both June 30, 2024 and December 31, 2023. (4) Embedded derivatives within asset host contracts are presented within other invested assets on the interim condensed consolidated balance sheets. Embedded derivatives within liability host contracts are presented within PABs and other liabilities on the interim condensed consolidated balance sheets. The following describes the valuation methodologies used to measure assets and liabilities at fair value. Investments Securities, Short-term Investments and Other Investments When available, the estimated fair value of these financial instruments is based on quoted prices in active markets that are readily and regularly obtainable. Generally, these are the most liquid of the Company’s securities holdings, and valuation of these securities does not involve management’s judgment. When quoted prices in active markets are not available, the determination of estimated fair value of securities is based on market standard valuation methodologies, giving priority to observable inputs. The significant inputs to the market standard valuation methodologies for certain types of securities with reasonable levels of price transparency are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. When observable inputs are not available, the market standard valuation methodologies rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs can be based, in large part, on management’s judgment or estimation and cannot be supported by reference to market activity. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such investments. The estimated fair value of short-term investments and other investments is determined on a basis consistent with the methodologies described herein. The valuation approaches and key inputs for each category of assets or liabilities that are classified within Level 2 and Level 3 of the fair value hierarchy are presented below. The primary valuation approaches are the market approach, which considers recent prices from market transactions involving identical or similar assets or liabilities, and the income approach, which converts expected future amounts (e.g., cash flows) to a single current, discounted amount. The valuation of most instruments listed below is determined using independent pricing sources, matrix pricing, discounted cash flow methodologies or other similar techniques that use either observable market inputs or unobservable inputs. Instrument Level 2 Observable Inputs Level 3 Unobservable Inputs Fixed maturity securities AFS U.S. corporate and Foreign corporate securities Valuation Approaches: Principally the market and income approaches. Valuation Approaches: Principally the market approach. Key Inputs: Key Inputs: • quoted prices in markets that are not active • illiquidity premium • benchmark yields; spreads off benchmark yields; new issuances; issuer ratings • delta spread adjustments to reflect specific credit-related issues • trades of identical or comparable securities; duration • credit spreads • privately-placed securities are valued using the additional key inputs: • quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2 • market yield curve; call provisions • observable prices and spreads for similar public or private securities that incorporate the credit quality and industry sector of the issuer • independent non-binding broker quotations • delta spread adjustments to reflect specific credit-related issues U.S. government and agency securities, Municipals and Foreign government securities Valuation Approaches: Principally the market approach. Valuation Approaches: Principally the market approach. Key Inputs: Key Inputs: • quoted prices in markets that are not active • independent non-binding broker quotations • benchmark U.S. Treasury yield or other yields • quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2 • the spread off the U.S. Treasury yield curve for the identical security • issuer ratings and issuer spreads; broker-dealer quotations • credit spreads • comparable securities that are actively traded Structured Products Valuation Approaches: Principally the market and income approaches. Valuation Approaches: Principally the market and income approaches. Key Inputs: Key Inputs: • quoted prices in markets that are not active • credit spreads • spreads for actively traded securities; spreads off benchmark yields • quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2 • expected prepayment speeds and volumes • current and forecasted loss severity; ratings; geographic region • independent non-binding broker quotations • weighted average coupon and weighted average maturity • credit ratings • average delinquency rates; DSCR • credit ratings • issuance-specific information, including, but not limited to: • collateral type; structure of the security; vintage of the loans • payment terms of the underlying assets • payment priority within the tranche; deal performance Instrument Level 2 Observable Inputs Level 3 Unobservable Inputs Short-term investments and Other investments • Certain short-term investments and certain other investments are of a similar nature and class to the fixed maturity securities AFS described above; while certain other investments are similar to equity securities. The valuation approaches and observable inputs used in their valuation are also similar to those described above. Other investments contain equity securities valued using quoted prices in markets that are not considered active. • Certain short-term investments and certain other investments are of a similar nature and class to the fixed maturity securities AFS described above, while certain other investments are similar to equity securities. The valuation approaches and unobservable inputs used in their valuation are also similar to those described above. Other investments contain equity securities that use key unobservable inputs such as credit ratings, issuance structures and those described above for fixed maturities AFS. Other investments also include certain REJV and use the valuation approach and key inputs as described for OLPI below. Separate account assets and Separate account liabilities (1) Mutual funds and hedge funds without readily determinable fair values as prices are not published publicly Key Input: • N/A • quoted prices or reported NAV provided by the fund managers OLPI • N/A Valued giving consideration to the underlying holdings Key Inputs: • liquidity; bid/ask spreads; performance record of the fund manager • other relevant variables that may impact the exit value of the particular partnership interest __________________ (1) Estimated fair value equals carrying value, based on the value of the underlying assets, including: mutual fund interests, fixed maturity securities, equity securities, derivatives, hedge funds, OLPI, short-term investments and cash and cash equivalents. The estimated fair value of fixed maturity securities, equity securities, derivatives, short-term investments and cash and cash equivalents is determined on a basis consistent with the assets described under “— Securities, Short-term Investments and Other Investments” and “— Derivatives — Freestanding Derivatives.” Derivatives The estimated fair value of derivatives is determined through the use of quoted market prices for exchange-traded derivatives, or through the use of pricing models for OTC-bilateral and OTC-cleared derivatives. The determination of estimated fair value, when quoted market values are not available, is based on market standard valuation methodologies and inputs that management believes are consistent with what other market participants would use when pricing such instruments. Derivative valuations can be affected by changes in interest rates, foreign currency exchange rates, financial indices, credit spreads, default risk, nonperformance risk, volatility, liquidity and changes in estimates and assumptions used in the pricing models. The significant inputs to the pricing models for most OTC-bilateral and OTC-cleared derivatives are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. With respect to certain OTC-bilateral and OTC-cleared derivatives, management may rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs may involve significant management judgment or estimation. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such derivatives. Most inputs for OTC-bilateral and OTC-cleared derivatives are mid-market inputs but, in certain cases, liquidity adjustments are made when they are deemed more representative of exit value. Market liquidity, as well as the use of different methodologies, assumptions and inputs, may have a material effect on the estimated fair values of the Company’s derivatives and could materially affect net income. The credit risk of both the counterparty and the Company is considered in determining the estimated fair value for all OTC-bilateral and OTC-cleared derivatives, and any potential credit adjustment is based on the net exposure by counterparty after taking into account the effects of netting agreements and collateral arrangements. The Company values its OTC-bilateral and OTC-cleared derivatives using standard swap curves which may include a spread to the risk-free rate, depending upon specific collateral arrangements. This credit spread is appropriate for those parties that execute trades at pricing levels consistent with similar collateral arrangements. As the Company and its significant derivative counterparties generally execute trades at such pricing levels and hold sufficient collateral, additional credit risk adjustments are not currently required in the valuation process. The Company’s ability to consistently execute at such pricing levels is, in part, due to the netting agreements and collateral arrangements that are in place with all of its significant derivative counterparties. An evaluation of the requirement to make additional credit risk adjustments is performed by the Company each reporting period. Freestanding Derivatives Level 2 Valuation Approaches and Key Inputs: This level includes all types of derivatives utilized by the Company with the exception of exchange-traded derivatives included within Level 1 and those derivatives with unobservable inputs as described in Level 3. Level 3 Valuation Approaches and Key Inputs: These valuation methodologies generally use the same inputs as described in the corresponding sections for Level 2 measurements of derivatives. However, these derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. Freestanding derivatives are principally valued using the income approach. Valuations of non-option-based derivatives utilize present value techniques, whereas valuations of option-based derivatives utilize option pricing models. Key inputs are as follows: Instrument Interest Rate Foreign Currency Credit Equity Market Inputs common to Level 2 and Level 3 by instrument type • swap yield curves • swap yield curves • swap yield curves • swap yield curves • basis curves • basis curves • credit curves • spot equity index levels • interest rate volatility (1) • currency spot rates • recovery rates • dividend yield curves • cross currency basis curves • equity volatility (1) Level 3 • swap yield curves (2) • swap yield curves (2) • swap yield curves (2) • dividend yield curves (2) • basis curves (2) • basis curves (2) • credit curves (2) • equity volatility (1), (2) • repurchase rates • cross currency basis curves (2) • credit spreads • correlation between model inputs (1) • interest rate volatility (1), (2) • currency correlation • repurchase rates • independent non-binding broker quotations __________________ (1) Option-based only. (2) Extrapolation beyond the observable limits of the curve(s). Embedded Derivatives Embedded derivatives principally include equity-indexed annuity contracts and investment risk within funds withheld related to certain reinsurance agreements. Embedded derivatives are recorded at estimated fair value with changes in estimated fair value reported in net income. The estimated fair value of the embedded derivatives within funds withheld related to certain ceded reinsurance and experience refund related to certain assumed reinsurance is determined based on the change in estimated fair value of the underlying assets held by the Company in a reference portfolio backing the reinsurance liability. The estimated fair value of the underlying assets is determined as described in “— Investments — Securities, Short-term Investments and Other Investments.” The estimated fair value of these embedded derivatives is included, along with their underlying host contracts, in other liabilities and other invested assets on the interim condensed consolidated balance sheets with changes in estimated fair value recorded in net derivative gains (losses). Changes in the credit spreads on the underlying assets, interest rates and market volatility may result in significant fluctuations in the estimated fair value of these embedded derivatives that could materially affect net income. The estimated fair value of the embedded equity indexed derivatives, based on the present value of future equity returns to the policyholder using actuarial and present value assumptions including expectations concerning policyholder behavior, is calculated by the Company’s actuarial department. The calculation is based on in-force business and uses standard capital market techniques, such as Black-Scholes, to calculate the value of the portion of the embedded derivative for which the terms are set. The portion of the embedded derivative covering the period beyond where terms are set is calculated as the present value of amounts expected to be spent to provide equity indexed returns in those periods. The valuation of these embedded derivatives also includes the establishment of a risk margin, as well as changes in nonperformance risk. MRBs See Note 5 for information on the Company’s valuation approaches and key inputs for MRBs. Transfers between Levels Overall, transfers between levels occur when there are changes in the observability of inputs and market activity. Transfers into or out of Level 3: Assets and liabilities are transferred into Level 3 when a significant input cannot be corroborated with market observable data. This occurs when market activity decreases significantly and underlying inputs cannot be observed, current prices are not available, and/or when there are significant variances in quoted prices, thereby affecting transparency. Assets and liabilities are transferred out of Level 3 when circumstances change such that a significant input can be corroborated with market observable data. This may be due to a significant increase in market activity, a specific event, or one or more significant input(s) becoming observable. Assets and Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) The following table presents certain quantitative information about the significant unobservable inputs used in the fair value measurement, and the sensitivity of the estimated fair value to changes in those inputs, for the more significant asset and liability classes measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at: June 30, 2024 December 31, 2023 Impact of Valuation Techniques Significant Range Weighted Range Weighted Fixed maturity securities AFS (3) U.S. corporate and foreign corporate • Matrix pricing • Offered quotes (4) 53 - 125 93 4 - 131 95 Increase • Market pricing • Quoted prices (4) 27 - 111 94 — - 110 93 Increase RMBS • Market pricing • Quoted prices (4) — - 116 96 — - 112 93 Increase (5) ABS & CLO • Market pricing • Quoted prices (4) 84 - 103 96 78 - 101 94 Increase (5) Derivatives Interest rate • Present value techniques • Swap yield (6) 428 - 452 437 367 - 399 385 Increase (7) Credit • Consensus pricing • Offered quotes (8) MRBs Direct and assumed guaranteed minimum benefits • Option pricing techniques • Mortality rates: Ages 0 - 40 0.01% - 0.13% 0.05% 0.01% - 0.13% 0.05% (9) Ages 41 - 60 0.05% - 0.67% 0.22% 0.05% - 0.67% 0.22% (9) Ages 61 - 115 0.35% - 100% 1.23% 0.35% - 100% 1.23% (9) • Lapse rates: Durations 1 - 10 0.80% - 20.10% 8.72% 0.80% - 20.10% 8.72% Decrease (10) Durations 11 - 20 3.10% - 10.10% 4.34% 3.10% - 10.10% 4.34% Decrease (10) Durations 21 - 116 0.10% - 10.10% 4.59% 0.10% - 10.10% 4.59% Decrease (10) • Utilization rates 0.20% - 22% 0.44% 0.20% - 22% 0.44% Increase (11) • Withdrawal rates 0.25% - 7.75% 4.47% 0.25% - 7.75% 4.47% (12) • Long-term equity volatilities 16.37% - 21.85% 18.55% 16.37% - 21.85% 18.55% Increase (13) • Nonperformance risk spread 0.33% - 0.66% 0.73% 0.38% - 0.70% 0.73% Decrease (14) __________________ (1) The weighted average for fixed maturity securities AFS and derivatives is determined based on the estimated fair value of the securities and derivatives. The weighted average for MRBs is determined based on a combination of account values and experience data. (2) The impact of a decrease in input would have resulted in the opposite impact on estimated fair value. For MRBs, changes to direct and assumed guaranteed minimum benefits are based on liability positions. (3) Significant increases (decreases) in expected default rates in isolation would have resulted in substantially lower (higher) valuations. (4) Range and weighted average are presented in accordance with the market convention for fixed maturity securities AFS of dollars per hundred dollars of par. (5) Changes in the assumptions used for the probability of default would have been accompanied by a directionally similar change in the assumption used for the loss severity and a directionally opposite change in the assumptions used for prepayment rates. (6) Ranges represent the rates across different yield curves and are presented in basis points. The swap yield curves are utilized among different types of derivatives to project cash flows, as well as to discount future cash flows to present value. Since this valuation methodology uses a range of inputs across a yield curve to value the derivative, presenting a range is more representative of the unobservable input used in the valuation. (7) Changes in estimated fair value are based on long U.S. dollar net asset positions and will be inversely impacted for short U.S. dollar net asset positions. (8) At June 30, 2024 and December 31, 2023, independent non-binding broker quotations were used in the determination of 0% and less than 1%, respectively, of the total net derivative estimated fair value. (9) Mortality rates vary by age and by demographic characteristics such as gender. Mortality rate assumptions are based on company experience. A mortality improvement assumption is also applied. For any given contract, mortality rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. For contracts that contain only a GMDB, any increase (decrease) in mortality rates result in an increase (decrease) in the estimated fair value of MRBs. Generally, for contracts that contain both a GMDB and a living benefit (e.g., GMIB, GMWB, GMAB), any increase (decrease) in mortality rates result in a decrease (increase) in the estimated fair value of MRBs. (10) Base lapse rates are adjusted at the contract level based on a comparison of the actuarially calculated guaranteed values and the current policyholder account value, as well as other factors, such as the applicability of any surrender charges. A dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in the money contracts are less likely to lapse. Lapse rates are also generally assumed to be lower in periods when a surrender charge applies. For any given contract, lapse rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. (11) The utilization rate assumption estimates the percentage of contractholders with GMIBs or a lifetime withdrawal benefit who will elect to utilize the benefit upon becoming eligible. The rates may vary by the type of guarantee, the amount by which the guaranteed amount is greater than the account value, the contract’s withdrawal history and by the age of the policyholder. For any given contract, utilization rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. (12) The withdrawal rate represents the percentage of account balance that any given policyholder will elect to withdraw from the contract each year. The withdrawal rate assumption varies by age and duration of the contract, and also by other factors such as benefit type. For any given contract, withdrawal rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. For GMWBs, any increase (decrease) in withdrawal rates results in an increase (decrease) in the estimated fair value of the guarantees. For GMABs and GMIBs, any increase (decrease) in withdrawal rates results in a decrease (increase) in the estimated fair value. (13) Long-term equity volatilities represent equity volatility beyond the period for which observable equity volatilities are available. For any given contract, long-term equity volatility rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. (14) Nonperformance risk spread varies by duration and by currency. For any given contract, multiple nonperformance risk spreads will apply, depending on the duration of the cash flow being discounted for purposes of valuing the MRBs. All other classes of securities classified within Level 3, including those within Other investments, Separate account assets, and Embedded derivatives within funds withheld related to certain ceded reinsurance, use the same valuation techniques and significant unobservable inputs as previously described for Level 3 securities. Generally, all other classes of assets and liabilities classified within Level 3 that are not included above use the same valuation techniques and significant unobservable inputs as previously described for Level 3. The sensitivity of the estimated fair value to changes in the significant unobservable inputs for these other assets and liabilities is similar in nature to that described in the preceding table. The valuation techniques and significant unobservable inputs used in the fair value measurement for the more significant assets measured at estimated fair value on a nonrecurring basis and determined using significant unobservable inputs (Level 3) are summarized in “— Nonrecurring Fair Value Measurements.” The following tables summarize the change of assets (liabilities) measured at estimated fair value on a recurring basis using significant unobservable inputs (Level 3), excluding MRBs (see Note 5): Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Fixed Maturity Securities AFS Corporate (6) Structured Municipals Foreign Short-term (In millions) Three Months Ended June 30, 2024 Balance, beginning of period $ 17,154 $ 3,543 $ — $ 15 $ 11 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (29) 10 — — — Total realized/unrealized gains (losses) included in AOCI (137) 13 — (4) — Purchases (3) 1,148 934 — — 1 Sales (3) (620) (104) — — (9) Issuances (3) — — — — — Settlements (3) — — — — — Transfers into Level 3 (4) 64 51 — — — Transfers out of Level 3 (4) (105) (334) — — — Balance, end of period $ 17,475 $ 4,113 $ — $ 11 $ 3 Three Months Ended June 30, 2023 Balance, beginning of period $ 15,717 $ 3,501 $ — $ 15 $ 57 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (11) 7 — (1) — Total realized/unrealized gains (losses) included in AOCI (101) (20) — 3 (1) Purchases (3) 808 67 4 — 5 Sales (3) (393) (86) — — (44) Issuances (3) — — — — — Settlements (3) — — — — — Transfers into Level 3 (4) 125 34 — — — Transfers out of Level 3 (4) (129) (94) — — — Balance, end of period $ 16,016 $ 3,409 $ 4 $ 17 $ 17 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at June 30, 2024 (5) $ (11) $ 9 $ — $ — $ — Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at June 30, 2023 (5) $ (10) $ 8 $ — $ (1) $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at June 30, 2024 (5) $ (147) $ 12 $ — $ (4) $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at June 30, 2023 (5) $ (110) $ (21) $ — $ 3 $ (1) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Other Investments Net Net Embedded Separate (In millions) Three Months Ended June 30, 2024 Balance, beginning of period $ 1,403 $ (121) $ 285 $ 980 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) 28 (1) 121 (5) Total realized/unrealized gains (losses) included in AOCI — (14) — — Purchases (3) 12 — — 44 Sales (3) (9) — — (50) Issuances (3) — — — — Settlements (3) — 67 (1) — Transfers into Level 3 (4) — — — — Transfers out of Level 3 (4) — (6) — — Balance, end of period $ 1,434 $ (75) $ 405 $ 969 Three Months Ended June 30, 2023 Balance, beginning of period $ 1,052 $ (271) $ 168 $ 1,000 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) 63 (12) 212 (10) Total realized/unrealized gains (losses) included in AOCI — (39) — — Purchases (3) — — — 72 Sales (3) — — — (20) Issuances (3) — — — — Settlements (3) — 44 (2) — Transfers into Level 3 (4) — — — 12 Transfers out of Level 3 (4) — — — — Balance, end of period $ 1,115 $ (278) $ 378 $ 1,054 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at June 30, 2024 (5) $ 28 $ — $ 121 $ — Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at June 30, 2023 (5) $ 64 $ 1 $ 212 $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at June 30, 2024 (5) $ — $ (9) $ — $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at June 30, 2023 (5) $ — $ (48) $ — $ — Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Fixed Maturity Securities AFS Corporate (6) Structured Municipals Foreign Short-term (In millions) Six Months Ended June 30, 2024 Balance, beginning of period $ 17,115 $ 3,196 $ — $ 14 $ 15 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (42) 14 — 2 — Total realized/unrealized gains (losses) included in AOCI (317) 53 — (5) — Purchases (3) 1,783 1,104 — — 3 Sales (3) (1,038) (257) — — (15) Issuances (3) — — — — — Settlements (3) — — — — — Transfers into Level 3 (4) 97 101 — — — Transfers out of Level 3 (4) (123) (98) — — — Balance, end of period $ 17,475 $ 4,113 $ — $ 11 $ 3 Six Months Ended June 30, 2023 Balance, beginning of period $ 14,733 $ 3,373 $ — $ 15 $ 47 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (18) 1 — (1) — Total realized/unrealized gains (losses) included in AOCI 285 — — 2 — Purchases (3) 2,015 153 4 2 17 Sales (3) (848) (175) — (1) (47) Issuances (3) — — — — — |
Equity
Equity | 6 Months Ended |
Jun. 30, 2024 | |
Equity [Abstract] | |
Equity | 12. Equity AOCI Information regarding changes in the balances of each component of AOCI attributable to Metropolitan Life Insurance Company was as follows: Three Months Unrealized Investment Gains (Losses), Net of Related Offsets (1) Deferred FPBs Discount Rate Remeasurement Gains (Losses) MRBs Instrument-Specific Credit Risk Remeasurement Gains (Losses) Foreign Defined Total (In millions) Balance, beginning of period $ (7,854) $ 796 $ 618 $ (13) $ (112) $ (163) $ (6,728) OCI before reclassifications (1,290) 135 1,505 (13) (20) — 317 Deferred income tax benefit (expense) 317 (28) (330) 3 3 — (35) AOCI before reclassifications, net of income tax (8,827) 903 1,793 (23) (129) (163) (6,446) Amounts reclassified from AOCI 153 (103) — — — 3 53 Deferred income tax benefit (expense) (37) 22 — — — — (15) Amounts reclassified from AOCI, net of income tax 116 (81) — — — 3 38 Balance, end of period $ (8,711) $ 822 $ 1,793 $ (23) $ (129) $ (160) $ (6,408) Three Months Unrealized Investment Gains (Losses), Net of Related Offsets (1) Deferred FPBs Discount Rate Remeasurement Gains (Losses) MRBs Instrument-Specific Credit Risk Remeasurement Gains (Losses) Foreign Defined Total (In millions) Balance, beginning of period $ (8,167) $ 1,568 $ (106) $ 149 $ (139) $ (137) $ (6,832) OCI before reclassifications (2,114) (101) 1,051 (73) 17 — (1,220) Deferred income tax benefit (expense) 452 21 (219) 16 (5) — 265 AOCI before reclassifications, net of income tax (9,829) 1,488 726 92 (127) (137) (7,787) Amounts reclassified from AOCI 829 (379) — — — 3 453 Deferred income tax benefit (expense) (167) 79 — — — (1) (89) Amounts reclassified from AOCI, net of income tax 662 (300) — — — 2 364 Balance, end of period $ (9,167) $ 1,188 $ 726 $ 92 $ (127) $ (135) $ (7,423) Six Months Unrealized Deferred FPBs Discount Rate Remeasurement Gains (Losses) MRBs Instrument-Specific Credit Risk Remeasurement Gains (Losses) Foreign Defined Total (In millions) Balance, beginning of period $ (6,495) $ 705 $ (807) $ 33 $ (143) $ (165) $ (6,872) OCI before reclassifications (3,214) (8) 3,309 (71) 19 — 35 Deferred income tax benefit (expense) 760 2 (709) 15 (5) — 63 AOCI before reclassifications, net of income tax (8,949) 699 1,793 (23) (129) (165) (6,774) Amounts reclassified from AOCI 312 156 — — — 6 474 Deferred income tax benefit (expense) (74) (33) — — — (1) (108) Amounts reclassified from AOCI, net of income tax 238 123 — — — 5 366 Balance, end of period $ (8,711) $ 822 $ 1,793 $ (23) $ (129) $ (160) $ (6,408) Six Months Unrealized Deferred FPBs Discount Rate Remeasurement Gains (Losses) MRBs Instrument-Specific Credit Risk Remeasurement Gains (Losses) Foreign Defined Total (In millions) Balance, beginning of period $ (11,161) $ 1,557 $ 1,529 $ 80 $ (187) $ (138) $ (8,320) OCI before reclassifications 1,698 58 (1,017) 15 77 (1) 830 Deferred income tax benefit (expense) (346) (12) 214 (3) (17) — (164) AOCI before reclassifications, net of income tax (9,809) 1,603 726 92 (127) (139) (7,654) Amounts reclassified from AOCI 804 (525) — — — 5 284 Deferred income tax benefit (expense) (162) 110 — — — (1) (53) Amounts reclassified from AOCI, net of income tax 642 (415) — — — 4 231 Balance, end of period $ (9,167) $ 1,188 $ 726 $ 92 $ (127) $ (135) $ (7,423) __________________ (1) Primarily unrealized gains (losses) on fixed maturity securities. Information regarding amounts reclassified out of each component of AOCI was as follows: Three Months Six Months 2024 2023 2024 2023 AOCI Components Amounts Reclassified from AOCI Consolidated Statements of (In millions) Net unrealized investment gains (losses): Net unrealized investment gains (losses) $ (142) $ (828) $ (288) $ (787) Net investment gains (losses) Net unrealized investment gains (losses) 1 1 — 3 Net investment income Net unrealized investment gains (losses) (12) (2) (24) (20) Net derivative gains (losses) Net unrealized investment gains (losses), before income tax (153) (829) (312) (804) Income tax (expense) benefit 37 167 74 162 Net unrealized investment gains (losses), net of income tax (116) (662) (238) (642) Deferred gains (losses) on derivatives - cash flow hedges: Interest rate derivatives 6 13 14 27 Net investment income Interest rate derivatives — 55 2 57 Net investment gains (losses) Foreign currency exchange rate derivatives 1 1 2 2 Net investment income Foreign currency exchange rate derivatives 95 310 (175) 439 Net investment gains (losses) Credit derivatives 1 — 1 — Net investment gains (losses) Gains (losses) on cash flow hedges, before income tax 103 379 (156) 525 Income tax (expense) benefit (22) (79) 33 (110) Gains (losses) on cash flow hedges, net of income tax 81 300 (123) 415 Defined benefit plans adjustment: (1) Amortization of net actuarial gains (losses) (4) (3) (7) (6) Amortization of prior service (costs) credit 1 — 1 1 Amortization of defined benefit plan items, before income tax (3) (3) (6) (5) Income tax (expense) benefit — 1 1 1 Amortization of defined benefit plan items, net of income tax (3) (2) (5) (4) Total reclassifications, net of income tax $ (38) $ (364) $ (366) $ (231) __________________ (1) These AOCI components are included in the computation of net periodic benefit costs. |
Other Revenues and Other Expens
Other Revenues and Other Expenses | 6 Months Ended |
Jun. 30, 2024 | |
Other Income and Expenses [Abstract] | |
Other Revenues and Other Expenses Disclosure | 13. Other Revenues and Other Expenses Other Revenues Information on other revenues, which primarily includes fees related to service contracts from customers, was as follows: Three Months Six Months 2024 2023 2024 2023 (In millions) Prepaid legal plans $ 117 $ 115 $ 237 $ 230 Administrative services-only contracts 66 62 132 123 Recordkeeping and administrative services (1) 36 37 74 74 Other revenue from service contracts from customers 14 11 23 21 Total revenues from service contracts from customers 233 225 466 448 Other (2) 214 194 436 386 Total other revenues $ 447 $ 419 $ 902 $ 834 __________________ (1) Related to products and businesses no longer actively marketed by the Company. (2) Primarily includes reinsurance ceded. See Note 16. Other Expenses Information on other expenses was as follows: Three Months Six Months 2024 2023 2024 2023 (In millions) General and administrative expenses (1) $ 675 $ 677 $ 1,348 $ 1,338 Pension, postretirement and postemployment benefit costs 55 50 110 100 Premium taxes, other taxes, and licenses & fees 108 106 205 199 Commissions and other variable expenses 496 467 983 1,181 Capitalization of DAC (27) (12) (52) (89) Amortization of DAC and VOBA 68 74 138 151 Interest expense on debt 30 34 62 64 Total other expenses $ 1,405 $ 1,396 $ 2,794 $ 2,944 __________________ (1) Includes ($25) million and ($65) million for the three months and six months ended June 30, 2024, respectively, and ($27) million and ($57) million for the three months and six months ended June 30, 2023, respectively, for the net change in cash surrender value of investments in certain life insurance policies, net of premiums paid. Affiliated Expenses See Note 16 for a discussion of affiliated expenses included in the table above. |
Income Tax
Income Tax | 6 Months Ended |
Jun. 30, 2024 | |
Income Tax Disclosure [Abstract] | |
Income Tax | 14. Income Tax For both the three months and six months ended June 30, 2024, the effective tax rate on income (loss) before provision for income tax was 19%. The Company’s effective tax rate for the three months ended June 30, 2024 differed from the U.S. statutory rate of 21% primarily due to tax benefits from (i) non-taxable investment income and (ii) low income housing and other tax credits, partially offset by the impact of tax equity investments now accounted for under the proportional amortization method. The Company’s effective tax rate for the six months ended June 30, 2024 differed from the U.S. statutory rate of 21% primarily due to tax benefits from (i) non-taxable investment income, (ii) low income housing and other tax credits, partially offset by the impact of tax equity investments now accounted for under the proportional amortization method, and (iii) the corporate tax deduction for stock compensation. |
Contingencies, Commitments and
Contingencies, Commitments and Guarantees | 6 Months Ended |
Jun. 30, 2024 | |
Commitments and Contingencies Disclosure [Abstract] | |
Contingencies, Commitments and Guarantees | 15. Contingencies, Commitments and Guarantees Contingencies Litigation The Company is a defendant in a large number of litigation matters. Putative or certified class action litigation and other litigation and claims and assessments against the Company, in addition to those discussed below and those otherwise provided for in the Company’s interim condensed consolidated financial statements, have arisen in the course of the Company’s business, including, but not limited to, in connection with its activities as an insurer, mortgage lending bank, employer, investor, investment advisor, broker-dealer, and taxpayer. The Company also receives and responds to subpoenas or other inquiries seeking a broad range of information from state regulators, including state insurance commissioners; state attorneys general or other state governmental authorities; federal regulators, including the U.S. Securities and Exchange Commission; federal governmental authorities, including congressional committees; and the Financial Industry Regulatory Authority, as well as from local and national regulators and government authorities in jurisdictions outside the United States where the Company conducts business. The issues involved in information requests and regulatory matters vary widely, but can include inquiries or investigations concerning the Company’s compliance with applicable insurance and other laws and regulations. The Company cooperates in these inquiries. It is not possible to predict the ultimate outcome of all pending investigations and legal proceedings. The Company establishes liabilities for litigation and regulatory loss contingencies when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. In certain circumstances where liabilities have been established there may be coverage under one or more corporate insurance policies, pursuant to which there may be an insurance recovery. Insurance recoveries are recognized as gains when any contingencies relating to the insurance claim have been resolved, which is the earlier of when the gains are realized or realizable. It is possible that some of the matters could require the Company to pay damages or make other expenditures or establish accruals in amounts that could not be reasonably estimated at June 30, 2024. While the potential future charges could be material in the particular quarterly or annual periods in which they are recorded, based on information currently known to management, management does not believe any such charges are likely to have a material effect on the Company’s financial position. Given the large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation, it is possible that an adverse outcome in certain matters could, from time to time, have a material effect on the Company’s consolidated net income or cash flows in particular quarterly or annual periods. Matters as to Which an Estimate Can Be Made For some matters, the Company is able to estimate a reasonably possible range of loss. For matters where a loss is believed to be reasonably possible, but not probable, the Company has not made an accrual. As of June 30, 2024, the Company estimates the aggregate range of reasonably possible losses in excess of amounts accrued for these matters to be $0 to $125 million. Matters as to Which an Estimate Cannot Be Made For other matters, the Company is not currently able to estimate the reasonably possible loss or range of loss. The Company is often unable to estimate the possible loss or range of loss until developments in such matters have provided sufficient information to support an assessment of the range of possible loss, such as quantification of a damage demand from plaintiffs, discovery from other parties and investigation of factual allegations, rulings by the court on motions or appeals, analysis by experts, and the progress of settlement negotiations. On a quarterly and annual basis, the Company reviews relevant information with respect to litigation contingencies and updates its accruals, disclosures and estimates of reasonably possible losses or ranges of loss based on such reviews. Asbestos-Related Claims Metropolitan Life Insurance Company is and has been a defendant in a large number of asbestos-related suits filed primarily in state courts. These suits principally allege that the plaintiff or plaintiffs suffered personal injury resulting from exposure to asbestos and seek both actual and punitive damages. Metropolitan Life Insurance Company has never engaged in the business of manufacturing or selling asbestos-containing products, nor has Metropolitan Life Insurance Company issued liability or workers’ compensation insurance to companies in the business of manufacturing or selling asbestos-containing products. The lawsuits principally have focused on allegations with respect to certain research, publication and other activities of one or more of Metropolitan Life Insurance Company’s employees during the period from the 1920s through approximately the 1950s and allege that Metropolitan Life Insurance Company learned or should have learned of certain health risks posed by asbestos and, among other things, improperly publicized or failed to disclose those health risks. Metropolitan Life Insurance Company believes that it should not have legal liability in these cases. The outcome of most asbestos litigation matters, however, is uncertain and can be impacted by numerous variables, including differences in legal rulings in various jurisdictions, the nature of the alleged injury and factors unrelated to the ultimate legal merit of the claims asserted against Metropolitan Life Insurance Company. Metropolitan Life Insurance Company’s defenses include that: (i) Metropolitan Life Insurance Company owed no duty to the plaintiffs; (ii) plaintiffs did not rely on any actions of Metropolitan Life Insurance Company; (iii) Metropolitan Life Insurance Company’s conduct was not the cause of the plaintiffs’ injuries; and (iv) plaintiffs’ exposure occurred after the dangers of asbestos were known. During the course of the litigation, certain trial courts have granted motions dismissing claims against Metropolitan Life Insurance Company, while other trial courts have denied Metropolitan Life Insurance Company’s motions. There can be no assurance that Metropolitan Life Insurance Company will receive favorable decisions on motions in the future. While most cases brought to date have settled, Metropolitan Life Insurance Company intends to continue to defend aggressively against claims based on asbestos exposure, including defending claims at trials. As reported in the 2023 Annual Report, Metropolitan Life Insurance Company received approximately 2,565 asbestos-related claims in 2023. For the six months ended June 30, 2024 and 2023, Metropolitan Life Insurance Company received approximately 1,556 and 1,306 new asbestos-related claims, respectively. See Note 19 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report for historical information concerning asbestos claims and Metropolitan Life Insurance Company’s update in its recorded liability at December 31, 2023. The number of asbestos cases that may be brought, the aggregate amount of any liability that Metropolitan Life Insurance Company may incur, and the total amount paid in settlements in any given year are uncertain and may vary significantly from year to year. The ability of Metropolitan Life Insurance Company to estimate its ultimate asbestos exposure is subject to considerable uncertainty, and the conditions impacting its liability can be dynamic and subject to change. The availability of reliable data is limited and it is difficult to predict the numerous variables that can affect liability estimates, including the number of future claims, the cost to resolve claims, the disease mix and severity of disease in pending and future claims, the willingness of courts to allow plaintiffs to pursue claims against Metropolitan Life Insurance Company when exposure to asbestos took place after the dangers of asbestos exposure were well known, and the impact of any possible future adverse verdicts and their amounts. The ability to make estimates regarding ultimate asbestos exposure declines significantly as the estimates relate to years further in the future. In the Company’s judgment, there is a future point after which losses cease to be probable and reasonably estimable. It is reasonably possible that the Company’s total exposure to asbestos claims may be materially greater than the asbestos liability currently accrued and that future charges to income may be necessary, but management does not believe any such charges are likely to have a material effect on the Company’s financial position. The Company believes adequate provision has been made in its interim condensed consolidated financial statements for all probable and reasonably estimable losses for asbestos-related claims. Metropolitan Life Insurance Company’s recorded asbestos liability covers pending claims, claims not yet asserted, and legal defense costs and is based on estimates and includes significant assumptions underlying its analysis. Metropolitan Life Insurance Company reevaluates on a quarterly and annual basis its exposure from asbestos litigation, including studying its claims experience, reviewing external literature regarding asbestos claims experience in the United States, assessing relevant trends impacting asbestos liability and considering numerous variables that can affect its asbestos liability exposure on an overall or per claim basis. Based upon its regular reevaluation of its exposure from asbestos litigation, Metropolitan Life Insurance Company has updated its liability analysis for asbestos-related claims through June 30, 2024. Total Asset Recovery Services, LLC. v. MetLife, Inc., et al. (Supreme Court of the State of New York, County of New York, filed December 27, 2017) Total Asset Recovery Services (the “Relator”) brought an action under the qui tam provision of the New York False Claims Act (the “Act”) on behalf of itself and the State of New York. The Relator originally filed this action under seal in 2010, and the complaint was unsealed on December 19, 2017. The Relator alleges that MetLife, Inc., Metropolitan Life Insurance Company and several other insurance companies violated the Act by filing false unclaimed property reports with the State of New York from 1986 to 2017, to avoid having to escheat the proceeds of more than 25,000 life insurance policies, including policies for which the defendants escheated funds as part of their demutualizations in the late 1990s. The Relator seeks treble damages and other relief. The Appellate Division of the New York State Supreme Court, First Department, reversed the court’s order granting MetLife, Inc. and Metropolitan Life Insurance Company’s motion to dismiss and remanded the case to the trial court where the Relator has filed an amended complaint. The Company intends to defend the action vigorously. Matters Related to Group Annuity Benefits In 2018, the Company announced that it identified a material weakness in its internal control over financial reporting related to the practices and procedures for estimating reserves for certain group annuity benefits. Several regulators have made inquiries into the issue, and it is possible that other jurisdictions may pursue similar investigations or inquiries. The Company could be exposed to lawsuits, and additional legal actions relating to this issue. These may result in payments, including damages, fines, penalties, interest and other amounts assessed or awarded by courts or regulatory authorities under applicable escheat, tax, securities, Employee Retirement Income Security Act of 1974, or other laws or regulations. The Company could incur significant costs in connection with these actions. Commitments Mortgage Loan Commitments The Company commits to lend funds under mortgage loan commitments. The amounts of these mortgage loan commitments were $2.5 billion and $3.3 billion at June 30, 2024 and December 31, 2023, respectively. Commitments to Fund Partnership Investments, Bank Credit Facilities and Private Corporate Bond Investments The Company commits to fund partnership investments and to lend funds under bank credit facilities and private corporate bond investments. The amounts of these unfunded commitments were $4.3 billion and $4.4 billion at June 30, 2024 and December 31, 2023, respectively. Guarantees In the normal course of its business, the Company has provided certain indemnities and guarantees to third parties such that it may be required to make payments now or in the future. In the context of acquisition, disposition, investment and other transactions, the Company has provided indemnities and guarantees, including those related to tax, environmental and other specific liabilities and other indemnities and guarantees that are triggered by, among other things, breaches of representations, warranties or covenants provided by the Company. In addition, in the normal course of business, the Company provides indemnifications to counterparties in contracts with triggers similar to the foregoing, as well as for certain other liabilities, such as third-party lawsuits. These obligations are often subject to time limitations that vary in duration, including contractual limitations and those that arise by operation of law, such as applicable statutes of limitation. In some cases, the maximum potential obligation under the indemnities and guarantees is subject to a contractual limitation ranging from less than $1 million to $550 million, with a cumulative maximum of $649 million, while in other cases such limitations are not specified or applicable. Since certain of these obligations are not subject to limitations, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these guarantees in the future. Management believes that it is unlikely the Company will have to make any material payments under these indemnities or guarantees. In addition, the Company indemnifies its directors and officers as provided in its charters and by-laws. Also, the Company indemnifies its agents for liabilities incurred as a result of their representation of the Company’s interests. Since these indemnities are generally not subject to limitation with respect to duration or amount, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these indemnities in the future. |
Related Party Transactions
Related Party Transactions | 6 Months Ended |
Jun. 30, 2024 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 16. Related Party Transactions Service Agreements The Company has entered into various agreements with affiliates for services necessary to conduct its activities. Typical services provided under these agreements include personnel, policy administrative functions and distribution services. The bases for such charges are modified and adjusted by management when necessary or appropriate to reflect fairly and equitably the actual cost incurred by the Company and/or its affiliates. Expenses and fees incurred with affiliates related to these agreements, recorded in other expenses, were $740 million and $1.5 billion for the three months and six months ended June 30, 2024, respectively, and $737 million and $1.5 billion for the three months and six months ended June 30, 2023, respectively. Total revenues received from affiliates related to these agreements were $10 million and $21 million for the three months and six months ended June 30, 2024, respectively, and $15 million and $29 million for the three months and six months ended June 30, 2023, respectively. The Company had net payables to affiliates, related to the items discussed above, of $23 million and $56 million at June 30, 2024 and December 31, 2023, respectively. See Note 9 for additional information on related party transactions. Related Party Reinsurance Transactions The Company has reinsurance agreements with certain of MetLife, Inc.’s subsidiaries, including MetLife Reinsurance Company of Charleston (“MRC”), MetLife Reinsurance Company of Vermont, MTL, Superior Vision Insurance, Inc. and MetLife Insurance K.K., all of which are related parties. Information regarding the significant effects of affiliated reinsurance on the interim condensed consolidated statements of operations and comprehensive income (loss) was as follows: Three Months Six Months 2024 2023 2024 2023 (In millions) Premiums Reinsurance assumed $ 1 $ 2 $ 2 $ (25) Reinsurance ceded (102) (89) (205) (173) Net premiums $ (101) $ (87) $ (203) $ (198) Universal life and investment-type product policy fees Reinsurance assumed $ 5 $ 1 $ 8 $ 1 Reinsurance ceded (1) (2) (1) (4) Net universal life and investment-type product policy fees $ 4 $ (1) $ 7 $ (3) Other revenues Reinsurance assumed $ 35 $ 24 $ 63 $ 46 Reinsurance ceded 117 116 232 231 Net other revenues $ 152 $ 140 $ 295 $ 277 Policyholder benefits and claims Reinsurance assumed $ 11 $ 18 $ 23 $ (151) Reinsurance ceded (82) (68) (168) (145) Net policyholder benefits and claims $ (71) $ (50) $ (145) $ (296) Policyholder liability remeasurement (gains) losses Reinsurance assumed $ — $ — $ — $ (39) Reinsurance ceded (2) — — (5) Net policyholder liability remeasurement (gains) losses $ (2) $ — $ — $ (44) Interest credited to PABs Reinsurance assumed $ 90 $ 88 $ 179 $ 161 Reinsurance ceded (2) (3) (5) (6) Net interest credited to PABs $ 88 $ 85 $ 174 $ 155 Other expenses Reinsurance assumed $ 11 $ 11 $ 23 $ 215 Reinsurance ceded 54 65 110 128 Net other expenses $ 65 $ 76 $ 133 $ 343 Information regarding the significant effects of affiliated reinsurance on the interim condensed consolidated balance sheets was as follows at: June 30, 2024 December 31, 2023 Assumed Ceded Assumed Ceded (In millions) Assets Premiums, reinsurance and other receivables $ 173 $ 11,234 $ 164 $ 11,302 DAC and VOBA 149 (158) 158 (160) Total assets $ 322 $ 11,076 $ 322 $ 11,142 Liabilities FPBs $ 2,093 $ — $ 2,236 $ — PABs 9,003 — 9,040 — Other policy-related balances 66 (42) 65 (35) Other liabilities 804 9,888 957 10,267 Total liabilities $ 11,966 $ 9,846 $ 12,298 $ 10,232 The Company ceded two blocks of business to an affiliate on a 75% coinsurance with funds withheld basis. Certain contractual features of these agreements qualify as embedded derivatives, which are separately accounted for at estimated fair value on the Company’s interim condensed consolidated balance sheets. The embedded derivatives related to the funds withheld associated with these reinsurance agreements are included within other liabilities and were ($46) million and ($39) million at June 30, 2024 and December 31, 2023, respectively. Net derivative gains (losses) associated with these embedded derivatives were $4 million and $7 million for the three months and six months ended June 30, 2024, respectively, and ($23) million and ($29) million for the three months and six months ended June 30, 2023, respectively. Certain contractual features of the closed block agreement with MRC qualify as embedded derivatives, which are separately accounted for at estimated fair value on the Company’s interim condensed consolidated balance sheets. The embedded derivative related to the funds withheld associated with this reinsurance agreement was included within other liabilities and was ($401) million and ($265) million at June 30, 2024 and December 31, 2023, respectively. Net derivative gains (losses) associated with the embedded derivative were $57 million and $136 million for the three months and six months ended June 30, 2024, respectively, and $114 million and ($51) million for the three months and six months ended June 30, 2023, respectively. |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Jun. 30, 2024 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Business, Basis of Presentati_2
Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2024 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Use of Estimates | The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the interim condensed consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company’s business and operations. Actual results could differ from these estimates. |
Consolidation of Subsidiaries | The accompanying interim condensed consolidated financial statements are unaudited and reflect all adjustments (including normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in conformity with GAAP. Interim results are not necessarily indicative of full year performance. The December 31, 2023 consolidated balance sheet data was derived from audited consolidated financial statements included in Metropolitan Life Insurance Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”), which include all disclosures required by GAAP. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company included in the 2023 Annual Report. Consolidation The accompanying interim condensed consolidated financial statements include the accounts of Metropolitan Life Insurance Company and its subsidiaries, as well as partnerships and joint ventures in which the Company has a controlling financial interest, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany accounts and transactions have been eliminated. The Company uses the equity method of accounting, unless the fair value option (“FVO”) is applied, for real estate joint ventures and other limited partnership interests (“investee”) when it has more than a minor ownership interest or more than a minor influence over the investee’s operations. The Company generally recognizes its share of the investee’s earnings in net investment income on a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period. Since the Company is a member of a controlled group of affiliated companies, its results may not be indicative of those of a stand-alone entity. Closed block assets, liabilities, revenues and expenses are combined on a line-by-line basis with the assets, liabilities, revenues and expenses outside the closed block based on the nature of the particular item. |
New Accounting Pronouncements | Recent Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (each, an “ASU”) to the FASB Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. The following tables provide a description of ASUs recently issued by the FASB and the impact of their adoption on the Company’s consolidated financial statements. Adopted Accounting Pronouncements The table below describes the impacts of ASUs adopted by the Company. Standard Description Effective Date and Impact on Financial Statements ASU 2023-02, Investments—Equity Method and Joint Ventures (Topic 323): Accounting for Investments in Tax Credit Structures Using the Proportional Amortization Method The amendments in this update permit reporting entities to elect to account for their tax equity investments, regardless of the tax credit program from which the income tax credits are received, using the proportional amortization method if certain conditions are met. In addition, disclosures describing the nature of the investments and related income tax credits and benefits will be required. January 1, 2024. The Company adopted this update, applying a modified retrospective basis. The Company has elected to use the proportional amortization method to account for its tax equity investments that meet the required criteria. The adoption of this update resulted in a decrease to retained earnings of $219 million, net of income tax, primarily related to the Company’s tax equity investments reported within other invested assets, as of January 1, 2024. Future Adoption of Accounting Pronouncements ASUs not listed below were assessed and either determined to be not applicable or are not expected to have a material impact on the Company’s consolidated financial statements or disclosures. ASUs issued but not yet adopted as of June 30, 2024 that are currently being assessed and may or may not have a material impact on the Company’s consolidated financial statements or disclosures are summarized in the table below. Standard Description Effective Date and Impact on Financial Statements ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures Among other things, the amendments in this update require that public business entities, on an annual basis: (i) disclose specific categories in the rate reconciliation; and (ii) provide additional information for reconciling items that meet a quantitative threshold. In addition, the amendments in this update require that all entities disclose on an annual basis the following information about income taxes paid: (i) the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes; and (ii) the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than five percent of total income taxes paid (net of refunds received). Effective for annual periods beginning January 1, 2025, to be applied prospectively with an option for retrospective application (with early adoption permitted). The Company is evaluating the impact of the guidance on its consolidated financial statements. ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures The amendments in this update are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The key amendments include: (i) disclosures on significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss on an annual and interim basis; (ii) disclosures on an amount for other segment items by reportable segment and a description of its composition on an annual and interim basis. The other segment items category is the difference between segment revenue less the significant expenses disclosed and each reported measure of segment profit or loss; (iii) providing all annual disclosures on a reportable segment’s profit or loss and assets currently required by FASB ASC Topic 280, Segment Reporting in interim periods; and (iv) specifying the title and position of the CODM. Effective for annual periods beginning January 1, 2024 and interim periods beginning January 1, 2025, to be applied on a retrospective basis unless it is impracticable (with early adoption permitted). The Company is evaluating the impact of the guidance on its consolidated financial statements. |
Closed Block | On April 7, 2000 (the “Demutualization Date”), Metropolitan Life Insurance Company converted from a mutual life insurance company to a stock life insurance company and became a wholly-owned subsidiary of MetLife, Inc. The conversion was pursuant to an order by the New York Superintendent of Insurance approving Metropolitan Life Insurance Company’s plan of reorganization, as amended (the “Plan of Reorganization”). On the Demutualization Date, Metropolitan Life Insurance Company established a closed block for the benefit of holders of certain individual life insurance policies of Metropolitan Life Insurance Company. See Note 9 to the Notes to the Consolidated Financial Statements included in the 2023 Annual Report for further information on the closed block. Experience within the closed block, in particular mortality and investment yields, as well as realized and unrealized gains and losses, directly impact the policyholder dividend obligation. Amortization of the closed block DAC, which resides outside of the closed block, is based upon policy count within the closed block. |
Investments | Maturities of Fixed Maturity Securities AFS Actual maturities may differ from contractual maturities due to the exercise of call or prepayment options. Fixed maturity securities AFS not due at a single maturity date have been presented in the year of final contractual maturity. Structured Products are shown separately, as they are not due at a single maturity. Evaluation and Measurement Methodologies See Note 10 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report for a description of the Company’s Evaluation and Measurement Methodologies of Fixed Maturity Securities AFS for Credit Loss. ACL Methodology The Company records an allowance for expected lifetime credit loss in earnings within net investment gains (losses) in an amount that represents the portion of the amortized cost basis of mortgage loans that the Company does not expect to collect, resulting in mortgage loans being presented at the net amount expected to be collected. In determining the Company’s ACL, management applies significant judgment to estimate expected lifetime credit loss, including: (i) pooling mortgage loans that share similar risk characteristics, (ii) considering expected lifetime credit loss over the contractual term of its mortgage loans adjusted for expected prepayments and any extensions, and (iii) considering past events and current and forecasted economic conditions. Each of the Company’s commercial, agricultural and residential mortgage loan portfolio segments are evaluated separately. The ACL is calculated for each mortgage loan portfolio segment based on inputs unique to each loan portfolio segment. On a quarterly basis, mortgage loans within a portfolio segment that share similar risk characteristics, such as internal risk ratings or consumer credit scores, are pooled for calculation of ACL. On an ongoing basis, mortgage loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), such as collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is reasonably possible or probable), are evaluated individually for credit loss. The ACL for loans evaluated individually are established using the same methodologies for all three portfolio segments. For example, the ACL for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost when foreclosure is probable. Accordingly, the change in the estimated fair value of collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the ACL which is recorded on a quarterly basis as a charge or credit to earnings in net investment gains (losses). Commercial and Agricultural Mortgage Loan Portfolio Segments Within each loan portfolio segment, commercial and agricultural loans are pooled by internal risk rating. Estimated lifetime loss rates, which vary by internal risk rating, are applied to the amortized cost of each loan, excluding accrued investment income, on a quarterly basis to develop the ACL. Internal risk ratings are based on an assessment of the loan’s credit quality, which can change over time. The estimated lifetime loss rates are based on several loan portfolio segment-specific factors, including (i) the Company’s experience with defaults and loss severity, (ii) expected default and loss severity over the forecast period, (iii) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, (iv) loan specific characteristics including loan-to-value (“LTV”) ratios, and (v) internal risk ratings. These evaluations are revised as conditions change and new information becomes available. The Company uses its several decades of historical default and loss severity experience which capture multiple economic cycles. The Company uses a forecast of economic assumptions for a two-year period for most of its commercial and agricultural mortgage loans, while a one-year period is used for loans originated in certain markets. After the applicable forecast period, the Company reverts to its historical loss experience using a straight-line basis over two years. For evaluations of commercial mortgage loans, in addition to historical experience, management considers factors that include the impact of a rapid change to the economy, which may not be reflected in the loan portfolio, recent loss and recovery trend experience as compared to historical loss and recovery experience, and loan specific characteristics including debt service coverage ratios (“DSCR”). In estimating expected lifetime credit loss over the term of its commercial mortgage loans, the Company adjusts for expected prepayment and extension experience during the forecast period using historical prepayment and extension experience considering the expected position in the economic cycle and the loan profile (i.e., floating rate, shorter-term fixed rate and longer-term fixed rate) and after the forecast period using long-term historical prepayment experience. For evaluations of agricultural mortgage loans, in addition to historical experience, management considers factors that include increased stress in certain sectors, which may be evidenced by higher delinquency rates, or a change in the number of higher risk loans. In estimating expected lifetime credit loss over the term of its agricultural mortgage loans, the Company’s experience is much less sensitive to the position in the economic cycle and by loan profile; accordingly, historical prepayment experience is used, while extension terms are not prevalent with the Company’s agricultural mortgage loans. Commercial mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, an analysis of the property financial statements and rent roll, lease rollover analysis, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios, DSCR and tenant creditworthiness. The monitoring process focuses on higher risk loans, which include those that are classified as restructured, delinquent or in foreclosure, as well as loans with higher LTV ratios and lower DSCR. Agricultural mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios and borrower creditworthiness, as well as reviews on a geographic and property-type basis. The monitoring process for agricultural mortgage loans also focuses on higher risk loans. For commercial mortgage loans, the primary credit quality indicator is the DSCR, which compares a property’s net operating income to amounts needed to service the principal and interest due under the loan. Generally, the lower the DSCR, the higher the risk of experiencing a credit loss. The Company also reviews the LTV ratio of its commercial mortgage loan portfolio. LTV ratios compare the unpaid principal balance of the loan to the estimated fair value of the underlying collateral. Generally, the higher the LTV ratio, the higher the risk of experiencing a credit loss. The DSCR and the values utilized in calculating the ratio are updated routinely. In addition, the LTV ratio is routinely updated for all but the lowest risk loans as part of the Company’s ongoing review of its commercial mortgage loan portfolio. For agricultural mortgage loans, the Company’s primary credit quality indicator is the LTV ratio. The values utilized in calculating this ratio are developed in connection with the ongoing review of the agricultural mortgage loan portfolio and are routinely updated. After commercial and agricultural mortgage loans are approved, the Company makes commitments to lend and, typically, borrowers draw down on some or all of the commitments. The timing of mortgage loan funding is based on the commitment expiration dates. A liability for credit loss for unfunded commercial and agricultural mortgage loan commitments that is not unconditionally cancellable is recognized in earnings and is reported within net investment gains (losses). The liability is based on estimated lifetime loss rates as described above and the amount of the outstanding commitments, which for lines of credit, considers estimated utilization rates. When the commitment is funded or expires, the liability is adjusted accordingly. Residential Mortgage Loan Portfolio Segment The Company’s residential mortgage loan portfolio is comprised primarily of purchased closed end, amortizing residential mortgage loans, including both performing loans purchased within 12 months of origination and reperforming loans purchased after they have been performing for at least 12 months post-modification. Residential mortgage loans are pooled by loan type (i.e., new origination and reperforming) and pooled by similar risk profiles (including consumer credit score and LTV ratios). Estimated lifetime loss rates, which vary by loan type and risk profile, are applied to the amortized cost of each loan excluding accrued investment income on a quarterly basis to develop the ACL. The estimated lifetime loss rates are based on several factors, including (i) industry historical experience and expected results over the forecast period for defaults, (ii) loss severity, (iii) prepayment rates, (iv) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, and (v) loan pool specific characteristics including consumer credit scores, LTV ratios, payment history and home prices. These evaluations are revised as conditions change and new information becomes available. The Company uses industry historical experience which captures multiple economic cycles as the Company has purchased most of its residential mortgage loans in the last five years. The Company uses a forecast of economic assumptions for a two-year period for most of its residential mortgage loans. After the applicable forecast period, the Company reverts to industry historical loss experience using a straight-line basis over one year. For residential mortgage loans, the Company’s primary credit quality indicator is whether the loan is performing or nonperforming. The Company generally defines nonperforming residential mortgage loans as those that are 60 or more days past due and/or in nonaccrual status which is assessed monthly. Generally, nonperforming residential mortgage loans have a higher risk of experiencing a credit loss. Past Due and Nonaccrual Mortgage Loans Leased Real Estate Investments - Operating Leases Variable Interest Entities |
Derivatives | The Company is exposed to various risks relating to its ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. The Company uses a variety of strategies to manage these risks, including the use of derivatives. The Company designates and accounts for the following as fair value hedges when they have met the requirements of fair value hedging: (i) interest rate swaps to convert fixed rate assets and liabilities to floating rate assets and liabilities, and (ii) foreign currency swaps to hedge the foreign currency fair value exposure of foreign currency denominated assets and liabilities. The Company designates and accounts for the following as cash flow hedges when they have met the requirements of cash flow hedging: (i) interest rate swaps to convert floating rate assets and liabilities to fixed rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency cash flow exposure of foreign currency denominated assets and liabilities, (iii) interest rate forwards and credit forwards to lock in the price to be paid for forward purchases of investments, and (iv) interest rate swaps and interest rate forwards to hedge the forecasted purchases of fixed-rate investments. The Company may be exposed to credit-related losses in the event of nonperformance by its counterparties to derivatives. Generally, the current credit exposure of the Company’s derivatives is limited to the net positive estimated fair value of derivatives at the reporting date after taking into consideration the existence of master netting or similar agreements and any collateral received pursuant to such agreements. The Company manages its credit risk related to derivatives by entering into transactions with creditworthy counterparties in jurisdictions in which it understands that close-out netting should be enforceable and establishing and monitoring exposure limits. The Company’s bilateral contracts between two counterparties (“OTC-bilateral”) derivative transactions are governed by International Swaps and Derivatives Association, Inc. (“ISDA”) Master Agreements which provide for legally enforceable set-off and close-out netting of exposures to specific counterparties in the event of early termination of a transaction, which includes, but is not limited to, events of default and bankruptcy. In the event of an early termination, close-out netting permits the Company (subject to financial regulations such as the Orderly Liquidation Authority under Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act) to set off receivables from the counterparty against payables to the same counterparty arising out of all included transactions and to apply collateral to the obligations without application of the automatic stay, upon the counterparty’s bankruptcy. All of the Company’s ISDA Master Agreements also include Credit Support Annex provisions which require both the pledging and accepting of collateral in connection with its OTC-bilateral derivatives as required by applicable law. Additionally, the Company is required to pledge initial margin for certain new OTC-bilateral derivative transactions to third party custodians. The Company’s over-the-counter cleared (“OTC-cleared”) derivatives are effected through central clearing counterparties and its exchange-traded derivatives are effected through regulated exchanges. Such positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by brokers and central clearinghouses to such derivatives. See Note 11 for a description of the impact of credit risk on the valuation of derivatives. |
Segment Information (Tables)
Segment Information (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Segment Reporting [Abstract] | |
Segment Reporting Information, by Segment | Three Months Ended June 30, 2024 Group Benefits RIS MetLife Corporate Total Adjustments Total (In millions) Revenues Premiums $ 5,337 $ 1,455 $ 572 $ 2 $ 7,366 $ — $ 7,366 Universal life and investment-type product policy fees 229 59 88 5 381 — 381 Net investment income 303 1,679 921 116 3,019 (116) 2,903 Other revenues 189 70 37 123 419 28 447 Net investment gains (losses) — — — — — (106) (106) Net derivative gains (losses) — — — — — 60 60 Total revenues 6,058 3,263 1,618 246 11,185 (134) 11,051 Expenses Policyholder benefits and claims and policyholder dividends 4,488 2,099 1,064 1 7,652 (15) 7,637 Policyholder liability remeasurement (gains) losses 1 (14) 16 — 3 — 3 MRB remeasurement (gains) losses — — — — — (130) (130) Interest credited to PABs 48 708 99 84 939 18 957 Capitalization of deferred policy acquisition costs (“DAC”) (3) (25) 1 — (27) — (27) Amortization of DAC and value of business acquired (“VOBA”) 7 9 49 3 68 — 68 Interest expense on debt 1 3 3 23 30 — 30 Other expenses 885 100 193 155 1,333 1 1,334 Total expenses 5,427 2,880 1,425 266 9,998 (126) 9,872 Provision for income tax expense (benefit) 131 80 38 (21) 228 — 228 Adjusted earnings $ 500 $ 303 $ 155 $ 1 959 Adjustments to: Total revenues (134) Total expenses 126 Provision for income tax (expense) benefit — Net income (loss) $ 951 $ 951 Three Months Ended June 30, 2023 Group Benefits RIS MetLife Corporate & Other Total Adjustments Total Consolidated (In millions) Revenues Premiums $ 5,189 $ 179 $ 585 $ — $ 5,953 $ — $ 5,953 Universal life and investment-type product policy fees 223 60 138 1 422 — 422 Net investment income 320 1,660 1,044 46 3,070 (197) 2,873 Other revenues 181 69 50 122 422 (3) 419 Net investment gains (losses) — — — — — (659) (659) Net derivative gains (losses) — — — — — (232) (232) Total revenues 5,913 1,968 1,817 169 9,867 (1,091) 8,776 Expenses Policyholder benefits and claims and policyholder dividends 4,588 837 1,123 1 6,549 3 6,552 Policyholder liability remeasurement (gains) losses 3 (8) 22 — 17 — 17 MRB remeasurement (gains) losses — — — — — (670) (670) Interest credited to PABs 48 609 156 81 894 (1) 893 Capitalization of DAC (5) (5) 1 (3) (12) — (12) Amortization of DAC and VOBA 7 7 56 4 74 — 74 Interest expense on debt 1 3 3 27 34 — 34 Other expenses 837 83 187 247 1,354 (54) 1,300 Total expenses 5,479 1,526 1,548 357 8,910 (722) 8,188 Provision for income tax expense (benefit) 92 92 53 (80) 157 (79) 78 Adjusted earnings $ 342 $ 350 $ 216 $ (108) 800 Adjustments to: Total revenues (1,091) Total expenses 722 Provision for income tax (expense) benefit 79 Net income (loss) $ 510 $ 510 Six Months Ended June 30, 2024 Group Benefits RIS MetLife Corporate & Other Total Adjustments Total Consolidated (In millions) Revenues Premiums $ 10,804 $ 1,631 $ 1,144 $ 1 $ 13,580 $ — $ 13,580 Universal life and investment-type product policy fees 451 124 158 7 740 — 740 Net investment income 608 3,355 1,831 206 6,000 (240) 5,760 Other revenues 378 132 87 245 842 60 902 Net investment gains (losses) — — — — — (242) (242) Net derivative gains (losses) — — — — — 4 4 Total revenues 12,241 5,242 3,220 459 21,162 (418) 20,744 Expenses Policyholder benefits and claims and policyholder dividends 9,433 2,926 2,110 1 14,470 (28) 14,442 Policyholder liability remeasurement (gains) losses (2) (22) 40 — 16 — 16 MRB remeasurement (gains) losses — — — — — (716) (716) Interest credited to PABs 96 1,384 193 167 1,840 40 1,880 Capitalization of DAC (7) (46) 1 — (52) — (52) Amortization of DAC and VOBA 13 17 99 9 138 — 138 Interest expense on debt 1 7 7 47 62 — 62 Other expenses 1,757 202 393 290 2,642 4 2,646 Total expenses 11,291 4,468 2,843 514 19,116 (700) 18,416 Provision for income tax expense (benefit) 200 162 74 (55) 381 61 442 Adjusted earnings $ 750 $ 612 $ 303 $ — 1,665 Adjustments to: Total revenues (418) Total expenses 700 Provision for income tax (expense) benefit (61) Net income (loss) $ 1,886 $ 1,886 Six Months Ended June 30, 2023 Group Benefits RIS MetLife Corporate & Other Total Adjustments Total Consolidated (In millions) Revenues Premiums $ 10,405 $ 233 $ 1,163 $ 1 $ 11,802 $ — $ 11,802 Universal life and investment-type product policy fees 441 127 283 1 852 — 852 Net investment income 623 3,211 2,033 89 5,956 (398) 5,558 Other revenues 360 132 106 244 842 (8) 834 Net investment gains (losses) — — — — — (761) (761) Net derivative gains (losses) — — — — — (792) (792) Total revenues 11,829 3,703 3,585 335 19,452 (1,959) 17,493 Expenses Policyholder benefits and claims and policyholder dividends 9,282 1,370 2,239 1 12,892 6 12,898 Policyholder liability remeasurement (gains) losses (1) (76) 37 — (40) — (40) MRB remeasurement (gains) losses — — — — — (426) (426) Interest credited to PABs 94 1,172 311 147 1,724 — 1,724 Capitalization of DAC (11) (24) 1 (55) (89) — (89) Amortization of DAC and VOBA 13 15 115 8 151 — 151 Interest expense on debt 1 6 6 51 64 — 64 Other expenses 1,646 380 393 448 2,867 (49) 2,818 Total expenses 11,024 2,843 3,102 600 17,569 (469) 17,100 Provision for income tax expense (benefit) 170 179 94 (155) 288 (314) (26) Adjusted earnings $ 635 $ 681 $ 389 $ (110) 1,595 Adjustments to: Total revenues (1,959) Total expenses 469 Provision for income tax (expense) benefit 314 Net income (loss) $ 419 $ 419 The following table presents total assets with respect to the Company’s segments, as well as Corporate & Other, at: June 30, 2024 December 31, 2023 (In millions) Group Benefits $ 33,669 $ 34,185 RIS 177,906 180,625 MetLife Holdings 129,230 133,219 Corporate & Other 31,069 30,656 Total $ 371,874 $ 378,685 |
Future Policy Benefits (Tables)
Future Policy Benefits (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Insurance [Abstract] | |
Schedule of Liability for Future Policy Benefits, by Product Segment | The Company’s FPBs on the interim condensed consolidated balance sheets was as follows at: June 30, 2024 December 31, 2023 (In millions) Traditional and Limited-Payment Contracts: RIS - Annuities $ 46,998 $ 48,695 MetLife Holdings - Long-term care 14,455 15,240 Deferred Profit Liabilities: RIS - Annuities 3,005 3,000 Additional Insurance Liabilities: MetLife Holdings - Universal and variable universal life 1,913 1,841 MetLife Holdings - Participating life 43,039 43,586 Other long-duration (1) 6,278 6,605 Short-duration and other 10,347 10,215 Total $ 126,035 $ 129,182 __________________ (1) This balance represents liabilities for various smaller product lines across all segments. |
Liability for Future Policy Benefit, Activity | Information regarding these products was as follows: Six Months 2024 2023 (Dollars in millions) Present Value of Expected Net Premiums Balance, beginning of period, at current discount rate at balance sheet date $ — $ — Balance, beginning of period, at original discount rate $ — $ — Effect of actual variances from expected experience (1) (2) 2 Adjusted balance (2) 2 Issuances 1,575 183 Net premiums collected (1,573) (185) Ending balance at original discount rate — — Balance, end of period, at current discount rate at balance sheet date $ — $ — Present Value of Expected FPBs Balance, beginning of period, at current discount rate at balance sheet date $ 48,886 $ 48,190 Balance, beginning of period, at original discount rate $ 47,991 $ 49,194 Effect of actual variances from expected experience (1) (55) (299) Adjusted balance 47,936 48,895 Issuances 1,572 183 Interest accrual 1,197 1,196 Benefit payments (2,224) (2,386) Ending balance at original discount rate 48,481 47,888 Effect of changes in discount rate assumptions (1,146) (385) Balance, end of period, at current discount rate at balance sheet date 47,335 47,503 Cumulative amount of fair value hedging adjustments (337) (204) Net liability for FPBs $ 46,998 $ 47,299 Undiscounted - Expected future benefit payments $ 90,171 $ 93,997 Discounted - Expected future benefit payments (at current discount rate at balance sheet date) $ 47,335 $ 47,503 Weighted-average duration of the liability 9 years 9 years Weighted-average interest accretion (original locked-in) rate 5.1 % 5.1 % Weighted-average current discount rate at balance sheet date 5.6 % 5.4 % __________________ (1) For the six months ended June 30, 2024, the net effect of actual variances from expected experience was partially offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $30 million. For the six months ended June 30, 2023, the net effect of actual variances from expected experience was largely offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $225 million. Excluding the corresponding impact in DPL, for the six months ended June 30, 2023, the net effect of actual variances from expected experience was primarily driven by favorable mortality and the amendment of an affiliated reinsurance treaty. Six Months 2024 2023 (Dollars in millions) Present Value of Expected Net Premiums Balance, beginning of period, at current discount rate at balance sheet date $ 5,687 $ 5,775 Balance, beginning of period, at original discount rate $ 5,566 $ 5,807 Effect of actual variances from expected experience 13 83 Adjusted balance 5,579 5,890 Interest accrual 141 149 Net premiums collected (286) (293) Ending balance at original discount rate 5,434 5,746 Effect of changes in discount rate assumptions (80) 3 Balance, end of period, at current discount rate at balance sheet date $ 5,354 $ 5,749 Present Value of Expected FPBs Balance, beginning of period, at current discount rate at balance sheet date $ 20,927 $ 19,619 Balance, beginning of period, at original discount rate $ 20,494 $ 20,165 Effect of actual variances from expected experience 31 99 Adjusted balance 20,525 20,264 Interest accrual 540 534 Benefit payments (421) (382) Ending balance at original discount rate 20,644 20,416 Effect of changes in discount rate assumptions (835) (169) Balance, end of period, at current discount rate at balance sheet date 19,809 20,247 Net liability for FPBs $ 14,455 $ 14,498 Undiscounted: Expected future gross premiums $ 10,280 $ 10,893 Expected future benefit payments $ 44,653 $ 45,653 Discounted (at current discount rate at balance sheet date): Expected future gross premiums $ 6,715 $ 7,089 Expected future benefit payments $ 19,809 $ 20,247 Weighted-average duration of the liability 14 years 15 years Weighted-average interest accretion (original locked-in) rate 5.4 % 5.4 % Weighted-average current discount rate at balance sheet date 5.8 % 5.5 % |
Additional Liability, Long-Duration Insurance | Information regarding these additional insurance liabilities was as follows: Six Months 2024 2023 Universal and Variable Universal Life (Dollars in millions) Balance, beginning of period $ 1,841 $ 1,642 Less: Accumulated other comprehensive income (loss) (“AOCI”) adjustment (14) (63) Balance, beginning of period, before AOCI adjustment 1,855 1,705 Effect of actual variances from expected experience 18 6 Adjusted balance 1,873 1,711 Assessments accrual 44 47 Interest accrual 48 44 Excess benefits paid (36) (41) Balance, end of period, before AOCI adjustment 1,929 1,761 Add: AOCI adjustment (16) 2 Balance, end of period 1,913 1,763 Less: Reinsurance recoverables 1,913 649 Balance, end of period, net of reinsurance $ — $ 1,114 Weighted-average duration of the liability 16 years 17 years Weighted-average interest accretion rate 5.2 % 5.2 % The Company’s gross premiums or assessments and interest expense recognized in the interim condensed consolidated statements of operations and comprehensive income (loss) for long-duration contracts, excluding MetLife Holdings’ participating life contracts, were as follows: Six Months 2024 2023 Gross Premiums or Assessments (1) Interest Expense (2) Gross Premiums or Assessments (1) Interest Expense (2) (In millions) Traditional and Limited-Payment Contracts: RIS - Annuities $ 1,613 $ 1,197 $ 168 $ 1,196 MetLife Holdings - Long-term care 362 399 366 385 Deferred Profit Liabilities: RIS - Annuities N/A 74 N/A 70 Additional Insurance Liabilities: MetLife Holdings - Universal and variable universal life 198 48 236 44 Other long-duration 374 153 400 152 Total $ 2,547 $ 1,871 $ 1,170 $ 1,847 __________________ (1) Gross premiums are related to traditional and limited-payment contracts and are included in premiums. Assessments are related to additional insurance liabilities and are included in universal life and investment-type product policy fees and net investment income. (2) Interest expense is included in policyholder benefits and claims. |
Liabilities for Unpaid Claims and Claim Expenses | Information regarding the liabilities for unpaid claims and claim adjustment expenses was as follows: Six Months 2024 2023 (In millions) Balance, beginning of period $ 11,609 $ 11,300 Less: Reinsurance recoverables 1,740 1,633 Net balance, beginning of period 9,869 9,667 Incurred related to: Current period 10,373 10,270 Prior periods (1) (240) (32) Total incurred 10,133 10,238 Paid related to: Current period (6,108) (5,919) Prior periods (4,073) (4,020) Total paid (10,181) (9,939) Net balance, end of period 9,821 9,966 Add: Reinsurance recoverables 1,998 1,794 Balance, end of period (included in FPBs and other policy-related balances) $ 11,819 $ 11,760 __________________ (1) For the six months ended June 30, 2024 and 2023, incurred claims and claim adjustment expenses associated with prior periods decreased due to favorable claims experience in the respective current period. |
Policyholder Account Balances (
Policyholder Account Balances (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Insurance [Abstract] | |
Policyholder Account Balances | The Company’s PABs on the interim condensed consolidated balance sheets were as follows at: June 30, 2024 December 31, 2023 (In millions) Group Benefits - Group life $ 7,487 $ 7,605 RIS: Capital markets investment products and stable value GICs 59,253 58,554 Annuities and risk solutions 10,991 10,650 MetLife Holdings - Annuities 10,118 10,888 Other 15,925 16,197 Total $ 103,774 $ 103,894 |
Policyholder Account Balance Rollforward | Information regarding this liability was as follows: Six Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 7,605 $ 7,954 Deposits 1,799 1,644 Policy charges (327) (318) Surrenders and withdrawals (1,676) (1,573) Benefit payments (6) (6) Net transfers from (to) separate accounts (3) 1 Interest credited 95 93 Balance, end of period $ 7,487 $ 7,795 Weighted-average annual crediting rate 2.6 % 2.4 % At period end: Cash surrender value $ 7,427 $ 7,732 Net amount at risk, excluding offsets from reinsurance: In the event of death $ 264,497 $ 251,590 Six Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 58,554 $ 58,508 Deposits 33,817 34,800 Surrenders and withdrawals (33,744) (36,458) Interest credited 1,066 890 Effect of foreign currency translation and other, net (440) 750 Balance, end of period $ 59,253 $ 58,490 Weighted-average annual crediting rate 3.7 % 3.1 % Cash surrender value at period end $ 1,445 $ 1,776 Six Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 10,650 $ 10,244 Deposits 657 348 Policy charges (57) (87) Surrenders and withdrawals (186) (88) Benefit payments (287) (271) Net transfers from (to) separate accounts 20 54 Interest credited 225 213 Other (31) (9) Balance, end of period $ 10,991 $ 10,404 Weighted-average annual crediting rate 4.2 % 4.2 % At period end: Cash surrender value $ 6,952 $ 6,672 Net amount at risk, excluding offsets from ceded reinsurance: In the event of death $ 35,769 $ 36,065 Six Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 10,888 $ 12,598 Deposits 81 129 Policy charges (6) (6) Surrenders and withdrawals (870) (1,004) Benefit payments (206) (218) Net transfers from (to) separate accounts 58 47 Interest credited 166 182 Other 7 13 Balance, end of period $ 10,118 $ 11,741 Weighted-average annual crediting rate 3.2 % 3.0 % At period end: Cash surrender value $ 9,458 $ 10,964 Net amount at risk, excluding offsets from ceded reinsurance (1): In the event of death $ 2,541 $ 3,246 At annuitization or exercise of other living benefits $ 665 $ 770 __________________ (1) Includes amounts for certain variable annuities recorded as PABs with the related guarantees recorded as MRBs which are disclosed in “MetLife Holdings – Annuities” in Note 5. |
Policyholder Account Balance, Guaranteed Minimum Crediting Rate | The Group Benefits segment’s group life product account values by range of guaranteed minimum crediting rates (“GMCR”) and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or greater than 0.50% but less than 1.50% Equal to or greater than 1.50% above GMCR Total (In millions) June 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ 819 $ 4,574 $ 5,393 Equal to or greater than 2% but less than 4% 1,217 9 59 1 1,286 Equal to or greater than 4% 697 — 39 34 770 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 38 Total $ 1,914 $ 9 $ 917 $ 4,609 $ 7,487 June 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 910 $ 4,615 $ 5,525 Equal to or greater than 2% but less than 4% 1,252 10 63 2 1,327 Equal to or greater than 4% 746 1 43 34 824 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 119 Total $ 1,998 $ 11 $ 1,016 $ 4,651 $ 7,795 The RIS segment’s capital markets investment products and stable value GICs account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or greater than 0.50% but less than 1.50% Equal to or greater than 1.50% above GMCR Total (In millions) June 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ — $ 2,647 $ 2,647 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 56,606 Total $ — $ — $ — $ 2,647 $ 59,253 June 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 1 $ 2,595 $ 2,596 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 55,894 Total $ — $ — $ 1 $ 2,595 $ 58,490 The RIS segment’s annuity and risk solutions account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or greater than 0.50% but less than 1.50% Equal to or greater than 1.50% above GMCR Total (In millions) June 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ 19 $ 1,748 $ 1,767 Equal to or greater than 2% but less than 4% 201 35 11 421 668 Equal to or greater than 4% 3,509 — 268 5 3,782 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 4,774 Total $ 3,710 $ 35 $ 298 $ 2,174 $ 10,991 June 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 53 $ 1,406 $ 1,459 Equal to or greater than 2% but less than 4% 227 35 44 448 754 Equal to or greater than 4% 3,673 117 14 6 3,810 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 4,381 Total $ 3,900 $ 152 $ 111 $ 1,860 $ 10,404 The MetLife Holdings segment’s annuity account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or greater than 0.50% but less than 1.50% Equal to or greater than 1.50% above GMCR Total (In millions) June 30, 2024 Equal to or greater than 0% but less than 2% $ 4 $ 195 $ 446 $ 38 $ 683 Equal to or greater than 2% but less than 4% 1,048 6,754 467 198 8,467 Equal to or greater than 4% 409 145 19 — 573 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 395 Total $ 1,461 $ 7,094 $ 932 $ 236 $ 10,118 June 30, 2023 Equal to or greater than 0% but less than 2% $ 444 $ 158 $ 219 $ 25 $ 846 Equal to or greater than 2% but less than 4% 3,914 5,441 390 72 9,817 Equal to or greater than 4% 609 3 14 — 626 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 452 Total $ 4,967 $ 5,602 $ 623 $ 97 $ 11,741 |
Market Risk Benefits (Tables)
Market Risk Benefits (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Insurance [Abstract] | |
Market Risk Benefit | The Company’s MRB assets and MRB liabilities on the interim condensed consolidated balance sheets were as follows at: June 30, 2024 December 31, 2023 Asset Liability Net Asset Liability Net (In millions) MetLife Holdings - Annuities $ 211 $ 2,366 $ 2,155 $ 156 $ 2,858 $ 2,702 Other 19 25 6 21 20 (1) Total $ 230 $ 2,391 $ 2,161 $ 177 $ 2,878 $ 2,701 |
Market Risk Benefit, Activity | Information regarding MetLife Holdings annuity products was as follows: Six Months 2024 2023 (In millions) Balance, beginning of period $ 2,702 $ 3,071 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk $ 2,741 $ 3,164 Attributed fees collected 151 160 Benefit payments (44) (21) Effect of changes in interest rates (544) (15) Effect of changes in capital markets (286) (504) Effect of changes in equity index volatility 24 (98) Actual policyholder behavior different from expected behavior 109 44 Effect of foreign currency translation and other, net (1) 30 174 Effect of changes in risk margin (57) (35) Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk 2,124 2,869 Cumulative effect of changes in the instrument-specific credit risk 31 (109) Balance, end of period $ 2,155 $ 2,760 At period end: Net amount at risk, excluding offsets from hedging (2): In the event of death $ 2,541 $ 3,246 At annuitization or exercise of other living benefits $ 665 $ 770 Weighted-average attained age of contractholders: In the event of death 71 years 70 years At annuitization or exercise of other living benefits 71 years 70 years __________________ (1) Included is the covariance impact from aggregating the market observable inputs, mostly driven by interest rate and capital market volatility. (2) Includes amounts for certain variable annuity guarantees recorded as MRBs on contracts also recorded as PABs which are disclosed in “MetLife Holdings – Annuities” in Note 4. Six Months 2024 2023 (In millions) Balance, beginning of period $ (1) $ 25 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk $ 2 $ 34 Attributed fees collected 1 1 Effect of changes in interest rates (6) 2 Actual policyholder behavior different from expected behavior — (26) Effect of foreign currency translation and other, net 12 15 Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk 9 26 Cumulative effect of changes in the instrument-specific credit risk (3) (7) Balance, end of period $ 6 $ 19 |
Separate Account (Tables)
Separate Account (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Separate Accounts Disclosure [Abstract] | |
Separate Account Liabilities | The Company’s separate account liabilities on the interim condensed consolidated balance sheets were as follows at: June 30, 2024 December 31, 2023 (In millions) RIS: Stable Value and Risk Solutions $ 32,256 $ 35,562 Annuities 11,246 11,659 MetLife Holdings - Annuities 28,780 29,162 Other 7,303 6,814 Total $ 79,585 $ 83,197 |
Separate Account, Liability Rollforward | The balances of and changes in separate account liabilities were as follows: RIS RIS MetLife Holdings (In millions) Six Months Ended June 30, 2024 Balance, beginning of period $ 35,562 $ 11,659 $ 29,162 Premiums and deposits 541 25 123 Policy charges (108) (10) (296) Surrenders and withdrawals (2,919) (401) (1,851) Benefit payments (49) — (259) Investment performance 490 (95) 1,964 Net transfers from (to) general account (20) — (58) Other (1) (1,241) 68 (5) Balance, end of period $ 32,256 $ 11,246 $ 28,780 Six Months Ended June 30, 2023 Balance, beginning of period $ 43,249 $ 11,694 $ 28,443 Premiums and deposits 1,069 120 139 Policy charges (121) (11) (305) Surrenders and withdrawals (7,532) (360) (1,359) Benefit payments (44) — (242) Investment performance 1,145 448 2,924 Net transfers from (to) general account (57) 3 (47) Other (667) (102) — Balance, end of period $ 37,042 $ 11,792 $ 29,553 Cash surrender value at June 30, 2024 (2) $ 28,766 N/A $ 28,643 Cash surrender value at June 30, 2023 (2) $ 32,886 N/A $ 29,471 __________________ (1) Other for RIS stable value and risk solutions primarily includes changes related to unsettled trades of mortgage-backed securities. (2) Cash surrender value represents the amount of the contractholders’ account balances distributable at the balance sheet date less policy loans and certain surrender charges. |
Fair Value, Separate Account Investment | The Company’s aggregate fair value of assets, by major investment asset category, supporting separate account liabilities was as follows at: June 30, 2024 Group Benefits RIS MetLife Holdings Total (In millions) Fixed maturity securities: Bonds: Foreign government $ — $ 530 $ — $ 530 U.S. government and agency — 9,237 — 9,237 Public utilities — 1,065 — 1,065 Municipals — 275 — 275 Corporate bonds: Materials — 125 — 125 Communications — 750 — 750 Consumer — 1,742 — 1,742 Energy — 828 — 828 Financial — 2,465 — 2,465 Industrial and other — 698 — 698 Technology — 468 — 468 Foreign — 1,915 — 1,915 Total corporate bonds — 8,991 — 8,991 Total bonds — 20,098 — 20,098 Mortgage-backed securities — 9,211 — 9,211 Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”) — 2,097 — 2,097 Redeemable preferred stock — 9 — 9 Total fixed maturity securities — 31,415 — 31,415 Equity securities: Common stock: Industrial, miscellaneous and all other — 2,308 — 2,308 Banks, trust and insurance companies — 690 — 690 Public utilities — 62 — 62 Non-redeemable preferred stock — — — — Mutual funds 1,270 3,796 34,718 39,784 Total equity securities 1,270 6,856 34,718 42,844 Other invested assets — 1,351 — 1,351 Total investments 1,270 39,622 34,718 75,610 Other assets — 3,975 — 3,975 Total $ 1,270 $ 43,597 $ 34,718 $ 79,585 December 31, 2023 Group Benefits RIS MetLife Holdings Total (In millions) Fixed maturity securities: Bonds: Foreign government $ — $ 509 $ — $ 509 U.S. government and agency — 9,603 — 9,603 Public utilities — 1,066 — 1,066 Municipals — 346 — 346 Corporate bonds: Materials — 143 — 143 Communications — 883 — 883 Consumer — 1,843 — 1,843 Energy — 906 — 906 Financial — 2,670 — 2,670 Industrial and other — 757 — 757 Technology — 541 — 541 Foreign — 1,889 — 1,889 Total corporate bonds — 9,632 — 9,632 Total bonds — 21,156 — 21,156 Mortgage-backed securities — 9,515 — 9,515 ABS & CLO — 2,341 — 2,341 Redeemable preferred stock — 9 — 9 Total fixed maturity securities — 33,021 — 33,021 Equity securities: Common stock: Industrial, miscellaneous and all other — 2,338 — 2,338 Banks, trust and insurance companies — 716 — 716 Public utilities — 65 — 65 Non-redeemable preferred stock — — — — Mutual funds 1,159 3,672 34,728 39,559 Total equity securities 1,159 6,791 34,728 42,678 Other invested assets — 1,425 — 1,425 Total investments 1,159 41,237 34,728 77,124 Other assets — 6,073 — 6,073 Total $ 1,159 $ 47,310 $ 34,728 $ 83,197 |
Deferred Policy Acquisition C_2
Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Deferred Policy Acquisition Costs and Present Value of Future Insurance Profits, Net [Abstract] | |
Deferred Policy Acquisition Costs | Information regarding total DAC and VOBA by segment, as well as Corporate & Other, was as follows at: Group Benefits RIS MetLife Holdings (1) Corporate & Other Total (In millions) DAC: Balance at January 1, 2024 $ 255 $ 155 $ 2,723 $ 158 $ 3,291 Capitalizations 7 46 (1) — 52 Amortization (13) (16) (99) (9) (137) Balance at June 30, 2024 $ 249 $ 185 $ 2,623 $ 149 $ 3,206 Balance at January 1, 2023 $ 264 $ 137 $ 3,220 $ 120 $ 3,741 Capitalizations 11 24 (1) 55 89 Amortization (13) (14) (115) (8) (150) Balance at June 30, 2023 $ 262 $ 147 $ 3,104 $ 167 $ 3,680 Total DAC and VOBA: Balance at June 30, 2024 $ 3,219 Balance at June 30, 2023 $ 3,695 Balance at December 31, 2023 $ 3,305 __________________ (1) Includes DAC balances primarily related to whole life, variable annuities, disability income, term life, long-term care and universal life products. |
Unearned Revenue | Information regarding the Company’s unearned revenue primarily related to universal life and variable universal life products by segment included in other policy-related balances was as follows: Six Months RIS MetLife Holdings Total (In millions) Balance, beginning of period $ 16 $ 5 $ 21 Deferrals 1 — 1 Amortization (2) — (2) Balance, end of period $ 15 $ 5 $ 20 Six Months RIS MetLife Holdings Total (In millions) Balance, beginning of period $ 18 $ 227 $ 245 Deferrals 1 20 21 Amortization (2) (9) (11) Balance, end of period $ 17 $ 238 $ 255 |
Closed Block (Tables)
Closed Block (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Closed Block Disclosure [Abstract] | |
Closed block liabilities and assets | Information regarding the liabilities and assets designated to the closed block was as follows at: June 30, 2024 December 31, 2023 (In millions) Closed Block Liabilities FPBs $ 35,492 $ 36,142 Other policy-related balances 283 319 Policyholder dividends payable 172 174 Policyholder dividend obligation — — Current income tax payable 4 — Other liabilities 797 668 Total closed block liabilities 36,748 37,303 Assets Designated to the Closed Block Investments: Fixed maturity securities available-for-sale (“AFS”), at estimated fair value 19,247 19,939 Mortgage loans 5,938 6,151 Policy loans 3,876 3,960 Real estate and real estate joint ventures (“REJV”) 688 668 Other invested assets 498 506 Total investments 30,247 31,224 Cash and cash equivalents 759 717 Accrued investment income 374 383 Premiums, reinsurance and other receivables 67 54 Current income tax recoverable — 3 Deferred income tax asset 397 312 Total assets designated to the closed block 31,844 32,693 Excess of closed block liabilities over assets designated to the closed block 4,904 4,610 AOCI: Unrealized investment gains (losses), net of income tax (1,204) (820) Unrealized gains (losses) on derivatives, net of income tax 164 130 Total amounts included in AOCI (1,040) (690) Maximum future earnings to be recognized from closed block assets and liabilities $ 3,864 $ 3,920 |
Closed block revenues and expenses | Information regarding the closed block revenues and expenses was as follows: Three Months Six Months 2024 2023 2024 2023 (In millions) Revenues Premiums $ 216 $ 226 $ 434 $ 461 Net investment income 342 341 685 679 Net investment gains (losses) (13) 5 (20) 9 Net derivative gains (losses) 2 5 7 3 Total revenues 547 577 1,106 1,152 Expenses Policyholder benefits and claims 415 445 819 858 Policyholder dividends 86 89 176 186 Other expenses 20 22 40 44 Total expenses 521 556 1,035 1,088 Revenues, net of expenses before provision for income tax expense (benefit) 26 21 71 64 Provision for income tax expense (benefit) 5 4 15 13 Revenues, net of expenses and provision for income tax expense (benefit) $ 21 $ 17 $ 56 $ 51 |
Investments (Tables)
Investments (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Investments, Debt and Equity Securities [Abstract] | |
Fixed Maturity Securities Available-for-Sale by Sector | The following table presents fixed maturity securities AFS by sector. U.S. corporate and foreign corporate sectors include redeemable preferred stock. Residential mortgage-backed securities (“RMBS”) includes agency, prime, prime investor, non-qualified residential mortgage, alternative, reperforming and sub-prime mortgage-backed securities. ABS & CLO includes securities collateralized by consumer loans, corporate loans and broadly syndicated bank loans. Municipals includes taxable and tax-exempt revenue bonds and, to a much lesser extent, general obligations of states, municipalities and political subdivisions. Commercial mortgage-backed securities (“CMBS”) primarily includes securities collateralized by multiple commercial mortgage loans. RMBS, ABS & CLO and CMBS are, collectively, “Structured Products.” June 30, 2024 December 31, 2023 Amortized Gross Unrealized Estimated Amortized Gross Unrealized Estimated Sector Allowance for Credit Loss (“ACL”) Gains Losses ACL Gains Losses (In millions) U.S. corporate $ 52,045 $ (27) $ 684 $ 3,855 $ 48,847 $ 52,479 $ (62) $ 1,126 $ 3,050 $ 50,493 Foreign corporate 27,381 (2) 334 3,284 24,429 27,520 (2) 536 2,839 25,215 U.S. government and agency 25,542 — 97 3,100 22,539 23,100 — 243 2,283 21,060 RMBS 22,572 (1) 183 2,190 20,564 20,700 (1) 228 1,979 18,948 ABS & CLO 12,188 (7) 47 318 11,910 12,049 (6) 30 432 11,641 Municipals 5,837 — 148 508 5,477 6,429 — 318 428 6,319 CMBS 5,828 (7) 26 433 5,414 6,387 (11) 28 570 5,834 Foreign government 3,167 (33) 109 267 2,976 3,416 (50) 156 227 3,295 Total fixed maturity securities AFS $ 154,560 $ (77) $ 1,628 $ 13,955 $ 142,156 $ 152,080 $ (132) $ 2,665 $ 11,808 $ 142,805 |
Available-for-sale fixed maturity securities by contractual maturity date | The amortized cost, net of ACL, and estimated fair value of fixed maturity securities AFS, by contractual maturity date, were as follows at June 30, 2024: Due in One Due After Due After Due After Structured Total Fixed (In millions) Amortized cost, net of ACL $ 5,015 $ 24,950 $ 27,900 $ 56,045 $ 40,573 $ 154,483 Estimated fair value $ 4,907 $ 24,189 $ 26,450 $ 48,722 $ 37,888 $ 142,156 |
Continuous Gross Unrealized Losses for Fixed Maturity Securities Available for Sale | The following table presents the estimated fair value and gross unrealized losses of fixed maturity securities AFS in an unrealized loss position without an ACL by sector and aggregated by length of time that the securities have been in a continuous unrealized loss position. June 30, 2024 December 31, 2023 Less than 12 Months Equal to or Greater Less than 12 Months Equal to or Greater Sector & Credit Quality Estimated Gross Estimated Gross Estimated Gross Estimated Gross (Dollars in millions) U.S. corporate $ 5,310 $ 136 $ 25,251 $ 3,701 $ 3,537 $ 95 $ 25,752 $ 2,924 Foreign corporate 2,376 84 15,847 3,200 714 64 16,982 2,775 U.S. government and agency 6,186 121 11,194 2,979 4,322 228 9,980 2,055 RMBS 2,615 43 12,667 2,147 1,470 37 12,813 1,941 ABS & CLO 751 3 4,928 314 937 20 8,250 410 Municipals 412 9 2,199 499 262 10 2,102 418 CMBS 702 6 3,475 426 587 23 4,096 542 Foreign government 385 7 1,455 251 431 12 1,452 212 Total fixed maturity securities AFS $ 18,737 $ 409 $ 77,016 $ 13,517 $ 12,260 $ 489 $ 81,427 $ 11,277 Investment grade $ 17,504 $ 364 $ 73,674 $ 13,098 $ 11,499 $ 453 $ 77,325 $ 10,849 Below investment grade 1,233 45 3,342 419 761 36 4,102 428 Total fixed maturity securities AFS $ 18,737 $ 409 $ 77,016 $ 13,517 $ 12,260 $ 489 $ 81,427 $ 11,277 Total number of securities in an unrealized loss position 2,588 8,129 1,679 8,441 |
Debt Securities, Available-for-Sale, Allowance for Credit Loss | The rollforward of ACL for fixed maturity securities AFS by sector is as follows: U.S. Foreign Corporate Foreign RMBS ABS & CLO CMBS Total Three Months Ended June 30, 2024 (In millions) Balance, at beginning of period $ 10 $ 2 $ 35 $ 1 $ 7 $ 11 $ 66 ACL not previously recorded 14 — — — — — 14 Changes for securities with previously recorded ACL 6 — — — — — 6 Securities sold or exchanged (3) — (2) — — (4) (9) Balance, at end of period $ 27 $ 2 $ 33 $ 1 $ 7 $ 7 $ 77 Three Months Ended June 30, 2023 Balance, at beginning of period $ 57 $ 3 $ 68 $ — $ — $ 7 $ 135 ACL not previously recorded — — — — — — — Changes for securities with previously recorded ACL 6 (1) 2 — — — 7 Securities sold or exchanged — — — — — — — Balance, at end of period $ 63 $ 2 $ 70 $ — $ — $ 7 $ 142 U.S. Foreign Foreign RMBS ABS & CLO CMBS Total (In millions) Six Months Ended June 30, 2024 Balance, at beginning of period $ 62 $ 2 $ 50 $ 1 $ 6 $ 11 $ 132 ACL not previously recorded 14 — — — — — 14 Changes for securities with previously recorded ACL 6 — (2) — 1 — 5 Securities sold or exchanged (55) — (15) — — (4) (74) Balance, at end of period $ 27 $ 2 $ 33 $ 1 $ 7 $ 7 $ 77 Six Months Ended June 30, 2023 Balance, at beginning of period $ 28 $ 3 $ 68 $ — $ — $ 15 $ 114 ACL not previously recorded 31 — — — — — 31 Changes for securities with previously recorded ACL 6 (1) 2 — — 2 9 Securities sold or exchanged (2) — — — — (10) (12) Balance, at end of period $ 63 $ 2 $ 70 $ — $ — $ 7 $ 142 |
Disclosure of Mortgage Loans Net of Valuation Allowance | Mortgage loans are summarized as follows at: June 30, 2024 December 31, 2023 Portfolio Segment Carrying % of Carrying % of (Dollars in millions) Commercial $ 35,433 58.5 % $ 37,129 59.3 % Agricultural 15,588 25.7 15,831 25.3 Residential 10,089 16.7 10,133 16.2 Total amortized cost 61,110 100.9 63,093 100.8 ACL (533) (0.9) (509) (0.8) Total mortgage loans $ 60,577 100.0 % $ 62,584 100.0 % |
Allowance for Loan and Lease Losses, Provision for Loss, Net | The rollforward of ACL for mortgage loans, by portfolio segment, is as follows: Six Months Ended June 30, 2024 2023 Commercial Agricultural Residential Total Commercial Agricultural Residential Total (In millions) Balance, beginning of period $ 210 $ 152 $ 147 $ 509 $ 174 $ 105 $ 169 $ 448 Provision (release) 74 6 (37) 43 37 48 5 90 Charge-offs, net of recoveries (12) (7) — (19) — (13) — (13) Balance, end of period $ 272 $ 151 $ 110 $ 533 $ 211 $ 140 $ 174 $ 525 |
Financing Receivable, Modified | These mortgage loan modifications are summarized as follows: Three Months Ended June 30, 2024 2023 Maturity Extension Weighted Average Life Increase Maturity Extension Weighted Average Life Increase Amortized Cost Affected Loans (in Years) % of Book Value Amortized Cost Affected Loans (in Years) % of Book Value (Dollars in millions) Commercial $ 137 Less than one year < 1% $ 149 One year < 1% Six Months Ended June 30, 2024 2023 Maturity Extension Weighted Average Life Increase Maturity Extension Weighted Average Life Increase Amortized Cost Affected Loans (in Years) % of Book Value Amortized Cost Affected Loans (in Years) % of Book Value (Dollars in millions) Commercial $ 167 Less than one year <1% $ 180 Less than one year < 1% |
Disclosure of the mortgage loans portfolio segment by the recorded investment, prior to valuation allowances, by credit quality indicator categories | The amortized cost of commercial mortgage loans by credit quality indicator and vintage year was as follows at June 30, 2024: Credit Quality Indicator 2024 2023 2022 2021 2020 Prior Revolving Total % of (Dollars in millions) LTV ratios: Less than 65% $ 839 $ 1,603 $ 1,035 $ 1,682 $ 867 $ 9,166 $ 2,251 $ 17,443 49.2 % 65% to 75% 32 226 3,013 1,388 841 3,802 — 9,302 26.3 76% to 80% — — 314 192 74 1,705 — 2,285 6.4 Greater than 80% 1 42 598 746 568 4,448 — 6,403 18.1 Total $ 872 $ 1,871 $ 4,960 $ 4,008 $ 2,350 $ 19,121 $ 2,251 $ 35,433 100.0 % DSCR: > 1.20x $ 837 $ 1,397 $ 4,284 $ 3,708 $ 2,092 $ 15,920 $ 2,251 $ 30,489 86.0 % 1.00x - 1.20x 5 385 528 300 119 1,816 — 3,153 8.9 <1.00x 30 89 148 — 139 1,385 — 1,791 5.1 Total $ 872 $ 1,871 $ 4,960 $ 4,008 $ 2,350 $ 19,121 $ 2,251 $ 35,433 100.0 % The amortized cost of agricultural mortgage loans by credit quality indicator and vintage year was as follows at June 30, 2024: Credit Quality Indicator 2024 2023 2022 2021 2020 Prior Revolving Total % of (Dollars in millions) LTV ratios: Less than 65% $ 257 $ 770 $ 1,981 $ 1,465 $ 1,885 $ 6,703 $ 1,326 $ 14,387 92.3 % 65% to 75% 5 47 73 193 126 494 125 1,063 6.8 76% to 80% — — — — — — — — — Greater than 80% — — — 14 29 77 18 138 0.9 Total $ 262 $ 817 $ 2,054 $ 1,672 $ 2,040 $ 7,274 $ 1,469 $ 15,588 100.0 % The amortized cost of residential mortgage loans by credit quality indicator and vintage year was as follows at June 30, 2024: Credit Quality Indicator 2024 2023 2022 2021 2020 Prior Revolving Total % of (Dollars in millions) Performance indicators: Performing $ 87 $ 331 $ 1,833 $ 948 $ 147 $ 6,424 $ — $ 9,770 96.8 % Nonperforming (1) — 7 53 16 6 237 — 319 3.2 Total $ 87 $ 338 $ 1,886 $ 964 $ 153 $ 6,661 $ — $ 10,089 100.0 % __________________ (1) Includes residential mortgage loans in process of foreclosure of $125 million and $134 million at June 30, 2024 and December 31, 2023, respectively. |
Schedule of Past Due and Non Accrual Mortgage Loans | The past due and nonaccrual mortgage loans at amortized cost, prior to ACL, by portfolio segment, were as follows: Past Due Past Due Nonaccrual Portfolio Segment June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 (In millions) Commercial $ 271 $ 19 $ — $ — $ 381 $ 303 Agricultural 188 40 15 — 182 206 Residential 319 343 — — 319 343 Total $ 778 $ 402 $ 15 $ — $ 882 $ 852 |
Disclosure Real Estate and Real Estate Joint Ventures | Real estate investments, by income type, as well as income earned, were as follows at and for the periods indicated: June 30, 2024 December 31, 2023 Three Months Six Months 2024 2023 2024 2023 Income Type Carrying Value Income (In millions) Wholly-owned real estate: Leased real estate $ 1,656 $ 1,594 $ 38 $ 41 $ 76 $ 83 Other real estate 518 506 77 83 120 129 REJV 6,895 6,590 (57) (7) (107) (43) Total real estate and REJV $ 9,069 $ 8,690 $ 58 $ 117 $ 89 $ 169 |
Debt Securities, Trading, and Equity Securities, FV-NI | The following table presents FVO securities and equity securities by asset type. FVO securities include fixed maturity and equity securities to support asset and liability management strategies for certain insurance products and investments in certain separate accounts. June 30, 2024 December 31, 2023 Cost Net Unrealized Gains (Losses) (1) Estimated Fair Value Cost Net Unrealized Gains (Losses) (1) Estimated Fair Value Asset Type (In millions) FVO securities $ 315 $ 493 $ 808 $ 379 $ 367 $ 746 Equity securities Common stock (2) $ 119 $ 49 $ 168 $ 118 $ 45 $ 163 Non-redeemable preferred stock 173 15 188 177 7 184 Total equity securities $ 292 $ 64 $ 356 $ 295 $ 52 $ 347 __________________ (1) Represents cumulative changes in estimated fair value, recognized in earnings, and not in OCI. (2) Includes common stock and certain mutual funds. |
Securities Lending and Repurchase Agreements | A summary of these transactions and agreements accounted for as secured borrowings were as follows: June 30, 2024 December 31, 2023 Securities (1) Securities (1) Agreement Type Estimated Fair Value Cash Collateral Received from Counterparties (2) Reinvestment Portfolio at Estimated Estimated Fair Value Cash Collateral Received from Counterparties (2) Reinvestment Portfolio at Estimated (In millions) Securities lending $ 5,761 $ 5,964 $ 5,837 $ 5,528 $ 5,684 $ 5,565 Repurchase agreements $ 2,984 $ 2,975 $ 2,912 $ 3,029 $ 2,975 $ 2,913 __________________ (1) These securities were included within fixed maturity securities AFS, short-term investments and cash equivalents at both June 30, 2024 and December 31, 2023. (2) The liability for cash collateral is included within payables for collateral under securities loaned and other transactions. Contractual maturities of these transactions and agreements accounted for as secured borrowings were as follows: June 30, 2024 December 31, 2023 Remaining Maturities Remaining Maturities Security Type Open (1) 1 Month Over 1 Over 6 Total Open (1) 1 Month Over 1 Over 6 Months to 1 Year Total (In millions) Cash collateral liability by security type: Securities lending: U.S. government and agency $ 1,238 $ 2,676 $ 2,050 $ — $ 5,964 $ 943 $ 2,523 $ 2,218 $ — $ 5,684 Repurchase agreements: U.S. government and agency $ — $ 2,975 $ — $ — $ 2,975 $ — $ 2,975 $ — $ — $ 2,975 __________________ (1) The related security could be returned to the Company on the next business day, which would require the Company to immediately return the cash collateral. |
Invested Assets on Deposit and Pledged as Collateral | Invested assets on deposit and pledged as collateral are presented below at estimated fair value for all asset classes, except mortgage loans, which are presented at carrying value, and were as follows at: June 30, 2024 December 31, 2023 (In millions) Invested assets on deposit (regulatory deposits) $ 101 $ 105 Invested assets pledged as collateral (1) 21,242 21,177 Total invested assets on deposit and pledged as collateral $ 21,343 $ 21,282 __________________ (1) The Company has pledged invested assets in connection with various agreements and transactions, including funding agreements and secured debt (see Notes 4 and 14 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report). For information regarding invested assets pledged in connection with derivative transactions, see Note 10. |
Schedule of Variable Interest Entities | The following table presents the total assets and total liabilities relating to investment-related VIEs for which the Company has concluded that it is the primary beneficiary and which are consolidated at: June 30, 2024 December 31, 2023 Asset Type Total Total Total Total (In millions) REJV $ 1,739 $ — $ 1,427 $ — Mortgage loan joint ventures 204 1 171 — Renewable energy partnership (primarily other invested assets) 61 — 65 — Investment funds (primarily other invested assets) 88 2 61 — Total $ 2,092 $ 3 $ 1,724 $ — Unconsolidated VIEs The carrying amount and maximum exposure to loss relating to VIEs in which the Company holds a significant variable interest but is not the primary beneficiary and which have not been consolidated were as follows at: June 30, 2024 December 31, 2023 Asset Type Carrying Maximum Carrying Maximum (In millions) Fixed maturity securities AFS (2) $ 36,626 $ 36,626 $ 35,370 $ 35,370 Other limited partnership interests (“OLPI”) 6,757 8,614 7,319 9,452 Other invested assets 1,156 1,351 1,318 1,405 REJV 73 236 104 267 Total $ 44,612 $ 46,827 $ 44,111 $ 46,494 __________________ (1) The maximum exposure to loss relating to fixed maturity securities AFS and FVO securities is equal to their carrying amounts or the carrying amounts of retained interests. The maximum exposure to loss relating to OLPI and REJV is equal to the carrying amounts plus any unrecognized unfunded commitments. For certain of its investments in other invested assets, the Company’s return is in the form of income tax credits which are guaranteed by creditworthy third parties. For such investments, the maximum exposure to loss is equal to the carrying amounts plus any unfunded commitments, reduced by income tax credits guaranteed by third parties. Such a maximum loss would be expected to occur only upon bankruptcy of the issuer or investee. (2) For variable interests in Structured Products included within fixed maturity securities AFS, the Company’s involvement is limited to that of a passive investor in mortgage-backed or asset-backed securities issued by trusts that do not have substantial equity. |
Components of Net Investment Income | The composition of net investment income by asset type was as follows: Three Months Six Months Asset Type 2024 2023 2024 2023 (In millions) Fixed maturity securities AFS $ 1,848 $ 1,897 $ 3,678 $ 3,743 Mortgage loans 823 829 1,651 1,619 Policy loans 71 75 141 148 Real estate and REJV 58 117 89 169 OLPI 174 91 332 92 Cash, cash equivalents and short-term investments 87 89 178 173 FVO securities 29 46 95 96 Operating joint venture 13 7 29 21 Equity securities 3 4 6 5 Other 124 46 205 125 Subtotal investment income 3,230 3,201 6,404 6,191 Less: Investment expenses 327 328 644 633 Net investment income $ 2,903 $ 2,873 $ 5,760 $ 5,558 Net Investment Income Information Net realized and unrealized gains (losses) recognized in net investment income: Net realized gains (losses) from sales and disposals $ (15) $ — $ (15) $ — Net unrealized gains (losses) from changes in estimated fair value (primarily FVO securities and REJV) 53 76 140 134 Net realized and unrealized gains (losses) recognized in net investment income $ 38 $ 76 $ 125 $ 134 Changes in estimated fair value subsequent to purchase of FVO securities still held at the end of the respective periods and recognized in net investment income $ 44 $ 45 $ 108 $ 92 Equity method investments net investment income (primarily REJV, OLPI, tax credit and renewable energy partnerships and an operating joint venture) $ 148 $ 65 $ 284 $ 27 |
Components of Net Investment Gains (Losses) | The composition of net investment gains (losses) by asset type and transaction type was as follows: Three Months Six Months Asset Type 2024 2023 2024 2023 (In millions) Fixed maturity securities AFS $ (138) $ (746) $ (217) $ (694) Equity securities 3 7 9 2 Mortgage loans 16 33 (55) (116) Real estate and REJV (excluding changes in estimated fair value) 12 62 39 64 OLPI (excluding changes in estimated fair value) (1) (9) 2 (47) 9 Other gains (losses) 3 8 (2) 14 Subtotal (113) (634) (273) (721) Change in estimated fair value of OLPI and REJV 2 1 5 (4) Non-investment portfolio gains (losses) 5 (26) 26 (36) Subtotal 7 (25) 31 (40) Net investment gains (losses) $ (106) $ (659) $ (242) $ (761) Transaction Type Realized gains (losses) on investments sold or disposed (1) $ (126) $ (3) $ (299) $ 80 Impairment (losses) — (684) — (690) Recognized gains (losses): Change in ACL recognized in earnings 7 47 14 (115) Unrealized net gains (losses) recognized in earnings 8 7 17 — Total recognized gains (losses) 15 54 31 (115) Non-investment portfolio gains (losses) 5 (26) 26 (36) Net investment gains (losses) $ (106) $ (659) $ (242) $ (761) Net Investment Gains (Losses) Information Changes in estimated fair value subsequent to purchase of equity securities still held at the end of the respective periods and recognized in net investment gains (losses) $ 6 $ 8 $ 17 $ 5 Other gains (losses) include: Gains (losses) on disposed investments which were previously in a qualified cash flow hedging relationship $ 1 $ (27) $ 3 $ (25) Foreign currency gains (losses) $ (1) $ (36) $ 8 $ (51) Net Realized Investment Gains (Losses) From Sales and Disposals of Investments: Recognized in net investment gains (losses) $ (126) $ (3) $ (299) $ 80 Recognized in net investment income (15) — (15) — Net realized investment gains (losses) from sales and disposals of investments $ (141) $ (3) $ (314) $ 80 __________________ (1) Includes a net loss of $2 million and $38 million during the three months and six months ended June 30, 2024, respectively, for private equity investments sold. During the three months ended June 30, 2024, the Company sold a $48 million portfolio of investments to a fund for proceeds of $46 million in cash and receivables secured by the value of the fund. During the six months ended June 30, 2024, the Company sold $638 million in portfolios of investments to a fund for proceeds of $600 million in cash and receivables secured by the value of the fund. An affiliate has entered into an agreement to serve as the investment manager of the fund for which it will receive a management fee. |
Schedule of Realized Gain (Loss) | The composition of net investment gains (losses) for these securities is as follows: Three Months Six Months Fixed Maturity Securities AFS 2024 2023 2024 2023 (In millions) Proceeds $ 4,754 $ 3,291 $ 7,784 $ 11,713 Gross investment gains $ 67 $ 27 $ 115 $ 266 Gross investment (losses) (195) (102) (388) (262) Realized gains (losses) on sales and disposals (128) (75) (273) 4 Net credit loss (provision) release (change in ACL recognized in earnings) (10) (10) 56 (31) Impairment (losses) — (661) — (667) Net credit loss (provision) release and impairment (losses) (10) (671) 56 (698) Net investment gains (losses) $ (138) $ (746) $ (217) $ (694) Equity Securities Realized gains (losses) on sales and disposals $ (1) $ — $ (2) $ (2) Unrealized net gains (losses) recognized in earnings 4 7 11 4 Net investment gains (losses) $ 3 $ 7 $ 9 $ 2 |
Schedule of Related Party Transactions | The Company transfers invested assets primarily consisting of fixed maturity securities AFS, mortgage loans, and real estate and REJV to and from affiliates. Invested assets transferred to and from affiliates were as follows: Three Months Six Months 2024 2023 2024 2023 (In millions) Estimated fair value of invested assets transferred to affiliates $ — $ 4 $ 140 $ 4 Amortized cost of invested assets transferred to affiliates $ — $ 4 $ 137 $ 4 Net investment gains (losses) recognized on transfers $ — $ — $ 3 $ — Estimated fair value of invested assets transferred from affiliates $ 2 $ 645 $ 4 $ 1,160 Recurring related party investments and related net investment income were as follows at and for the periods ended: June 30, 2024 December 31, 2023 Three Months Six Months 2024 2023 2024 2023 Investment Type/ Related Party Carrying Value Net Investment Income (In millions) Affiliated investments (1) MetLife, Inc. $ 990 $ 1,130 $ 4 $ 5 $ 9 $ 10 Affiliated investments (2) Metropolitan General Insurance Company 163 150 — — — — Other invested assets $ 1,153 $ 1,280 $ 4 $ 5 $ 9 $ 10 ________________ (1) Represents an investment in affiliated senior unsecured notes which have maturity dates from July 2026 to December 2031 and bear interest, payable semi-annually, at rates per annum ranging from 1.61% to 2.16%. See Note 10 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report for further information. (2) Represents an investment in affiliated preferred stock with a dividend yield of 7.50% that will be cumulative and payable annually in arrears. The shares can be redeemed, at MetLife General Insurance Company’s option, after December 15, 2028. |
Derivatives (Tables)
Derivatives (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Primary Risks Managed by Derivatives | The following table presents the primary underlying risk exposure, gross notional amount, and estimated fair value of the Company’s derivatives, excluding embedded derivatives, held at: June 30, 2024 December 31, 2023 Primary Underlying Risk Exposure Gross Notional Amount Estimated Fair Value Gross Estimated Fair Value Assets Liabilities Assets Liabilities (In millions) Derivatives Designated as Hedging Instruments: Fair value hedges: Interest rate swaps Interest rate $ 4,870 $ 1,094 $ 610 $ 4,443 $ 1,257 $ 508 Foreign currency swaps Foreign currency exchange rate 1,317 37 13 1,459 55 1 Subtotal 6,187 1,131 623 5,902 1,312 509 Cash flow hedges: Interest rate swaps Interest rate 3,788 — 323 3,789 1 246 Interest rate forwards Interest rate 369 — 81 970 — 175 Foreign currency swaps Foreign currency exchange rate 31,966 2,181 851 30,342 1,977 846 Subtotal 36,123 2,181 1,255 35,101 1,978 1,267 Total qualifying hedges 42,310 3,312 1,878 41,003 3,290 1,776 Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate swaps Interest rate 15,482 1,428 731 15,516 1,476 638 Interest rate floors Interest rate 8,078 29 — 13,921 39 — Interest rate caps Interest rate 24,970 236 — 28,890 355 — Interest rate futures Interest rate 70 — — 25 — — Interest rate options Interest rate 37,416 216 66 39,226 361 27 Synthetic GICs Interest rate 5,966 — — 6,145 — — Foreign currency swaps Foreign currency exchange rate 4,259 454 9 4,304 446 24 Foreign currency forwards Foreign currency exchange rate 1,097 8 4 1,176 8 10 Credit default swaps — purchased Credit 749 6 3 809 3 7 Credit default swaps — written Credit 11,522 197 5 10,007 186 4 Equity futures Equity market 647 3 1 941 3 — Equity index options Equity market 13,203 222 189 17,703 339 193 Equity total return swaps Equity market 2,020 1 100 1,912 — 218 Total non-designated or nonqualifying derivatives 125,479 2,800 1,108 140,575 3,216 1,121 Total $ 167,789 $ 6,112 $ 2,986 $ 181,578 $ 6,506 $ 2,897 |
The Effects of Derivatives on the Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) | The following table presents the interim condensed consolidated financial statement location and amount of gain (loss) recognized on fair value, cash flow, nonqualifying hedging relationships and embedded derivatives: Three Months Ended June 30, 2024 Net Net Net Policyholder Interest Credited to PABs OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ — $ — N/A $ (41) $ (14) N/A Hedged items — — N/A 34 12 N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) (2) — N/A — (7) N/A Hedged items 2 — N/A — 7 N/A Subtotal — — N/A (7) (2) N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A $ (71) Amount of gains (losses) reclassified from AOCI into income 6 — — — — (6) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A 206 Amount of gains (losses) reclassified from AOCI into income 1 95 — — — (96) Foreign currency transaction gains (losses) on hedged items — (99) — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A — Amount of gains (losses) reclassified from AOCI into income — 1 — — — (1) Subtotal 7 (3) — — — 32 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — N/A (79) N/A N/A N/A Foreign currency exchange rate derivatives (1) — N/A 7 N/A N/A N/A Credit derivatives — purchased (1) — N/A 5 N/A N/A N/A Credit derivatives — written (1) — N/A (14) N/A N/A N/A Equity derivatives (1) (11) N/A (86) N/A N/A N/A Foreign currency transaction gains (losses) on hedged items — N/A (15) N/A N/A N/A Subtotal (11) N/A (182) N/A N/A N/A Earned income on derivatives 53 — 118 (2) (43) — Synthetic GICs N/A N/A 3 N/A N/A N/A Embedded derivatives N/A N/A 121 N/A N/A N/A Total $ 49 $ (3) $ 60 $ (9) $ (45) $ 32 Three Months Ended June 30, 2023 Net Investment Income Net Investment Gains (Losses) Net Derivative Gains (Losses) Policyholder Benefits and Claims Interest Credited to PABs OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ — $ — N/A $ (135) $ (32) N/A Hedged items (1) — N/A 121 31 N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) (6) — N/A — 13 N/A Hedged items 5 — N/A — (11) N/A Subtotal (2) — N/A (14) 1 N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A $ (156) Amount of gains (losses) reclassified from AOCI into income 13 55 — — — (68) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A 56 Amount of gains (losses) reclassified from AOCI into income 1 310 — — — (311) Foreign currency transaction gains (losses) on hedged items — (293) — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A (1) Amount of gains (losses) reclassified from AOCI into income — — — — — — Subtotal 14 72 — — — (480) Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — N/A (336) N/A N/A N/A Foreign currency exchange rate derivatives (1) — N/A (44) N/A N/A N/A Credit derivatives — purchased (1) — N/A (8) N/A N/A N/A Credit derivatives — written (1) — N/A 60 N/A N/A N/A Equity derivatives (1) (36) N/A (348) N/A N/A N/A Foreign currency transaction gains (losses) on hedged items — N/A 39 N/A N/A N/A Subtotal (36) N/A (637) N/A N/A N/A Earned income on derivatives 39 — 189 3 (34) — Synthetic GICs N/A N/A 4 N/A N/A N/A Embedded derivatives N/A N/A 212 N/A N/A N/A Total $ 15 $ 72 $ (232) $ (11) $ (33) $ (480) Six Months Ended June 30, 2024 Net Net Net Policyholder Interest Credited to PABs OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ — $ — N/A $ (150) $ (53) N/A Hedged items — — N/A 137 50 N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) 2 — N/A — (31) N/A Hedged items — — N/A — 35 N/A Subtotal 2 — N/A (13) 1 N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A $ (215) Amount of gains (losses) reclassified from AOCI into income 14 2 — — — (16) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A 207 Amount of gains (losses) reclassified from AOCI into income 2 (175) — — — 173 Foreign currency transaction gains (losses) on hedged items — 164 — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A — Amount of gains (losses) reclassified from AOCI into income — 1 — — — (1) Subtotal 16 (8) — — — 148 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — N/A (278) N/A N/A N/A Foreign currency exchange rate derivatives (1) — N/A 81 N/A N/A N/A Credit derivatives — purchased (1) — N/A 5 N/A N/A N/A Credit derivatives — written (1) — N/A 9 N/A N/A N/A Equity derivatives (1) (36) N/A (367) N/A N/A N/A Foreign currency transaction gains (losses) on hedged items — N/A (51) N/A N/A N/A Subtotal (36) N/A (601) N/A N/A N/A Earned income on derivatives 83 — 245 (6) (91) — Synthetic GICs N/A N/A 5 N/A N/A N/A Embedded derivatives N/A N/A 355 N/A N/A N/A Total $ 65 $ (8) $ 4 $ (19) $ (90) $ 148 Six Months Ended June 30, 2023 Net Investment Income Net Investment Gains (Losses) Net Derivative Gains (Losses) Policyholder Benefits and Claims Interest Credited to PABs OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ (1) $ — N/A $ (9) $ — N/A Hedged items — — N/A (5) (1) N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) (22) — N/A — 13 N/A Hedged items 21 — N/A — (11) N/A Subtotal (2) — N/A (14) 1 N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A $ 44 Amount of gains (losses) reclassified from AOCI into income 27 57 — — — (84) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A 15 Amount of gains (losses) reclassified from AOCI into income 2 439 — — — (441) Foreign currency transaction gains (losses) on hedged items — (417) — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A (1) Amount of gains (losses) reclassified from AOCI into income — — — — — — Subtotal 29 79 — — — (467) Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — N/A (397) N/A N/A N/A Foreign currency exchange rate derivatives (1) — N/A (139) N/A N/A N/A Credit derivatives — purchased (1) — N/A (17) N/A N/A N/A Credit derivatives — written (1) — N/A 66 N/A N/A N/A Equity derivatives (1) (42) N/A (751) N/A N/A N/A Foreign currency transaction gains (losses) on hedged items — N/A 71 N/A N/A N/A Subtotal (42) N/A (1,167) N/A N/A N/A Earned income on derivatives 82 — 434 8 (67) — Synthetic GICs N/A N/A 9 N/A N/A N/A Embedded derivatives N/A N/A (68) N/A N/A N/A Total $ 67 $ 79 $ (792) $ (6) $ (66) $ (467) __________________ (1) Excludes earned income on derivatives. |
Fair Value Hedges | The following table presents the balance sheet classification, carrying amount and cumulative fair value hedging adjustments for items designated and qualifying as hedged items in fair value hedges: Balance Sheet Line Item Carrying Amount of the Cumulative Amount June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 (In millions) Fixed maturity securities AFS $ 118 $ 120 $ 1 $ 1 Mortgage loans $ 208 $ 345 $ (5) $ (10) FPBs $ (2,661) $ (2,863) $ 337 $ 191 PABs $ (2,198) $ (1,844) $ 141 $ 2 __________________ (1) Includes ($101) million and ($113) million of hedging adjustments on discontinued hedging relationships at June 30, 2024 and December 31, 2023, respectively. |
Schedule of estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps | The following table presents the estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps at: June 30, 2024 December 31, 2023 Rating Agency Designation of Referenced Estimated Maximum Weighted Estimated Maximum Weighted (Dollars in millions) Aaa/Aa/A Single name credit default swaps (3) $ — $ — — $ — $ 10 0.5 Credit default swaps referencing indices 82 4,125 2.6 80 3,831 2.7 Subtotal 82 4,125 2.6 80 3,841 2.7 Baa Single name credit default swaps (3) 1 55 1.8 1 55 2.3 Credit default swaps referencing indices 105 7,213 4.4 102 5,982 5.6 Subtotal 106 7,268 4.4 103 6,037 5.5 Ba Credit default swaps referencing indices 2 25 2.5 2 25 3.0 Subtotal 2 25 2.5 2 25 3.0 B Credit default swaps referencing indices 5 74 4.5 1 74 5.0 Subtotal 5 74 4.5 1 74 5.0 Caa Credit default swaps referencing indices (3) 30 2.0 (4) 30 2.5 Subtotal (3) 30 2.0 (4) 30 2.5 Total $ 192 $ 11,522 3.7 $ 182 $ 10,007 4.4 __________________ (1) The rating agency designations are based on availability and the midpoint of the applicable ratings among Moody’s Investors Service (“Moody’s”), S&P Global Ratings (“S&P”) and Fitch Ratings. If no rating is available from a rating agency, then an internally developed rating is used. (2) The weighted average years to maturity of the credit default swaps is calculated based on weighted average gross notional amounts. (3) Single name credit default swaps may be referenced to the credit of corporations, foreign governments, or municipals. |
Estimated Fair Value of Derivative Assets and Liabilities after Master Netting Agreements and Cash Collateral | The estimated fair values of the Company’s net derivative assets and net derivative liabilities after the application of master netting agreements and collateral were as follows at: June 30, 2024 December 31, 2023 Derivatives Subject to a Master Netting Arrangement or a Similar Arrangement Assets Liabilities Assets Liabilities (In millions) Gross estimated fair value of derivatives: OTC-bilateral (1) $ 6,083 $ 3,013 $ 6,534 $ 2,892 OTC-cleared (1) 143 41 112 13 Exchange-traded 3 1 3 — Total gross estimated fair value of derivatives presented on the interim condensed consolidated balance sheets (1) 6,229 3,055 6,649 2,905 Gross amounts not offset on the interim condensed consolidated balance sheets: Gross estimated fair value of derivatives: (2) OTC-bilateral (2,411) (2,411) (2,350) (2,350) OTC-cleared (12) (12) (4) (4) Exchange-traded (1) (1) — — Cash collateral: (3), (4) OTC-bilateral (2,645) — (2,872) — OTC-cleared (113) — (105) (1) Securities collateral: (5) OTC-bilateral (1,021) (602) (1,283) (542) OTC-cleared — (29) — (8) Exchange-traded — — — — Net amount after application of master netting agreements and collateral $ 26 $ — $ 35 $ — __________________ (1) At June 30, 2024 and December 31, 2023, derivative assets included income (expense) accruals reported in accrued investment income or in other liabilities of $117 million and $143 million, respectively, and derivative liabilities included (income) expense accruals reported in accrued investment income or in other liabilities of $69 million and $8 million, respectively. (2) Estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals. (3) Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives, where the central clearinghouse treats variation margin as collateral, is included in cash and cash equivalents, short-term investments or in fixed maturity securities AFS, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet. (4) The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange- traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after app lication of netting agreements. At June 30, 2024 and December 31, 2023, the Company received excess cash collateral of $48 million and $154 million, respectively, and provided excess cash collateral of $4 million for both periods, which are not included in the table above due to the foregoing limitation. (5) Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at June 30, 2024, none of the collateral had been sold or re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities AFS on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At June 30, 2024 and December 31, 2023, the Company received excess securities collateral with an estimated fair value of $455 million and $286 million, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At June 30, 2024 and December 31, 2023, the Company provided excess securities collateral with an estimated fair value of $905 million and $1.1 billion, respectively, for its OTC-bilateral derivatives, $416 million and $495 million, respectively, for its OTC-cleared derivatives, and $31 million and $56 million, respectively, for its exchange-traded derivatives, which are not included in the table above due to th e foregoing limitation. |
Estimated Fair Value of Derivative Assets and Liabilities after Master Netting Agreements and Cash Collateral | The estimated fair values of the Company’s net derivative assets and net derivative liabilities after the application of master netting agreements and collateral were as follows at: June 30, 2024 December 31, 2023 Derivatives Subject to a Master Netting Arrangement or a Similar Arrangement Assets Liabilities Assets Liabilities (In millions) Gross estimated fair value of derivatives: OTC-bilateral (1) $ 6,083 $ 3,013 $ 6,534 $ 2,892 OTC-cleared (1) 143 41 112 13 Exchange-traded 3 1 3 — Total gross estimated fair value of derivatives presented on the interim condensed consolidated balance sheets (1) 6,229 3,055 6,649 2,905 Gross amounts not offset on the interim condensed consolidated balance sheets: Gross estimated fair value of derivatives: (2) OTC-bilateral (2,411) (2,411) (2,350) (2,350) OTC-cleared (12) (12) (4) (4) Exchange-traded (1) (1) — — Cash collateral: (3), (4) OTC-bilateral (2,645) — (2,872) — OTC-cleared (113) — (105) (1) Securities collateral: (5) OTC-bilateral (1,021) (602) (1,283) (542) OTC-cleared — (29) — (8) Exchange-traded — — — — Net amount after application of master netting agreements and collateral $ 26 $ — $ 35 $ — __________________ (1) At June 30, 2024 and December 31, 2023, derivative assets included income (expense) accruals reported in accrued investment income or in other liabilities of $117 million and $143 million, respectively, and derivative liabilities included (income) expense accruals reported in accrued investment income or in other liabilities of $69 million and $8 million, respectively. (2) Estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals. (3) Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives, where the central clearinghouse treats variation margin as collateral, is included in cash and cash equivalents, short-term investments or in fixed maturity securities AFS, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet. (4) The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange- traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after app lication of netting agreements. At June 30, 2024 and December 31, 2023, the Company received excess cash collateral of $48 million and $154 million, respectively, and provided excess cash collateral of $4 million for both periods, which are not included in the table above due to the foregoing limitation. (5) Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at June 30, 2024, none of the collateral had been sold or re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities AFS on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At June 30, 2024 and December 31, 2023, the Company received excess securities collateral with an estimated fair value of $455 million and $286 million, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At June 30, 2024 and December 31, 2023, the Company provided excess securities collateral with an estimated fair value of $905 million and $1.1 billion, respectively, for its OTC-bilateral derivatives, $416 million and $495 million, respectively, for its OTC-cleared derivatives, and $31 million and $56 million, respectively, for its exchange-traded derivatives, which are not included in the table above due to th e foregoing limitation. |
Estimated Fair Value of OTC-bilateral derivatives after considering effect of netting agreements | The following table presents the estimated fair value of the Company’s OTC-bilateral derivatives that were in a net liability position after considering the effect of netting agreements, together with the estimated fair value and balance sheet location of the collateral pledged. June 30, 2024 December 31, 2023 Derivatives Strength-Contingent Derivatives Total Derivatives Strength-Contingent Derivatives Total (In millions) Estimated fair value of derivatives in a net liability position (1) $ 595 $ 7 $ 602 $ 542 $ — $ 542 Estimated fair value of collateral provided: Fixed maturity securities AFS $ 916 $ 8 $ 924 $ 896 $ — $ 896 __________________ (1) After taking into consideration the existence of netting agreements. The following table presents the estimated fair value and balance sheet location of the Company’s embedded derivatives that have been separated from their host contracts at: Balance Sheet Location June 30, 2024 December 31, 2023 (In millions) Embedded derivatives within asset host contracts: Assumed on affiliated reinsurance Other invested assets $ 148 $ 41 Funds withheld on affiliated reinsurance Other invested assets (22) (26) Total $ 126 $ 15 Embedded derivatives within liability host contracts: Assumed on affiliated reinsurance Other liabilities $ — $ 104 Funds withheld on affiliated reinsurance Other liabilities (447) (304) Fixed annuities with equity indexed returns PABs 168 163 Total $ (279) $ (37) |
Embedded Derivatives | The following table presents the estimated fair value of the Company’s OTC-bilateral derivatives that were in a net liability position after considering the effect of netting agreements, together with the estimated fair value and balance sheet location of the collateral pledged. June 30, 2024 December 31, 2023 Derivatives Strength-Contingent Derivatives Total Derivatives Strength-Contingent Derivatives Total (In millions) Estimated fair value of derivatives in a net liability position (1) $ 595 $ 7 $ 602 $ 542 $ — $ 542 Estimated fair value of collateral provided: Fixed maturity securities AFS $ 916 $ 8 $ 924 $ 896 $ — $ 896 __________________ (1) After taking into consideration the existence of netting agreements. The following table presents the estimated fair value and balance sheet location of the Company’s embedded derivatives that have been separated from their host contracts at: Balance Sheet Location June 30, 2024 December 31, 2023 (In millions) Embedded derivatives within asset host contracts: Assumed on affiliated reinsurance Other invested assets $ 148 $ 41 Funds withheld on affiliated reinsurance Other invested assets (22) (26) Total $ 126 $ 15 Embedded derivatives within liability host contracts: Assumed on affiliated reinsurance Other liabilities $ — $ 104 Funds withheld on affiliated reinsurance Other liabilities (447) (304) Fixed annuities with equity indexed returns PABs 168 163 Total $ (279) $ (37) |
Fair Value (Tables)
Fair Value (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Fair Value Disclosures [Abstract] | |
Recurring Fair Value Measurements | The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy, including those items for which the Company has elected the FVO, are presented below at: June 30, 2024 Fair Value Hierarchy Level 1 Level 2 Level 3 Total Estimated Fair Value (In millions) Assets Fixed maturity securities AFS: U.S. corporate $ — $ 39,926 $ 8,921 $ 48,847 Foreign corporate — 15,875 8,554 24,429 U.S. government and agency 10,834 11,705 — 22,539 RMBS — 18,818 1,746 20,564 ABS & CLO — 10,043 1,867 11,910 Municipals — 5,477 — 5,477 CMBS — 4,914 500 5,414 Foreign government — 2,965 11 2,976 Total fixed maturity securities AFS 10,834 109,723 21,599 142,156 Short-term investments 1,479 186 3 1,668 Other investments 46 91 1,434 1,571 Derivative assets: (1) Interest rate — 3,003 — 3,003 Foreign currency exchange rate — 2,680 — 2,680 Credit — 203 — 203 Equity market 3 217 6 226 Total derivative assets 3 6,103 6 6,112 Embedded derivatives within asset host contracts (4) — — 126 126 MRBs — — 230 230 Separate account assets (2) 13,630 64,986 969 79,585 Total assets (3) $ 25,992 $ 181,089 $ 24,367 $ 231,448 Liabilities Derivative liabilities: (1) Interest rate $ — $ 1,730 $ 81 $ 1,811 Foreign currency exchange rate — 877 — 877 Credit — 8 — 8 Equity market 1 289 — 290 Total derivative liabilities 1 2,904 81 2,986 Embedded derivatives within liability host contracts (4) — — (279) (279) MRBs — — 2,391 2,391 Separate account liabilities (2) — 3 — 3 Total liabilities $ 1 $ 2,907 $ 2,193 $ 5,101 December 31, 2023 Fair Value Hierarchy Level 1 Level 2 Level 3 Total Estimated Fair Value (In millions) Assets Fixed maturity securities AFS: U.S. corporate $ — $ 41,718 $ 8,775 $ 50,493 Foreign corporate — 16,875 8,340 25,215 U.S. government and agency 8,963 12,097 — 21,060 RMBS 3 17,616 1,329 18,948 ABS & CLO — 10,109 1,532 11,641 Municipals — 6,319 — 6,319 CMBS — 5,499 335 5,834 Foreign government — 3,281 14 3,295 Total fixed maturity securities AFS 8,966 113,514 20,325 142,805 Short-term investments 2,745 288 15 3,048 Other investments 76 77 1,317 1,470 Derivative assets: (1) Interest rate — 3,489 — 3,489 Foreign currency exchange rate — 2,486 — 2,486 Credit — 181 8 189 Equity market 3 332 7 342 Total derivative assets 3 6,488 15 6,506 Embedded derivatives within asset host contracts (4) — — 15 15 MRBs — — 177 177 Separate account assets (2) 13,945 68,284 968 83,197 Total assets (3) $ 25,735 $ 188,651 $ 22,832 $ 237,218 Liabilities Derivative liabilities: (1) Interest rate $ — $ 1,419 $ 175 $ 1,594 Foreign currency exchange rate — 881 — 881 Credit — 11 — 11 Equity market — 411 — 411 Total derivative liabilities — 2,722 175 2,897 Embedded derivatives within liability host contracts (4) — — (37) (37) MRBs — — 2,878 2,878 Separate account liabilities (2) 4 4 — 8 Total liabilities $ 4 $ 2,726 $ 3,016 $ 5,746 __________________ (1) Derivative assets are presented within other invested assets on the interim condensed consolidated balance sheets and derivative liabilities are presented within other liabilities on the interim condensed consolidated balance sheets. The amounts are presented gross in the tables above to reflect the presentation on the interim condensed consolidated balance sheets, but are presented net for purposes of the rollforward in the Fair Value Measurements Using Significant Unobservable Inputs (Level 3) tables. (2) Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders whose liability is reflected within separate account liabilities. Separate account liabilities are set equal to the estimated fair value of separate account assets. Separate account liabilities presented in the tables above represent derivative liabilities. (3) Total assets included in the fair value hierarchy exclude OLPI that are measured at estimated fair value using the net asset value (“NAV”) per share (or its equivalent) practical expedient. The estimated fair value of such investments was $48 million at both June 30, 2024 and December 31, 2023. (4) Embedded derivatives within asset host contracts are presented within other invested assets on the interim condensed consolidated balance sheets. Embedded derivatives within liability host contracts are presented within PABs and other liabilities on the interim condensed consolidated balance sheets. |
Fair Value Inputs, Quantitative Information | The following table presents certain quantitative information about the significant unobservable inputs used in the fair value measurement, and the sensitivity of the estimated fair value to changes in those inputs, for the more significant asset and liability classes measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at: June 30, 2024 December 31, 2023 Impact of Valuation Techniques Significant Range Weighted Range Weighted Fixed maturity securities AFS (3) U.S. corporate and foreign corporate • Matrix pricing • Offered quotes (4) 53 - 125 93 4 - 131 95 Increase • Market pricing • Quoted prices (4) 27 - 111 94 — - 110 93 Increase RMBS • Market pricing • Quoted prices (4) — - 116 96 — - 112 93 Increase (5) ABS & CLO • Market pricing • Quoted prices (4) 84 - 103 96 78 - 101 94 Increase (5) Derivatives Interest rate • Present value techniques • Swap yield (6) 428 - 452 437 367 - 399 385 Increase (7) Credit • Consensus pricing • Offered quotes (8) MRBs Direct and assumed guaranteed minimum benefits • Option pricing techniques • Mortality rates: Ages 0 - 40 0.01% - 0.13% 0.05% 0.01% - 0.13% 0.05% (9) Ages 41 - 60 0.05% - 0.67% 0.22% 0.05% - 0.67% 0.22% (9) Ages 61 - 115 0.35% - 100% 1.23% 0.35% - 100% 1.23% (9) • Lapse rates: Durations 1 - 10 0.80% - 20.10% 8.72% 0.80% - 20.10% 8.72% Decrease (10) Durations 11 - 20 3.10% - 10.10% 4.34% 3.10% - 10.10% 4.34% Decrease (10) Durations 21 - 116 0.10% - 10.10% 4.59% 0.10% - 10.10% 4.59% Decrease (10) • Utilization rates 0.20% - 22% 0.44% 0.20% - 22% 0.44% Increase (11) • Withdrawal rates 0.25% - 7.75% 4.47% 0.25% - 7.75% 4.47% (12) • Long-term equity volatilities 16.37% - 21.85% 18.55% 16.37% - 21.85% 18.55% Increase (13) • Nonperformance risk spread 0.33% - 0.66% 0.73% 0.38% - 0.70% 0.73% Decrease (14) __________________ (1) The weighted average for fixed maturity securities AFS and derivatives is determined based on the estimated fair value of the securities and derivatives. The weighted average for MRBs is determined based on a combination of account values and experience data. (2) The impact of a decrease in input would have resulted in the opposite impact on estimated fair value. For MRBs, changes to direct and assumed guaranteed minimum benefits are based on liability positions. (3) Significant increases (decreases) in expected default rates in isolation would have resulted in substantially lower (higher) valuations. (4) Range and weighted average are presented in accordance with the market convention for fixed maturity securities AFS of dollars per hundred dollars of par. (5) Changes in the assumptions used for the probability of default would have been accompanied by a directionally similar change in the assumption used for the loss severity and a directionally opposite change in the assumptions used for prepayment rates. (6) Ranges represent the rates across different yield curves and are presented in basis points. The swap yield curves are utilized among different types of derivatives to project cash flows, as well as to discount future cash flows to present value. Since this valuation methodology uses a range of inputs across a yield curve to value the derivative, presenting a range is more representative of the unobservable input used in the valuation. (7) Changes in estimated fair value are based on long U.S. dollar net asset positions and will be inversely impacted for short U.S. dollar net asset positions. (8) At June 30, 2024 and December 31, 2023, independent non-binding broker quotations were used in the determination of 0% and less than 1%, respectively, of the total net derivative estimated fair value. (9) Mortality rates vary by age and by demographic characteristics such as gender. Mortality rate assumptions are based on company experience. A mortality improvement assumption is also applied. For any given contract, mortality rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. For contracts that contain only a GMDB, any increase (decrease) in mortality rates result in an increase (decrease) in the estimated fair value of MRBs. Generally, for contracts that contain both a GMDB and a living benefit (e.g., GMIB, GMWB, GMAB), any increase (decrease) in mortality rates result in a decrease (increase) in the estimated fair value of MRBs. (10) Base lapse rates are adjusted at the contract level based on a comparison of the actuarially calculated guaranteed values and the current policyholder account value, as well as other factors, such as the applicability of any surrender charges. A dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in the money contracts are less likely to lapse. Lapse rates are also generally assumed to be lower in periods when a surrender charge applies. For any given contract, lapse rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. (11) The utilization rate assumption estimates the percentage of contractholders with GMIBs or a lifetime withdrawal benefit who will elect to utilize the benefit upon becoming eligible. The rates may vary by the type of guarantee, the amount by which the guaranteed amount is greater than the account value, the contract’s withdrawal history and by the age of the policyholder. For any given contract, utilization rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. (12) The withdrawal rate represents the percentage of account balance that any given policyholder will elect to withdraw from the contract each year. The withdrawal rate assumption varies by age and duration of the contract, and also by other factors such as benefit type. For any given contract, withdrawal rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. For GMWBs, any increase (decrease) in withdrawal rates results in an increase (decrease) in the estimated fair value of the guarantees. For GMABs and GMIBs, any increase (decrease) in withdrawal rates results in a decrease (increase) in the estimated fair value. (13) Long-term equity volatilities represent equity volatility beyond the period for which observable equity volatilities are available. For any given contract, long-term equity volatility rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. (14) Nonperformance risk spread varies by duration and by currency. For any given contract, multiple nonperformance risk spreads will apply, depending on the duration of the cash flow being discounted for purposes of valuing the MRBs. |
Fair Value, Measured on Recurring Basis, Unobservable Input Reconciliation | The following tables summarize the change of assets (liabilities) measured at estimated fair value on a recurring basis using significant unobservable inputs (Level 3), excluding MRBs (see Note 5): Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Fixed Maturity Securities AFS Corporate (6) Structured Municipals Foreign Short-term (In millions) Six Months Ended June 30, 2024 Balance, beginning of period $ 17,115 $ 3,196 $ — $ 14 $ 15 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (42) 14 — 2 — Total realized/unrealized gains (losses) included in AOCI (317) 53 — (5) — Purchases (3) 1,783 1,104 — — 3 Sales (3) (1,038) (257) — — (15) Issuances (3) — — — — — Settlements (3) — — — — — Transfers into Level 3 (4) 97 101 — — — Transfers out of Level 3 (4) (123) (98) — — — Balance, end of period $ 17,475 $ 4,113 $ — $ 11 $ 3 Six Months Ended June 30, 2023 Balance, beginning of period $ 14,733 $ 3,373 $ — $ 15 $ 47 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (18) 1 — (1) — Total realized/unrealized gains (losses) included in AOCI 285 — — 2 — Purchases (3) 2,015 153 4 2 17 Sales (3) (848) (175) — (1) (47) Issuances (3) — — — — — Settlements (3) — — — — — Transfers into Level 3 (4) 280 103 — — — Transfers out of Level 3 (4) (431) (46) — — — Balance, end of period $ 16,016 $ 3,409 $ 4 $ 17 $ 17 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at June 30, 2024 (5) $ (10) $ 13 $ — $ 2 $ — Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at June 30, 2023 (5) $ (17) $ 9 $ — $ (1) $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at June 30, 2024 (5) $ (323) $ 48 $ — $ (5) $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at June 30, 2023 (5) $ 272 $ (4) $ — $ 1 $ (1) Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Other Investments Net Net Embedded Separate Accounts (9) (In millions) Six Months Ended June 30, 2024 Balance, beginning of period $ 1,317 $ (160) $ 52 $ 968 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) 111 (1) 355 (19) Total realized/unrealized gains (losses) included in AOCI — (40) — — Purchases (3) 17 — — 82 Sales (3) (11) — — (58) Issuances (3) — — — — Settlements (3) — 134 (2) — Transfers into Level 3 (4) — — — 3 Transfers out of Level 3 (4) — (8) — (7) Balance, end of period $ 1,434 $ (75) $ 405 $ 969 Six Months Ended June 30, 2023 Balance, beginning of period $ 1,022 $ (331) $ 458 $ 995 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) 91 (27) (68) (18) Total realized/unrealized gains (losses) included in AOCI — 43 — — Purchases (3) 2 — — 170 Sales (3) — — — (109) Issuances (3) — — — — Settlements (3) — 98 (12) 1 Transfers into Level 3 (4) — — — 15 Transfers out of Level 3 (4) — (61) — — Balance, end of period $ 1,115 $ (278) $ 378 $ 1,054 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at June 30, 2024 (5) $ 117 $ — $ 355 $ — Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at June 30, 2023 (5) $ 93 $ 2 $ (68) $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at June 30, 2024 (5) $ — $ (21) $ — $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at June 30, 2023 (5) $ — $ 7 $ — $ — __________________ (1) Amortization of premium/accretion of discount is included within net investment income. Impairments and changes in ACL charged to net income (loss) on certain securities are included in net investment gains (losses). Lapses associated with net embedded derivatives are included in net derivative gains (losses). Substantially all realized/unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses). (2) Interest and dividend accruals, as well as cash interest coupons and dividends received, are excluded from the rollforward. (3) Items purchased/issued and then sold/settled in the same period are excluded from the rollforward. Fees attributed to embedded derivatives are included in settlements. (4) Items transferred into and then out of Level 3 in the same period are excluded from the rollforward. (5) Changes in unrealized gains (losses) included in net income (loss) and included in AOCI relate to assets and liabilities still held at the end of the respective periods. Substantially all changes in unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses). (6) Comprised of U.S. and foreign corporate securities. (7) Freestanding derivative assets and liabilities are presented net for purposes of the rollforward. (8) Embedded derivative assets and liabilities are presented net for purposes of the rollforward. (9) Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders within separate account liabilities. Therefore, such changes in estimated fair value are not recorded in net income (loss). For the purpose of this disclosure, these changes are presented within net income (loss). Separate account assets and liabilities are presented net for the purposes of the rollforward. |
Nonrecurring Fair Value Measurements | The following table presents information for assets measured at estimated fair value on a nonrecurring basis during the periods and still held at the reporting dates (for example, when there is evidence of impairment), using significant unobservable inputs (Level 3). June 30, 2024 December 31, 2023 (In millions) Carrying value after measurement: Mortgage loans (1) $ 501 $ 295 Three Months Six Months 2024 2023 2024 2023 (In millions) Realized gains (losses) net: Mortgage loans (1) $ (47) $ (31) $ (84) $ (105) __________________ (1) Estimated fair values of impaired mortgage loans are based on the underlying collateral or discounted cash flows. See Note 9. |
Fair Value of Financial Instruments Carried at Other Than Fair Value | The carrying values and estimated fair values for such financial instruments, and their corresponding placement in the fair value hierarchy, are summarized as follows at: June 30, 2024 Fair Value Hierarchy Carrying Level 1 Level 2 Level 3 Total (In millions) Assets Mortgage loans $ 60,577 $ — $ — $ 57,070 $ 57,070 Policy loans $ 5,713 $ — $ — $ 6,010 $ 6,010 Other invested assets $ 1,936 $ — $ 1,656 $ 297 $ 1,953 Premiums, reinsurance and other receivables $ 13,916 $ — $ 438 $ 13,607 $ 14,045 Liabilities PABs $ 87,707 $ — $ — $ 85,512 $ 85,512 Long-term debt $ 1,647 $ — $ 1,715 $ — $ 1,715 Other liabilities $ 11,979 $ — $ 902 $ 11,060 $ 11,962 Separate account liabilities $ 26,884 $ — $ 26,884 $ — $ 26,884 December 31, 2023 Fair Value Hierarchy Carrying Level 1 Level 2 Level 3 Total (In millions) Assets Mortgage loans $ 62,584 $ — $ — $ 59,511 $ 59,511 Policy loans $ 5,671 $ — $ — $ 6,042 $ 6,042 Other invested assets $ 1,778 $ — $ 1,794 $ — $ 1,794 Premiums, reinsurance and other receivables $ 14,028 $ — $ 221 $ 14,053 $ 14,274 Liabilities PABs $ 87,518 $ — $ — $ 86,093 $ 86,093 Long-term debt $ 1,886 $ — $ 1,958 $ — $ 1,958 Other liabilities $ 11,481 $ — $ 141 $ 11,333 $ 11,474 Separate account liabilities $ 29,204 $ — $ 29,204 $ — $ 29,204 |
Equity (Tables)
Equity (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Equity [Abstract] | |
Components of Accumulated Other Comprehensive Income (Loss) | Information regarding changes in the balances of each component of AOCI attributable to Metropolitan Life Insurance Company was as follows: Three Months Unrealized Investment Gains (Losses), Net of Related Offsets (1) Deferred FPBs Discount Rate Remeasurement Gains (Losses) MRBs Instrument-Specific Credit Risk Remeasurement Gains (Losses) Foreign Defined Total (In millions) Balance, beginning of period $ (7,854) $ 796 $ 618 $ (13) $ (112) $ (163) $ (6,728) OCI before reclassifications (1,290) 135 1,505 (13) (20) — 317 Deferred income tax benefit (expense) 317 (28) (330) 3 3 — (35) AOCI before reclassifications, net of income tax (8,827) 903 1,793 (23) (129) (163) (6,446) Amounts reclassified from AOCI 153 (103) — — — 3 53 Deferred income tax benefit (expense) (37) 22 — — — — (15) Amounts reclassified from AOCI, net of income tax 116 (81) — — — 3 38 Balance, end of period $ (8,711) $ 822 $ 1,793 $ (23) $ (129) $ (160) $ (6,408) Three Months Unrealized Investment Gains (Losses), Net of Related Offsets (1) Deferred FPBs Discount Rate Remeasurement Gains (Losses) MRBs Instrument-Specific Credit Risk Remeasurement Gains (Losses) Foreign Defined Total (In millions) Balance, beginning of period $ (8,167) $ 1,568 $ (106) $ 149 $ (139) $ (137) $ (6,832) OCI before reclassifications (2,114) (101) 1,051 (73) 17 — (1,220) Deferred income tax benefit (expense) 452 21 (219) 16 (5) — 265 AOCI before reclassifications, net of income tax (9,829) 1,488 726 92 (127) (137) (7,787) Amounts reclassified from AOCI 829 (379) — — — 3 453 Deferred income tax benefit (expense) (167) 79 — — — (1) (89) Amounts reclassified from AOCI, net of income tax 662 (300) — — — 2 364 Balance, end of period $ (9,167) $ 1,188 $ 726 $ 92 $ (127) $ (135) $ (7,423) Six Months Unrealized Deferred FPBs Discount Rate Remeasurement Gains (Losses) MRBs Instrument-Specific Credit Risk Remeasurement Gains (Losses) Foreign Defined Total (In millions) Balance, beginning of period $ (6,495) $ 705 $ (807) $ 33 $ (143) $ (165) $ (6,872) OCI before reclassifications (3,214) (8) 3,309 (71) 19 — 35 Deferred income tax benefit (expense) 760 2 (709) 15 (5) — 63 AOCI before reclassifications, net of income tax (8,949) 699 1,793 (23) (129) (165) (6,774) Amounts reclassified from AOCI 312 156 — — — 6 474 Deferred income tax benefit (expense) (74) (33) — — — (1) (108) Amounts reclassified from AOCI, net of income tax 238 123 — — — 5 366 Balance, end of period $ (8,711) $ 822 $ 1,793 $ (23) $ (129) $ (160) $ (6,408) Six Months Unrealized Deferred FPBs Discount Rate Remeasurement Gains (Losses) MRBs Instrument-Specific Credit Risk Remeasurement Gains (Losses) Foreign Defined Total (In millions) Balance, beginning of period $ (11,161) $ 1,557 $ 1,529 $ 80 $ (187) $ (138) $ (8,320) OCI before reclassifications 1,698 58 (1,017) 15 77 (1) 830 Deferred income tax benefit (expense) (346) (12) 214 (3) (17) — (164) AOCI before reclassifications, net of income tax (9,809) 1,603 726 92 (127) (139) (7,654) Amounts reclassified from AOCI 804 (525) — — — 5 284 Deferred income tax benefit (expense) (162) 110 — — — (1) (53) Amounts reclassified from AOCI, net of income tax 642 (415) — — — 4 231 Balance, end of period $ (9,167) $ 1,188 $ 726 $ 92 $ (127) $ (135) $ (7,423) __________________ (1) Primarily unrealized gains (losses) on fixed maturity securities. |
Reclassification out of Accumulated Other Comprehensive Income (Loss) | Information regarding amounts reclassified out of each component of AOCI was as follows: Three Months Six Months 2024 2023 2024 2023 AOCI Components Amounts Reclassified from AOCI Consolidated Statements of (In millions) Net unrealized investment gains (losses): Net unrealized investment gains (losses) $ (142) $ (828) $ (288) $ (787) Net investment gains (losses) Net unrealized investment gains (losses) 1 1 — 3 Net investment income Net unrealized investment gains (losses) (12) (2) (24) (20) Net derivative gains (losses) Net unrealized investment gains (losses), before income tax (153) (829) (312) (804) Income tax (expense) benefit 37 167 74 162 Net unrealized investment gains (losses), net of income tax (116) (662) (238) (642) Deferred gains (losses) on derivatives - cash flow hedges: Interest rate derivatives 6 13 14 27 Net investment income Interest rate derivatives — 55 2 57 Net investment gains (losses) Foreign currency exchange rate derivatives 1 1 2 2 Net investment income Foreign currency exchange rate derivatives 95 310 (175) 439 Net investment gains (losses) Credit derivatives 1 — 1 — Net investment gains (losses) Gains (losses) on cash flow hedges, before income tax 103 379 (156) 525 Income tax (expense) benefit (22) (79) 33 (110) Gains (losses) on cash flow hedges, net of income tax 81 300 (123) 415 Defined benefit plans adjustment: (1) Amortization of net actuarial gains (losses) (4) (3) (7) (6) Amortization of prior service (costs) credit 1 — 1 1 Amortization of defined benefit plan items, before income tax (3) (3) (6) (5) Income tax (expense) benefit — 1 1 1 Amortization of defined benefit plan items, net of income tax (3) (2) (5) (4) Total reclassifications, net of income tax $ (38) $ (364) $ (366) $ (231) __________________ (1) These AOCI components are included in the computation of net periodic benefit costs. |
Other Revenues and Other Expe_2
Other Revenues and Other Expenses (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Other Income and Expenses [Abstract] | |
Disaggregation of Revenue | Information on other revenues, which primarily includes fees related to service contracts from customers, was as follows: Three Months Six Months 2024 2023 2024 2023 (In millions) Prepaid legal plans $ 117 $ 115 $ 237 $ 230 Administrative services-only contracts 66 62 132 123 Recordkeeping and administrative services (1) 36 37 74 74 Other revenue from service contracts from customers 14 11 23 21 Total revenues from service contracts from customers 233 225 466 448 Other (2) 214 194 436 386 Total other revenues $ 447 $ 419 $ 902 $ 834 __________________ (1) Related to products and businesses no longer actively marketed by the Company. (2) Primarily includes reinsurance ceded. See Note 16. |
Other Expenses | Information on other expenses was as follows: Three Months Six Months 2024 2023 2024 2023 (In millions) General and administrative expenses (1) $ 675 $ 677 $ 1,348 $ 1,338 Pension, postretirement and postemployment benefit costs 55 50 110 100 Premium taxes, other taxes, and licenses & fees 108 106 205 199 Commissions and other variable expenses 496 467 983 1,181 Capitalization of DAC (27) (12) (52) (89) Amortization of DAC and VOBA 68 74 138 151 Interest expense on debt 30 34 62 64 Total other expenses $ 1,405 $ 1,396 $ 2,794 $ 2,944 __________________ (1) Includes ($25) million and ($65) million for the three months and six months ended June 30, 2024, respectively, and ($27) million and ($57) million for the three months and six months ended June 30, 2023, respectively, for the net change in cash surrender value of investments in certain life insurance policies, net of premiums paid. |
Related Party Transactions (Tab
Related Party Transactions (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Related Party Transactions [Abstract] | |
Effects of reinsurance | Information regarding the significant effects of affiliated reinsurance on the interim condensed consolidated statements of operations and comprehensive income (loss) was as follows: Three Months Six Months 2024 2023 2024 2023 (In millions) Premiums Reinsurance assumed $ 1 $ 2 $ 2 $ (25) Reinsurance ceded (102) (89) (205) (173) Net premiums $ (101) $ (87) $ (203) $ (198) Universal life and investment-type product policy fees Reinsurance assumed $ 5 $ 1 $ 8 $ 1 Reinsurance ceded (1) (2) (1) (4) Net universal life and investment-type product policy fees $ 4 $ (1) $ 7 $ (3) Other revenues Reinsurance assumed $ 35 $ 24 $ 63 $ 46 Reinsurance ceded 117 116 232 231 Net other revenues $ 152 $ 140 $ 295 $ 277 Policyholder benefits and claims Reinsurance assumed $ 11 $ 18 $ 23 $ (151) Reinsurance ceded (82) (68) (168) (145) Net policyholder benefits and claims $ (71) $ (50) $ (145) $ (296) Policyholder liability remeasurement (gains) losses Reinsurance assumed $ — $ — $ — $ (39) Reinsurance ceded (2) — — (5) Net policyholder liability remeasurement (gains) losses $ (2) $ — $ — $ (44) Interest credited to PABs Reinsurance assumed $ 90 $ 88 $ 179 $ 161 Reinsurance ceded (2) (3) (5) (6) Net interest credited to PABs $ 88 $ 85 $ 174 $ 155 Other expenses Reinsurance assumed $ 11 $ 11 $ 23 $ 215 Reinsurance ceded 54 65 110 128 Net other expenses $ 65 $ 76 $ 133 $ 343 Information regarding the significant effects of affiliated reinsurance on the interim condensed consolidated balance sheets was as follows at: June 30, 2024 December 31, 2023 Assumed Ceded Assumed Ceded (In millions) Assets Premiums, reinsurance and other receivables $ 173 $ 11,234 $ 164 $ 11,302 DAC and VOBA 149 (158) 158 (160) Total assets $ 322 $ 11,076 $ 322 $ 11,142 Liabilities FPBs $ 2,093 $ — $ 2,236 $ — PABs 9,003 — 9,040 — Other policy-related balances 66 (42) 65 (35) Other liabilities 804 9,888 957 10,267 Total liabilities $ 11,966 $ 9,846 $ 12,298 $ 10,232 |
Business, Basis of Presentati_3
Business, Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) $ in Millions | 6 Months Ended | ||
Jun. 30, 2024 USD ($) Segment | Jan. 01, 2024 USD ($) | Dec. 31, 2023 USD ($) | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||
Number of segments | Segment | 3 | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Retained earnings, decrease | $ (7,315) | $ (7,645) | |
Cumulative Effect, Period of Adoption, Adjustment | Pro Forma | Accounting Standards Update 2023-02 | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Retained earnings, decrease | $ 219 |
Segment Information (Earnings)
Segment Information (Earnings) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2024 | Mar. 31, 2024 | Jun. 30, 2023 | Mar. 31, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Revenues | ||||||
Premiums | $ 7,366 | $ 5,953 | $ 13,580 | $ 11,802 | ||
Universal life and investment-type product policy fees | 381 | 422 | 740 | 852 | ||
Net investment income | 2,903 | 2,873 | 5,760 | 5,558 | ||
Other revenues | 447 | 419 | 902 | 834 | ||
Net investment gains (losses) | (106) | (659) | (242) | (761) | ||
Net derivative gains (losses) | 60 | (232) | 4 | (792) | ||
Total revenues | 11,051 | 8,776 | 20,744 | 17,493 | ||
Expenses | ||||||
Policyholder benefits and claims and policyholder dividends | 7,637 | 6,552 | 14,442 | 12,898 | ||
Policyholder liability remeasurement (gains) losses | 3 | 17 | 16 | (40) | ||
Market risk benefit remeasurement (gains) losses | (130) | (670) | (716) | (426) | ||
Interest credited to policyholder account balances | 957 | 893 | 1,880 | 1,724 | ||
Capitalization of DAC | (27) | (12) | (52) | (89) | ||
Amortization of DAC and VOBA | 68 | 74 | 138 | 151 | ||
Interest expense on debt | 30 | 34 | 62 | 64 | ||
Other expenses | 1,334 | 1,300 | 2,646 | 2,818 | ||
Total expenses | 9,872 | 8,188 | 18,416 | 17,100 | ||
Provision for income tax expense (benefit) | 228 | 78 | 442 | (26) | ||
Net income (loss) | 951 | $ 935 | 510 | $ (91) | 1,886 | 419 |
Operating Segments | ||||||
Revenues | ||||||
Premiums | 7,366 | 5,953 | 13,580 | 11,802 | ||
Universal life and investment-type product policy fees | 381 | 422 | 740 | 852 | ||
Net investment income | 3,019 | 3,070 | 6,000 | 5,956 | ||
Other revenues | 419 | 422 | 842 | 842 | ||
Net investment gains (losses) | 0 | 0 | 0 | 0 | ||
Net derivative gains (losses) | 0 | 0 | 0 | 0 | ||
Total revenues | 11,185 | 9,867 | 21,162 | 19,452 | ||
Expenses | ||||||
Policyholder benefits and claims and policyholder dividends | 7,652 | 6,549 | 14,470 | 12,892 | ||
Policyholder liability remeasurement (gains) losses | 3 | 17 | 16 | (40) | ||
Market risk benefit remeasurement (gains) losses | 0 | 0 | 0 | 0 | ||
Interest credited to policyholder account balances | 939 | 894 | 1,840 | 1,724 | ||
Capitalization of DAC | (27) | (12) | (52) | (89) | ||
Amortization of DAC and VOBA | 68 | 74 | 138 | 151 | ||
Interest expense on debt | 30 | 34 | 62 | 64 | ||
Other expenses | 1,333 | 1,354 | 2,642 | 2,867 | ||
Total expenses | 9,998 | 8,910 | 19,116 | 17,569 | ||
Provision for income tax expense (benefit) | 228 | 157 | 381 | 288 | ||
Adjusted earnings | 959 | 800 | 1,665 | 1,595 | ||
Segment Reconciling Items | ||||||
Revenues | ||||||
Premiums | 0 | 0 | 0 | 0 | ||
Universal life and investment-type product policy fees | 0 | 0 | 0 | 0 | ||
Net investment income | (116) | (197) | (240) | (398) | ||
Other revenues | 28 | (3) | 60 | (8) | ||
Net investment gains (losses) | (106) | (659) | (242) | (761) | ||
Net derivative gains (losses) | 60 | (232) | 4 | (792) | ||
Total revenues | (134) | (1,091) | (418) | (1,959) | ||
Expenses | ||||||
Policyholder benefits and claims and policyholder dividends | (15) | 3 | (28) | 6 | ||
Policyholder liability remeasurement (gains) losses | 0 | 0 | 0 | 0 | ||
Market risk benefit remeasurement (gains) losses | (130) | (670) | (716) | (426) | ||
Interest credited to policyholder account balances | 18 | (1) | 40 | 0 | ||
Capitalization of DAC | 0 | 0 | 0 | 0 | ||
Amortization of DAC and VOBA | 0 | 0 | 0 | 0 | ||
Interest expense on debt | 0 | 0 | 0 | 0 | ||
Other expenses | 1 | (54) | 4 | (49) | ||
Total expenses | (126) | (722) | (700) | (469) | ||
Provision for income tax expense (benefit) | 0 | (79) | 61 | (314) | ||
Group Benefits | ||||||
Expenses | ||||||
Capitalization of DAC | (7) | (11) | ||||
Group Benefits | Operating Segments | ||||||
Revenues | ||||||
Premiums | 5,337 | 5,189 | 10,804 | 10,405 | ||
Universal life and investment-type product policy fees | 229 | 223 | 451 | 441 | ||
Net investment income | 303 | 320 | 608 | 623 | ||
Other revenues | 189 | 181 | 378 | 360 | ||
Net investment gains (losses) | 0 | 0 | 0 | 0 | ||
Net derivative gains (losses) | 0 | 0 | 0 | 0 | ||
Total revenues | 6,058 | 5,913 | 12,241 | 11,829 | ||
Expenses | ||||||
Policyholder benefits and claims and policyholder dividends | 4,488 | 4,588 | 9,433 | 9,282 | ||
Policyholder liability remeasurement (gains) losses | 1 | 3 | (2) | (1) | ||
Market risk benefit remeasurement (gains) losses | 0 | 0 | 0 | 0 | ||
Interest credited to policyholder account balances | 48 | 48 | 96 | 94 | ||
Capitalization of DAC | (3) | (5) | (7) | (11) | ||
Amortization of DAC and VOBA | 7 | 7 | 13 | 13 | ||
Interest expense on debt | 1 | 1 | 1 | 1 | ||
Other expenses | 885 | 837 | 1,757 | 1,646 | ||
Total expenses | 5,427 | 5,479 | 11,291 | 11,024 | ||
Provision for income tax expense (benefit) | 131 | 92 | 200 | 170 | ||
Adjusted earnings | 500 | 342 | 750 | 635 | ||
RIS | ||||||
Expenses | ||||||
Capitalization of DAC | (46) | (24) | ||||
RIS | Operating Segments | ||||||
Revenues | ||||||
Premiums | 1,455 | 179 | 1,631 | 233 | ||
Universal life and investment-type product policy fees | 59 | 60 | 124 | 127 | ||
Net investment income | 1,679 | 1,660 | 3,355 | 3,211 | ||
Other revenues | 70 | 69 | 132 | 132 | ||
Net investment gains (losses) | 0 | 0 | 0 | 0 | ||
Net derivative gains (losses) | 0 | 0 | 0 | 0 | ||
Total revenues | 3,263 | 1,968 | 5,242 | 3,703 | ||
Expenses | ||||||
Policyholder benefits and claims and policyholder dividends | 2,099 | 837 | 2,926 | 1,370 | ||
Policyholder liability remeasurement (gains) losses | (14) | (8) | (22) | (76) | ||
Market risk benefit remeasurement (gains) losses | 0 | 0 | 0 | 0 | ||
Interest credited to policyholder account balances | 708 | 609 | 1,384 | 1,172 | ||
Capitalization of DAC | (25) | (5) | (46) | (24) | ||
Amortization of DAC and VOBA | 9 | 7 | 17 | 15 | ||
Interest expense on debt | 3 | 3 | 7 | 6 | ||
Other expenses | 100 | 83 | 202 | 380 | ||
Total expenses | 2,880 | 1,526 | 4,468 | 2,843 | ||
Provision for income tax expense (benefit) | 80 | 92 | 162 | 179 | ||
Adjusted earnings | 303 | 350 | 612 | 681 | ||
MetLife Holdings | ||||||
Expenses | ||||||
Capitalization of DAC | 1 | 1 | ||||
MetLife Holdings | Operating Segments | ||||||
Revenues | ||||||
Premiums | 572 | 585 | 1,144 | 1,163 | ||
Universal life and investment-type product policy fees | 88 | 138 | 158 | 283 | ||
Net investment income | 921 | 1,044 | 1,831 | 2,033 | ||
Other revenues | 37 | 50 | 87 | 106 | ||
Net investment gains (losses) | 0 | 0 | 0 | 0 | ||
Net derivative gains (losses) | 0 | 0 | 0 | 0 | ||
Total revenues | 1,618 | 1,817 | 3,220 | 3,585 | ||
Expenses | ||||||
Policyholder benefits and claims and policyholder dividends | 1,064 | 1,123 | 2,110 | 2,239 | ||
Policyholder liability remeasurement (gains) losses | 16 | 22 | 40 | 37 | ||
Market risk benefit remeasurement (gains) losses | 0 | 0 | 0 | 0 | ||
Interest credited to policyholder account balances | 99 | 156 | 193 | 311 | ||
Capitalization of DAC | 1 | 1 | 1 | 1 | ||
Amortization of DAC and VOBA | 49 | 56 | 99 | 115 | ||
Interest expense on debt | 3 | 3 | 7 | 6 | ||
Other expenses | 193 | 187 | 393 | 393 | ||
Total expenses | 1,425 | 1,548 | 2,843 | 3,102 | ||
Provision for income tax expense (benefit) | 38 | 53 | 74 | 94 | ||
Adjusted earnings | 155 | 216 | 303 | 389 | ||
Corporate & Other | ||||||
Expenses | ||||||
Capitalization of DAC | 0 | (55) | ||||
Corporate & Other | Operating Segments | ||||||
Revenues | ||||||
Premiums | 2 | 0 | 1 | 1 | ||
Universal life and investment-type product policy fees | 5 | 1 | 7 | 1 | ||
Net investment income | 116 | 46 | 206 | 89 | ||
Other revenues | 123 | 122 | 245 | 244 | ||
Net investment gains (losses) | 0 | 0 | 0 | 0 | ||
Net derivative gains (losses) | 0 | 0 | 0 | 0 | ||
Total revenues | 246 | 169 | 459 | 335 | ||
Expenses | ||||||
Policyholder benefits and claims and policyholder dividends | 1 | 1 | 1 | 1 | ||
Policyholder liability remeasurement (gains) losses | 0 | 0 | 0 | 0 | ||
Market risk benefit remeasurement (gains) losses | 0 | 0 | 0 | 0 | ||
Interest credited to policyholder account balances | 84 | 81 | 167 | 147 | ||
Capitalization of DAC | 0 | (3) | 0 | (55) | ||
Amortization of DAC and VOBA | 3 | 4 | 9 | 8 | ||
Interest expense on debt | 23 | 27 | 47 | 51 | ||
Other expenses | 155 | 247 | 290 | 448 | ||
Total expenses | 266 | 357 | 514 | 600 | ||
Provision for income tax expense (benefit) | (21) | (80) | (55) | (155) | ||
Adjusted earnings | $ 1 | $ (108) | $ 0 | $ (110) |
Segment Information (Total Asse
Segment Information (Total Assets) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Segment Reporting Information [Line Items] | ||
Total assets | $ 371,874 | $ 378,685 |
Group Benefits | ||
Segment Reporting Information [Line Items] | ||
Total assets | 33,669 | 34,185 |
RIS | ||
Segment Reporting Information [Line Items] | ||
Total assets | 177,906 | 180,625 |
MetLife Holdings | ||
Segment Reporting Information [Line Items] | ||
Total assets | 129,230 | 133,219 |
Corporate & Other | ||
Segment Reporting Information [Line Items] | ||
Total assets | $ 31,069 | $ 30,656 |
Segment Information (Narrative)
Segment Information (Narrative) (Details) | 6 Months Ended |
Jun. 30, 2024 Segment | |
Segment Reporting [Abstract] | |
Number of segments | 3 |
Future Policy Benefits - FPB on
Future Policy Benefits - FPB on Balance Sheet (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 | Jun. 30, 2023 |
Net liability for FPBs | $ 126,035 | $ 129,182 | |
Fixed & Immediate Annuities | RIS | |||
Net liability for FPBs | 46,998 | 48,695 | $ 47,299 |
Long-term Care | MetLife Holdings | |||
Net liability for FPBs | 14,455 | 15,240 | $ 14,498 |
Fixed & Immediate Annuities for Deferred Profit Liabilities | RIS | |||
Net liability for FPBs | 3,005 | 3,000 | |
Universal and Variable Universal Life | MetLife Holdings | |||
Net liability for FPBs | 1,913 | 1,841 | |
Participating Life Insurance Contract | MetLife Holdings | |||
Net liability for FPBs | 43,039 | 43,586 | |
Long-Duration Insurance, Other | |||
Net liability for FPBs | 6,278 | 6,605 | |
Short-Duration Insurance, Other | |||
Net liability for FPBs | $ 10,347 | $ 10,215 |
Future Policy Benefits - Disagg
Future Policy Benefits - Disaggregate Rollforwards (Details) - USD ($) $ in Millions | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward] | |||
Net liability for FPBs | $ 126,035 | $ 129,182 | |
Fixed & Immediate Annuities | RIS | |||
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward] | |||
Balance, beginning of period, at current discount rate at balance sheet date | 0 | $ 0 | |
Balance, beginning of period, at original discount rate | 0 | 0 | |
Effect of actual variances from expected experience (1) | (2) | 2 | |
Adjusted balance | (2) | 2 | |
Issuances | 1,575 | 183 | |
Net premiums collected | (1,573) | (185) | |
Ending balance at original discount rate | 0 | 0 | |
Balance, end of period, at current discount rate at balance sheet date | 0 | 0 | |
Balance, beginning of period, at current discount rate at balance sheet date | 48,886 | 48,190 | |
Balance, beginning of period, at original discount rate | 47,991 | 49,194 | |
Effect of actual variances from expected experience (1) | (55) | (299) | |
Adjusted balance | 47,936 | 48,895 | |
Issuances | 1,572 | 183 | |
Interest accrual | 1,197 | 1,196 | |
Benefit payments | (2,224) | (2,386) | |
Ending balance at original discount rate | 48,481 | 47,888 | |
Effect of changes in discount rate assumptions | (1,146) | (385) | |
Balance, end of period, at current discount rate at balance sheet date | 47,335 | 47,503 | |
Cumulative amount of fair value hedging adjustments | (337) | (204) | |
Net liability for FPBs | 46,998 | 47,299 | 48,695 |
Undiscounted - Expected future benefit payments | 90,171 | 93,997 | |
Discounted - Expected future benefit payments | $ 47,335 | $ 47,503 | 48,886 |
Weighted-average duration of the liability | 9 years | 9 years | |
Weighted-average interest accretion (original locked-in) rate | 5.10% | 5.10% | |
Weighted-average current discount rate at balance sheet date | 5.60% | 5.40% | |
Deferred Profit Liability Offset to Actual Versus Expected | $ 30 | $ 225 | |
Long-term Care | MetLife Holdings | |||
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward] | |||
Balance, beginning of period, at current discount rate at balance sheet date | 5,687 | 5,775 | |
Balance, beginning of period, at original discount rate | 5,566 | 5,807 | |
Effect of actual variances from expected experience (1) | 13 | 83 | |
Adjusted balance | 5,579 | 5,890 | |
Interest accrual | 141 | 149 | |
Net premiums collected | (286) | (293) | |
Ending balance at original discount rate | 5,434 | 5,746 | |
Effect of changes in discount rate assumptions | (80) | 3 | |
Balance, end of period, at current discount rate at balance sheet date | 5,354 | 5,749 | |
Balance, beginning of period, at current discount rate at balance sheet date | 20,927 | 19,619 | |
Balance, beginning of period, at original discount rate | 20,494 | 20,165 | |
Effect of actual variances from expected experience (1) | 31 | 99 | |
Adjusted balance | 20,525 | 20,264 | |
Interest accrual | 540 | 534 | |
Benefit payments | (421) | (382) | |
Ending balance at original discount rate | 20,644 | 20,416 | |
Effect of changes in discount rate assumptions | (835) | (169) | |
Balance, end of period, at current discount rate at balance sheet date | 19,809 | 20,247 | |
Net liability for FPBs | 14,455 | 14,498 | 15,240 |
Undiscounted - Expected future gross premiums | 10,280 | 10,893 | |
Undiscounted - Expected future benefit payments | 44,653 | 45,653 | |
Discounted - Expected future gross premiums | 6,715 | 7,089 | |
Discounted - Expected future benefit payments | $ 19,809 | $ 20,247 | $ 20,927 |
Weighted-average duration of the liability | 14 years | 15 years | |
Weighted-average interest accretion (original locked-in) rate | 5.40% | 5.40% | |
Weighted-average current discount rate at balance sheet date | 5.80% | 5.50% |
Future Policy Benefits - FPB -
Future Policy Benefits - FPB - Additional Insurance Liabilities (Details) - Universal and Variable Universal Life - MetLife Holdings - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Additional Liability, Long-Duration Insurance [Roll Forward] | ||
Balance, beginning of period | $ 1,841 | $ 1,642 |
Less: AOCI adjustment | (14) | (63) |
Balance, beginning of period, before AOCI adjustment | 1,855 | 1,705 |
Effect of actual variances from expected experience | 18 | 6 |
Adjusted balance | 1,873 | 1,711 |
Assessments accrual | 44 | 47 |
Interest accrual | 48 | 44 |
Excess benefits paid | (36) | (41) |
Balance, end of period, before AOCI adjustment | 1,929 | 1,761 |
Add: AOCI adjustment | (16) | 2 |
Balance, end of period | 1,913 | 1,763 |
Less: Reinsurance recoverables | 1,913 | 649 |
Balance, end of period, net of reinsurance | $ 0 | $ 1,114 |
Weighted-average duration of the liability | 16 years | 17 years |
Weighted-average interest accretion rate | 5.20% | 5.20% |
Future Policy Benefits - FPB In
Future Policy Benefits - FPB Income Statement (Details) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Principal Transaction Revenue [Line Items] | ||
Gross Premiums or Assessments (1) | $ 2,547 | $ 1,170 |
Interest Expense (2) | 1,871 | 1,847 |
Fixed & Immediate Annuities | RIS | ||
Principal Transaction Revenue [Line Items] | ||
Gross Premiums or Assessments (1) | 1,613 | 168 |
Interest Expense (2) | 1,197 | 1,196 |
Long-term Care | MetLife Holdings | ||
Principal Transaction Revenue [Line Items] | ||
Gross Premiums or Assessments (1) | 362 | 366 |
Interest Expense (2) | 399 | 385 |
Fixed & Immediate Annuities for Deferred Profit Liabilities | RIS | ||
Principal Transaction Revenue [Line Items] | ||
Interest Expense (2) | 74 | 70 |
Universal and Variable Universal Life | MetLife Holdings | ||
Principal Transaction Revenue [Line Items] | ||
Gross Premiums or Assessments (1) | 198 | 236 |
Interest Expense (2) | 48 | 44 |
Long-Duration Insurance, Other | ||
Principal Transaction Revenue [Line Items] | ||
Gross Premiums or Assessments (1) | 374 | 400 |
Interest Expense (2) | $ 153 | $ 152 |
Future Policy Benefits (Rollfor
Future Policy Benefits (Rollforward of Unpaid Claims) (Details) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] | ||
Balance, beginning of period | $ 11,609 | $ 11,300 |
Less: Reinsurance recoverables | 1,740 | 1,633 |
Net balance, beginning of period | 9,869 | 9,667 |
Incurred related to: | ||
Current period | 10,373 | 10,270 |
Prior periods (1) | (240) | (32) |
Total incurred | 10,133 | 10,238 |
Paid related to: | ||
Current period | (6,108) | (5,919) |
Prior periods | (4,073) | (4,020) |
Total paid | (10,181) | (9,939) |
Net balance, end of period | 9,821 | 9,966 |
Add: Reinsurance recoverables | 1,998 | 1,794 |
Balance, end of period (included in FPBs and other policy-related balances) | $ 11,819 | $ 11,760 |
Policyholder Account Balances -
Policyholder Account Balances - Amounts on Balance Sheet (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 | Jun. 30, 2023 | Dec. 31, 2022 |
Policyholder Account Balance [Line Items] | ||||
Policyholder Account Balance | $ 103,774 | $ 103,894 | ||
Other | ||||
Policyholder Account Balance [Line Items] | ||||
Policyholder Account Balance | 15,925 | 16,197 | ||
Group Life | Group Benefits | ||||
Policyholder Account Balance [Line Items] | ||||
Policyholder Account Balance | 7,487 | 7,605 | $ 7,795 | $ 7,954 |
Capital Markets Investment Products and Stable Value GICs | RIS | ||||
Policyholder Account Balance [Line Items] | ||||
Policyholder Account Balance | 59,253 | 58,554 | 58,490 | 58,508 |
Annuities and Risk Solutions | RIS | ||||
Policyholder Account Balance [Line Items] | ||||
Policyholder Account Balance | 10,991 | 10,650 | 10,404 | 10,244 |
Annuities | MetLife Holdings | ||||
Policyholder Account Balance [Line Items] | ||||
Policyholder Account Balance | $ 10,118 | $ 10,888 | $ 11,741 | $ 12,598 |
Policyholder Account Balances_2
Policyholder Account Balances - LDTI Rollforward (Details) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Policyholder Account Balance [Roll Forward] | ||
Balance, beginning of period | $ 103,894 | |
Balance, end of period | 103,774 | |
Group Life | Group Benefits | ||
Policyholder Account Balance [Roll Forward] | ||
Balance, beginning of period | 7,605 | $ 7,954 |
Deposits | 1,799 | 1,644 |
Policy charges | (327) | (318) |
Surrenders and withdrawals | (1,676) | (1,573) |
Benefit payments | (6) | (6) |
Net transfers from (to) separate accounts | (3) | 1 |
Interest credited | 95 | 93 |
Balance, end of period | $ 7,487 | $ 7,795 |
Weighted-average annual crediting rate | 2.60% | 2.40% |
Cash surrender value | $ 7,427 | $ 7,732 |
Group Life | In the event of death | Group Benefits | ||
Policyholder Account Balance [Roll Forward] | ||
Policyholder Account Balance, Net Amount at Risk | 264,497 | 251,590 |
Capital Markets Investment Products and Stable Value GICs | RIS | ||
Policyholder Account Balance [Roll Forward] | ||
Balance, beginning of period | 58,554 | 58,508 |
Deposits | 33,817 | 34,800 |
Surrenders and withdrawals | (33,744) | (36,458) |
Interest credited | 1,066 | 890 |
Effect of foreign currency translation and other, net | (440) | 750 |
Balance, end of period | $ 59,253 | $ 58,490 |
Weighted-average annual crediting rate | 3.70% | 3.10% |
Cash surrender value | $ 1,445 | $ 1,776 |
Annuities and Risk Solutions | RIS | ||
Policyholder Account Balance [Roll Forward] | ||
Balance, beginning of period | 10,650 | 10,244 |
Deposits | 657 | 348 |
Policy charges | (57) | (87) |
Surrenders and withdrawals | (186) | (88) |
Benefit payments | (287) | (271) |
Net transfers from (to) separate accounts | 20 | 54 |
Interest credited | 225 | 213 |
Other | (31) | (9) |
Balance, end of period | $ 10,991 | $ 10,404 |
Weighted-average annual crediting rate | 4.20% | 4.20% |
Cash surrender value | $ 6,952 | $ 6,672 |
Annuities and Risk Solutions | In the event of death | RIS | ||
Policyholder Account Balance [Roll Forward] | ||
Policyholder Account Balance, Net Amount at Risk | 35,769 | 36,065 |
Annuities | MetLife Holdings | ||
Policyholder Account Balance [Roll Forward] | ||
Balance, beginning of period | 10,888 | 12,598 |
Deposits | 81 | 129 |
Policy charges | (6) | (6) |
Surrenders and withdrawals | (870) | (1,004) |
Benefit payments | (206) | (218) |
Net transfers from (to) separate accounts | 58 | 47 |
Interest credited | 166 | 182 |
Other | 7 | 13 |
Balance, end of period | $ 10,118 | $ 11,741 |
Weighted-average annual crediting rate | 3.20% | 3% |
Cash surrender value | $ 9,458 | $ 10,964 |
Annuities | In the event of death | MetLife Holdings | ||
Policyholder Account Balance [Roll Forward] | ||
Policyholder Account Balance, Net Amount at Risk | 2,541 | 3,246 |
Annuities | At annuitization or exercise of other living benefits | MetLife Holdings | ||
Policyholder Account Balance [Roll Forward] | ||
Policyholder Account Balance, Net Amount at Risk | $ 665 | $ 770 |
Policyholder Account Balances_3
Policyholder Account Balances - Range of Guaranteed Minimum Crediting Rate (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 | Jun. 30, 2023 | Dec. 31, 2022 |
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | $ 103,774 | $ 103,894 | ||
Group Life | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 7,487 | 7,605 | $ 7,795 | $ 7,954 |
Group Life | Equal to or greater than 0% but less than 2% | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | $ 5,393 | $ 5,525 | ||
Group Life | Equal to or greater than 0% but less than 2% | Group Benefits | Minimum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 0% | 0% | ||
Group Life | Equal to or greater than 0% but less than 2% | Group Benefits | Maximum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 2% | 2% | ||
Group Life | Equal to or greater than 2% but less than 4% | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | $ 1,286 | $ 1,327 | ||
Group Life | Equal to or greater than 2% but less than 4% | Group Benefits | Minimum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 2% | 2% | ||
Group Life | Equal to or greater than 2% but less than 4% | Group Benefits | Maximum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 4% | 4% | ||
Group Life | Equal to or greater than 4% | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | $ 770 | $ 824 | ||
Group Life | Equal to or greater than 4% | Group Benefits | Minimum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 4% | 4% | ||
Group Life | Products with either a fixed rate or no GMCR | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | $ 38 | $ 119 | ||
Group Life | At GMCR | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 1,914 | 1,998 | ||
Group Life | At GMCR | Equal to or greater than 0% but less than 2% | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 0 | 0 | ||
Group Life | At GMCR | Equal to or greater than 2% but less than 4% | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 1,217 | 1,252 | ||
Group Life | At GMCR | Equal to or greater than 4% | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 697 | 746 | ||
Group Life | Greater than 0% but less than 0.50% above GMCR | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 9 | 11 | ||
Group Life | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 0% but less than 2% | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 0 | 0 | ||
Group Life | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 2% but less than 4% | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 9 | 10 | ||
Group Life | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 4% | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 0 | 1 | ||
Group Life | Equal to or greater than 0.50% but less than 1.50% above GMCR | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 917 | 1,016 | ||
Group Life | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 819 | 910 | ||
Group Life | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 59 | 63 | ||
Group Life | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 4% | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 39 | 43 | ||
Group Life | Equal to or greater than 1.50% above GMCR | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 4,609 | 4,651 | ||
Group Life | Equal to or greater than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 4,574 | 4,615 | ||
Group Life | Equal to or greater than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 1 | 2 | ||
Group Life | Equal to or greater than 1.50% above GMCR | Equal to or greater than 4% | Group Benefits | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 34 | 34 | ||
Capital Markets Investment Products and Stable Value GICs | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 59,253 | 58,554 | 58,490 | 58,508 |
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 0% but less than 2% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | $ 2,647 | $ 2,596 | ||
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 0% but less than 2% | RIS | Minimum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 0% | 0% | ||
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 0% but less than 2% | RIS | Maximum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 2% | 2% | ||
Capital Markets Investment Products and Stable Value GICs | Products with either a fixed rate or no GMCR | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | $ 56,606 | $ 55,894 | ||
Capital Markets Investment Products and Stable Value GICs | At GMCR | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 0 | 0 | ||
Capital Markets Investment Products and Stable Value GICs | At GMCR | Equal to or greater than 0% but less than 2% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 0 | 0 | ||
Capital Markets Investment Products and Stable Value GICs | Greater than 0% but less than 0.50% above GMCR | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 0 | 0 | ||
Capital Markets Investment Products and Stable Value GICs | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 0% but less than 2% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 0 | 0 | ||
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 0.50% but less than 1.50% above GMCR | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 0 | 1 | ||
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 0 | 1 | ||
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 1.50% above GMCR | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 2,647 | 2,595 | ||
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 2,647 | 2,595 | ||
Annuities and Risk Solutions | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 10,991 | 10,650 | 10,404 | 10,244 |
Annuities and Risk Solutions | Equal to or greater than 0% but less than 2% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | $ 1,767 | $ 1,459 | ||
Annuities and Risk Solutions | Equal to or greater than 0% but less than 2% | RIS | Minimum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 0% | 0% | ||
Annuities and Risk Solutions | Equal to or greater than 0% but less than 2% | RIS | Maximum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 2% | 2% | ||
Annuities and Risk Solutions | Equal to or greater than 2% but less than 4% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | $ 668 | $ 754 | ||
Annuities and Risk Solutions | Equal to or greater than 2% but less than 4% | RIS | Minimum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 2% | 2% | ||
Annuities and Risk Solutions | Equal to or greater than 2% but less than 4% | RIS | Maximum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 4% | 4% | ||
Annuities and Risk Solutions | Equal to or greater than 4% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | $ 3,782 | $ 3,810 | ||
Annuities and Risk Solutions | Equal to or greater than 4% | RIS | Minimum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 4% | 4% | ||
Annuities and Risk Solutions | Products with either a fixed rate or no GMCR | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | $ 4,774 | $ 4,381 | ||
Annuities and Risk Solutions | At GMCR | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 3,710 | 3,900 | ||
Annuities and Risk Solutions | At GMCR | Equal to or greater than 0% but less than 2% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 0 | 0 | ||
Annuities and Risk Solutions | At GMCR | Equal to or greater than 2% but less than 4% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 201 | 227 | ||
Annuities and Risk Solutions | At GMCR | Equal to or greater than 4% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 3,509 | 3,673 | ||
Annuities and Risk Solutions | Greater than 0% but less than 0.50% above GMCR | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 35 | 152 | ||
Annuities and Risk Solutions | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 0% but less than 2% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 0 | 0 | ||
Annuities and Risk Solutions | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 2% but less than 4% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 35 | 35 | ||
Annuities and Risk Solutions | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 4% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 0 | 117 | ||
Annuities and Risk Solutions | Equal to or greater than 0.50% but less than 1.50% above GMCR | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 298 | 111 | ||
Annuities and Risk Solutions | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 19 | 53 | ||
Annuities and Risk Solutions | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 11 | 44 | ||
Annuities and Risk Solutions | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 4% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 268 | 14 | ||
Annuities and Risk Solutions | Equal to or greater than 1.50% above GMCR | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 2,174 | 1,860 | ||
Annuities and Risk Solutions | Equal to or greater than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 1,748 | 1,406 | ||
Annuities and Risk Solutions | Equal to or greater than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 421 | 448 | ||
Annuities and Risk Solutions | Equal to or greater than 1.50% above GMCR | Equal to or greater than 4% | RIS | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 5 | 6 | ||
Annuities | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 10,118 | $ 10,888 | 11,741 | $ 12,598 |
Annuities | Equal to or greater than 0% but less than 2% | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | $ 683 | $ 846 | ||
Annuities | Equal to or greater than 0% but less than 2% | MetLife Holdings | Minimum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 0% | 0% | ||
Annuities | Equal to or greater than 0% but less than 2% | MetLife Holdings | Maximum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 2% | 2% | ||
Annuities | Equal to or greater than 2% but less than 4% | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | $ 8,467 | $ 9,817 | ||
Annuities | Equal to or greater than 2% but less than 4% | MetLife Holdings | Minimum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 2% | 2% | ||
Annuities | Equal to or greater than 2% but less than 4% | MetLife Holdings | Maximum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 4% | 4% | ||
Annuities | Equal to or greater than 4% | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | $ 573 | $ 626 | ||
Annuities | Equal to or greater than 4% | MetLife Holdings | Minimum | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Range of Guaranteed Minimum Credit Rating | 4% | 4% | ||
Annuities | Products with either a fixed rate or no GMCR | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | $ 395 | $ 452 | ||
Annuities | At GMCR | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 1,461 | 4,967 | ||
Annuities | At GMCR | Equal to or greater than 0% but less than 2% | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 4 | 444 | ||
Annuities | At GMCR | Equal to or greater than 2% but less than 4% | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 1,048 | 3,914 | ||
Annuities | At GMCR | Equal to or greater than 4% | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 409 | 609 | ||
Annuities | Greater than 0% but less than 0.50% above GMCR | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 7,094 | 5,602 | ||
Annuities | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 0% but less than 2% | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 195 | 158 | ||
Annuities | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 2% but less than 4% | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 6,754 | 5,441 | ||
Annuities | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 4% | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 145 | 3 | ||
Annuities | Equal to or greater than 0.50% but less than 1.50% above GMCR | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 932 | 623 | ||
Annuities | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 446 | 219 | ||
Annuities | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 467 | 390 | ||
Annuities | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 4% | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 19 | 14 | ||
Annuities | Equal to or greater than 1.50% above GMCR | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 236 | 97 | ||
Annuities | Equal to or greater than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 38 | 25 | ||
Annuities | Equal to or greater than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | 198 | 72 | ||
Annuities | Equal to or greater than 1.50% above GMCR | Equal to or greater than 4% | MetLife Holdings | ||||
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items] | ||||
Policyholder Account Balance, Guaranteed Minimum Credit Rating | $ 0 | $ 0 |
Market Risk Benefits Balance Sh
Market Risk Benefits Balance Sheet (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Market Risk Benefit [Line Items] | ||
Asset | $ 230 | $ 177 |
Liability | 2,391 | 2,878 |
Net | 2,161 | 2,701 |
Investment Product | MetLife Holdings | ||
Market Risk Benefit [Line Items] | ||
Asset | 211 | 156 |
Liability | 2,366 | 2,858 |
Net | 2,155 | 2,702 |
Insurance, Other | ||
Market Risk Benefit [Line Items] | ||
Asset | 19 | 21 |
Liability | 25 | 20 |
Net | $ 6 | $ (1) |
Market Risk Benefits Rollforwar
Market Risk Benefits Rollforward (Details) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Market Risk Benefit [Line Items] | ||
Beginning balance | $ 2,701 | |
Ending balance | 2,161 | |
Other Segments | ||
Market Risk Benefit [Line Items] | ||
Beginning balance | (1) | $ 25 |
Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk | 2 | 34 |
Attributed fees collected | 1 | 1 |
Effect of changes in interest rates | (6) | 2 |
Actual policyholder behavior different from expected behavior | 0 | (26) |
Effect of foreign currency translation and other, net (1) | 12 | 15 |
Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk | 9 | 26 |
Cumulative effect of changes in the instrument-specific credit risk | (3) | (7) |
Ending balance | 6 | 19 |
Variable Annuity | MetLife Holdings | ||
Market Risk Benefit [Line Items] | ||
Beginning balance | 2,702 | 3,071 |
Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk | 2,741 | 3,164 |
Attributed fees collected | 151 | 160 |
Benefit payments | (44) | (21) |
Effect of changes in interest rates | (544) | (15) |
Effect of changes in capital markets | (286) | (504) |
Effect of changes in equity index volatility | 24 | (98) |
Actual policyholder behavior different from expected behavior | 109 | 44 |
Effect of foreign currency translation and other, net (1) | 30 | 174 |
Effect of changes in risk margin | (57) | (35) |
Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk | 2,124 | 2,869 |
Cumulative effect of changes in the instrument-specific credit risk | 31 | (109) |
Ending balance | 2,155 | 2,760 |
Variable Annuity | MetLife Holdings | In the event of death | ||
Market Risk Benefit [Line Items] | ||
Net amount at risk | $ 2,541 | $ 3,246 |
Average attained age of policyholders | 71 years | 70 years |
Variable Annuity | MetLife Holdings | At annuitization or exercise of other living benefits | ||
Market Risk Benefit [Line Items] | ||
Net amount at risk | $ 665 | $ 770 |
Average attained age of policyholders | 71 years | 70 years |
Separate Account Liabilities Ba
Separate Account Liabilities Balance Sheet (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 | Jun. 30, 2023 | Dec. 31, 2022 |
Separate Account, Liability [Line Items] | ||||
Separate account liabilities | $ 79,585 | $ 83,197 | ||
Stable Value and Risk Solutions | RIS | ||||
Separate Account, Liability [Line Items] | ||||
Separate account liabilities | 32,256 | 35,562 | $ 37,042 | $ 43,249 |
Annuities | RIS | ||||
Separate Account, Liability [Line Items] | ||||
Separate account liabilities | 11,246 | 11,659 | 11,792 | 11,694 |
Annuities | MetLife Holdings | ||||
Separate Account, Liability [Line Items] | ||||
Separate account liabilities | 28,780 | 29,162 | $ 29,553 | $ 28,443 |
Insurance, Other | ||||
Separate Account, Liability [Line Items] | ||||
Separate account liabilities | $ 7,303 | $ 6,814 |
Separate Account Liabilities Ro
Separate Account Liabilities Rollforward (Details) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Separate Account, Liability [Roll Forward] | ||
Balance, beginning of period | $ 83,197 | |
Balance, end of period | 79,585 | |
RIS | Stable Value and Risk Solutions | ||
Separate Account, Liability [Roll Forward] | ||
Balance, beginning of period | 35,562 | $ 43,249 |
Premiums and deposits | 541 | 1,069 |
Policy charges | (108) | (121) |
Surrenders and withdrawals | (2,919) | (7,532) |
Benefit payments | (49) | (44) |
Investment performance | 490 | 1,145 |
Net transfers from (to) general account | (20) | (57) |
Other (1) | (1,241) | (667) |
Balance, end of period | 32,256 | 37,042 |
Cash Surrender Value | 28,766 | 32,886 |
RIS | Annuities | ||
Separate Account, Liability [Roll Forward] | ||
Balance, beginning of period | 11,659 | 11,694 |
Premiums and deposits | 25 | 120 |
Policy charges | (10) | (11) |
Surrenders and withdrawals | (401) | (360) |
Benefit payments | 0 | 0 |
Investment performance | (95) | 448 |
Net transfers from (to) general account | 0 | 3 |
Other (1) | 68 | (102) |
Balance, end of period | 11,246 | 11,792 |
MetLife Holdings | Annuities | ||
Separate Account, Liability [Roll Forward] | ||
Balance, beginning of period | 29,162 | 28,443 |
Premiums and deposits | 123 | 139 |
Policy charges | (296) | (305) |
Surrenders and withdrawals | (1,851) | (1,359) |
Benefit payments | (259) | (242) |
Investment performance | 1,964 | 2,924 |
Net transfers from (to) general account | (58) | (47) |
Other (1) | (5) | 0 |
Balance, end of period | 28,780 | 29,553 |
Cash Surrender Value | $ 28,643 | $ 29,471 |
Separate Account Assets Fair Va
Separate Account Assets Fair Value (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | $ 79,585 | $ 83,197 |
Other invested assets | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 1,351 | 1,425 |
Separate Account, Debt Security | Materials | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 125 | 143 |
Separate Account, Debt Security | Communications | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 750 | 883 |
Separate Account, Debt Security | Consumer | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 1,742 | 1,843 |
Separate Account, Debt Security | Energy | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 828 | 906 |
Separate Account, Debt Security | Financial Services Sector | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 2,465 | 2,670 |
Separate Account, Debt Security | Commercial and Industrial Sector | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 698 | 757 |
Separate Account, Debt Security | Technology | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 468 | 541 |
Separate Account, Debt Security | Foreign | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 1,915 | 1,889 |
Separate Account, Debt Security | Foreign government | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 530 | 509 |
Separate Account, Debt Security | U.S. government and agency | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 9,237 | 9,603 |
Separate Account, Debt Security | Public utilities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 1,065 | 1,066 |
Separate Account, Debt Security | Municipals | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 275 | 346 |
Separate Account, Debt Security | Total corporate bonds | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 8,991 | 9,632 |
Separate Account, Debt Security | Total Bonds | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 20,098 | 21,156 |
Separate Account, Debt Security | Mortgage-backed securities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 9,211 | 9,515 |
Separate Account, Debt Security | Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”) | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 2,097 | 2,341 |
Separate Account, Debt Security | Redeemable preferred stock | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 9 | 9 |
Separate Account, Debt Security | Fixed Maturities [Member] | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 31,415 | 33,021 |
Separate Account, Equity Security | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 42,844 | 42,678 |
Separate Account, Equity Security | Non-redeemable preferred stock | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Separate Account, Equity Security | Financial Services Sector | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 690 | 716 |
Separate Account, Equity Security | Commercial and Industrial Sector | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 2,308 | 2,338 |
Separate Account, Equity Security | Public utilities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 62 | 65 |
Separate Account, Equity Security | Mutual funds | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 39,784 | 39,559 |
Investments | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 75,610 | 77,124 |
Other Assets | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 3,975 | 6,073 |
Group Benefits | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 1,270 | 1,159 |
Group Benefits | Other invested assets | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Materials | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Communications | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Consumer | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Energy | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Financial Services Sector | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Commercial and Industrial Sector | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Technology | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Foreign | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Foreign government | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | U.S. government and agency | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Public utilities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Municipals | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Total corporate bonds | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Total Bonds | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Mortgage-backed securities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”) | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Redeemable preferred stock | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Debt Security | Fixed Maturities [Member] | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Equity Security | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 1,270 | 1,159 |
Group Benefits | Separate Account, Equity Security | Non-redeemable preferred stock | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Equity Security | Financial Services Sector | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Equity Security | Commercial and Industrial Sector | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Equity Security | Public utilities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
Group Benefits | Separate Account, Equity Security | Mutual funds | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 1,270 | 1,159 |
Group Benefits | Investments | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 1,270 | 1,159 |
Group Benefits | Other Assets | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
RIS | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 43,597 | 47,310 |
RIS | Other invested assets | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 1,351 | 1,425 |
RIS | Separate Account, Debt Security | Materials | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 125 | 143 |
RIS | Separate Account, Debt Security | Communications | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 750 | 883 |
RIS | Separate Account, Debt Security | Consumer | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 1,742 | 1,843 |
RIS | Separate Account, Debt Security | Energy | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 828 | 906 |
RIS | Separate Account, Debt Security | Financial Services Sector | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 2,465 | 2,670 |
RIS | Separate Account, Debt Security | Commercial and Industrial Sector | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 698 | 757 |
RIS | Separate Account, Debt Security | Technology | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 468 | 541 |
RIS | Separate Account, Debt Security | Foreign | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 1,915 | 1,889 |
RIS | Separate Account, Debt Security | Foreign government | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 530 | 509 |
RIS | Separate Account, Debt Security | U.S. government and agency | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 9,237 | 9,603 |
RIS | Separate Account, Debt Security | Public utilities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 1,065 | 1,066 |
RIS | Separate Account, Debt Security | Municipals | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 275 | 346 |
RIS | Separate Account, Debt Security | Total corporate bonds | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 8,991 | 9,632 |
RIS | Separate Account, Debt Security | Total Bonds | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 20,098 | 21,156 |
RIS | Separate Account, Debt Security | Mortgage-backed securities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 9,211 | 9,515 |
RIS | Separate Account, Debt Security | Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”) | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 2,097 | 2,341 |
RIS | Separate Account, Debt Security | Redeemable preferred stock | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 9 | 9 |
RIS | Separate Account, Debt Security | Fixed Maturities [Member] | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 31,415 | 33,021 |
RIS | Separate Account, Equity Security | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 6,856 | 6,791 |
RIS | Separate Account, Equity Security | Non-redeemable preferred stock | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
RIS | Separate Account, Equity Security | Financial Services Sector | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 690 | 716 |
RIS | Separate Account, Equity Security | Commercial and Industrial Sector | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 2,308 | 2,338 |
RIS | Separate Account, Equity Security | Public utilities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 62 | 65 |
RIS | Separate Account, Equity Security | Mutual funds | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 3,796 | 3,672 |
RIS | Investments | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 39,622 | 41,237 |
RIS | Other Assets | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 3,975 | 6,073 |
MetLife Holdings | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 34,718 | 34,728 |
MetLife Holdings | Other invested assets | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Materials | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Communications | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Consumer | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Energy | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Financial Services Sector | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Commercial and Industrial Sector | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Technology | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Foreign | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Foreign government | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | U.S. government and agency | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Public utilities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Municipals | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Total corporate bonds | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Total Bonds | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Mortgage-backed securities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”) | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Redeemable preferred stock | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Debt Security | Fixed Maturities [Member] | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Equity Security | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 34,718 | 34,728 |
MetLife Holdings | Separate Account, Equity Security | Non-redeemable preferred stock | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Equity Security | Financial Services Sector | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Equity Security | Commercial and Industrial Sector | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Equity Security | Public utilities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 0 | 0 |
MetLife Holdings | Separate Account, Equity Security | Mutual funds | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 34,718 | 34,728 |
MetLife Holdings | Investments | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | 34,718 | 34,728 |
MetLife Holdings | Other Assets | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate account assets | $ 0 | $ 0 |
Deferred Policy Acquisition C_3
Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue - DAC VOBA by Segment (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
DAC: | |||||
DAC, Beginning Balance | $ 3,291 | $ 3,741 | |||
Capitalizations | $ 27 | $ 12 | 52 | 89 | |
Amortization | (137) | (150) | |||
DAC, Ending Balance | 3,206 | 3,680 | 3,206 | 3,680 | |
DAC and VOBA | 3,219 | 3,695 | 3,219 | 3,695 | $ 3,305 |
Group Benefits | |||||
DAC: | |||||
DAC, Beginning Balance | 255 | 264 | |||
Capitalizations | 7 | 11 | |||
Amortization | (13) | (13) | |||
DAC, Ending Balance | 249 | 262 | 249 | 262 | |
RIS | |||||
DAC: | |||||
DAC, Beginning Balance | 155 | 137 | |||
Capitalizations | 46 | 24 | |||
Amortization | (16) | (14) | |||
DAC, Ending Balance | 185 | 147 | 185 | 147 | |
MetLife Holdings | |||||
DAC: | |||||
DAC, Beginning Balance | 2,723 | 3,220 | |||
Capitalizations | (1) | (1) | |||
Amortization | (99) | (115) | |||
DAC, Ending Balance | 2,623 | 3,104 | 2,623 | 3,104 | |
Corporate & Other | |||||
DAC: | |||||
DAC, Beginning Balance | 158 | 120 | |||
Capitalizations | 0 | 55 | |||
Amortization | (9) | (8) | |||
DAC, Ending Balance | $ 149 | $ 167 | $ 149 | $ 167 |
Deferred Policy Acquisition C_4
Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue - Unearned Revenue (Details) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Unearned Revenue [Roll Forward] | ||
Deferred Revenue, Current, Beginning Balance | $ 21 | $ 245 |
Deferrals | 1 | 21 |
Amortization | (2) | (11) |
Deferred Revenue, Current, Ending Balance | 20 | 255 |
RIS | ||
Unearned Revenue [Roll Forward] | ||
Deferred Revenue, Current, Beginning Balance | 16 | 18 |
Deferrals | 1 | 1 |
Amortization | (2) | (2) |
Deferred Revenue, Current, Ending Balance | 15 | 17 |
MetLife Holdings | ||
Unearned Revenue [Roll Forward] | ||
Deferred Revenue, Current, Beginning Balance | 5 | 227 |
Deferrals | 0 | 20 |
Amortization | 0 | (9) |
Deferred Revenue, Current, Ending Balance | $ 5 | $ 238 |
Closed Block (Liabilities and A
Closed Block (Liabilities and Assets) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Closed Block Liabilities | ||
FPBs | $ 35,492 | $ 36,142 |
Other policy-related balances | 283 | 319 |
Policyholder dividends payable | 172 | 174 |
Policyholder dividend obligation | 0 | 0 |
Current income tax payable | 4 | 0 |
Other liabilities | 797 | 668 |
Total closed block liabilities | 36,748 | 37,303 |
Assets Designated to the Closed Block | ||
Fixed maturity securities available-for-sale (“AFS”), at estimated fair value | 19,247 | 19,939 |
Mortgage loans | 5,938 | 6,151 |
Policy loans | 3,876 | 3,960 |
Real estate and real estate joint ventures (“REJV”) | 688 | 668 |
Other invested assets | 498 | 506 |
Total investments | 30,247 | 31,224 |
Cash and cash equivalents | 759 | 717 |
Accrued investment income | 374 | 383 |
Premiums, reinsurance and other receivables | 67 | 54 |
Current income tax recoverable | 0 | 3 |
Deferred income tax asset | 397 | 312 |
Total assets designated to the closed block | 31,844 | 32,693 |
Excess of closed block liabilities over assets designated to the closed block | 4,904 | 4,610 |
AOCI: | ||
Unrealized investment gains (losses), net of income tax | (1,204) | (820) |
Unrealized gains (losses) on derivatives, net of income tax | 164 | 130 |
Total amounts included in AOCI | (1,040) | (690) |
Maximum future earnings to be recognized from closed block assets and liabilities | $ 3,864 | $ 3,920 |
Closed Block (Revenues and Expe
Closed Block (Revenues and Expenses) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Revenues | ||||
Premiums | $ 216 | $ 226 | $ 434 | $ 461 |
Net investment income | 342 | 341 | 685 | 679 |
Net investment gains (losses) | (13) | 5 | (20) | 9 |
Net derivative gains (losses) | 2 | 5 | 7 | 3 |
Total revenues | 547 | 577 | 1,106 | 1,152 |
Expenses | ||||
Policyholder benefits and claims | 415 | 445 | 819 | 858 |
Policyholder dividends | 86 | 89 | 176 | 186 |
Other expenses | 20 | 22 | 40 | 44 |
Total expenses | 521 | 556 | 1,035 | 1,088 |
Revenues, net of expenses before provision for income tax expense (benefit) | 26 | 21 | 71 | 64 |
Provision for income tax expense (benefit) | 5 | 4 | 15 | 13 |
Revenues, net of expenses and provision for income tax expense (benefit) | $ 21 | $ 17 | $ 56 | $ 51 |
Investments (Fixed Maturity Sec
Investments (Fixed Maturity Securities Available-For-Sale by Sector) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Mar. 31, 2024 | Dec. 31, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 |
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | $ 154,560 | $ 152,080 | ||||
Allowance for Credit Loss for Debt Securities | (77) | $ (66) | (132) | $ (142) | $ (135) | $ (114) |
Gross Unrealized Gains | 1,628 | 2,665 | ||||
Gross Unrealized Losses | 13,955 | 11,808 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | 142,156 | 142,805 | ||||
U.S. corporate | ||||||
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | 52,045 | 52,479 | ||||
Allowance for Credit Loss for Debt Securities | (27) | (10) | (62) | (63) | (57) | (28) |
Gross Unrealized Gains | 684 | 1,126 | ||||
Gross Unrealized Losses | 3,855 | 3,050 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | 48,847 | 50,493 | ||||
Foreign corporate | ||||||
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | 27,381 | 27,520 | ||||
Allowance for Credit Loss for Debt Securities | (2) | (2) | (2) | (2) | (3) | (3) |
Gross Unrealized Gains | 334 | 536 | ||||
Gross Unrealized Losses | 3,284 | 2,839 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | 24,429 | 25,215 | ||||
U.S. government and agency | ||||||
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | 25,542 | 23,100 | ||||
Allowance for Credit Loss for Debt Securities | 0 | 0 | ||||
Gross Unrealized Gains | 97 | 243 | ||||
Gross Unrealized Losses | 3,100 | 2,283 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | 22,539 | 21,060 | ||||
RMBS | ||||||
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | 22,572 | 20,700 | ||||
Allowance for Credit Loss for Debt Securities | (1) | (1) | (1) | 0 | 0 | 0 |
Gross Unrealized Gains | 183 | 228 | ||||
Gross Unrealized Losses | 2,190 | 1,979 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | 20,564 | 18,948 | ||||
ABS & CLO | ||||||
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | 12,188 | 12,049 | ||||
Allowance for Credit Loss for Debt Securities | (7) | (7) | (6) | 0 | 0 | 0 |
Gross Unrealized Gains | 47 | 30 | ||||
Gross Unrealized Losses | 318 | 432 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | 11,910 | 11,641 | ||||
Municipals | ||||||
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | 5,837 | 6,429 | ||||
Allowance for Credit Loss for Debt Securities | 0 | 0 | ||||
Gross Unrealized Gains | 148 | 318 | ||||
Gross Unrealized Losses | 508 | 428 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | 5,477 | 6,319 | ||||
CMBS | ||||||
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | 5,828 | 6,387 | ||||
Allowance for Credit Loss for Debt Securities | (7) | (11) | (11) | (7) | (7) | (15) |
Gross Unrealized Gains | 26 | 28 | ||||
Gross Unrealized Losses | 433 | 570 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | 5,414 | 5,834 | ||||
Foreign government | ||||||
Debt Securities, Available-for-sale [Line Items] | ||||||
Amortized Cost | 3,167 | 3,416 | ||||
Allowance for Credit Loss for Debt Securities | (33) | $ (35) | (50) | $ (70) | $ (68) | $ (68) |
Gross Unrealized Gains | 109 | 156 | ||||
Gross Unrealized Losses | 267 | 227 | ||||
Estimated Fair Value of Fixed Maturity Securities AFS | $ 2,976 | $ 3,295 |
Investments (Maturities of Fixe
Investments (Maturities of Fixed Maturity Securities) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Available-for-sale Securities, Debt Maturities [Abstract] | ||
Amortized Cost, Due in one year or less | $ 5,015 | |
Amortized Cost, Due after one year through five years | 24,950 | |
Amortized Cost, Due after five years through ten years | 27,900 | |
Amortized Cost, Due after ten years | 56,045 | |
Amortized Cost, Structured Securities | 40,573 | |
Amortized Cost, net of ACL | 154,483 | |
Estimated Fair Value, Due in one year or less | 4,907 | |
Estimated Fair Value, Due after one year through five years | 24,189 | |
Estimated Fair Value, Due after five years through ten years | 26,450 | |
Estimated Fair Value, Due after ten years | 48,722 | |
Estimated Fair Value, Structured Securities | 37,888 | |
Estimated Fair Value of Fixed Maturity Securities AFS | $ 142,156 | $ 142,805 |
Investments (Continuous Gross U
Investments (Continuous Gross Unrealized Losses for Fixed Maturity Securities Available For Sale) Details (Details) $ in Millions | Jun. 30, 2024 USD ($) | Dec. 31, 2023 USD ($) |
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | $ 18,737 | $ 12,260 |
Less than 12 months Gross Unrealized Loss | $ 409 | $ 489 |
Total number of securities in an unrealized loss position less than 12 months | 2,588 | 1,679 |
Equal to or Greater than 12 Months Estimated Fair Value | $ 77,016 | $ 81,427 |
Equal to or Greater than 12 Months Gross Unrealized Loss | $ 13,517 | $ 11,277 |
Total number of securities in an unrealized loss position equal or greater than 12 months | 8,129 | 8,441 |
U.S. corporate | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | $ 5,310 | $ 3,537 |
Less than 12 months Gross Unrealized Loss | 136 | 95 |
Equal to or Greater than 12 Months Estimated Fair Value | 25,251 | 25,752 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 3,701 | 2,924 |
Foreign corporate | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 2,376 | 714 |
Less than 12 months Gross Unrealized Loss | 84 | 64 |
Equal to or Greater than 12 Months Estimated Fair Value | 15,847 | 16,982 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 3,200 | 2,775 |
U.S. government and agency | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 6,186 | 4,322 |
Less than 12 months Gross Unrealized Loss | 121 | 228 |
Equal to or Greater than 12 Months Estimated Fair Value | 11,194 | 9,980 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 2,979 | 2,055 |
RMBS | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 2,615 | 1,470 |
Less than 12 months Gross Unrealized Loss | 43 | 37 |
Equal to or Greater than 12 Months Estimated Fair Value | 12,667 | 12,813 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 2,147 | 1,941 |
ABS & CLO | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 751 | 937 |
Less than 12 months Gross Unrealized Loss | 3 | 20 |
Equal to or Greater than 12 Months Estimated Fair Value | 4,928 | 8,250 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 314 | 410 |
Municipals | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 412 | 262 |
Less than 12 months Gross Unrealized Loss | 9 | 10 |
Equal to or Greater than 12 Months Estimated Fair Value | 2,199 | 2,102 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 499 | 418 |
CMBS | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 702 | 587 |
Less than 12 months Gross Unrealized Loss | 6 | 23 |
Equal to or Greater than 12 Months Estimated Fair Value | 3,475 | 4,096 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 426 | 542 |
Foreign government | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 385 | 431 |
Less than 12 months Gross Unrealized Loss | 7 | 12 |
Equal to or Greater than 12 Months Estimated Fair Value | 1,455 | 1,452 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 251 | 212 |
Investment Grade | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 17,504 | 11,499 |
Less than 12 months Gross Unrealized Loss | 364 | 453 |
Equal to or Greater than 12 Months Estimated Fair Value | 73,674 | 77,325 |
Equal to or Greater than 12 Months Gross Unrealized Loss | 13,098 | 10,849 |
Below Investment Grade | ||
Debt Securities, Available-for-sale [Line Items] | ||
Less than 12 months Estimated Fair Value | 1,233 | 761 |
Less than 12 months Gross Unrealized Loss | 45 | 36 |
Equal to or Greater than 12 Months Estimated Fair Value | 3,342 | 4,102 |
Equal to or Greater than 12 Months Gross Unrealized Loss | $ 419 | $ 428 |
Investments (ACL for Fixed Matu
Investments (ACL for Fixed Maturity Securities AFS By Sector) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items] | ||||
Allowance, beginning of period | $ 66 | $ 135 | $ 132 | $ 114 |
ACL not previously recorded | 14 | 0 | 14 | 31 |
Changes for securities with previously recorded ACL | 6 | 7 | 5 | 9 |
Securities sold or exchanged | (9) | 0 | (74) | (12) |
Allowance, end of period | 77 | 142 | 77 | 142 |
U.S. corporate | ||||
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items] | ||||
Allowance, beginning of period | 10 | 57 | 62 | 28 |
ACL not previously recorded | 14 | 0 | 14 | 31 |
Changes for securities with previously recorded ACL | 6 | 6 | 6 | 6 |
Securities sold or exchanged | (3) | 0 | (55) | (2) |
Allowance, end of period | 27 | 63 | 27 | 63 |
Foreign corporate | ||||
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items] | ||||
Allowance, beginning of period | 2 | 3 | 2 | 3 |
ACL not previously recorded | 0 | 0 | 0 | 0 |
Changes for securities with previously recorded ACL | 0 | (1) | 0 | (1) |
Securities sold or exchanged | 0 | 0 | 0 | 0 |
Allowance, end of period | 2 | 2 | 2 | 2 |
Foreign government | ||||
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items] | ||||
Allowance, beginning of period | 35 | 68 | 50 | 68 |
ACL not previously recorded | 0 | 0 | 0 | 0 |
Changes for securities with previously recorded ACL | 0 | 2 | (2) | 2 |
Securities sold or exchanged | (2) | 0 | (15) | 0 |
Allowance, end of period | 33 | 70 | 33 | 70 |
RMBS | ||||
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items] | ||||
Allowance, beginning of period | 1 | 0 | 1 | 0 |
ACL not previously recorded | 0 | 0 | 0 | 0 |
Changes for securities with previously recorded ACL | 0 | 0 | 0 | 0 |
Securities sold or exchanged | 0 | 0 | 0 | 0 |
Allowance, end of period | 1 | 0 | 1 | 0 |
ABS & CLO | ||||
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items] | ||||
Allowance, beginning of period | 7 | 0 | 6 | 0 |
ACL not previously recorded | 0 | 0 | 0 | 0 |
Changes for securities with previously recorded ACL | 0 | 0 | 1 | 0 |
Securities sold or exchanged | 0 | 0 | 0 | 0 |
Allowance, end of period | 7 | 0 | 7 | 0 |
CMBS | ||||
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items] | ||||
Allowance, beginning of period | 11 | 7 | 11 | 15 |
ACL not previously recorded | 0 | 0 | 0 | 0 |
Changes for securities with previously recorded ACL | 0 | 0 | 0 | 2 |
Securities sold or exchanged | (4) | 0 | (4) | (10) |
Allowance, end of period | $ 7 | $ 7 | $ 7 | $ 7 |
Investments (Mortgage Loans by
Investments (Mortgage Loans by Portfolio Segment) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 | Jun. 30, 2023 | Dec. 31, 2022 |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Mortgage Loans, Gross | $ 61,110 | $ 63,093 | ||
Allowance for Credit Loss | (533) | (509) | $ (525) | $ (448) |
Total mortgage loans | $ 60,577 | $ 62,584 | ||
Percentage Of mortgage total recorded investment To Mortgage Loans On Real Estate Commercial And Consumer Net | 100.90% | 100.80% | ||
Percentage of Allowance for Credit Losses for Financing Receivables | (0.90%) | (0.80%) | ||
Percentage Of Mortgage Loans On Real Estate To Mortgage Loans On Real Estate Commercial And Consumer Net | 100% | 100% | ||
Commercial Mortgage Loans | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Mortgage Loans, Gross | $ 35,433 | $ 37,129 | ||
Allowance for Credit Loss | $ (272) | $ (210) | (211) | (174) |
Percentage Of Mortgage Loans, Gross | 58.50% | 59.30% | ||
Residential Mortgage Loans | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Mortgage Loans, Gross | $ 10,089 | $ 10,133 | ||
Allowance for Credit Loss | $ (110) | $ (147) | (174) | (169) |
Percentage Of Mortgage Loans, Gross | 16.70% | 16.20% | ||
Agricultural Mortgage Loans | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Mortgage Loans, Gross | $ 15,588 | $ 15,831 | ||
Allowance for Credit Loss | $ (151) | $ (152) | $ (140) | $ (105) |
Percentage Of Mortgage Loans, Gross | 25.70% | 25.30% |
Investments (Mortgage Loans All
Investments (Mortgage Loans Allowance for Credit Loss Rollforward by Portfolio Segment) (Details) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Balance, beginning of period | $ 509 | $ 448 |
Provision (release) | 43 | 90 |
Charge-offs, net of recoveries | (19) | (13) |
Balance, end of period | 533 | 525 |
Commercial Mortgage Loans | ||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Balance, beginning of period | 210 | 174 |
Provision (release) | 74 | 37 |
Charge-offs, net of recoveries | (12) | 0 |
Balance, end of period | 272 | 211 |
Residential Mortgage Loans | ||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Balance, beginning of period | 147 | 169 |
Provision (release) | (37) | 5 |
Charge-offs, net of recoveries | 0 | 0 |
Balance, end of period | 110 | 174 |
Agricultural Mortgage Loans | ||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Balance, beginning of period | 152 | 105 |
Provision (release) | 6 | 48 |
Charge-offs, net of recoveries | (7) | (13) |
Balance, end of period | $ 151 | $ 140 |
Investments (Modifications to B
Investments (Modifications to Borrowers Experiencing Financial Difficulty) (Details) - Commercial Mortgage Loans - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Maximum | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Financing Receivable, Modified, Weighted Average Term Increase | Less than one year | One year | Less than one year | Less than one year |
Financing Receivable, Modified in Period, to Total Financing Receivables, Percentage | 1% | 1% | 1% | 1% |
Extended Maturity | ||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||
Financing Receivable, Troubled Debt Restructuring, Postmodification | $ 137 | $ 149 | $ 167 | $ 180 |
Investments (Credit Quality of
Investments (Credit Quality of Commercial Mortgage Loans) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Mortgage Loans, Gross | $ 61,110 | $ 63,093 |
Commercial Mortgage Loans | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | 872 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 1,871 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 4,960 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 4,008 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 2,350 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 19,121 | |
Financing Receivable, Revolving | 2,251 | |
Mortgage Loans, Gross | $ 35,433 | $ 37,129 |
Loans Receivable Commercial Mortgage Percentage | 100% | |
Commercial Mortgage Loans | Greater than 1.20x | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 837 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 1,397 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 4,284 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 3,708 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 2,092 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 15,920 | |
Financing Receivable, Revolving | 2,251 | |
Mortgage Loans, Gross | $ 30,489 | |
Loans Receivable Commercial Mortgage Percentage | 86% | |
Commercial Mortgage Loans | 1.00x - 1.20x | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 5 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 385 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 528 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 300 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 119 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 1,816 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 3,153 | |
Loans Receivable Commercial Mortgage Percentage | 8.90% | |
Commercial Mortgage Loans | Less than 1.00x | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 30 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 89 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 148 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 0 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 139 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 1,385 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 1,791 | |
Loans Receivable Commercial Mortgage Percentage | 5.10% | |
Commercial Mortgage Loans | Less than 65% | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 839 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 1,603 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 1,035 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 1,682 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 867 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 9,166 | |
Financing Receivable, Revolving | 2,251 | |
Mortgage Loans, Gross | $ 17,443 | |
Loans Receivable Commercial Mortgage Percentage | 49.20% | |
Commercial Mortgage Loans | 65% to 75% | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 32 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 226 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 3,013 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 1,388 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 841 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 3,802 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 9,302 | |
Loans Receivable Commercial Mortgage Percentage | 26.30% | |
Commercial Mortgage Loans | 76% to 80% | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 0 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 0 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 314 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 192 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 74 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 1,705 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 2,285 | |
Loans Receivable Commercial Mortgage Percentage | 6.40% | |
Commercial Mortgage Loans | Greater than 80% | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 1 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 42 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 598 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 746 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 568 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 4,448 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 6,403 | |
Loans Receivable Commercial Mortgage Percentage | 18.10% |
Investments (Credit Quality o_2
Investments (Credit Quality of Agricultural and Residential Mortgage Loans) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Mortgage Loans, Gross | $ 61,110 | $ 63,093 |
Mortgage Loans in Process of Foreclosure, Amount | 125 | 134 |
Residential Mortgage Loans | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | 87 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 338 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 1,886 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 964 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 153 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 6,661 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 10,089 | 10,133 |
Loans Receivable Residential Mortgage Percentage | 100% | |
Residential Mortgage Loans | Performing | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 87 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 331 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 1,833 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 948 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 147 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 6,424 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 9,770 | |
Loans Receivable Residential Mortgage Percentage | 96.80% | |
Residential Mortgage Loans | Nonperforming | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 0 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 7 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 53 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 16 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 6 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 237 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 319 | |
Loans Receivable Residential Mortgage Percentage | 3.20% | |
Agricultural Mortgage Loans | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 262 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 817 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 2,054 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 1,672 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 2,040 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 7,274 | |
Financing Receivable, Revolving | 1,469 | |
Mortgage Loans, Gross | $ 15,588 | $ 15,831 |
Loans Receivable Agricultural Mortgage Percentage | 100% | |
Agricultural Mortgage Loans | Less than 65% | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 257 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 770 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 1,981 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 1,465 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 1,885 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 6,703 | |
Financing Receivable, Revolving | 1,326 | |
Mortgage Loans, Gross | $ 14,387 | |
Loans Receivable Agricultural Mortgage Percentage | 92.30% | |
Agricultural Mortgage Loans | 65% to 75% | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 5 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 47 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 73 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 193 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 126 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 494 | |
Financing Receivable, Revolving | 125 | |
Mortgage Loans, Gross | $ 1,063 | |
Loans Receivable Agricultural Mortgage Percentage | 6.80% | |
Agricultural Mortgage Loans | 76% to 80% | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 0 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 0 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 0 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 0 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 0 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 0 | |
Financing Receivable, Revolving | 0 | |
Mortgage Loans, Gross | $ 0 | |
Loans Receivable Agricultural Mortgage Percentage | 0% | |
Agricultural Mortgage Loans | Greater than 80% | ||
Financing Receivable, Credit Quality Indicator [Line Items] | ||
Financing Receivable, Year One, Originated, Current Fiscal Year | $ 0 | |
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year | 0 | |
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year | 0 | |
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year | 14 | |
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year | 29 | |
Financing Receivable, Originated, More than Five Years before Current Fiscal Year | 77 | |
Financing Receivable, Revolving | 18 | |
Mortgage Loans, Gross | $ 138 | |
Loans Receivable Agricultural Mortgage Percentage | 0.90% |
Investments (Past Due and Inter
Investments (Past Due and Interest Accrual Status of Mortgage Loans) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Financing Receivable, Nonaccrual [Line Items] | ||
Mortgage Loans, Gross | $ 61,110 | $ 63,093 |
Greater than 90 Days Past Due and Still Accruing Interest | 15 | 0 |
Financing Receivable, Nonaccrual | 882 | 852 |
Financial Asset, Past Due | ||
Financing Receivable, Nonaccrual [Line Items] | ||
Mortgage Loans, Gross | 778 | 402 |
Commercial Mortgage Loans | ||
Financing Receivable, Nonaccrual [Line Items] | ||
Mortgage Loans, Gross | 35,433 | 37,129 |
Greater than 90 Days Past Due and Still Accruing Interest | 0 | 0 |
Financing Receivable, Nonaccrual | 381 | 303 |
Commercial Mortgage Loans | Financial Asset, Past Due | ||
Financing Receivable, Nonaccrual [Line Items] | ||
Mortgage Loans, Gross | 271 | 19 |
Residential Mortgage Loans | ||
Financing Receivable, Nonaccrual [Line Items] | ||
Mortgage Loans, Gross | 10,089 | 10,133 |
Greater than 90 Days Past Due and Still Accruing Interest | 0 | 0 |
Financing Receivable, Nonaccrual | 319 | 343 |
Residential Mortgage Loans | Financial Asset, Past Due | ||
Financing Receivable, Nonaccrual [Line Items] | ||
Mortgage Loans, Gross | 319 | 343 |
Agricultural Mortgage Loans | ||
Financing Receivable, Nonaccrual [Line Items] | ||
Mortgage Loans, Gross | 15,588 | 15,831 |
Greater than 90 Days Past Due and Still Accruing Interest | 15 | 0 |
Financing Receivable, Nonaccrual | 182 | 206 |
Agricultural Mortgage Loans | Financial Asset, Past Due | ||
Financing Receivable, Nonaccrual [Line Items] | ||
Mortgage Loans, Gross | $ 188 | $ 40 |
Investments (Real Estate and Re
Investments (Real Estate and Real Estate Joint Ventures) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Real Estate [Line Items] | |||||
Leased real estate investments, Carrying Value | $ 1,656 | $ 1,656 | $ 1,594 | ||
Other real estate investments, Carrying Value | 518 | 518 | 506 | ||
Real estate joint ventures, Carrying Value | 6,895 | 6,895 | 6,590 | ||
Real Estate Investments, Net | 9,069 | 9,069 | $ 8,690 | ||
Income (Loss) from Equity Method Investments | 148 | $ 65 | 284 | $ 27 | |
Gross Investment Income, Operating | 3,230 | 3,201 | 6,404 | 6,191 | |
Real Estate and Real Estate Joint Ventures | |||||
Real Estate [Line Items] | |||||
Gross Investment Income, Operating | 58 | 117 | 89 | 169 | |
Leased real estate | |||||
Real Estate [Line Items] | |||||
Operating Lease, Lease Income | $ 38 | $ 41 | $ 76 | $ 83 | |
Operating Lease, Lease Income | Revenues | Revenues | Revenues | Revenues | |
Other real estate | |||||
Real Estate [Line Items] | |||||
Operating Lease, Lease Income | $ 77 | $ 83 | $ 120 | $ 129 | |
Operating Lease, Lease Income | Revenues | Revenues | Revenues | Revenues | |
Real estate joint ventures | |||||
Real Estate [Line Items] | |||||
Income (Loss) from Equity Method Investments | $ (57) | $ (7) | $ (107) | $ (43) |
Investments (FVO Securities and
Investments (FVO Securities and Equity Securities) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
FVO Securities | ||
Debt and Equity Securities, FV-NI [Line Items] | ||
Debt Securities, Trading, and Equity Securities, FV-NI, Cost | $ 315 | $ 379 |
Equity and Trading Securities, FV-NI, Unrealized Gains (Losses) | 493 | 367 |
Debt Securities, Trading, and Equity Securities, FV-NI | 808 | 746 |
Common Stock | ||
Debt and Equity Securities, FV-NI [Line Items] | ||
Equity Securities, FV-NI, Cost | 119 | 118 |
Equity and Trading Securities, FV-NI, Unrealized Gains (Losses) | 49 | 45 |
Equity Securities, FV-NI | 168 | 163 |
Non-redeemable preferred stock | ||
Debt and Equity Securities, FV-NI [Line Items] | ||
Equity Securities, FV-NI, Cost | 173 | 177 |
Equity and Trading Securities, FV-NI, Unrealized Gains (Losses) | 15 | 7 |
Equity Securities, FV-NI | 188 | 184 |
Equity securities | ||
Debt and Equity Securities, FV-NI [Line Items] | ||
Equity Securities, FV-NI, Cost | 292 | 295 |
Equity and Trading Securities, FV-NI, Unrealized Gains (Losses) | 64 | 52 |
Equity Securities, FV-NI | $ 356 | $ 347 |
Investments (Securities Lending
Investments (Securities Lending and Repurchase Agreements) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | $ 5,964 | $ 5,684 |
Securities Lending Reinvestment Portfolio Estimated Fair Value | 5,837 | 5,565 |
Estimated fair value | ||
Securities Financing Transaction [Line Items] | ||
Securities loaned | 5,761 | 5,528 |
Securities Sold under Agreements to Repurchase | 2,984 | 3,029 |
Repurchase Agreements | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 2,975 | 2,975 |
Securities Lending Reinvestment Portfolio Estimated Fair Value | $ 2,912 | $ 2,913 |
Investments (Securities Lendi_2
Investments (Securities Lending and Repurchase Agreements Remaining Tenor) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | $ 5,964 | $ 5,684 |
Repurchase Agreements | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 2,975 | 2,975 |
U.S. government and agency | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 5,964 | 5,684 |
U.S. government and agency | Open (1) | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 1,238 | 943 |
U.S. government and agency | 1 Month or Less | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 2,676 | 2,523 |
U.S. government and agency | Over 1 Month to 6 Months | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 2,050 | 2,218 |
U.S. government and agency | Over 6 Months to 1 Year | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 0 | 0 |
U.S. government and agency | Repurchase Agreements | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 2,975 | 2,975 |
U.S. government and agency | Repurchase Agreements | Open (1) | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 0 | 0 |
U.S. government and agency | Repurchase Agreements | 1 Month or Less | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 2,975 | 2,975 |
U.S. government and agency | Repurchase Agreements | Over 1 Month to 6 Months | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | 0 | 0 |
U.S. government and agency | Repurchase Agreements | Over 6 Months to 1 Year | ||
Securities Financing Transaction [Line Items] | ||
Cash collateral on deposit from counterparties | $ 0 | $ 0 |
Investments (Invested Assets on
Investments (Invested Assets on Deposit and Pledged as Collateral) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Investments, Debt and Equity Securities [Abstract] | ||
Invested assets on deposit (regulatory deposits) | $ 101 | $ 105 |
Invested assets pledged as collateral (1) | 21,242 | 21,177 |
Total invested assets on deposit and pledged as collateral | $ 21,343 | $ 21,282 |
Investments (Consolidated Varia
Investments (Consolidated Variable Interest Entities) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Variable Interest Entity [Line Items] | ||
Total Assets | $ 371,874 | $ 378,685 |
Total Liabilities | 357,995 | 365,069 |
Variable Interest Entity | ||
Variable Interest Entity [Line Items] | ||
Total Assets | 2,092 | 1,724 |
Total Liabilities | 3 | 0 |
Real estate joint ventures | Variable Interest Entity | ||
Variable Interest Entity [Line Items] | ||
Total Assets | 1,739 | 1,427 |
Total Liabilities | 0 | 0 |
Mortgage loans | Variable Interest Entity | ||
Variable Interest Entity [Line Items] | ||
Total Assets | 204 | 171 |
Total Liabilities | 1 | 0 |
Renewable energy partnership | Variable Interest Entity | ||
Variable Interest Entity [Line Items] | ||
Total Assets | 61 | 65 |
Total Liabilities | 0 | 0 |
Investment funds (primarily other invested assets) | Variable Interest Entity | ||
Variable Interest Entity [Line Items] | ||
Total Assets | 88 | 61 |
Total Liabilities | $ 2 | $ 0 |
Investments (Unconsolidated Var
Investments (Unconsolidated Variable Interest Entities) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Variable Interest Entity [Line Items] | ||
Total Assets | $ 371,874 | $ 378,685 |
Variable Interest Entity, Not Primary Beneficiary | ||
Variable Interest Entity [Line Items] | ||
Total Assets | 44,612 | 44,111 |
Maximum Exposure to Loss | 46,827 | 46,494 |
Variable Interest Entity, Not Primary Beneficiary | Fixed Maturity Securities | ||
Variable Interest Entity [Line Items] | ||
Total Assets | 36,626 | 35,370 |
Maximum Exposure to Loss | 36,626 | 35,370 |
Variable Interest Entity, Not Primary Beneficiary | Partnership Interest [Member] | ||
Variable Interest Entity [Line Items] | ||
Total Assets | 6,757 | 7,319 |
Maximum Exposure to Loss | 8,614 | 9,452 |
Variable Interest Entity, Not Primary Beneficiary | Other invested assets | ||
Variable Interest Entity [Line Items] | ||
Total Assets | 1,156 | 1,318 |
Maximum Exposure to Loss | 1,351 | 1,405 |
Variable Interest Entity, Not Primary Beneficiary | Real estate joint ventures | ||
Variable Interest Entity [Line Items] | ||
Total Assets | 73 | 104 |
Maximum Exposure to Loss | $ 236 | $ 267 |
Investments (Net Investment Inc
Investments (Net Investment Income) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | $ 3,230 | $ 3,201 | $ 6,404 | $ 6,191 |
Less: Investment expenses | 327 | 328 | 644 | 633 |
Net investment income | 2,903 | 2,873 | 5,760 | 5,558 |
Other Investments | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | 124 | 46 | 205 | 125 |
Equity securities | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | 3 | 4 | 6 | 5 |
Operating Joint Venture | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | 13 | 7 | 29 | 21 |
FVO Securities | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | 29 | 46 | 95 | 96 |
Cash, cash equivalents and short-term investments | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | 87 | 89 | 178 | 173 |
Other limited partnership interests | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | 174 | 91 | 332 | 92 |
Real Estate and Real Estate Joint Ventures | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | 58 | 117 | 89 | 169 |
Policy Loans | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | 71 | 75 | 141 | 148 |
Mortgage loans | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | 823 | 829 | 1,651 | 1,619 |
Fixed Maturity Securities | ||||
Net Investment Income [Line Items] | ||||
Gross Investment Income, Operating | $ 1,848 | $ 1,897 | $ 3,678 | $ 3,743 |
Investments (Supplemental Net I
Investments (Supplemental Net Investment Income) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Net Investment Income [Line Items] | ||||
Net realized gains (losses) from sales and disposals | $ (141) | $ (3) | $ (314) | $ 80 |
Equity Securities, FV-NI, Unrealized Gain (Loss) | 4 | 7 | 11 | 4 |
Income (Loss) from Equity Method Investments | 148 | 65 | 284 | 27 |
Net investment Income | ||||
Net Investment Income [Line Items] | ||||
Net realized gains (losses) from sales and disposals | (15) | 0 | (15) | 0 |
Debt and Equity Securities, Unrealized Gain (Loss) | 53 | 76 | 140 | 134 |
Debt and Equity Securities, Gain (Loss) | 38 | 76 | 125 | 134 |
FVO Securities | ||||
Net Investment Income [Line Items] | ||||
Equity Securities, FV-NI, Unrealized Gain (Loss) | $ 44 | $ 45 | $ 108 | $ 92 |
Investments (Components of Net
Investments (Components of Net Investment Gains Losses - Asset Type) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Marketable Securities, Gain (Loss) [Abstract] | ||||
Fixed maturity securities AFS | $ (138) | $ (746) | $ (217) | $ (694) |
Equity Securities, FV-NI, Gain (Loss) | 3 | 7 | 9 | 2 |
Other net investment gains (losses): | ||||
Mortgage loans | 16 | 33 | (55) | (116) |
Real estate and REJV (excluding changes in estimated fair value) | 12 | 62 | 39 | 64 |
OLPI (excluding changes in estimated fair value) (1) | (9) | 2 | (47) | 9 |
Other gains (losses) | 3 | 8 | (2) | 14 |
Subtotal - investment portfolio gains (losses) | (113) | (634) | (273) | (721) |
Change In Estimated Fair Value Of Other Limited Partnership Interests And Real Estate Joint Ventures | 2 | 1 | 5 | (4) |
Non-investment portfolio gains (losses) | 5 | (26) | 26 | (36) |
Subtotal | 7 | (25) | 31 | (40) |
Net investment gains (losses) | $ (106) | $ (659) | $ (242) | $ (761) |
Investments (Components of Ne_2
Investments (Components of Net Investment Gains Losses - Transaction Type) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Gain (Loss) on Securities [Line Items] | ||||
Realized gains (losses) on investments sold or disposed | $ (126) | $ (3) | $ (299) | $ 80 |
Impairment (losses) | 0 | (684) | 0 | (690) |
Change in allowance for credit loss recognized in earnings | 7 | 47 | 14 | (115) |
Unrealized net gains (losses) recognized in earnings | 8 | 7 | 17 | 0 |
Total recognized gains (losses) | 15 | 54 | 31 | (115) |
Non-investment portfolio gains (losses) | 5 | (26) | 26 | (36) |
Net investment gains (losses) | (106) | $ (659) | (242) | $ (761) |
Private Equity Funds | ||||
Gain (Loss) on Securities [Line Items] | ||||
Realized gains (losses) on investments sold or disposed | 2 | 38 | ||
Equity Method Investment, Amount Sold | 48 | 638 | ||
Proceeds from Sale of Equity Method Investments | $ 46 | $ 600 |
Investments (Supplemental Net_2
Investments (Supplemental Net Investment Gains (Losses)) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Net Investment Income [Line Items] | ||||
Equity Securities, FV-NI, Unrealized Gain (Loss) | $ 4 | $ 7 | $ 11 | $ 4 |
Foreign Currency Transaction Gain (Loss), Realized | (1) | (36) | 8 | (51) |
Realized gains (losses) on investments sold or disposed | (126) | (3) | (299) | 80 |
Net realized gains (losses) from sales and disposals | (141) | (3) | (314) | 80 |
Net investment Income | ||||
Net Investment Income [Line Items] | ||||
Net realized gains (losses) from sales and disposals | (15) | 0 | (15) | 0 |
Cash Flow Hedging [Member] | ||||
Net Investment Income [Line Items] | ||||
Realized gains (losses) on investments sold or disposed | 1 | (27) | 3 | (25) |
Equity securities | ||||
Net Investment Income [Line Items] | ||||
Equity Securities, FV-NI, Unrealized Gain (Loss) | $ 6 | $ 8 | $ 17 | $ 5 |
Investments (Fixed Maturity S_2
Investments (Fixed Maturity Securities AFS - Sales and Disposals and Credit Loss) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Debt Securities, Available-for-sale [Line Items] | ||||
Proceeds | $ 4,754 | $ 3,291 | $ 7,784 | $ 11,713 |
Gross investment gains | 67 | 27 | 115 | 266 |
Gross investment (losses) | (195) | (102) | (388) | (262) |
Realized gains (losses) on sales and disposals | (128) | (75) | (273) | 4 |
Net credit loss (provision) release (change in ACL recognized in earnings) | (10) | (10) | 56 | (31) |
Impairment (losses) | 0 | (661) | 0 | (667) |
Net credit loss (provision) release and impairment (losses) | (10) | (671) | 56 | (698) |
Net investment gains (losses) | (126) | (3) | (299) | 80 |
Equity securities, Realized gains(losses) on sales and disposals | (1) | 0 | (2) | (2) |
Equity Securities, FV-NI, Unrealized Gain (Loss) | 4 | 7 | 11 | 4 |
Equity Securities, FV-NI, Gain (Loss) | 3 | 7 | 9 | 2 |
Fixed Maturity Securities | ||||
Debt Securities, Available-for-sale [Line Items] | ||||
Net investment gains (losses) | $ (138) | $ (746) | $ (217) | $ (694) |
Investments (Recurring Related
Investments (Recurring Related Party Investments Transactions) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Related Party Transaction [Line Items] | |||||
Other invested assets - VIE | $ 16,865 | $ 16,865 | $ 17,040 | ||
Metropolitan General Insurance Company | |||||
Related Party Transaction [Line Items] | |||||
Preferred Stock Dividend Yield Percentage | 7.50% | 7.50% | |||
Minimum | |||||
Related Party Transaction [Line Items] | |||||
Debt Instrument, Interest Rate, Stated Percentage | 1.61% | 1.61% | |||
Maximum | |||||
Related Party Transaction [Line Items] | |||||
Debt Instrument, Interest Rate, Stated Percentage | 2.16% | 2.16% | |||
Metlife Inc | |||||
Related Party Transaction [Line Items] | |||||
Other invested assets - VIE | $ 990 | $ 990 | 1,130 | ||
OtherOperatingIncomeRelatedAndNonrelatedParty | 4 | $ 5 | 9 | $ 10 | |
Metropolitan General Insurance Company | |||||
Related Party Transaction [Line Items] | |||||
Other invested assets - VIE | 163 | 163 | 150 | ||
OtherOperatingIncomeRelatedAndNonrelatedParty | 0 | 0 | 0 | ||
Affiliated Entity | |||||
Related Party Transaction [Line Items] | |||||
Assets Transferred To Affiliates, Estimated Fair Value | 0 | 4 | 140 | 4 | |
Transfers of Financial Assets Accounted for as Sale, Amortized Cost of Assets Obtained as Proceeds | 0 | 4 | 137 | 4 | |
Securitization or Asset-backed Financing Arrangement, Financial Asset for which Transfer is Accounted as Sale, Gain (Loss) on Sale | 0 | 0 | 3 | 0 | |
Assets Transferred From Affiliates Estimated Fair Value | 2 | 645 | 4 | 1,160 | |
Other invested assets - VIE | 1,153 | 1,153 | $ 1,280 | ||
Affiliated Entity | Other Investments | |||||
Related Party Transaction [Line Items] | |||||
OtherOperatingIncomeRelatedAndNonrelatedParty | $ 4 | $ 5 | $ 9 | $ 10 |
Investments (Fixed Maturity S_3
Investments (Fixed Maturity Securities AFS - Narrative) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Debt Securities, Available-for-sale [Line Items] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | $ 142,156 | $ 142,805 |
Gross Unrealized Losses | $ (13,955) | $ (11,808) |
Investments (Evaluation of Fixe
Investments (Evaluation of Fixed Maturity Securities AFS in an Unrealized Loss Position - Narrative) (Details) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2024 | Dec. 31, 2023 | |
Debt Securities, Available-for-sale [Line Items] | ||
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss | $ 13,900 | |
Equal to or Greater than 12 Months Gross Unrealized Loss | 13,517 | $ 11,277 |
Below Investment Grade | ||
Debt Securities, Available-for-sale [Line Items] | ||
Equal to or Greater than 12 Months Gross Unrealized Loss | 419 | $ 428 |
Fixed maturity securities without an allowance for credit loss | ||
Debt Securities, Available-for-sale [Line Items] | ||
Change in Gross Unrealized Temporary Loss | $ 2,200 |
Investments (Mortgage Loans - N
Investments (Mortgage Loans - Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||||
Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums | $ (749) | $ (749) | $ (720) | ||
Financing Receivable, Purchase | 198 | $ 100 | 453 | $ 857 | |
Mortgage Loans Contributed To Joint Ventures | $ 181 | $ 181 | |||
Percentage of Mortgage Loans Classified as Performing | 99% | 99% | 99% | ||
Commercial Mortgage Loans | |||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||||
Interest Receivable | $ 189 | $ 189 | $ 196 | ||
Amortized Cost of Mortgage Loans Foreclosed during the period | 171 | ||||
Amortized Cost of Mortgage Loans Delinquent during the period | 171 | ||||
Residential Mortgage Loans | |||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||||
Interest Receivable | 79 | 79 | 79 | ||
Agricultural Mortgage Loans | |||||
Accounts, Notes, Loans and Financing Receivable [Line Items] | |||||
Interest Receivable | $ 158 | $ 158 | $ 166 |
Investments (Real Estate and _2
Investments (Real Estate and Real Estate Joint Ventures - Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Investments, All Other Investments [Abstract] | |||||
Real Estate Acquired Through Foreclosure | $ 263 | $ 263 | $ 190 | ||
Depreciation | 23 | $ 22 | 44 | $ 42 | |
Real Estate Investment Property, Net | $ 683 | $ 683 | $ 638 |
Investments (Tax Equity Investm
Investments (Tax Equity Investments - Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2024 | Dec. 31, 2023 | |
Investments, Debt and Equity Securities [Abstract] | |||
Carrying Value of Tax Equity Investments | $ 787 | $ 787 | $ 1,000 |
Income Tax Credits And Other Income Tax Benefits | 38 | 75 | |
Tax Equity Investments Amortization Expense | $ 34 | $ 67 |
Investments (Cash Equivalents -
Investments (Cash Equivalents - Narrative) (Details) - USD ($) $ in Billions | Jun. 30, 2024 | Dec. 31, 2023 |
Investments, Debt and Equity Securities [Abstract] | ||
Cash equivalents | $ 4.5 | $ 3.5 |
Investments (Concentrations of
Investments (Concentrations of Credit Risk - Narrative) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Investments, Debt and Equity Securities [Abstract] | ||
Fair Value, Concentration of Risk, Investments | $ 0 | $ 0 |
Investments (Invested Assets _2
Investments (Invested Assets on Deposits and Pledged as Collateral - Narrative) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Investments, Debt and Equity Securities [Abstract] | ||
Federal Home Loan Bank Stock | $ 637 | $ 637 |
Investments (Related Party Inve
Investments (Related Party Investment Transactions - Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Related Party Transaction [Line Items] | |||||
Other invested assets - VIE | $ 16,865 | $ 16,865 | $ 17,040 | ||
Costs and Expenses, Related Party | 76 | $ 69 | 152 | $ 137 | |
Subsidiary of Common Parent | |||||
Related Party Transaction [Line Items] | |||||
Other invested assets - VIE | $ 2,700 | $ 2,700 | $ 2,800 |
Derivatives (Primary Risks) (De
Derivatives (Primary Risks) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | $ 6,112 | $ 6,506 |
Estimated Fair Value Liabilities | 2,986 | 2,897 |
Derivative, Notional Amount | 167,789 | 181,578 |
Derivatives Designated as Hedging Instruments: | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 3,312 | 3,290 |
Estimated Fair Value Liabilities | 1,878 | 1,776 |
Derivative, Notional Amount | 42,310 | 41,003 |
Derivatives Designated as Hedging Instruments: | Fair Value Hedges [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 1,131 | 1,312 |
Estimated Fair Value Liabilities | 623 | 509 |
Derivative, Notional Amount | 6,187 | 5,902 |
Derivatives Designated as Hedging Instruments: | Fair Value Hedges [Member] | Interest rate swaps | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 1,094 | 1,257 |
Estimated Fair Value Liabilities | 610 | 508 |
Derivative, Notional Amount | 4,870 | 4,443 |
Derivatives Designated as Hedging Instruments: | Fair Value Hedges [Member] | Foreign currency swaps | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 37 | 55 |
Estimated Fair Value Liabilities | 13 | 1 |
Derivative, Notional Amount | 1,317 | 1,459 |
Derivatives Designated as Hedging Instruments: | Cash Flow Hedges [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 2,181 | 1,978 |
Estimated Fair Value Liabilities | 1,255 | 1,267 |
Derivative, Notional Amount | 36,123 | 35,101 |
Derivatives Designated as Hedging Instruments: | Cash Flow Hedges [Member] | Interest rate swaps | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 0 | 1 |
Estimated Fair Value Liabilities | 323 | 246 |
Derivative, Notional Amount | 3,788 | 3,789 |
Derivatives Designated as Hedging Instruments: | Cash Flow Hedges [Member] | Interest rate forwards | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 0 | 0 |
Estimated Fair Value Liabilities | 81 | 175 |
Derivative, Notional Amount | 369 | 970 |
Derivatives Designated as Hedging Instruments: | Cash Flow Hedges [Member] | Foreign currency swaps | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 2,181 | 1,977 |
Estimated Fair Value Liabilities | 851 | 846 |
Derivative, Notional Amount | 31,966 | 30,342 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 2,800 | 3,216 |
Estimated Fair Value Liabilities | 1,108 | 1,121 |
Derivative, Notional Amount | 125,479 | 140,575 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate swaps | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 1,428 | 1,476 |
Estimated Fair Value Liabilities | 731 | 638 |
Derivative, Notional Amount | 15,482 | 15,516 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate floors | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 29 | 39 |
Estimated Fair Value Liabilities | 0 | 0 |
Derivative, Notional Amount | 8,078 | 13,921 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate caps | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 236 | 355 |
Estimated Fair Value Liabilities | 0 | 0 |
Derivative, Notional Amount | 24,970 | 28,890 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate futures | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 0 | 0 |
Estimated Fair Value Liabilities | 0 | 0 |
Derivative, Notional Amount | 70 | 25 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate options | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 216 | 361 |
Estimated Fair Value Liabilities | 66 | 27 |
Derivative, Notional Amount | 37,416 | 39,226 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Synthetic GICs | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 0 | 0 |
Estimated Fair Value Liabilities | 0 | 0 |
Derivative, Notional Amount | 5,966 | 6,145 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Foreign currency swaps | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 454 | 446 |
Estimated Fair Value Liabilities | 9 | 24 |
Derivative, Notional Amount | 4,259 | 4,304 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Foreign currency forwards | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 8 | 8 |
Estimated Fair Value Liabilities | 4 | 10 |
Derivative, Notional Amount | 1,097 | 1,176 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Credit default swaps — purchased | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 6 | 3 |
Estimated Fair Value Liabilities | 3 | 7 |
Derivative, Notional Amount | 749 | 809 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Credit default swaps — written | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 197 | 186 |
Estimated Fair Value Liabilities | 5 | 4 |
Derivative, Notional Amount | 11,522 | 10,007 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Equity futures | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 3 | 3 |
Estimated Fair Value Liabilities | 1 | 0 |
Derivative, Notional Amount | 647 | 941 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Equity index options | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 222 | 339 |
Estimated Fair Value Liabilities | 189 | 193 |
Derivative, Notional Amount | 13,203 | 17,703 |
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Equity Total Return Swaps [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 1 | 0 |
Estimated Fair Value Liabilities | 100 | 218 |
Derivative, Notional Amount | $ 2,020 | $ 1,912 |
Derivatives Derivatives (Effect
Derivatives Derivatives (Effects on the Consolidated Statement of Operations and Comprehensive Income (Loss) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | $ 60 | $ (232) | $ 4 | $ (792) | |
Gain (Loss) on Derivative Instruments, Net, Pretax | 60 | (232) | 4 | (792) | |
Net Investment Income | (2,903) | (2,873) | (5,760) | (5,558) | |
Net policyholder benefits and claims | (7,525) | (6,436) | (14,215) | (12,659) | |
Interest credited to policyholder account balances | (957) | (893) | (1,880) | (1,724) | |
Net investment gains (losses) | (106) | (659) | (242) | (761) | |
Net Embedded Derivatives | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Gain (Loss) on Derivative Instruments, Net, Pretax | 121 | 212 | 355 | (68) | |
Cash Flow Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 0 | 0 | 0 | 0 | |
Net Investment Income | (7) | (14) | (16) | (29) | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | (3) | 72 | (8) | 79 | |
Other Comprehensive Income (Loss), before Tax | 32 | (480) | 148 | (467) | |
Fair Value Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Net Investment Income | 0 | (2) | (2) | (2) | |
Net policyholder benefits and claims | (7) | (14) | (13) | (14) | |
Interest credited to policyholder account balances | (2) | (1) | (1) | (1) | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Fixed Maturities [Member] | Designated as Hedging Instrument [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Hedged Asset, Discontinued Fair Value Hedge, Cumulative Increase (Decrease) | (101) | (101) | $ (113) | ||
Interest rate contracts | Cash Flow Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 0 | 0 | 0 | 0 | |
Net Investment Income | (6) | (13) | (14) | (27) | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | 0 | 55 | 2 | 57 | |
Other Comprehensive Income (Loss), before Tax | (6) | (68) | (16) | (84) | |
Currency Swap [Member] | Cash Flow Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 0 | 0 | 0 | 0 | |
Net Investment Income | (1) | (1) | (2) | (2) | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | 95 | 310 | (175) | 439 | |
Other Comprehensive Income (Loss), before Tax | (96) | (311) | 173 | (441) | |
Foreign Currency Gain (Loss) [Member] | Cash Flow Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 0 | 0 | 0 | 0 | |
Net Investment Income | 0 | 0 | 0 | 0 | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | (99) | (293) | 164 | (417) | |
Other Comprehensive Income (Loss), before Tax | 0 | 0 | 0 | 0 | |
Derivative [Member] | Currency Swap [Member] | Fair Value Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Net Investment Income | (2) | (6) | (2) | (22) | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | (7) | (13) | (31) | (13) | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Derivative [Member] | Interest Rate Swap [Member] | Fair Value Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Net Investment Income | 0 | 0 | 0 | (1) | |
Net policyholder benefits and claims | 41 | 135 | 150 | 9 | |
Interest credited to policyholder account balances | (14) | (32) | (53) | 0 | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Fixed Maturity Securities | Currency Swap [Member] | Fair Value Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Net Investment Income | (2) | (5) | 0 | (21) | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | (7) | (11) | (35) | (11) | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Fixed Maturity Securities | Interest Rate Swap [Member] | Fair Value Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Net Investment Income | 0 | (1) | 0 | 0 | |
Net policyholder benefits and claims | 34 | 121 | 137 | (5) | |
Interest credited to policyholder account balances | (12) | (31) | (50) | (1) | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Credit forwards | Cash Flow Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 0 | 0 | 0 | 0 | |
Net Investment Income | 0 | 0 | 0 | 0 | |
Net policyholder benefits and claims | 0 | 0 | 0 | 0 | |
Interest credited to policyholder account balances | 0 | 0 | 0 | 0 | |
Net investment gains (losses) | 1 | 0 | 1 | 0 | |
Other Comprehensive Income (Loss), before Tax | (1) | 0 | (1) | 0 | |
Accumulated Other Comprehensive Income (Loss) | Currency Swap [Member] | Cash Flow Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Other Comprehensive Income (Loss), before Tax | 206 | 56 | 207 | 15 | |
Accumulated Other Comprehensive Income (Loss) | Interest Rate Swap [Member] | Cash Flow Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Other Comprehensive Income (Loss), before Tax | (71) | (156) | (215) | 44 | |
Accumulated Other Comprehensive Income (Loss) | Credit forwards | Cash Flow Hedging [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Other Comprehensive Income (Loss), before Tax | 0 | (1) | 0 | (1) | |
Not Designated as Hedging Instrument [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | (182) | (637) | (601) | (1,167) | |
Net Investment Income | (11) | (36) | (36) | (42) | |
Not Designated as Hedging Instrument [Member] | Nonoperating Income (Expense) [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Gain (Loss) on Derivative Instruments, Net, Pretax | 118 | 189 | 245 | 434 | |
Net Investment Income | (53) | (39) | (83) | (82) | |
Net policyholder benefits and claims | 2 | (3) | 6 | (8) | |
Interest credited to policyholder account balances | (43) | (34) | (91) | (67) | |
Net investment gains (losses) | 0 | 0 | 0 | 0 | |
Other Comprehensive Income (Loss), before Tax | 0 | 0 | 0 | 0 | |
Not Designated as Hedging Instrument [Member] | Synthetic GICs [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Gain (Loss) on Derivative Instruments, Net, Pretax | 3 | 4 | 5 | 9 | |
Equity Market Risk [Member] | Not Designated as Hedging Instrument [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | (86) | (348) | (367) | (751) | |
Net Investment Income | (11) | (36) | (36) | (42) | |
Foreign Currency Gain (Loss) [Member] | Not Designated as Hedging Instrument [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | (15) | 39 | (51) | 71 | |
Net Investment Income | 0 | 0 | 0 | 0 | |
Interest Rate Risk [Member] | Not Designated as Hedging Instrument [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | (79) | (336) | (278) | (397) | |
Net Investment Income | 0 | 0 | 0 | 0 | |
Foreign Exchange [Member] | Not Designated as Hedging Instrument [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 7 | (44) | 81 | (139) | |
Net Investment Income | 0 | 0 | 0 | 0 | |
Credit Default Swap, Buying Protection [Member] | Not Designated as Hedging Instrument [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | 5 | (8) | 5 | (17) | |
Net Investment Income | 0 | 0 | 0 | 0 | |
Credit Default Swap, Selling Protection [Member] | Not Designated as Hedging Instrument [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Derivative, Gain (Loss) on Derivative, Net | (14) | 60 | 9 | 66 | |
Net Investment Income | 0 | 0 | 0 | 0 | |
Effects of Derivatives on Consolidated Statements of Operations and Comprehensive Income (Loss) [Member] | |||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Net Investment Income | (49) | (15) | (65) | (67) | |
Net policyholder benefits and claims | 9 | 11 | 19 | 6 | |
Interest credited to policyholder account balances | 45 | 33 | 90 | 66 | |
Net investment gains (losses) | (3) | 72 | (8) | 79 | |
Other Comprehensive Income (Loss), before Tax | $ 32 | $ (480) | $ 148 | $ (467) |
Derivatives (Fair Value Hedges)
Derivatives (Fair Value Hedges) (Details) - USD ($) $ in Millions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2024 | Dec. 31, 2023 | |
Derivative Instruments, Gain (Loss) [Line Items] | ||
Maximum Length of Time Hedged in Cash Flow Hedge | 5 years | 5 years |
Mortgage loans | Designated as Hedging Instrument [Member] | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Debt Instruments, Carrying Amount | $ (208) | $ (345) |
Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease) | (5) | (10) |
Future policy benefits [Member] | Designated as Hedging Instrument [Member] | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Debt Instruments, Carrying Amount | (2,661) | (2,863) |
Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease) | 337 | 191 |
Policyholder Account Balances [Member] | Designated as Hedging Instrument [Member] | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Debt Instruments, Carrying Amount | (2,198) | (1,844) |
Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease) | 141 | 2 |
Fixed Maturities [Member] | Designated as Hedging Instrument [Member] | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Hedged Asset, Discontinued Fair Value Hedge, Cumulative Increase (Decrease) | (101) | (113) |
Debt Instruments, Carrying Amount | (118) | (120) |
Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease) | $ 1 | $ 1 |
Derivatives (Credit Derivatives
Derivatives (Credit Derivatives) (Details) - USD ($) $ in Millions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2024 | Dec. 31, 2023 | |
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ 192 | $ 182 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 11,522 | $ 10,007 |
Weighted Average Years to Maturity | 3 years 8 months 12 days | 4 years 4 months 24 days |
Aaa/Aa/A | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ 82 | $ 80 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 4,125 | $ 3,841 |
Weighted Average Years to Maturity | 2 years 7 months 6 days | 2 years 8 months 12 days |
Aaa/Aa/A | Single name credit default swaps (3) | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ 0 | $ 0 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 0 | $ 10 |
Weighted Average Years to Maturity | 0 years | 6 months |
Aaa/Aa/A | Credit default swaps referencing indices | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ 82 | $ 80 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 4,125 | $ 3,831 |
Weighted Average Years to Maturity | 2 years 7 months 6 days | 2 years 8 months 12 days |
Baa [Member] | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ 106 | $ 103 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 7,268 | $ 6,037 |
Weighted Average Years to Maturity | 4 years 4 months 24 days | 5 years 6 months |
Baa [Member] | Single name credit default swaps (3) | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ 1 | $ 1 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 55 | $ 55 |
Weighted Average Years to Maturity | 1 year 9 months 18 days | 2 years 3 months 18 days |
Baa [Member] | Credit default swaps referencing indices | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ 105 | $ 102 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 7,213 | $ 5,982 |
Weighted Average Years to Maturity | 4 years 4 months 24 days | 5 years 7 months 6 days |
Ba | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ 2 | $ 2 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 25 | $ 25 |
Weighted Average Years to Maturity | 2 years 6 months | 3 years |
Ba | Credit default swaps referencing indices | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ 2 | $ 2 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 25 | $ 25 |
Weighted Average Years to Maturity | 2 years 6 months | 3 years |
Caa | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ (3) | $ (4) |
Maximum Amount of Future Payments under Credit Default Swaps | $ 30 | $ 30 |
Weighted Average Years to Maturity | 2 years | 2 years 6 months |
Caa | Credit default swaps referencing indices | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Credit Default Swaps | $ (3) | $ (4) |
Maximum Amount of Future Payments under Credit Default Swaps | $ 30 | $ 30 |
Weighted Average Years to Maturity | 2 years | 2 years 6 months |
B | ||
Credit Derivatives [Line Items] | ||
Maximum Amount of Future Payments under Credit Default Swaps | $ 74 | $ 74 |
Weighted Average Years to Maturity | 4 years 6 months | 5 years |
Estimated Fair Value of Credit Default Swaps | $ 5 | $ 1 |
B | Credit default swaps referencing indices | ||
Credit Derivatives [Line Items] | ||
Maximum Amount of Future Payments under Credit Default Swaps | $ 74 | $ 74 |
Weighted Average Years to Maturity | 4 years 6 months | 5 years |
Estimated Fair Value of Credit Default Swaps | $ 5 | $ 1 |
Derivatives (Estimated Fair Val
Derivatives (Estimated Fair Value of Derivative Assets and Liabilities after Master Netting Agreements and Cash Collateral) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Offsetting Assets [Line Items] | ||
Derivative Asset, Fair Value, Gross Asset Excluding Accruals | $ 6,229 | $ 6,649 |
Derivative Liability, Fair Value, Gross Liability Excluding Accruals | 3,055 | 2,905 |
Net amount of derivative assets after application of master netting agreements and cash collateral | 26 | 35 |
Net amount of derivative liabilities after application of master netting agreements and cash collateral | 0 | 0 |
Over the Counter [Member] | ||
Offsetting Assets [Line Items] | ||
Derivative Asset, Fair Value, Gross Asset Excluding Accruals | 6,083 | 6,534 |
Derivative Liability, Fair Value, Gross Liability Excluding Accruals | 3,013 | 2,892 |
Gross estimated fair value of derivative assets | (2,411) | (2,350) |
Gross estimated fair value of derivative liabilities | (2,411) | (2,350) |
Cash collateral on derivative assets | (2,645) | (2,872) |
Cash collateral on derivative liabilities | 0 | 0 |
Securities collateral on derivative assets | (1,021) | (1,283) |
Securities collateral on derivative liabilities | (602) | (542) |
Exchange Traded [Member] | ||
Offsetting Assets [Line Items] | ||
Derivative Asset, Fair Value, Gross Asset Excluding Accruals | 3 | 3 |
Derivative Liability, Fair Value, Gross Liability Excluding Accruals | 1 | 0 |
Gross estimated fair value of derivative assets | (1) | 0 |
Gross estimated fair value of derivative liabilities | (1) | 0 |
Securities collateral on derivative assets | 0 | 0 |
Securities collateral on derivative liabilities | 0 | 0 |
Cleared [Member] | ||
Offsetting Assets [Line Items] | ||
Derivative Asset, Fair Value, Gross Asset Excluding Accruals | 143 | 112 |
Derivative Liability, Fair Value, Gross Liability Excluding Accruals | 41 | 13 |
Gross estimated fair value of derivative assets | (12) | (4) |
Gross estimated fair value of derivative liabilities | (12) | (4) |
Cash collateral on derivative assets | (113) | (105) |
Cash collateral on derivative liabilities | 0 | (1) |
Securities collateral on derivative assets | 0 | 0 |
Securities collateral on derivative liabilities | $ (29) | $ (8) |
Derivatives (Credit Risk on Fre
Derivatives (Credit Risk on Freestanding Derivatives) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Credit Derivatives [Line Items] | ||
Derivative, Collateral, Right to Reclaim Cash | $ 4 | $ 4 |
Customer Securities for which Entity has Right to Sell or Repledge, Fair Value of Securities Sold or Repledged | 0 | |
Estimated Fair Value of Derivatives in Net Liability Position | 602 | 542 |
Exchange Traded [Member] | ||
Credit Derivatives [Line Items] | ||
Derivative Asset, Not Offset, Policy Election Deduction | (1) | 0 |
Derivative Liability, Not Offset, Policy Election Deduction | (1) | 0 |
Derivative, Collateral, Right to Reclaim Securities | 31 | 56 |
Over the Counter [Member] | ||
Credit Derivatives [Line Items] | ||
Derivative Asset, Not Offset, Policy Election Deduction | (2,411) | (2,350) |
Derivative Liability, Not Offset, Policy Election Deduction | (2,411) | (2,350) |
Excess securities collateral received on derivatives | 455 | 286 |
Derivative, Collateral, Right to Reclaim Securities | 905 | 1,100 |
Exchange Cleared [Member] | ||
Credit Derivatives [Line Items] | ||
Derivative Asset, Not Offset, Policy Election Deduction | (12) | (4) |
Derivative Liability, Not Offset, Policy Election Deduction | (12) | (4) |
Derivative, Collateral, Right to Reclaim Securities | 416 | 495 |
Fixed maturity securities AFS | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Collateral Provided | 924 | 896 |
Estimated fair value of derivatives in a net liability position (1) | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Derivatives in Net Liability Position | 595 | 542 |
Estimated fair value of derivatives in a net liability position (1) | Fixed maturity securities AFS | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Collateral Provided | 916 | 896 |
Derivatives Not Subject To Credit-Contingent Provisions | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Derivatives in Net Liability Position | 7 | 0 |
Derivatives Not Subject To Credit-Contingent Provisions | Fixed maturity securities AFS | ||
Credit Derivatives [Line Items] | ||
Estimated Fair Value of Collateral Provided | $ 8 | $ 0 |
Derivatives (Embedded Derivativ
Derivatives (Embedded Derivatives) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Derivatives, Fair Value [Line Items] | ||
Embedded derivatives within asset host contracts (4) | $ (126) | $ (15) |
Embedded derivatives within liability host contracts | 279 | 37 |
Assumed affiliated reinsurance | Other invested assets | ||
Derivatives, Fair Value [Line Items] | ||
Embedded derivatives within asset host contracts (4) | (148) | (41) |
Assumed affiliated reinsurance | Other liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Embedded derivatives within liability host contracts | 0 | 104 |
Fixed annuities with equity indexed returns [Member] | Policyholder Account Balances [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Embedded derivatives within liability host contracts | 168 | 163 |
Funds withheld and guarantees on reinsurance (including affiliated) | Other liabilities | ||
Derivatives, Fair Value [Line Items] | ||
Embedded derivatives within liability host contracts | 447 | 304 |
Funds withheld on affiliated reinsurance | Other invested assets | ||
Derivatives, Fair Value [Line Items] | ||
Embedded derivatives within asset host contracts (4) | $ (22) | $ (26) |
Derivatives (Narrative) (Detail
Derivatives (Narrative) (Details) - USD ($) $ in Millions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2024 | Dec. 31, 2023 | |
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | $ 6,112 | $ 6,506 |
Estimated Fair Value Liabilities | 2,986 | 2,897 |
Maximum Amount of Future Payments under Credit Default Swaps | $ 11,522 | $ 10,007 |
Derivative Instrument Detail [Abstract] | ||
Hedging exposure to variability in future cash flows for specific length of time | 5 years | 5 years |
Accumulated Other Comprehensive Income Loss | $ 1,000 | $ 894 |
Deferred net gains (losses) expected to be reclassified to earnings | 289 | |
Excess cash collateral received on derivatives | 48 | 154 |
Securities collateral received which the company is permitted to sell or repledge, amount that has been sold or repledged | 0 | |
Over the Counter [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Cash collateral on derivative assets | (2,645) | (2,872) |
Excess securities collateral received on derivatives | 455 | 286 |
Excess securities collateral provided on derivatives | 905 | 1,100 |
Exchange Traded [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Excess securities collateral provided on derivatives | 31 | 56 |
Accrued Liabilities [Member] | ||
Derivatives, Fair Value [Line Items] | ||
Estimated Fair Value Assets | 117 | 143 |
Estimated Fair Value Liabilities | $ 69 | $ 8 |
Derivatives Cash Flow Hedges (D
Derivatives Cash Flow Hedges (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Derivative Instruments, Gain (Loss) [Line Items] | |||||
Maximum Length of Time Hedged in Cash Flow Hedge | 5 years | 5 years | |||
Accumulated Other Comprehensive Income Loss | $ 1,000 | $ 1,000 | $ 894 | ||
Gain (Loss) on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net | $ 2 | $ 19 | $ 2 | $ 20 |
Fair Value (Recurring Fair Valu
Fair Value (Recurring Fair Value Measurements) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | $ 142,156 | $ 142,805 |
Short-term investments | 1,668 | 3,048 |
Derivative assets | 6,112 | 6,506 |
Embedded derivatives within asset host contracts (4) | 126 | 15 |
Market risk benefits, at estimated fair value | 230 | 177 |
Separate account assets | 79,585 | 83,197 |
Liabilities [Abstract] | ||
Derivative liabilities | 2,986 | 2,897 |
Embedded derivatives within liability host contracts | 279 | 37 |
Market risk benefits, at estimated fair value | 2,391 | 2,878 |
Separate account liabilities (2) | 79,585 | 83,197 |
Recurring | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Investments, Fair Value Disclosure | 48 | 48 |
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 142,156 | 142,805 |
Short-term investments | 1,668 | 3,048 |
Other investments | 1,571 | 1,470 |
Derivative assets | 6,112 | 6,506 |
Embedded derivatives within asset host contracts (4) | 126 | 15 |
Market risk benefits, at estimated fair value | 230 | 177 |
Separate account assets | 79,585 | 83,197 |
Total assets | 231,448 | 237,218 |
Liabilities [Abstract] | ||
Derivative liabilities | 2,986 | 2,897 |
Embedded derivatives within liability host contracts | (279) | (37) |
Market risk benefits, at estimated fair value | 2,391 | 2,878 |
Total liabilities | 5,101 | 5,746 |
Recurring | Interest rate | ||
Assets [Abstract] | ||
Derivative assets | 3,003 | 3,489 |
Liabilities [Abstract] | ||
Derivative liabilities | 1,811 | 1,594 |
Recurring | Foreign currency exchange rate | ||
Assets [Abstract] | ||
Derivative assets | 2,680 | 2,486 |
Liabilities [Abstract] | ||
Derivative liabilities | 877 | 881 |
Recurring | Credit | ||
Assets [Abstract] | ||
Derivative assets | 203 | 189 |
Liabilities [Abstract] | ||
Derivative liabilities | 8 | 11 |
Recurring | Equity market | ||
Assets [Abstract] | ||
Derivative assets | 226 | 342 |
Liabilities [Abstract] | ||
Derivative liabilities | 290 | 411 |
Recurring | Separate account liabilities (2) | ||
Liabilities [Abstract] | ||
Separate account liabilities (2) | 3 | 8 |
Recurring | U.S. corporate | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 48,847 | 50,493 |
Recurring | Foreign corporate | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 24,429 | 25,215 |
Recurring | U.S. government and agency | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 22,539 | 21,060 |
Recurring | RMBS | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 20,564 | 18,948 |
Recurring | ABS & CLO | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 11,910 | 11,641 |
Recurring | Municipals | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 5,477 | 6,319 |
Recurring | CMBS | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 5,414 | 5,834 |
Recurring | Foreign government | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 2,976 | 3,295 |
Recurring | Level 1 | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 10,834 | 8,966 |
Short-term investments | 1,479 | 2,745 |
Other investments | 46 | 76 |
Derivative assets | 3 | 3 |
Embedded derivatives within asset host contracts (4) | 0 | 0 |
Market risk benefits, at estimated fair value | 0 | 0 |
Separate account assets | 13,630 | 13,945 |
Total assets | 25,992 | 25,735 |
Liabilities [Abstract] | ||
Derivative liabilities | 1 | 0 |
Embedded derivatives within liability host contracts | 0 | 0 |
Market risk benefits, at estimated fair value | 0 | 0 |
Total liabilities | 1 | 4 |
Recurring | Level 1 | Interest rate | ||
Assets [Abstract] | ||
Derivative assets | 0 | 0 |
Liabilities [Abstract] | ||
Derivative liabilities | 0 | 0 |
Recurring | Level 1 | Foreign currency exchange rate | ||
Assets [Abstract] | ||
Derivative assets | 0 | 0 |
Liabilities [Abstract] | ||
Derivative liabilities | 0 | 0 |
Recurring | Level 1 | Credit | ||
Assets [Abstract] | ||
Derivative assets | 0 | 0 |
Liabilities [Abstract] | ||
Derivative liabilities | 0 | 0 |
Recurring | Level 1 | Equity market | ||
Assets [Abstract] | ||
Derivative assets | 3 | 3 |
Liabilities [Abstract] | ||
Derivative liabilities | 1 | 0 |
Recurring | Level 1 | Separate account liabilities (2) | ||
Liabilities [Abstract] | ||
Separate account liabilities (2) | 0 | 4 |
Recurring | Level 1 | U.S. corporate | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 0 |
Recurring | Level 1 | Foreign corporate | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 0 |
Recurring | Level 1 | U.S. government and agency | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 10,834 | 8,963 |
Recurring | Level 1 | RMBS | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 3 |
Recurring | Level 1 | ABS & CLO | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 0 |
Recurring | Level 1 | Municipals | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 0 |
Recurring | Level 1 | CMBS | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 0 |
Recurring | Level 1 | Foreign government | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 0 |
Recurring | Level 2 | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 109,723 | 113,514 |
Short-term investments | 186 | 288 |
Other investments | 91 | 77 |
Derivative assets | 6,103 | 6,488 |
Embedded derivatives within asset host contracts (4) | 0 | 0 |
Market risk benefits, at estimated fair value | 0 | 0 |
Separate account assets | 64,986 | 68,284 |
Total assets | 181,089 | 188,651 |
Liabilities [Abstract] | ||
Derivative liabilities | 2,904 | 2,722 |
Embedded derivatives within liability host contracts | 0 | 0 |
Market risk benefits, at estimated fair value | 0 | 0 |
Total liabilities | 2,907 | 2,726 |
Recurring | Level 2 | Interest rate | ||
Assets [Abstract] | ||
Derivative assets | 3,003 | 3,489 |
Liabilities [Abstract] | ||
Derivative liabilities | 1,730 | 1,419 |
Recurring | Level 2 | Foreign currency exchange rate | ||
Assets [Abstract] | ||
Derivative assets | 2,680 | 2,486 |
Liabilities [Abstract] | ||
Derivative liabilities | 877 | 881 |
Recurring | Level 2 | Credit | ||
Assets [Abstract] | ||
Derivative assets | 203 | 181 |
Liabilities [Abstract] | ||
Derivative liabilities | 8 | 11 |
Recurring | Level 2 | Equity market | ||
Assets [Abstract] | ||
Derivative assets | 217 | 332 |
Liabilities [Abstract] | ||
Derivative liabilities | 289 | 411 |
Recurring | Level 2 | Separate account liabilities (2) | ||
Liabilities [Abstract] | ||
Separate account liabilities (2) | 3 | 4 |
Recurring | Level 2 | U.S. corporate | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 39,926 | 41,718 |
Recurring | Level 2 | Foreign corporate | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 15,875 | 16,875 |
Recurring | Level 2 | U.S. government and agency | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 11,705 | 12,097 |
Recurring | Level 2 | RMBS | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 18,818 | 17,616 |
Recurring | Level 2 | ABS & CLO | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 10,043 | 10,109 |
Recurring | Level 2 | Municipals | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 5,477 | 6,319 |
Recurring | Level 2 | CMBS | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 4,914 | 5,499 |
Recurring | Level 2 | Foreign government | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 2,965 | 3,281 |
Recurring | Level 3 | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 21,599 | 20,325 |
Short-term investments | 3 | 15 |
Other investments | 1,434 | 1,317 |
Derivative assets | 6 | 15 |
Embedded derivatives within asset host contracts (4) | 126 | 15 |
Market risk benefits, at estimated fair value | 230 | 177 |
Separate account assets | 969 | 968 |
Total assets | 24,367 | 22,832 |
Liabilities [Abstract] | ||
Derivative liabilities | 81 | 175 |
Embedded derivatives within liability host contracts | (279) | (37) |
Market risk benefits, at estimated fair value | 2,391 | 2,878 |
Total liabilities | 2,193 | 3,016 |
Recurring | Level 3 | Interest rate | ||
Assets [Abstract] | ||
Derivative assets | 0 | 0 |
Liabilities [Abstract] | ||
Derivative liabilities | 81 | 175 |
Recurring | Level 3 | Foreign currency exchange rate | ||
Assets [Abstract] | ||
Derivative assets | 0 | 0 |
Liabilities [Abstract] | ||
Derivative liabilities | 0 | 0 |
Recurring | Level 3 | Credit | ||
Assets [Abstract] | ||
Derivative assets | 0 | 8 |
Liabilities [Abstract] | ||
Derivative liabilities | 0 | 0 |
Recurring | Level 3 | Equity market | ||
Assets [Abstract] | ||
Derivative assets | 6 | 7 |
Liabilities [Abstract] | ||
Derivative liabilities | 0 | 0 |
Recurring | Level 3 | Separate account liabilities (2) | ||
Liabilities [Abstract] | ||
Separate account liabilities (2) | 0 | 0 |
Recurring | Level 3 | U.S. corporate | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 8,921 | 8,775 |
Recurring | Level 3 | Foreign corporate | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 8,554 | 8,340 |
Recurring | Level 3 | U.S. government and agency | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 0 |
Recurring | Level 3 | RMBS | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 1,746 | 1,329 |
Recurring | Level 3 | ABS & CLO | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 1,867 | 1,532 |
Recurring | Level 3 | Municipals | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 0 | 0 |
Recurring | Level 3 | CMBS | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | 500 | 335 |
Recurring | Level 3 | Foreign government | ||
Assets [Abstract] | ||
Estimated Fair Value of Fixed Maturity Securities AFS | $ 11 | $ 14 |
Fair Value (Quantitative Inform
Fair Value (Quantitative Information) (Details) | Jun. 30, 2024 | Dec. 31, 2023 |
Minimum | Interest rate | Measurement Input, Swap Yield | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative Asset (Liability) Net, Measurement Input | 428 | 367 |
Minimum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Mortality rates: Ages 0 - 40 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0001 | 0.0001 |
Minimum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Mortality rates: Ages 41 - 60 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0005 | 0.0005 |
Minimum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Mortality rates: Ages 61 - 115 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0035 | 0.0035 |
Minimum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Lapse rates: Durations 1 - 10 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0080 | 0.0080 |
Minimum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Lapse rates: Durations 11 - 20 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0310 | 0.0310 |
Minimum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Lapse rates: Durations 21 - 116 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0010 | 0.0010 |
Minimum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Measurement Input, Utilization Rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0020 | 0.0020 |
Minimum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Measurement Input, Withdrawal Rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0025 | 0.0025 |
Minimum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Measurement Input, Long-Term Equity Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.1637 | 0.1637 |
Minimum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Nonperformance risk spread | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0033 | 0.0038 |
Minimum | U.S. corporate and foreign corporate | Valuation Technique, Matrix Pricing | Measurement Input, Offered Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 53 | 4 |
Minimum | U.S. corporate and foreign corporate | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 27 | 0 |
Minimum | RMBS | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 0 | 0 |
Minimum | ABS & CLO | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 84 | 78 |
Maximum | Interest rate | Measurement Input, Swap Yield | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative Asset (Liability) Net, Measurement Input | 452 | 399 |
Maximum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Mortality rates: Ages 0 - 40 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0013 | 0.0013 |
Maximum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Mortality rates: Ages 41 - 60 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0067 | 0.0067 |
Maximum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Mortality rates: Ages 61 - 115 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 1 | 1 |
Maximum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Lapse rates: Durations 1 - 10 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.2010 | 0.2010 |
Maximum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Lapse rates: Durations 11 - 20 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.1010 | 0.1010 |
Maximum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Lapse rates: Durations 21 - 116 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.1010 | 0.1010 |
Maximum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Measurement Input, Utilization Rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.22 | 0.22 |
Maximum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Measurement Input, Withdrawal Rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0775 | 0.0775 |
Maximum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Measurement Input, Long-Term Equity Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.2185 | 0.2185 |
Maximum | Market Risk Benefits direct and assumed guaranteed minimum benefits | Nonperformance risk spread | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0066 | 0.0070 |
Maximum | U.S. corporate and foreign corporate | Valuation Technique, Matrix Pricing | Measurement Input, Offered Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 125 | 131 |
Maximum | U.S. corporate and foreign corporate | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 111 | 110 |
Maximum | RMBS | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 116 | 112 |
Maximum | ABS & CLO | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 103 | 101 |
Weighted Average | Interest rate | Measurement Input, Swap Yield | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Derivative Asset (Liability) Net, Measurement Input | 437 | 385 |
Weighted Average | Market Risk Benefits direct and assumed guaranteed minimum benefits | Mortality rates: Ages 0 - 40 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0005 | 0.0005 |
Weighted Average | Market Risk Benefits direct and assumed guaranteed minimum benefits | Mortality rates: Ages 41 - 60 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0022 | 0.0022 |
Weighted Average | Market Risk Benefits direct and assumed guaranteed minimum benefits | Mortality rates: Ages 61 - 115 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0123 | 0.0123 |
Weighted Average | Market Risk Benefits direct and assumed guaranteed minimum benefits | Lapse rates: Durations 1 - 10 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0872 | 0.0872 |
Weighted Average | Market Risk Benefits direct and assumed guaranteed minimum benefits | Lapse rates: Durations 11 - 20 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0434 | 0.0434 |
Weighted Average | Market Risk Benefits direct and assumed guaranteed minimum benefits | Lapse rates: Durations 21 - 116 | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0459 | 0.0459 |
Weighted Average | Market Risk Benefits direct and assumed guaranteed minimum benefits | Measurement Input, Utilization Rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0044 | 0.0044 |
Weighted Average | Market Risk Benefits direct and assumed guaranteed minimum benefits | Measurement Input, Withdrawal Rate | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0447 | 0.0447 |
Weighted Average | Market Risk Benefits direct and assumed guaranteed minimum benefits | Measurement Input, Long-Term Equity Volatility | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.1855 | 0.1855 |
Weighted Average | Market Risk Benefits direct and assumed guaranteed minimum benefits | Nonperformance risk spread | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
MRBs direct and assumed guaranteed minimum benefits | 0.0073 | 0.0073 |
Weighted Average | U.S. corporate and foreign corporate | Valuation Technique, Matrix Pricing | Measurement Input, Offered Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 93 | 95 |
Weighted Average | U.S. corporate and foreign corporate | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 94 | 93 |
Weighted Average | RMBS | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 96 | 93 |
Weighted Average | ABS & CLO | Valuation Technique, Market Approach | Measurement Input, Quoted Price | ||
Fair Value Measurement Inputs and Valuation Techniques [Line Items] | ||
Debt Securities, Available-for-sale, Measurement Input | 96 | 94 |
Fair Value (Unobservable Input
Fair Value (Unobservable Input Reconciliation) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Net Derivatives | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | $ 0 | $ 1 | $ 0 | $ 2 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | (9) | (48) | (21) | 7 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Balance, beginning of period | (121) | (271) | (160) | (331) |
Total realized/unrealized gains (losses) included in net income (loss) | (1) | (12) | (1) | (27) |
Total realized/unrealized gains (losses) included in AOCI | (14) | (39) | (40) | 43 |
Purchases | 0 | 0 | 0 | 0 |
Sales | 0 | 0 | 0 | 0 |
Issuances | 0 | 0 | 0 | 0 |
Settlements | 67 | 44 | 134 | 98 |
Transfers into Level 3 | 0 | 0 | 0 | 0 |
Transfers out of Level 3 | (6) | 0 | (8) | (61) |
Balance, end of period | (75) | (278) | (75) | (278) |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | 1 | 0 | 2 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | (9) | (48) | (21) | 7 |
Net Embedded Derivatives | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 121 | 212 | 355 | (68) |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Balance, beginning of period | 285 | 168 | 52 | 458 |
Total realized/unrealized gains (losses) included in net income (loss) | 121 | 212 | 355 | (68) |
Total realized/unrealized gains (losses) included in AOCI | 0 | 0 | 0 | 0 |
Purchases | 0 | 0 | 0 | 0 |
Sales | 0 | 0 | 0 | 0 |
Issuances | 0 | 0 | 0 | 0 |
Settlements | (1) | (2) | (2) | (12) |
Transfers into Level 3 | 0 | 0 | 0 | 0 |
Transfers out of Level 3 | 0 | 0 | 0 | 0 |
Balance, end of period | 405 | 378 | 405 | 378 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 121 | 212 | 355 | (68) |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Corporate fixed maturity securities | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Balance, beginning of period | 17,154 | 15,717 | 17,115 | 14,733 |
Total realized/unrealized gains (losses) included in net income (loss) | (29) | (11) | (42) | (18) |
Total realized/unrealized gains (losses) included in AOCI | (137) | (101) | (317) | 285 |
Purchases | 1,148 | 808 | 1,783 | 2,015 |
Sales | (620) | (393) | (1,038) | (848) |
Issuances | 0 | 0 | 0 | 0 |
Settlements | 0 | 0 | 0 | 0 |
Transfers into Level 3 | 64 | 125 | 97 | 280 |
Transfers out of Level 3 | (105) | (129) | (123) | (431) |
Balance, end of period | 17,475 | 16,016 | 17,475 | 16,016 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | (11) | (10) | (10) | (17) |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | (147) | (110) | (323) | 272 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | (11) | (10) | (10) | (17) |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | (147) | (110) | (323) | 272 |
Structured Products | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Balance, beginning of period | 3,543 | 3,501 | 3,196 | 3,373 |
Total realized/unrealized gains (losses) included in net income (loss) | 10 | 7 | 14 | 1 |
Total realized/unrealized gains (losses) included in AOCI | 13 | (20) | 53 | 0 |
Purchases | 934 | 67 | 1,104 | 153 |
Sales | (104) | (86) | (257) | (175) |
Issuances | 0 | 0 | 0 | 0 |
Settlements | 0 | 0 | 0 | 0 |
Transfers into Level 3 | 51 | 34 | 101 | 103 |
Transfers out of Level 3 | (334) | (94) | (98) | (46) |
Balance, end of period | 4,113 | 3,409 | 4,113 | 3,409 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 9 | 8 | 13 | 9 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 12 | (21) | 48 | (4) |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 9 | 8 | 13 | 9 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 12 | (21) | 48 | (4) |
Municipals | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Balance, beginning of period | 0 | 0 | 0 | 0 |
Total realized/unrealized gains (losses) included in net income (loss) | 0 | 0 | 0 | 0 |
Total realized/unrealized gains (losses) included in AOCI | 0 | 0 | 0 | 0 |
Purchases | 0 | 4 | 0 | 4 |
Sales | 0 | 0 | 0 | 0 |
Issuances | 0 | 0 | 0 | 0 |
Settlements | 0 | 0 | 0 | 0 |
Transfers into Level 3 | 0 | 0 | 0 | 0 |
Transfers out of Level 3 | 0 | 0 | 0 | 0 |
Balance, end of period | 0 | 4 | 0 | 4 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Foreign government | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Balance, beginning of period | 15 | 15 | 14 | 15 |
Total realized/unrealized gains (losses) included in net income (loss) | 0 | (1) | 2 | (1) |
Total realized/unrealized gains (losses) included in AOCI | (4) | 3 | (5) | 2 |
Purchases | 0 | 0 | 0 | 2 |
Sales | 0 | 0 | 0 | (1) |
Issuances | 0 | 0 | 0 | 0 |
Settlements | 0 | 0 | 0 | 0 |
Transfers into Level 3 | 0 | 0 | 0 | 0 |
Transfers out of Level 3 | 0 | 0 | 0 | 0 |
Balance, end of period | 11 | 17 | 11 | 17 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | (1) | 2 | (1) |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | (4) | 3 | (5) | 1 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | (1) | 2 | (1) |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | (4) | 3 | (5) | 1 |
Short-term Investments | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Balance, beginning of period | 11 | 57 | 15 | 47 |
Total realized/unrealized gains (losses) included in net income (loss) | 0 | 0 | 0 | 0 |
Total realized/unrealized gains (losses) included in AOCI | 0 | (1) | 0 | 0 |
Purchases | 1 | 5 | 3 | 17 |
Sales | (9) | (44) | (15) | (47) |
Issuances | 0 | 0 | 0 | 0 |
Settlements | 0 | 0 | 0 | 0 |
Transfers into Level 3 | 0 | 0 | 0 | 0 |
Transfers out of Level 3 | 0 | 0 | 0 | 0 |
Balance, end of period | 3 | 17 | 3 | 17 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | (1) | 0 | (1) |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | (1) | 0 | (1) |
Other Investments | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Balance, beginning of period | 1,403 | 1,052 | 1,317 | 1,022 |
Total realized/unrealized gains (losses) included in net income (loss) | 28 | 63 | 111 | 91 |
Total realized/unrealized gains (losses) included in AOCI | 0 | 0 | 0 | 0 |
Purchases | 12 | 0 | 17 | 2 |
Sales | (9) | 0 | (11) | 0 |
Issuances | 0 | 0 | 0 | 0 |
Settlements | 0 | 0 | 0 | 0 |
Transfers into Level 3 | 0 | 0 | 0 | 0 |
Transfers out of Level 3 | 0 | 0 | 0 | 0 |
Balance, end of period | 1,434 | 1,115 | 1,434 | 1,115 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 28 | 64 | 117 | 93 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 28 | 64 | 117 | 93 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Separate Accounts | ||||
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] | ||||
Balance, beginning of period | 980 | 1,000 | 968 | 995 |
Total realized/unrealized gains (losses) included in net income (loss) | (5) | (10) | (19) | (18) |
Total realized/unrealized gains (losses) included in AOCI | 0 | 0 | 0 | 0 |
Purchases | 44 | 72 | 82 | 170 |
Sales | (50) | (20) | (58) | (109) |
Issuances | 0 | 0 | 0 | 0 |
Settlements | 0 | 0 | 0 | 1 |
Transfers into Level 3 | 0 | 12 | 3 | 15 |
Transfers out of Level 3 | 0 | 0 | (7) | 0 |
Balance, end of period | 969 | 1,054 | 969 | 1,054 |
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] | ||||
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period | 0 | 0 | 0 | 0 |
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period | $ 0 | $ 0 | $ 0 | $ 0 |
Fair Value (Financial Instrumen
Fair Value (Financial Instruments Carried at Other Than Fair Value) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Assets | ||
Policy loans | $ 5,713 | $ 5,671 |
Liabilities | ||
Separate account liabilities | 79,585 | 83,197 |
Carrying Value | ||
Assets | ||
Mortgage loans | 60,577 | 62,584 |
Policy loans | 5,713 | 5,671 |
Other invested assets | 1,936 | 1,778 |
Premiums, reinsurance and other receivables | 13,916 | 14,028 |
Liabilities | ||
PABs | 87,707 | 87,518 |
Long-term debt | 1,647 | 1,886 |
Other liabilities | 11,979 | 11,481 |
Separate account liabilities | 26,884 | 29,204 |
Estimated Fair Value | ||
Assets | ||
Mortgage loans | 57,070 | 59,511 |
Policy loans | 6,010 | 6,042 |
Other invested assets | 1,953 | 1,794 |
Premiums, reinsurance and other receivables | 14,045 | 14,274 |
Liabilities | ||
PABs | 85,512 | 86,093 |
Long-term debt | 1,715 | 1,958 |
Other liabilities | 11,962 | 11,474 |
Separate account liabilities | 26,884 | 29,204 |
Estimated Fair Value | Level 1 | ||
Assets | ||
Mortgage loans | 0 | 0 |
Policy loans | 0 | 0 |
Other invested assets | 0 | 0 |
Premiums, reinsurance and other receivables | 0 | 0 |
Liabilities | ||
PABs | 0 | 0 |
Long-term debt | 0 | 0 |
Other liabilities | 0 | 0 |
Separate account liabilities | 0 | 0 |
Estimated Fair Value | Level 2 | ||
Assets | ||
Mortgage loans | 0 | 0 |
Policy loans | 0 | 0 |
Other invested assets | 1,656 | 1,794 |
Premiums, reinsurance and other receivables | 438 | 221 |
Liabilities | ||
PABs | 0 | 0 |
Long-term debt | 1,715 | 1,958 |
Other liabilities | 902 | 141 |
Separate account liabilities | 26,884 | 29,204 |
Estimated Fair Value | Level 3 | ||
Assets | ||
Mortgage loans | 57,070 | 59,511 |
Policy loans | 6,010 | 6,042 |
Other invested assets | 297 | 0 |
Premiums, reinsurance and other receivables | 13,607 | 14,053 |
Liabilities | ||
PABs | 85,512 | 86,093 |
Long-term debt | 0 | 0 |
Other liabilities | 11,060 | 11,333 |
Separate account liabilities | $ 0 | $ 0 |
Fair Value (Nonrecurring Fair V
Fair Value (Nonrecurring Fair Value Measurements) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||||
Total mortgage loans | $ 60,577 | $ 60,577 | $ 62,584 | ||
Nonrecurring | |||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||||
Assets, Fair Value Adjustment | (47) | $ (31) | (84) | $ (105) | |
Fair Value, Inputs, Level 3 [Member] | Nonrecurring | |||||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||||
Total mortgage loans | $ 501 | $ 501 | $ 295 |
Equity (Components of Accumulat
Equity (Components of Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||
Beginning Balance | $ 13,293 | $ 14,176 | $ 13,616 | $ 13,395 |
Ending Balance | 13,879 | 13,599 | 13,879 | 13,599 |
Accumulated Other Comprehensive Income (Loss) | ||||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||
Beginning Balance | (6,728) | (6,832) | (6,872) | (8,320) |
OCI before reclassifications | 317 | (1,220) | 35 | 830 |
Deferred income tax benefit (expense) | (35) | 265 | 63 | (164) |
AOCI before reclassifications, net of income tax | (6,446) | (7,787) | (6,774) | (7,654) |
Amounts reclassified from AOCI | 53 | 453 | 474 | 284 |
Deferred income tax benefit (expense) | (15) | (89) | (108) | (53) |
Amounts reclassified from AOCI, net of income tax | 38 | 364 | 366 | 231 |
Ending Balance | (6,408) | (7,423) | (6,408) | (7,423) |
Unrealized Investment Gains (Losses), Net of Related Offsets | ||||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||
Beginning Balance | (7,854) | (8,167) | (6,495) | (11,161) |
OCI before reclassifications | (1,290) | (2,114) | (3,214) | 1,698 |
Deferred income tax benefit (expense) | 317 | 452 | 760 | (346) |
AOCI before reclassifications, net of income tax | (8,827) | (9,829) | (8,949) | (9,809) |
Amounts reclassified from AOCI | 153 | 829 | 312 | 804 |
Deferred income tax benefit (expense) | (37) | (167) | (74) | (162) |
Amounts reclassified from AOCI, net of income tax | 116 | 662 | 238 | 642 |
Ending Balance | (8,711) | (9,167) | (8,711) | (9,167) |
Unrealized Gains (Losses) on Derivatives | ||||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||
Beginning Balance | 796 | 1,568 | 705 | 1,557 |
OCI before reclassifications | 135 | (101) | (8) | 58 |
Deferred income tax benefit (expense) | (28) | 21 | 2 | (12) |
AOCI before reclassifications, net of income tax | 903 | 1,488 | 699 | 1,603 |
Amounts reclassified from AOCI | (103) | (379) | 156 | (525) |
Deferred income tax benefit (expense) | 22 | 79 | (33) | 110 |
Amounts reclassified from AOCI, net of income tax | (81) | (300) | 123 | (415) |
Ending Balance | 822 | 1,188 | 822 | 1,188 |
FPBs Discount Rate Remeasurement Gains (Losses) | ||||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||
Beginning Balance | 618 | (106) | (807) | 1,529 |
OCI before reclassifications | 1,505 | 1,051 | 3,309 | (1,017) |
Deferred income tax benefit (expense) | (330) | (219) | (709) | 214 |
AOCI before reclassifications, net of income tax | 1,793 | 726 | 1,793 | 726 |
Amounts reclassified from AOCI | 0 | 0 | 0 | 0 |
Deferred income tax benefit (expense) | 0 | 0 | 0 | 0 |
Amounts reclassified from AOCI, net of income tax | 0 | 0 | 0 | 0 |
Ending Balance | 1,793 | 726 | 1,793 | 726 |
MRBs Instrument-Specific Credit Risk Remeasurement Gains (Losses) | ||||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||
Beginning Balance | (13) | 149 | 33 | 80 |
OCI before reclassifications | (13) | (73) | (71) | 15 |
Deferred income tax benefit (expense) | 3 | 16 | 15 | (3) |
AOCI before reclassifications, net of income tax | (23) | 92 | (23) | 92 |
Amounts reclassified from AOCI | 0 | 0 | 0 | 0 |
Deferred income tax benefit (expense) | 0 | 0 | 0 | 0 |
Amounts reclassified from AOCI, net of income tax | 0 | 0 | 0 | 0 |
Ending Balance | (23) | 92 | (23) | 92 |
Foreign Currency Translation Adjustments | ||||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||
Beginning Balance | (112) | (139) | (143) | (187) |
OCI before reclassifications | (20) | 17 | 19 | 77 |
Deferred income tax benefit (expense) | 3 | (5) | (5) | (17) |
AOCI before reclassifications, net of income tax | (129) | (127) | (129) | (127) |
Amounts reclassified from AOCI | 0 | 0 | 0 | 0 |
Deferred income tax benefit (expense) | 0 | 0 | 0 | 0 |
Amounts reclassified from AOCI, net of income tax | 0 | 0 | 0 | 0 |
Ending Balance | (129) | (127) | (129) | (127) |
Defined Benefit Plans Adjustment | ||||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||
Beginning Balance | (163) | (137) | (165) | (138) |
OCI before reclassifications | 0 | 0 | 0 | (1) |
Deferred income tax benefit (expense) | 0 | 0 | 0 | 0 |
AOCI before reclassifications, net of income tax | (163) | (137) | (165) | (139) |
Amounts reclassified from AOCI | 3 | 3 | 6 | 5 |
Deferred income tax benefit (expense) | 0 | (1) | (1) | (1) |
Amounts reclassified from AOCI, net of income tax | 3 | 2 | 5 | 4 |
Ending Balance | $ (160) | $ (135) | $ (160) | $ (135) |
Equity (Reclassifications Out o
Equity (Reclassifications Out of Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2024 | Mar. 31, 2024 | Jun. 30, 2023 | Mar. 31, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
Net investment gains (losses) | $ (106) | $ (659) | $ (242) | $ (761) | ||
Net derivative gains (losses) | 60 | (232) | 4 | (792) | ||
Net investment income | 2,903 | 2,873 | 5,760 | 5,558 | ||
Income (loss) before provision for income tax | 1,179 | 588 | 2,328 | 393 | ||
Income tax (expense) benefit | (228) | (78) | (442) | 26 | ||
Net income (loss) | 951 | $ 935 | 510 | $ (91) | 1,886 | 419 |
Reclassification out of Accumulated Other Comprehensive Income | ||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
Net income (loss) | (38) | (364) | (366) | (231) | ||
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Investment Gains (Losses), Net of Related Offsets | ||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
Net investment gains (losses) | (142) | (828) | (288) | (787) | ||
Net derivative gains (losses) | (12) | (2) | (24) | (20) | ||
Net investment income | 1 | 1 | 0 | 3 | ||
Income (loss) before provision for income tax | (153) | (829) | (312) | (804) | ||
Income tax (expense) benefit | 37 | 167 | 74 | 162 | ||
Net income (loss) | (116) | (662) | (238) | (642) | ||
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) on Derivatives | ||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
Income (loss) before provision for income tax | 103 | 379 | (156) | 525 | ||
Income tax (expense) benefit | (22) | (79) | 33 | (110) | ||
Net income (loss) | 81 | 300 | (123) | 415 | ||
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) on Derivatives | Interest rate | ||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
Net investment gains (losses) | 0 | 55 | 2 | 57 | ||
Net investment income | 6 | 13 | 14 | 27 | ||
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) on Derivatives | Foreign currency swaps | ||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
Net investment gains (losses) | 95 | 310 | (175) | 439 | ||
Net investment income | 1 | 1 | 2 | 2 | ||
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) on Derivatives | Credit derivatives | ||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
Net investment gains (losses) | 1 | 0 | 1 | 0 | ||
Reclassification out of Accumulated Other Comprehensive Income | Defined Benefit Plans Adjustment | ||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
Amortization of net actuarial gains (losses) | (4) | (3) | (7) | (6) | ||
Amortization of prior service (costs) credit | 1 | 0 | 1 | 1 | ||
Income (loss) before provision for income tax | (3) | (3) | (6) | (5) | ||
Income tax (expense) benefit | 0 | 1 | 1 | 1 | ||
Net income (loss) | $ (3) | $ (2) | $ (5) | $ (4) |
Other Revenues (Details)
Other Revenues (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | $ 233 | $ 225 | $ 466 | $ 448 |
Other revenues | 447 | 419 | 902 | 834 |
Prepaid legal plans | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 117 | 115 | 237 | 230 |
Administrative services-only contracts | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 66 | 62 | 132 | 123 |
Recordkeeping and administrative services (1) | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 36 | 37 | 74 | 74 |
Other revenue from service contracts from customers | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenue from Contract with Customer, Excluding Assessed Tax | 14 | 11 | 23 | 21 |
Other Income | ||||
Disaggregation of Revenue [Line Items] | ||||
Other revenues | $ 214 | $ 194 | $ 436 | $ 386 |
Other Expenses (Other Expenses)
Other Expenses (Other Expenses) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Other Income and Expenses [Abstract] | ||||
General and administrative expenses (1) | $ 675 | $ 677 | $ 1,348 | $ 1,338 |
Pension, postretirement and postemployment benefit costs | 55 | 50 | 110 | 100 |
Premium taxes, other taxes, and licenses & fees | 108 | 106 | 205 | 199 |
Commissions and other variable expenses | 496 | 467 | 983 | 1,181 |
Capitalization of DAC | (27) | (12) | (52) | (89) |
Amortization of DAC and VOBA | 68 | 74 | 138 | 151 |
Interest expense on debt | 30 | 34 | 62 | 64 |
Total other expenses | 1,405 | 1,396 | 2,794 | 2,944 |
Net change in cash surrender value of investments, net of premiums paid | $ (25) | $ (27) | $ (65) | $ (57) |
Income Tax (Narrative) (Details
Income Tax (Narrative) (Details) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Income Tax Disclosure [Abstract] | ||||
Effective Income Tax Rate Reconciliation, Percent | 19% | 13% | 19% | (7.00%) |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21% | 21% | 21% | 21% |
Contingencies, Commitments an_2
Contingencies, Commitments and Guarantees (Contingencies - Narrative) (Details) $ in Millions | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2024 USD ($) Claims | Jun. 30, 2023 Claims | Dec. 31, 2023 Claims | |
Minimum | |||
Loss Contingencies | |||
Loss Contingency, Range of Possible Loss, Portion Not Accrued | $ 0 | ||
Maximum | |||
Loss Contingencies | |||
Loss Contingency, Range of Possible Loss, Portion Not Accrued | $ 125 | ||
Asbestos Related Claims | |||
Loss Contingencies | |||
Asbestos-Related Claims | Claims | 1,556 | 1,306 | 2,565 |
Contingencies, Commitments an_3
Contingencies, Commitments and Guarantees (Commitments and Guarantees - Narrative) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Contingencies, Commitments and Guarantees [Abstract] | ||
Cumulative maximum indemnities and guarantees contractual limitation | $ 649 | |
Liabilities for indemnities, guarantees and commitments | 2 | $ 2 |
Minimum | ||
Contingencies, Commitments and Guarantees [Abstract] | ||
Indemnities and guarantees contractual limitation range | 1 | |
Maximum | ||
Contingencies, Commitments and Guarantees [Abstract] | ||
Indemnities and guarantees contractual limitation range | 550 | |
Mortgage Loan Commitments | ||
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items] | ||
Fair Value Disclosure, Off-balance Sheet Risks, Face Amount, Liability | 2,500 | 3,300 |
Commitments to Fund Partnership Investments, Bank Credit Facilities, Bridge Loans and Private Corporate Bond Investments | ||
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items] | ||
Fair Value Disclosure, Off-balance Sheet Risks, Face Amount, Liability | $ 4,300 | $ 4,400 |
Related Party Transactions (Ser
Related Party Transactions (Service Agreements - Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Related Party Transaction [Line Items] | |||||
Other expenses | $ 1,405 | $ 1,396 | $ 2,794 | $ 2,944 | |
Revenues | 11,051 | 8,776 | 20,744 | 17,493 | |
Other liabilities | 24,228 | 24,228 | $ 23,719 | ||
Affiliated Entity [Member] | Services Necessary To Conduct The Company's Activities | |||||
Related Party Transaction [Line Items] | |||||
Other expenses | 740 | 737 | 1,500 | 1,500 | |
Revenues | 10 | $ 15 | 21 | $ 29 | |
Related Party | |||||
Related Party Transaction [Line Items] | |||||
Other liabilities | $ 23 | $ 23 | $ 56 |
Related Party Transactions (Eff
Related Party Transactions (Effects of Affiliated Reinsurance on Statements of Operations) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Premiums: | ||||
Net premiums | $ 7,366 | $ 5,953 | $ 13,580 | $ 11,802 |
Other revenues: | ||||
Net other revenues | 447 | 419 | 902 | 834 |
Interest Credited To Policyholder Account Balances [Abstract] | ||||
Net interest credited to PABs | 957 | 893 | 1,880 | 1,724 |
Other expenses: | ||||
Net other expenses | 1,405 | 1,396 | 2,794 | 2,944 |
Affiliated Entity [Member] | Assumed Reinsurance [Member] | ||||
Premiums: | ||||
Reinsurance assumed | 1 | 2 | 2 | 25 |
Universal life and investment-type product policy fees: | ||||
Reinsurance assumed | 5 | 1 | 8 | 1 |
Other revenues: | ||||
Reinsurance assumed | 35 | 24 | 63 | 46 |
Policyholder benefits and claims: | ||||
Reinsurance assumed | 11 | 18 | 23 | |
Reinsurance ceded | (151) | |||
Interest Credited To Policyholder Account Balances [Abstract] | ||||
Reinsurance assumed | 90 | 88 | 179 | 161 |
Other expenses: | ||||
Reinsurance assumed | 11 | 11 | 23 | 215 |
Policyholder Liability, Change in Fair Value, Gain (Loss) | 0 | 0 | 0 | 39 |
Affiliated Entity [Member] | Ceded Reinsurance [Member] | ||||
Premiums: | ||||
Reinsurance ceded | (102) | (89) | (205) | (173) |
Universal life and investment-type product policy fees: | ||||
Reinsurance ceded | (1) | (2) | (1) | (4) |
Other revenues: | ||||
Reinsurance ceded | 117 | 116 | 232 | 231 |
Policyholder benefits and claims: | ||||
Reinsurance ceded | (82) | (68) | (168) | (145) |
Interest Credited To Policyholder Account Balances [Abstract] | ||||
Reinsurance ceded | (2) | (3) | (5) | (6) |
Other expenses: | ||||
Reinsurance ceded | 54 | 65 | 110 | 128 |
Policyholder Liability, Change in Fair Value, Gain (Loss) | (2) | 0 | 0 | 5 |
Affiliated Entity [Member] | Reinsurance [Member] | ||||
Premiums: | ||||
Net premiums | (101) | (87) | (203) | (198) |
Universal life and investment-type product policy fees: | ||||
Insurance Commissions and Fees, Net Impact from Reinsurance | 4 | (1) | 7 | (3) |
Other revenues: | ||||
Net other revenues | 152 | 140 | 295 | 277 |
Policyholder benefits and claims: | ||||
Net policyholder benefits and claims | (71) | (50) | (145) | (296) |
Interest Credited To Policyholder Account Balances [Abstract] | ||||
Net interest credited to PABs | 88 | 85 | 174 | 155 |
Other expenses: | ||||
Net other expenses | 65 | 76 | 133 | 343 |
Policyholder Liability, Change in Fair Value, Gain (Loss) | $ (2) | $ 0 | $ 0 | $ (44) |
Related Party Transactions (E_2
Related Party Transactions (Effects of Affiliated Reinsurance on Balance Sheets) (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 | Jun. 30, 2023 |
Assets | |||
Premiums, reinsurance and other receivables | $ 28,893 | $ 28,236 | |
DAC and VOBA | 3,219 | 3,305 | $ 3,695 |
Liabilities: | |||
Net liability for FPBs | 126,035 | 129,182 | |
Policyholder account balances | 103,774 | 103,894 | |
Other policy-related balances | 8,361 | 8,289 | |
Other Liabilities | 24,228 | 23,719 | |
Assumed Reinsurance [Member] | Affiliated Entity [Member] | |||
Assets | |||
Premiums, reinsurance and other receivables | 173 | 164 | |
DAC and VOBA | 149 | 158 | |
Total assets | 322 | 322 | |
Liabilities: | |||
Net liability for FPBs | 2,093 | 2,236 | |
Policyholder account balances | 9,003 | 9,040 | |
Other policy-related balances | 66 | 65 | |
Other Liabilities | 804 | 957 | |
Total liabilities | 11,966 | 12,298 | |
Ceded Reinsurance [Member] | Affiliated Entity [Member] | |||
Assets | |||
Premiums, reinsurance and other receivables | 11,234 | 11,302 | |
Deferred Policy Acquisition Costs and Present Value of Future Insurance Profits, Ceded | (158) | (160) | |
Total assets | 11,076 | 11,142 | |
Liabilities: | |||
Liability for Future Policy Benefit, before Reinsurance, Ceded | 0 | 0 | |
Policyholder account balances | 0 | 0 | |
Other policy-related balances | (42) | (35) | |
Other Liabilities | 9,888 | 10,267 | |
Total liabilities | $ 9,846 | $ 10,232 |
Related Party Transactions (Rei
Related Party Transactions (Reinsurance Transactions - Narrative) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Schedule Of Effect Of Reinsurance On Income Statement [Line Items] | |||||
Net liability for FPBs | $ 126,035 | $ 126,035 | $ 129,182 | ||
Other invested assets - VIE | 16,865 | 16,865 | 17,040 | ||
Net other expenses | 1,405 | $ 1,396 | 2,794 | $ 2,944 | |
Embedded Derivative, Fair Value of Embedded Derivative Liability | 279 | 279 | 37 | ||
Affiliated Entity [Member] | |||||
Schedule Of Effect Of Reinsurance On Income Statement [Line Items] | |||||
Other invested assets - VIE | $ 1,153 | $ 1,153 | 1,280 | ||
Affiliated Entity [Member] | Funds Withheld On Ceded Reinsurance [Member] | |||||
Schedule Of Effect Of Reinsurance On Income Statement [Line Items] | |||||
Coinsurance Funds Withheld Basis, Percent | 75% | 75% | |||
Embedded Derivative, Fair Value of Embedded Derivative Liability | $ (46) | $ (46) | (39) | ||
Net derivatives gains (losses) | 4 | (23) | 7 | (29) | |
Affiliated Entity [Member] | Closed Block Liabilities Ceded To MetLife Reinsurance Of Charleston [Member] | |||||
Schedule Of Effect Of Reinsurance On Income Statement [Line Items] | |||||
Embedded Derivative, Fair Value of Embedded Derivative Liability | (401) | (401) | $ (265) | ||
Net derivatives gains (losses) | $ 57 | $ 114 | $ 136 | $ (51) |